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Abstract 
Mycobacterium tuberculosis is an important global cause of mortality and 
morbidity. The major host cell of Mycobacterium tuberculosis is the macrophage, 
and Mycobacterium tuberculosis is able to subvert the macrophage response in order 
to survive and replicate. The majority of infected individuals mount an immune 
response capable of controlling Mycobacterium tuberculosis infection. This requires 
the cytokines IL-12, TNFα, IL-1 and IFNγ, which promote eradication or control of 
infection. However, other immune factors, including IL-10 and type I IFN, can 
inhibit this protective response. 
 In this study we have used microarray analysis to study the temporal 
response of macrophages to Mycobacterium tuberculosis infection, in an unbiased 
fashion. In response to Mycobacterium tuberculosis infection, macrophages 
produced cytokines and chemokines, upregulated genes involved with major 
histocompatability class I antigen presentation, activated both pro- and anti-apoptotic 
genes and downregulated many genes involved in cell-division and metabolism. We 
also observed the early induction of genes regulated by the extracellular-regulated 
kinase (ERK) MAP kinase pathway, and the upregulation of genes known to be 
induced by type I IFN, leading us to further investigate the role of these pathways in 
the macrophage response to Mycobacterium tuberculosis. Both pathways were found 
to regulate the production of protective and detrimental cytokines in macrophages in 
response to Mycobacterium tuberculosis infection. In addition, microarray analysis 
found that these pathways controlled the transcription of numerous genes in response 
to Mycobacterium tuberculosis infection. Finally, type I IFN was found to inhibit the 
macrophage response to IFNγ, including IFNγ-mediated killing of Mycobacterium 
tuberculosis in macrophages, a crucial step in the control of Mycobacterium 
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tuberculosis infection in vivo. We have therefore identified important regulatory 
mechanisms in macrophages, which are likely have an important role during 
Mycobacterium tuberculosis infection in vivo. 
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1.1. Tuberculosis and Mycobacterium tuberculosis 
1.1.1. Tuberculosis: a major global health problem 
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis 
(Mtb), has been a cause of mortality in human beings for thousands of years (Salo et 
al, 1994). However, despite great progress in the understanding of TB since the 
discovery of Mtb by Robert Koch (Koch, 1882) there were 8.8 million new TB cases 
in 2010 and 1.45 million deaths (WHO, 2011). The majority of the global TB burden 
is in the developing world, particularly in Asia and Sub-Saharan Africa (WHO, 
2011). 
Following the discovery of effective antibiotics for the treatment of TB, such 
as Streptomycin, it was thought that TB could be controlled and potentially 
eradicated. However, there has been a steady increase in the global burden of TB 
over the last 20 years, for three important reasons (Dye and Williams, 2010). First, 
although antibiotics are a highly efficacious and cost-effective means of treating TB, 
the rise in multi-drug resistant (MDR) strains of Mtb has hampered these efforts, and 
threatens to become a major health problem (Jassal and Bishai, 2009). Essentially 
untreatable extensively drug-resistant (XDR) strains are now being reported, which 
are associated with high mortality in HIV patients (Jassal and Bishai, 2009). Second, 
the human immunodeficiency virus (HIV) epidemic has fuelled the global rise in TB 
cases. HIV infects and kills CD4
+
 T cells, leading to a greatly increased risk of 
developing TB (Kwan and Ernst, 2012). Almost a quarter of TB deaths in 2010 
occurred in HIV positive individuals, and TB is the biggest killer of patients with 
acquired immune deficiency syndrome (AIDS) (WHO, 2011). Finally, the lack of an 
effective vaccine against Mtb is a major problem (Kaufmann, 2012). Although the 
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current vaccine, Mycobacterium bovis bacillus Calmette–Guérin (BCG), can protect 
children against rare forms of disseminated TB (Trunz et al, 2006), its efficacy in 
protecting adults from pulmonary TB, the most common form of the disease, is 
highly variable (Colditz et al, 1994; Fine, 1995).  
1.1.2. The outcome of infection with Mtb 
TB is predominantly a lung infection, although it can disseminate to other 
organs (Lawn and Zumla, 2011). Mtb is spread from person to person via the aerosol 
route, in water droplets containing infectious bacteria which penetrate into the 
alveoli and initiate infection (Lawn and Zumla, 2011). There are several possible 
outcomes for an individual following infection with Mtb (Flynn and Chan, 2001b) 
which are summarised in Figure 1.1. 
A small percentage of infected individuals are unable to control the initial 
infection, and develop acute active disease, characterised by fever, weight loss, night 
sweats and a persistent cough (Flynn and Chan, 2001b; Lawn and Zumla, 2011). 
However, the majority of infected individuals mount an immune response capable of 
controlling, but not clearing, the infection (Barry et al, 2009). This state, known as 
latency, is defined by evidence of an adaptive immune response to Mtb antigens, as 
shown by the tuberculin skin test (TST) to mycobacterial antigens, or the IFNγ 
release assay (IGRA) to Mtb-specific antigens, with an absence of disease symptoms 
and contagiousness (Flynn and Chan, 2001b). However, it is becoming increasing 
appreciated that latency as determined by the TST or IGRA is likely to encompass a 
spectrum of different disease states, ranging from a resolved infection to subclinical 
disease (Barry et al, 2009). 
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Approximately one-third of the world’s population is latently infected with 
Mtb, and around 10% of these will go on develop active TB, often years after the 
initial infection (Dye et al, 1999) (Figure 1.1). The immune system is vital in 
maintaining latency, and factors that compromise the immune system, such as HIV 
co-infection or neutralisation of TNFα, dramatically increase the risk of reactivation 
(Keane et al, 2001; Kwan and Ernst, 2012) (Figure 1.1). 
 
Figure 1.1. The outcome of infection with Mtb 
1.1.3. Different strains of Mtb show increased virulence and may 
affect disease outcome 
One factor that may have an influence on disease outcome is the strain of Mtb 
with which an individual is infected (Nicol and Wilkinson, 2008). Research into Mtb 
genetics has revealed that the Mtb complex consists of seven main lineages (two of 
which include strains of M. africanum) which are associated with different 
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geographical regions (Gagneux and Small, 2007; Hershberg et al, 2008). These 
findings have prompted research to address whether different strains of Mtb are 
associated with changes in virulence, and changes in the immune response, 
predominantly by comparing different strains in animal models (Hershberg et al, 
2008) or human and mouse cells (Reed et al, 2004; Newton et al, 2006). Several 
strains of Mtb have been identified that show increased virulence in animal models 
compared to reference strains such as H37Rv, and prominent among these are 
members of the W-Beijing family (Parwati et al, 2010). Members of this family such 
as HN878 are hypervirulent in mouse models (Manca et al, 2001) and infection of 
humans with W-Beijing family members has been associated with an increased 
likelihood of reactivation (Kong et al, 2007). One mechanism behind the increased 
virulence of W-Beijing strains appears to be an ability to suppress the production of 
important cytokines from innate immune cells (Reed et al, 2004). In addition, other 
Mtb strains not in the W-Beijing lineage can suppress the host immune response; one 
study isolated an Mtb strain from a large outbreak in Leicester, the CH strain, and 
found that this strain induced higher levels of the immunosuppressive cytokine IL-
10, but lower levels of the protective cytokine IL-12p40 (Newton et al, 2006). Thus, 
the outcome of infection with Mtb may depend strongly on the virulence of the 
infecting strain, and how effectively that strain can subvert the immune response.  
1.2. Early events following Mtb infection 
Given the importance of the immune response in controlling Mtb, how the 
immune system responds to Mtb infection has been studied extensively in recent 
years, primarily using animal models. This has shown that the immune response to 
Mtb consists of several key stages, culminating in the control of the infection in the 
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lung (Figure 1.2). The first stages involve the interactions of Mtb with cells of the 
innate immune system, which is discussed below. 
 
Figure 1.2. An overview of the immune response to Mtb.  
1.2.1. The innate immune system 
The first immune cells encountered by Mtb following infection are those of 
the innate immune system (Figure 1.2). The role of innate immune cells, which 
include macrophages, dendritic cells (DCs) and neutrophils, is to rapidly detect and 
eliminate pathogens entering the body, and to activate the adaptive immune response 
(Medzhitov, 2007). Innate immune cells must therefore be able to respond 
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specifically to pathogens, such as Mtb, as inappropriate responses could lead to host 
damage or immunosuppression (Smale, 2010).  
Specificity is initially achieved through pattern recognition receptors (PRRs), 
germ-line encoded receptors expressed on immune cells (Janeway and Medzhitov, 
2002). PRRs recognise molecular structures that are unique to microorganisms, 
which are known as pathogen-associated molecular patterns (PAMPs) (Medzhitov, 
2007). A classic example of a PAMP is lipopolysaccharide (LPS), a molecule 
specific to the cell walls of gram-negative bacteria (Kawai and Akira, 2010). 
Recognition of a PAMP by a PRR on an immune cell stimulates various processes 
including phagocytosis, production of cytokines and chemokines and induction of 
antigen presentation (Medzhitov and Horng, 2009).  
1.2.2. Mtb infects cells of the innate immune system in the lung 
It is thought that the first innate immune cells to encounter Mtb are lung-
resident alveolar macrophages (Flynn and Chan, 2001a). Mtb infects alveolar 
macrophages and although these cells are specialised to destroy foreign material 
such as bacteria, it has long been recognised that Mtb has evolved to avoid these 
killing mechanisms, and actively replicates within macrophages (Armstrong and 
Hart, 1971). Replication results in inflammation and the influx of further innate 
immune cells into the lung, including monocytes, macrophages, DCs and neutrophils 
(Wolf et al, 2007; Skold and Behar, 2008). Although macrophages are thought to be 
the major infected cell type, experiments with GFP labelled Mtb have shown that 
monocytes, DCs and neutrophils can also become infected (Wolf et al, 2007). 
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Infected neutrophils have also been reported in the lungs of human TB patients (Eum 
et al, 2010). 
 
Figure 1.3. An overview of the macrophage response to Mtb 
1.2.3. The interactions between Mtb and macrophages 
As the macrophage is one of the major infected cell types during Mtb 
infection, and is thought to mediate Mtb killing, the interactions between Mtb and 
macrophages are crucial, and have been extensively studied (Pieters, 2008). These 
interactions are summarised in Figure 1.3. Several important processes are activated 
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in macrophages upon encountering Mtb, including phagocytosis and the destruction 
of Mtb, and the induction of cytokines downstream of recognition by PRRs (Pieters, 
2008; Kleinnijenhuis et al, 2011). However, Mtb can subvert these processes, 
allowing it to replicate within macrophages (Pieters, 2008) (Figure 1.3).  
1.2.3.1.  Mtb can avoid macrophage killing mechanisms 
A key function of macrophages is to take up and destroy foreign material, 
including bacteria, through a process called phagocytosis. Phagocytosis of Mtb into 
macrophages and other innate immune cells is stimulated through various receptors 
on the macrophage surface, including the mannose receptor (MR), dendritic cell-
specific intercellular adhesion molecule (ICAM)-3-grabbing nonintegrin (DC-SIGN) 
(Tailleux et al, 2003), Fc receptors and complement receptors (Ernst, 1998; Pieters, 
2001). Phagocytosis results in Mtb being contained within an intracellular vesicle 
known as the phagosome (Ernst, 1998) (Figure 1.3). 
Under normal circumstances, the phagosome enters the endosomal pathway, 
culminating in fusion with a lysosome, a process known as phagosome-lysosome 
fusion (Vergne et al, 2004). Lysosomes contain potent hydrolytic enzymes, and are 
highly acidic (pH 4.5-5), and this destroys phagocytosed material and generates 
antigens that are loaded onto major histocompatability (MHC) class II molecules and 
presented on the cell surface (Pieters, 2008). However, Mtb has a number of 
strategies for blocking phagosome-lysosome fusion, involving several different Mtb 
virulence factors (Pieters, 2008). As a result, phagosomes containing Mtb fail to 
acidify or to acquire mature lysosomal hydrolases (Sturgill-Koszycki et al, 1994; 
Russell, 2001). Mtb blocks the recruitment of phosphatidylinositol 3-phosphate 
(PI3P) to the phagosome, a process that is essential for phagosome maturation (Fratti 
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et al, 2003). This is achieved by the inhibition of the enzyme that generates PI3P, 
hVP34, and by the breakdown of PI3P through the activity of the Mtb encoded 
phosphatase SapM (Pieters, 2008). The mycobacterial kinase protein kinase G 
(PknG) is also required for the prevention of phagosome-lysosome fusion 
(Walburger et al, 2004), although the mechanism for this is currently unknown. 
Finally, Mtb actively induces the recruitment of Coronin-1 to the phagosome, which 
leads to the activation of the enzyme calcineurin, resulting in prevention of 
phagosome-lysosome fusion (Jayachandran et al, 2007). As a result of these 
virulence strategies, macrophages require activation by IFNγ, following the initiation 
of the adaptive immune response, in order to activate pathways leading to the 
destruction of intracellular Mtb (Pieters, 2008) (Figure 1.3). 
1.2.3.2.  Recognition of Mtb through PRRs on innate immune cells 
An important response of macrophages to Mtb infection is to produce 
cytokines which lead to the recruitment and activation of further immune cells to the 
lung (Kleinnijenhuis et al, 2011). Mtb is known to possess several different PAMPs, 
which are recognised by several different types of PRRs on innate cells such as 
macrophages and DCs (Figure 1.3).  
1.2.3.2.1. Toll-like receptors 
A major family of PRRs implicated in the recognition of Mtb are the Toll-
like receptors (TLRs), a family of type I transmembrane proteins expressed in innate 
immune cells, that recognise diverse components of microorganisms (Medzhitov, 
2007). Two major pathways are activated downstream of TLR signalling depending 
on the adaptor protein used (Kawai and Akira, 2010). All TLRs except TLR3 signal 
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through the myeloid differentiation primary response gene 88 (MyD88) adaptor 
protein, activating the MyD88-dependent pathway (Kawai and Akira, 2010). The 
cytokines IL-1 and IL-18 also signal through MyD88 (Dinarello, 2009). This 
pathway culminates in activation of the transcription factor NF-κB and the mitogen 
activated protein (MAP) kinases, leading to the induction of many genes, including 
pro-inflammatory cytokines (Kawai and Akira, 2010). TLR2 and TLR4 also require 
the adaptor toll-interleukin 1 receptor (TIR) domain containing adaptor protein 
(TIRAP) to activate the MyD88 pathway (Horng et al, 2002; Yamamoto et al, 2002). 
TLR3 and TLR4 activate the adaptor molecule TIR-domain-containing adapter-
inducing interferon-β (TRIF), and the TRIF dependent pathway. The TRIF-
dependent pathway is primarily involved in the induction of type I interferon (IFN) 
through activating the transcription factors IRF3 and IRF7 (Kawai and Akira, 2010).  
The main TLRs involved in the recognition of Mtb are TLR2, TLR4 and 
TLR9 (Kleinnijenhuis et al, 2011). TLR2, in complex with either TLR1 or TLR6, 
has been shown to recognise various cell wall components of Mtb such as 
lipoarabinomannan (LAM), lipomannan (LM), and the 38-kDa and 19-kDa 
glycoproteins (Kleinnijenhuis et al, 2011). TLR9 recognises unmethylated CpG 
motifs in mycobacterial DNA (Bafica et al, 2005). Finally, Mtb heat-shock proteins 
have been suggested to activate TLR4 (Bulut et al, 2005). Macrophages and DCs 
deficient in TLR2, TLR4 or TLR9 showed impaired production of the cytokines 
TNFα, IL-12, IL-1 and IL-10 in response to Mtb infection (Jang et al, 2004; Bafica 
et al, 2005; Pompei et al, 2007; Holscher et al, 2008; Kleinnijenhuis et al, 2009). 
However, despite a clear role for TLR signalling in vitro, the relevance of 
TLRs in the response to Mtb in vivo has been controversial (Korbel et al, 2008; 
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Reiling et al, 2008). Various groups have infected TLR2, TLR4 and TLR9 knockout 
mice, as well as double and triple knockouts, but results have been contradictory, 
with some observing a severe phenotype with single knockout mice (Abel et al, 
2002; Reiling et al, 2002; Drennan et al, 2004), whilst others find no effect even 
with mice triply deficient in TLR2, TLR4 and TLR9 (Holscher et al, 2008). These 
discrepancies are likely to result from differences in the strain and dose of Mtb used. 
For example, it has been suggested that TLRs play a more important role in response 
to high-dose Mtb infection (Reiling et al, 2002).  
However, MyD88
-/-
 mice, which are unable to signal through any TLR apart 
from TLR3, have consistently been observed to succumb rapidly to Mtb infection 
(Fremond et al, 2004; Scanga et al, 2004; Fremond et al, 2007; Holscher et al, 
2008). The explanation for this severe phenotype is now thought to be due to loss of 
IL-1 signalling, rather than TLR signalling (Korbel et al, 2008; Reiling et al, 2008), 
as IL-1 signals through MyD88 (Sims and Smith, 2010). The role of IL-1 in the 
immune response to Mtb is discussed below.  
1.2.3.2.2. Dectin-1 
Non-TLR PRRs can also recognise Mtb components and mediate lead to 
cytokine production in innate immune cells (Kleinnijenhuis et al, 2011). One of 
these is dectin-1, a receptor in the C-type lectin family expressed on monocytes, 
macrophages, DCs and a subset of T cells (Brown, 2006). Dectin-1 recognises β-
glucans, carbohydrate polymers found in fungal cell walls (Brown et al, 2002), and 
activates a Syk-CARD9-ERK dependent pathway leading to induction of TNFα, IL-
2 and IL-10 (Brown et al, 2003; LeibundGut-Landmann et al, 2007; Slack et al, 
2007; Zhang et al, 2009). Dectin-1 was shown to be required for optimal IL-12 
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production from splenic DCs infected with Mtb (Rothfuchs et al, 2007). However, 
dectin-1 appears to play a minimal role in the in vivo response to Mtb, as dectin-1 
deficient mice showed similar survival, bacterial loads and cytokine production 
following Mtb infection, compared to WT controls (Marakalala et al, 2011).  
1.2.3.2.3. DC-SIGN 
DC-SIGN, expressed predominantly on DCs, is another PRR in the C-type 
lectin family implicated in the recognition of Mtb (Kleinnijenhuis et al, 2011). DC-
SIGN is an important phagocytosis receptor for Mtb on human DCs and alveolar 
macrophages (Tailleux et al, 2003; Tailleux et al, 2005). However, it has been 
suggested that Mtb may target DC-SIGN in order to promote the production of IL-10 
from DCs, and suppress DC function (Geijtenbeek and van Kooyk, 2003), through a 
pathway involving Raf-1 and the acetylation of NF-κB (Gringhuis et al, 2007; 
Gringhuis et al, 2009). However, this potentially negative role of DC-SIGN is in 
conflict with the fact that mutations that increase the expression of DC-SIGN in 
humans are associated with protection against TB (Barreiro et al, 2006), and that in 
mice, deletion of a homolog of DC-SIGN, SIGNR3, leads to increased susceptibility 
to Mtb infection (Tanne et al, 2009).  
1.2.3.2.2. NOD2 
Nucleotide-binding oligomerisation domain-containing protein 2 (NOD2) is a 
member of the NOD-like receptor (NLR) family of PRRs and is expressed in the 
cytosol of a variety of immune cells (Franchi et al, 2009). NOD2 recognises the 
muramyl dipeptide (MDP) component of peptidoglycan, a structure found in the 
bacterial cell wall (Franchi et al, 2009). NOD2 was shown to be required for optimal 
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TNFα production from murine peritoneal macrophages infected with Mtb (Ferwerda 
et al, 2005; Yang et al, 2007). NOD2 recognition has subsequently been shown to 
mediate induction of IL-1 (Kleinnijenhuis et al, 2009) and type I IFNs (Pandey et al, 
2009) in Mtb infected macrophages. This recognition appears to be important for the 
immune response, as NOD2 deficient mice have impaired control of Mtb infection 
(Divangahi et al, 2008). 
1.2.4. Dendritic cells initiate the adaptive immune response to Mtb 
As the innate immune system is unable to control Mtb infection, the adaptive 
immune system is required to be activated in order mediate protection. The 
activation of the adaptive immune response, and in particular the activation of T 
cells, is a crucial stage in the immune response to Mtb (North and Jung, 2004; 
Cooper, 2009) (Figure 1.2). T cells are present in the periphery and lymphoid organs 
in a naive state; in order to become activated and fight infection they must recognise 
their specific cognate antigen on the surface of MHC molecules, whilst 
simultaneously receiving co-stimulatory signals (Banchereau and Steinman, 1998). 
CD4
+
 T cells recognise antigens on MHC class II molecules, whereas CD8
+
 T cells 
recognise antigen MHC class I molecules (Vyas et al, 2008). Different pathways 
lead to antigen presentation on MHC class I and MHC class II receptors (Vyas et al, 
2008). Antigens derived from cytosolic pathogens such as viruses and certain 
bacteria are processed in the cytosol and presented on MHC class I molecules to 
CD8
+
 T cells, whereas extracellular and phagosomal pathogens, such as Mtb, are 
largely processed via the endocytic pathway and presented on MHC class II 
molecules to CD4
+
 T cells (Vyas et al, 2008). However, it is also possible for 
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antigens in the endocytic pathway to be presented on MHC class I molecules, and 
vice versa, through a process known as cross-presentation, although the mechanisms 
behind this are not well understood (Vyas et al, 2008). In response to recognition of 
their cognate antigens, T cells produce IL-2, proliferate, acquire effector functions 
and migrate to the site of infection where they activate other cells of the immune 
system, in the case of CD4
+
 T cells, and directly kill infected cells, in the case of 
CD8
+
 T cells (Banchereau and Steinman, 1998).  
Cells capable of activating naive T cells are known as antigen presenting 
cells (APCs), and the most efficient of these is the DC (Banchereau and Steinman, 
1998). DCs capture antigen at the site of infection, and migrate to the lymphoid 
organs, where they present the antigen on both MHC class I and class II molecules. 
DCs also express the necessary costimulatory molecules, such as CD80 and CD86, 
and are therefore highly effective at activating naive T cells (Banchereau and 
Steinman, 1998). These abilities of DCs are controlled by recognition of foreign 
microorganisms through PRRs, with PRR recognition stimulating increased 
phagocytosis, upregulation of MHC class I and class II antigen presentation 
components and upregulation of costimulatory molecules and cytokines (Vyas et al, 
2008). The cytokine IFNγ, which is produced by T cells and NK cells, also 
stimulates increased antigen presentation in innate immune cells (Boehm et al, 
1997). 
CD4
+
 T cells are the key effector cell in controlling Mtb infection, and the 
events leading to activation of CD4
+
 T cells have been extensively studied (Cooper, 
2009). Following Mtb infection, evidence has consistently shown that DC migration 
from the lung to the lung-draining lymph nodes (LDLN) is required for the 
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activation of T cells (Cooper, 2009). It was first shown that live Mtb appears in the 
LDLN between 9 and 11 days post-infection, and that this precedes T cell activation 
(Chackerian et al, 2002). Subsequently, transfer of Mtb-specific naive CD4
+
 T cells 
confirmed that T cells were first activated in the LDLN, and then migrated to the 
lungs (Reiley et al, 2008; Wolf et al, 2008). A study using GFP-tagged Mtb showed 
that the major infected cell type in the LDLN were a population of CD11c
hi
 CD11b
hi
 
myeloid DCs, which were also present in the lungs (Wolf et al, 2007). This evidence 
strongly suggests that the T cell response is activated by a population of DCs that 
migrate from the lung to the LDLN, carrying Mtb antigens. Activated T cells then 
traffic to the infected lung and mediate control of the infection (Cooper, 2009; shown 
in Figure 1.2).  
CD8
+
 T cells specific to Mtb antigens are also activated following infection, 
and although not as critical for protection as CD4
+
 T cells, still play a role in limiting 
bacterial replication (North and Jung, 2004). Activation of CD8
+
 T cells during Mtb 
infection requires cross-presentation of phagosomal Mtb antigens on MHC class I 
molecules. Two pathways have been proposed for this process (Vyas et al, 2008). 
First, antigens may exit from the phagosome into the cytosol, and subsequently be 
processed by the proteasome and enter the endoplasmic reticulum (ER) via the TAP 
transporter, as in classical MHC class I antigen processing (the cytosolic pathway) 
(Vyas et al, 2008). Second, antigens in the phagosome may traffic to a vesicle 
containing recycled MHC class I molecules, and thus bypass the proteasome and ER 
(the vesicular pathway) (Vyas et al, 2008). Several studies have shown that cross-
presentation of a variety of Mtb antigens by human DCs requires the proteasome and 
the TAP transporter, although exactly how Mtb antigens exit from the phagosome 
Chapter 1: Introduction 
 
33 
 
remains unclear (Lewinsohn et al, 2006; Grotzke et al, 2009; Grotzke et al, 2010). 
However, in contrast to these studies, cross-presentation of the 19kDa antigen of Mtb 
was shown to be TAP-independent (Neyrolles et al, 2001) and cross-priming of 
apoptotic vesicles by bystander-DCs was also shown to be proteasome-independent 
(Schaible et al, 2003), supporting a role for the vesicular pathway. 
1.2.5. Apoptosis of innate immune cells promotes immunity to Mtb 
An important response of macrophages and other cells infected with Mtb is 
the induction of cell death via apoptosis (Behar et al, 2011). Cell death through 
apoptosis results in the cell breaking up into small membrane-bound vesicles, and is 
distinct from necrotic cell death which is characterised by disruption of the plasma 
membrane (Behar et al, 2011). Macrophage death by apoptosis promotes the host 
response to Mtb, first because it reduces the viability of Mtb (Oddo et al, 1998; 
Divangahi et al, 2009) and second because the apoptotic vesicles contain Mtb 
antigens, which are taken up by DCs and used to cross-prime CD8
+
 T cells, leading 
to an enhanced CD8
+
 T cell response (Schaible et al, 2003; Winau et al, 2006).  
The beneficial effects of apoptosis in the immune response are highlighted by 
the fact that virulent strains of Mtb are able to inhibit apoptosis in macrophages, 
leading instead to necrosis which promotes inflammation and bacterial dissemination 
(Chen et al, 2006; Gan et al, 2008; Divangahi et al, 2010). The virulent strain of 
Mtb, H37Rv, has consistently been shown to induce greater levels of necrosis in 
macrophages compared to the avirulent strain H37Ra, through increased disruption 
of the mitochondrial membrane (Chen et al, 2006) and manipulation of the synthesis 
of eicosanoids (Gan et al, 2008; Divangahi et al, 2010). Compared to H37Ra, 
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H37Rv also stimulates increased production of lipoxin A4 (LXA4), which promotes 
necrosis, but lower amounts of prostaglandin E2 (PGE2) (Chen et al, 2008; Urdahl et 
al, 2011). Recently, Mtb was also shown to prevent apoptosis in neutrophils 
(Blomgran et al, 2012). A pro-apoptotic mutant of Mtb induced more rapid 
activation of CD4
+
 and CD8
+
 T cells, in a neutrophil dependent manner, illustrating 
the importance of apoptosis in promoting the activation of the adaptive immune 
response (Blomgran et al, 2012). 
1.3. Factors involved in protection against Mtb infection 
1.3.1. CD4
+
 T cells 
In mouse models, it has been repeatedly demonstrated that CD4
+ 
T helper 
cells are essential for protection against Mtb (Flynn and Chan, 2001). Mice deficient 
in CD4 or MHC class II (required for the activation of CD4
+
 T cells), and mice 
depleted of CD4
+
 T cells by antibody treatment, could not control infection and had 
greatly reduced survival compared to control mice (Caruso et al, 1999; Scanga et al, 
2000; Mogues et al, 2001). Arrival of CD4
+ 
T cells into the lung, at around day 16-
18 post-infection, correlates with a plateau in bacteria numbers (Chackerian et al, 
2001). CD4
+
 are also critical for protection in humans, as killing of CD4
+
 T cells by 
HIV leads to a massively increased likelihood of developing active TB (Kwan and 
Ernst, 2012).  
1.3.2. The different subsets of effector CD4
+
 T cells 
CD4
+
 T helper (Th) cells can be separated into subsets based on the cytokines 
they secrete, which define their effector functions against different classes of 
pathogen (Mosmann and Coffman, 1989). Effector CD4
+
 T cells were first divided 
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into two subsets, Th1 and Th2 (Mosmann and Coffman, 1989). Th1 cells are 
responsible for the cell-mediated immune response, through the production of IFNγ, 
which activates macrophages in defence against intracellular pathogens (Mosmann 
and Coffman, 1989). Th2 cells, in contrast, produce IL-4, IL-5 and IL-13 and are 
involved in defence against extracellular pathogens such as helminths, through the 
activation of the humoral response, and the activation of mast cells and eosinophils 
(Sher and Coffman, 1992). More recently, a third subset has been described, Th17 
cells, which produce IL-17 and act against extracellular bacteria and fungi, in part 
through the activation of neutrophils (Stockinger and Veldhoen, 2007).  
Which subset of CD4
+
 T cell predominates during an infection is a critical 
decision for the immune system, and can mean the difference between life and death 
for the host. This decision depends on the cytokines produced by cells of the innate 
immune system (O'Garra, 1998). The generation of Th1 cells requires IL-12 (Hsieh 
et al, 1993; Murphy et al, 2000) which triggers Th1 development through STAT4 
and the transcription factor T-bet (Szabo et al, 2000). Th2 cells require IL-4 (Nelms 
et al, 1999) and the activation of the GATA-3 transcription factor (Zheng and 
Flavell, 1997; Ouyang et al, 1998; Ferber et al, 1999). Th17 cells, in contrast, 
require IL-6, TGF-β and IL-1 for development (Stockinger and Veldhoen, 2007; 
Korn et al, 2009), IL-23 for expansion and stabilization (Harrington et al, 2005) and 
activation of the transcription factor RORγt (Ivanov et al, 2006).  
1.3.3. IFNγ and cell-mediated immunity is critical for protection 
against Mtb 
In the case of Mtb infection, substantial evidence from both human and 
mouse studies has shown that the Th1 subset of CD4
+
 T cells is required for 
Chapter 1: Introduction 
 
36 
 
mediating protection against Mtb (Flynn and Chan, 2001). The evidence for this 
conclusion is discussed below. 
1.3.3.1. IL-12 is required for control of Mtb infection in mice 
IL-12 is a heterodimeric molecule consisting of a 35-kDa light chain (p35) 
and a 40-kDa heavy chain (p40), which together forms the cytokine IL-12p70 
(Trinchieri, 2003). As discussed above, IL-12p70 functions to stimulate Th1 
development and IFNγ production from naive CD4+ T cells (Hsieh et al, 1993) 
through activation of the T-bet transcription factor (Szabo et al, 2000). Mice 
deficient in both IL-12p35 and IL-12p40 are incapable of controlling Mtb infection, 
showing that the Th1 response is critical in protection against Mtb (Cooper et al, 
1997; Cooper et al, 2002). In support of the important role for IL-12 in IFNγ 
induction in T cells, mice deficient in T-bet, which is required for IL-12 stimulation 
of IFNγ production (Szabo et al, 2000), are also highly susceptible to Mtb infection 
(Sullivan et al, 2005).  
Cooper et al (2002) found that IL-12p40
-/-
 mice were more susceptible to Mtb 
than IL-12p35
-/- 
mice, suggesting IL-12p40 itself had activities that were 
independent of IL-12p70. This is partially due to the fact that IL-12p40 can associate 
with IL-23p19 to form the cytokine IL-23 (Oppmann et al, 2000), as IL-23 can 
partially compensate for loss of IL-12p70 in stimulating naive T cells (Khader et al, 
2005). However, IL-12p40 can also be secreted as homodimers (Trinchieri, 2003), 
and these have been shown to stimulate the migration of DCs from the lungs to the 
draining lymph nodes during Mtb infection, leading to the activation of the T cell 
response (Khader et al, 2006).  
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1.3.3.2. IFNγ activates macrophages to kill intracellular Mtb 
Further evidence for the requirement of the Th1 response comes from 
studying the role of IFNγ, the hallmark cytokine produced by Th1 cells (Mosmann 
and Coffman, 1989). Mice deficient in IFNγ die rapidly following aerosol infection 
(Cooper et al, 1993) or intravenous infection (Flynn et al, 1993) with Mtb. The key 
function of IFNγ in the immune response against Mtb is to activate macrophages, 
stimulating them to kill intracellular Mtb (Flynn and Chan, 2001a). As discussed 
above, Mtb is able to prevent phagosome-lysosome fusion in macrophages (Vergne 
et al, 2004). However, IFNγ activates additional killing mechanisms in macrophages, 
and this allows the immune system to control infection (Pieters, 2008). 
An important killing mechanism induced by IFNγ is the induction of the 
enzyme inducible nitric oxide synthase (iNOS) (Cooper, 2009). iNOS converts L-
arginine into reactive nitrogen intermediates (RNIs), such as nitric oxide (NO), 
which have strong anti-microbial activity (MacMicking et al, 1997a). IFNγ can 
stimulate Mtb killing in macrophages in vitro through iNOS induction and RNIs 
(Chan et al, 1992), and iNOS expression in vivo has been shown to depend on IFNγ 
signalling (Flynn et al, 1993; Skold and Behar, 2008). Mice deficient in iNOS, either 
through gene knockout or treatment with iNOS inhibitors, are highly susceptible to 
Mtb infection (Chan et al, 1995; MacMicking et al, 1997b; Scanga et al, 2001). 
However, as yet no evidence for a requirement for iNOS and RNIs has been found 
for Mtb killing in human macrophages (Flynn and Chan, 2001a), although increased 
iNOS has been detected in alveolar macrophages taken from TB patients (Nicholson 
et al, 1996).  
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Other mechanisms are also activated by IFNγ that lead to Mtb killing in 
macrophages. IFNγ stimulation has been shown to overcome the block in phagosome 
maturation leading to lysosome-mediated Mtb killing (Via et al, 1997), which is in 
part dependent on the p47 GTPase family member LRG-47 (although this protein is 
not present in humans) (MacMicking et al, 2003). Mice deficient in LRG-47 were 
highly susceptible to Mtb infection, illustrating the importance of this pathway 
(MacMicking et al, 2003). More recently, induction of autophagy has been shown to 
mediate killing of Mtb in macrophages, in response to IFNγ (Gutierrez et al, 2004). 
Autophagy leads to the delivery of antimicrobial ubiquitin peptides to the lysosome, 
resulting in Mtb killing (Alonso et al, 2007). Finally, members of the guanylate 
binding protein (GBP) family of GTPases may be involved in IFNγ mediated killing. 
Kim et al (2011) found that several members of this family, including GBP1, GBP6, 
GBP7 and GBP10 were required for optimum IFNγ-induced killing of BCG in 
murine macrophages. 
It has long been assumed that the major source of IFNγ during Mtb infection 
is CD4
+
 T cells (Flynn and Chan, 2001a). However, other immune cells such as 
CD8
+
 T cells, γδ T cells, NK cells and NK T cells are also capable of producing 
IFNγ. Recently, Gallegos et al (2011) showed that transfer of both WT and IFNγ-/- 
Mtb-specific CD4
+
 T cells into WT mice led to protection against Mtb, suggesting 
that CD4
+
 T cells may not be the major source of IFNγ. However, a recent study 
showed that around 70% of IFNγ+ cells in the lung of Mtb infected mice were CD4+ 
T cells, with CD8
+
 T cells making up the remaining populations (Bold and Ernst, 
2012). In addition, IFNγ production by CD8+ T cells was dependent on the presence 
of CD4
+
 T cells (Bold and Ernst, 2012). An alternative explanation for the results 
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observed by Gallegos et al (2011) may therefore be that CD4
+
 T cells have 
additional, IFNγ-independent mechanisms for controlling Mtb.  
1.3.3.3. Requirement for the Th1 response in human disease 
Data from patients with specific genetic defects in Th1-mediated immunity 
has also provided strong evidence for the role of the Th1 arm in protection from 
mycobacterial infection. Patients with genetic defects in this arm of the immune 
response develop a syndrome known as Mendelian susceptibility to mycobacterial 
disease (MSMD) which is characterised by life-threatening infections from normally 
non-pathogenic mycobacteria (Casanova et al, 2012). Examples include 
disseminated BCG infection following vaccination, and infection with environmental 
mycobacteria such as Mycobacterium avium and Mycobacterium kansasii (Casanova 
et al, 2012). 
Mutations in several genes are known to cause MSMD. These are IFNGR1 
and IFNGR1, the two components of the receptor for IFNγ; STAT1, the main 
transcription factor that activated by IFNγ; IL12B, encoding IL-12p40; IL12RB1, a 
component of the IL-12 receptor; TYK2, a kinase required for several signalling 
pathways including IL-12; and NEMO, required for the upregulation of IL-12 via 
CD40 signalling (Casanova and Abel, 2002; Casanova et al, 2012). More recently, 
primary deficiency in IRF8 was found to lead to selective loss of monocytes and 
dendritic cells, leading to MSMD (Hambleton et al, 2011). Similar results have been 
observed in mice deficient in IRF8 (Marquis et al, 2011). The loss of function of all 
these genes leads to impaired development of, or responsiveness to, IFNγ mediated 
immunity, illustrating the importance of the IFNγ response in defence against 
mycobacteria (Casanova and Abel, 2002; Casanova et al, 2012).  
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In addition to increased susceptibility to non-pathogenic mycobacteria, 
deficiencies in components of Th1 immunity have, in rare cases, been linked to 
susceptibility to Mtb (Casanova and Abel, 2002). One individual with partial 
IFNGR1 deficiency was found to have clinical TB (Jouanguy et al, 1997) and severe 
TB has been found in several children with IL12RB1 deficiency (Altare et al, 2001; 
Caragol et al, 2003; Ozbek et al, 2005). This condition, known as Mendelian 
susceptibility to TB (MST), further underlines the importance of Th1 immunity in 
resistance against Mtb (Alcais et al, 2009). 
1.3.4. The Th17 response in infection and vaccination 
The cytokine IL-17 is produced by several cell types including CD4
+
 Th17 
cells, although in Mtb infected mice γδ T cells have been shown to be a major source 
(Locksley et al, 2001). Mice deficient in the IL-17 receptor, IL-23p19 (required for 
Th17 development) or treated with neutralising antibody against IL-17 had similar 
levels of Mtb in the lungs compared to control mice (Khader et al, 2005; Aujla et al, 
2007; Redford et al, 2010). However, Redford et al (2010) found that anti-IL-17 
treated mice had dramatically lower Mtb in the spleen, suggesting that IL-17 may 
enhance the dissemination of Mtb from the lung to other organs. IL-17 has also been 
shown to mediate pathology in Mtb infected mice repeatedly vaccinated with BCG 
(Cruz et al, 2010).  
However, IL-17 may play a positive role in the recall response to Mtb 
following vaccination (Khader et al, 2007). Th17 cells appeared early in the lungs of 
mice vaccinated with an Mtb peptide, following challenge with Mtb, and were 
responsible for the subsequent recruitment of protective IFNγ+ Th1 cells into the 
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lung (Khader et al, 2007). Th17 cells were shown to trigger the production of 
chemokines such as Cxcl9, Cxcl10 and Cxcl11, which stimulated the influx of IFNγ 
producing T cell into the lung (Khader et al, 2007).  
1.3.5. CD8
+
 T cells 
The role of CD8
+
 T cells in Mtb infection is a matter of some controversy, 
but it is generally accepted that they are less critical than CD4
+
 T cell for protection 
(Cooper, 2009). The contribution of CD8
+
 T cells has been addressed by infecting 
mice genetically deficient in several components of MHC class I pathway, which is 
required for the activation of CD8
+
 T cells. The first study to address the role of 
CD8
+
 T cells in Mtb infection used mice deficient in beta-2-microglobulin, which 
binds to and stabilises MHC class I molecules on the cell surface. These mice were 
highly susceptible to Mtb infection, suggesting a vital role for CD8
+
 T cells (Flynn et 
al, 1992). However, beta-2-microglobulin also associates with the MHC class I 
homolog HFE, which regulates iron production, and this was shown to account for a 
large part of the increased susceptibility to Mtb (Schaible et al, 2002). Subsequent 
studies have shown, using mice specifically deficient in MHC class I (Rolph et al, 
2001) or mice depleted of CD8
+
 T cells by antibody treatment (Mogues et al, 2001), 
that loss of CD8
+
 T cells leads to a relatively mild phenotype, with around a 1-log 
increase in Mtb in the lung. However, CD8
+
 T cells may play an important role in 
maintaining control at later stages of infection, as depletion of CD8
+
 T cells from 
mice at later timepoints led to a massive increase in Mtb in the lung (van Pinxteren et 
al, 2000). CD8
+
 T cells can produce IFNγ, and can directly kill Mtb-infected cells, 
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which may explain the increased levels of bacteria observed in their absence 
(Serbina and Flynn, 1999; Serbina et al, 2000; Woodworth et al, 2008).  
1.3.6. IL-1α and IL-1β 
The IL-1 family of cytokines consists of 11 members that carry out diverse 
immunological functions (Sims and Smith, 2010). The best studied of these are IL-
1α, IL-1β and IL-18. IL-1β is secreted primarily by monocytes, macrophages and 
dendritic cells, and functions to induce the production of chemokines and adhesion 
molecules, leading to the influx of immune cells, especially neutrophils, to the site of 
infection (Dinarello, 2009). IL-1β also induces cytokines, such as IL-6, acute phase 
proteins and vasodilation, and is important for the development of the Th17 response 
(Dinarello, 2009). IL-1α also possesses potent pro-inflammatory activity, however it 
is expressed more widely than IL-1β and is not secreted, but retained on the cell 
membrane (Dinarello, 2009). IL-18 is an activator of the Th1 response, synergising 
with IL-12 to stimulate IFNγ production from T cells and NK cells (Okamura et al, 
1995; Ushio et al, 1996; Robinson et al, 1997). IL-1α and IL-1β both signal through 
the IL-1 receptor (IL-1R), and require MyD88 for their activities (Dinarello, 2009). 
Given the potent pro-inflammatory effects of IL-1 family members, their 
production is tightly regulated, and disregulation of IL-1 production in humans can 
result in severe autoinflammatory disorders (Dinarello, 2009). IL-1β is regulated at 
two stages. First, signals through TLRs or other PRRs leads to the transcription and 
translation of pro-IL-1β, which is inactive and retained with the cytoplasm. The 
second step requires assembly of a multi-protein complex called the inflammasome 
which activates the enzyme caspase-1. Caspase-1 cleaves pro-IL-1β to produce 
Chapter 1: Introduction 
 
43 
 
mature IL-1β, which is secreted from the cell (Schroder and Tschopp, 2010). Several 
proteins in the NLR family have been described to exhibit inflammasome activity, 
including NLRP1, NLRP3, IPAF and AIM2 (Schroder and Tschopp, 2010). 
Mice deficient in the IL-1 receptor show severely increased susceptibility to 
Mtb (Juffermans et al, 2000; Fremond et al, 2007; Mayer-Barber et al, 2010; Mayer-
Barber et al, 2011). IL-1α and IL-1β, despite signalling through the same receptor, 
play non-redundant roles in protecting against Mtb, as mice deficient in either 
cytokine show equivalent susceptibility to IL-1 receptor deficient mice (Mayer-
Barber et al, 2011). At present, the role of IL-1 in the immune response to Mtb is 
unclear. However, mice lacking IL-1 appear to have normal levels of TNFα, IL-12 
and IFNγ, suggesting a mechanism separate from effects on the cell mediated 
response (Cooper, 2009). 
1.3.7. TNFα in mouse and man 
TNFα is a cytokine produced by many cells, including macrophages and T 
cells, and has pleiotropic effects on the immune response, including cellular 
activation, cellular migration and apoptosis (Locksley et al, 2001). TNFα is crucial 
for the control of Mtb infection in mice; mice treated with TNFα neutralising 
antibodies, or mice genetically deficient in TNFα or its receptor, fail to control 
bacterial replication and die rapidly following infection (Flynn et al, 1995; Roach et 
al, 2002). TNFα is also required for the maintenance of latency, as treatment of mice 
with anti-TNFα antibody led to reactivation of active disease in mice (Scanga et al, 
1999). TNFα also maintains latency in humans, as treatment of rheumatoid arthritis 
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and Crohn’s disease patients with neutralising antibody against TNFα (Infliximab) is 
associated with an increased risk of TB reactivation (Keane et al, 2001). 
However, the critical function of TNFα in the immune response to Mtb is 
unclear. In vitro, TNFα synergises with IFNγ to activate macrophages to kill Mtb 
(Flesch et al, 1994) and mice deficient in the TNFα receptor or treated with TNFα 
neutralising antibodies had reduced iNOS and RNI expression (Flynn et al, 1995). 
TNFα also promotes apoptosis of Mtb infected macrophages which, as discussed 
above, can limit Mtb spread and lead to increased T cell priming (Behar et al, 2011). 
In a zebrafish larvae model of M. marinum infection, TNFα was shown to restrict 
mycobacterial growth, in part by preventing the necrosis of Mtb infected 
macrophages (Clay et al, 2008). However, it has long been considered that the most 
important function of TNFα in the immune response to Mtb is to promote the 
formation of the granuloma (Flynn et al, 2011; Ramakrishnan, 2012). However, as 
discussed below, recent evidence has challenged this hypothesis. 
1.3.8. The granuloma in Mtb infection 
The granuloma, a compact aggregate of immune cells, is the hallmark of Mtb 
infection (Flynn et al, 2011). Macrophages are the major constituents of the 
granuloma, many of which are infected with Mtb (Flynn et al, 2011). Other immune 
cells such as DCs, neutrophils, T cells, B cells, NK cells and fibroblasts are also 
associated with granulomas (Saunders and Britton, 2007). It has long been 
considered that the granuloma functions to sequester Mtb in a compact area, in order 
to prevent it spreading further within the infected lung, and to other organs (Saunders 
and Britton, 2007). However, recent evidence, particularly from the zebrafish larvae 
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model of M. marinum infection, has suggested that the granuloma and its associated 
macrophages may actually promote the dissemination of Mtb (Ramakrishnan, 2012).   
The formation of granulomas requires two key components (Saunders and 
Britton, 2007). First, an adaptive Th1 response is required, as shown by the fact that 
mice deficient in IFNγ do not generate granulomas following Mtb infection (Cooper 
et al, 1993). In addition, MSMD patients deficient in IFNγ or the IFNγ receptor fail 
to generate granulomas in infected tissues following infection with non-pathogenic 
mycobacteria (Casanova and Abel, 2002). Production of IFNγ by T cells is thought 
to mediate killing of Mtb within the granuloma, and thus control the infection 
(Saunders and Britton, 2007). The second key component in granuloma formation is 
the production of cytokines by cells of the innate immune system, and TNFα is 
thought to be the most critical. TNFα deficient mice generated poorly formed 
granulomas following Mtb infection, with high levels of necrosis and neutrophil 
infiltration (Bean et al, 1999). In addition, production of chemokines by innate 
immune cells is thought to lead to granuloma formation, through stimulating the 
recruitment of further immune cells, and TNFα has been shown to promote 
chemokine production (Roach et al, 2002). TNFα is also thought to orchestrate 
granuloma formation in human TB patients, and granuloma breakdown is thought to 
explain why patients receiving neutralising antibodies against TNFα (Infliximab) are 
at increased risk of reactivating latent TB (Keane et al, 2001).  
However, the role of TNFα in granuloma formation has been challenged in 
recent years. Treatment of cynomolgus macaques with TNFα neutralising antibodies 
prior to Mtb infection resulted in disseminated disease, but granulomas in the lung 
remained intact (Lin et al, 2011a). In addition, zebrafish larvae deficient in TNFα 
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formed granulomas faster than WT controls following M. marinum infection, 
although these granulomas eventually broke down due to excessive necrosis (Clay et 
al, 2008). Thus, TNFα may be involved in maintenance, rather than formation, of 
granulomas.  
Recent work, also using the zebrafish larvae model of M. marinum infection, 
has questioned whether the granuloma functions to prevent Mtb dissemination 
(Ramakrishnan, 2012). This was suggested by the fact that granuloma formation in 
this model dependent on the key mycobacterial virulence factor ESX-1 (Volkman et 
al, 2004). Subsequently, live imaging of granuloma formation in zebravish larvae 
has suggested that M. marinum induces the recruitment of macrophages to the 
granuloma in order to generate a fresh source of cells to infect (Davis and 
Ramakrishnan, 2009). These infected macrophages can then disseminate to other 
sites, leading to the spread of the infection (Davis and Ramakrishnan, 2009). Thus, 
Mtb and other mycobacteria may exploit the recruitment of cells to the granuloma in 
order to promote bacterial dissemination. However, as the zebrafish larvae model 
does not have an adaptive immune system, it will be important to confirm these 
results in models with an adaptive immune response.  
1.4. Factors that regulate the immune response to Mtb 
A potent immune response is required to efficiently clear or control an 
infection; however, this response must be tightly regulated to prevent an over 
exuberant immune response leading to immune-mediated pathology. This regulation 
is achieved through several specialised cells and soluble factors.  
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1.4.1. IL-10 and the suppression of the immune response to Mtb 
1.4.1.1. IL-10 background 
The cytokine IL-10 is an important regulator of the immune response (Moore 
et al, 2001). IL-10 signals through the IL-10 receptor (IL-10R) on target cells and 
mediates its activity primarily through the transcription factor STAT3 (Moore et al, 
2001). IL-10 is produced by a wide variety of immune cells including Th1 and Th17 
CD4
+
 T cells, regulatory T cells, CD8
+
 T cells, B cells, DCs, macrophages and 
neutrophils (Saraiva and O’Garra, 2010). 
IL-10 was first described as a product of Th2 cells that could inhibit the 
production of cytokines such as IFNγ from Th1 cells (Fiorentino et al, 1989; 
Fiorentino et al, 1991b). This effect was subsequently shown to be indirect, via the 
ability of IL-10 to suppress the production of IL-12 from APCs (D'Andrea et al, 
1993; Murphy et al, 1994). IL-10 can also inhibit numerous other pro-inflammatory 
cytokines and chemokines from macrophages and DCs, including IL-1, IL-6 and 
TNFα (Fiorentino et al, 1991a; Moore et al, 2001). In addition, IL-10 can inhibit 
antigen presentation by macrophages and DCs, through the downregulation of MHC 
class II and co-stimulatory molecules (de Waal Malefyt et al, 1991; Ding et al, 1993) 
and can inhibit macrophage killing of intracellular pathogens such as Mtb (Gazzinelli 
et al, 1992; O'Leary et al, 2011; Redford et al, 2011).  
Although cells of the innate immune system appear to be the major targets of 
IL-10, recent studies have shown that IL-10 may mediate some of its suppressive 
activities by acting on T cells. IL-10 signalling in T regulatory cells (Tregs) was 
found to maintain FoxP3 expression in a mouse model of colitis (Murai et al, 2009). 
More recently, IL-10 signalling in Tregs was shown to be required for the 
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suppression of the Th17 response (Chaudhry et al, 2011). However, further work is 
required to determine the significance of these pathways in the immune response.  
1.4.1.2. The regulation of IL-10 production in innate immune cells 
IL-10 production from immune cells is regulated at multiple levels; by 
chromatin modifications, at the transcriptional level by a wide range of transcription 
factors, and post-transcriptionally through the regulation of mRNA stability (Saraiva 
and O'Garra, 2010). Many mechanisms of IL-10 regulation are common to several 
immune cells, although cell-specific mechanisms are also in place (Saraiva and 
O'Garra, 2010). 
Many cells of the innate immune system, including macrophages, DCs and 
neutrophils, produce IL-10 in response to pathogens or pathogen derived products, 
through triggering of PRRs (Boonstra et al, 2006; Zhang et al, 2009). Stimulation of 
macrophages and DCs with TLR3, TLR4 and TLR9 agonists leads to IL-10 
production from macrophages and myeloid DCs, and involved both the MyD88 and 
TRIF dependent pathways (Boonstra et al, 2006). In addition to TLRs, the C-type 
lectins dectin-1 (LeibundGut-Landmann et al, 2007) and DC-SIGN (Geijtenbeek and 
van Kooyk, 2003; Gringhuis et al, 2007) can stimulate IL-10 production in innate 
immune cells. 
A key pathway for IL-10 downstream of PRR signalling is the extracellular 
signal-related kinase (ERK) MAP kinase pathway (Saraiva and O'Garra, 2010). 
Activation of ERK in response to TLR signalling requires the upstream MAP kinase 
family members tumour progression locus 2 (TPL2) and MEK1/2 (Symons et al, 
2006) and macrophages deficient in Tpl2, or treated with MEK1/2 inhibitors, 
produce markedly less IL-10 compared to controls in response to TLR ligands (Yi et 
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al, 2002; Agrawal et al, 2003; Dillon et al, 2004; Kaiser et al, 2009). The strength of 
ERK activation appears to correlate with IL-10 production in macrophages, myeloid 
DCs and pDCs (Kaiser et al, 2009). Activation of ERK is highest in macrophages 
following TLR stimulation, with moderate levels in myeloid DCs and undetectable 
amounts in pDCs (Kaiser et al, 2009). Downstream of ERK signalling, the 
transcription factor c-Fos can mediate IL-10 induction (Agrawal et al, 2003; Dillon 
et al, 2004; Kaiser et al, 2009). ERK is also required for induction of IL-10 
downstream of dectin-1 in DCs and neutrophils, through a pathway involving Syk 
and Card9 (Slack et al, 2007; Zhang et al, 2009; Dorhoi et al, 2010). ERK signalling 
has also been shown to promote IL-10 production from several CD4
+
 T cell subsets 
(Saraiva et al, 2009). 
Many other pathways have also been implicated in IL-10 production in innate 
immune cells (Saraiva and O'Garra, 2010). Downstream of LPS stimulation in 
macrophages, NF-κB p65 was recruited to a DNase1 hypersensitivity site in the IL-
10 promoter, and this was required for optimal IL-10 production (Saraiva et al, 
2005). NF-κB p50 homodimers are also recruited to the proximal IL-10 promoter, 
and macrophages from p50 deficient mice show impaired IL-10 production in 
response to LPS (Cao et al, 2006). In addition, and in keeping with a requirement for 
the TRIF-dependent pathway (Boonstra et al, 2006), type I IFN has been shown to 
promote IL-10 production in macrophages, in response to LPS (Chang et al, 2007; 
Iyer et al, 2010).  
1.4.1.3. The role of IL-10 in infectious disease 
Given the potent anti-inflammatory properties of IL-10, the impact of IL-10 
in the immune response to pathogens has been the focus of much study, primarily 
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using mice genetically deficient in IL-10 (Il10
-/-
 mice). Several studies have shown 
that IL-10 can play a detrimental role in the immune response to infection. Dai et al 
(1997) found that Il10
-/-
 mice had greatly reduced bacterial loads following infection 
with Listeria monocytogenes, and this was associated with a greatly increased Th1 
response and higher levels of IL-1, TNFα and IL-12. Similar results have been 
reported in mice infected with Leishmania major (Belkaid et al, 2001). Whereas WT 
mice failed to clear the parasites, leading to a chronic infection, Il10
-/-
 mice, and 
mice treated with IL-10R blocking antibodies, were able to clear the parasites, 
showing that the activities of IL-10 can result in pathogen persistence (Belkaid et al, 
2001).  
However, in other situations IL-10 is vital in protecting the host from 
immune-mediated pathology. Although Il10
-/-
 mice infected with Plasmodium 
chabaudi produced increased levels of IFNγ, TNFα and IL-12, this did not lead to 
improved pathogen clearance (Li et al, 1999). Instead, Il10
-/-
 mice developed a much 
more severe infection compared to WT controls, with increased fever and weight-
loss, and significant mortality (Li et al, 1999). Similar results were reported in the 
context of Toxoplasma gondii infection, with Il10
-/-
 mice developing severe immune-
mediated pathology and suffering severe mortality compared to WT controls, despite 
a greatly enhanced Th1 response (Gazzinelli et al, 1996).  
1.4.1.4. The role of IL-10 in Mtb infection 
IL-10 can inhibit several aspects of the immune response which are critical 
for protection against Mtb infection (Moore et al, 2001; Redford et al, 2010). IL-10 
can suppress the production of IL-12 from macrophages and DCs, leading to 
suppression of IFNγ production from T cells (Fiorentino et al, 1991b; D'Andrea et 
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al, 1993; Moore et al, 2001), a process which is crucial in protection against Mtb 
(Flynn and Chan, 2001a). In addition, IL-10 suppresses IL-1 and TNFα production 
from innate immune cells (Fiorentino et al, 1991a), and both these cytokines are 
needed to control Mtb infection (Flynn et al, 1995; Mayer-Barber et al, 2011). A 
large number of studies have addressed the effect of IL-10 on the response to Mtb, in 
both mice and human infection, but the results have often been contradictory 
(Redford et al, 2011). A summary of the effects of IL-10 on the immune response to 
Mtb is shown in Figure 1.4.  
1.4.1.4.1. Results from the mouse model 
A number of studies have addressed the role of IL-10 in Mtb infection by 
infecting Il10
-/-
 mice with Mtb, and comparing the subsequent immune response and 
bacterial loads to WT mice. Some studies have reported no difference in bacterial 
burden in the lungs between WT and Il10
-/-
 mice following Mtb infection (North, 
1998; Jung et al, 2003) suggesting that IL-10 may not play an important role in 
infection. A subsequent study found that although IL-10 did not affect Mtb-bacterial 
load, it protected mice against fatal immune-pathology, although this only occurred 
at late stages of infection (Higgins et al, 2009).  
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Figure 1.4. The effects of IL-10 on the immune response to Mtb 
However, other studies have found decreased burdens of Mtb in Il10
-/- 
mice 
(Roach et al, 2001; Beamer et al, 2008; Redford et al, 2010). In these studies, the 
increased resistance to Mtb in Il10
-/- 
mice correlated with an enhanced Th1 response, 
including increased production of IFNγ (Roach et al, 2001; Beamer et al, 2008; 
Redford et al, 2010). Levels of TNFα, IL-17, GM-CSF and IP-10 were also 
increased in the serum of Il10
-/- 
mice infected with Mtb (Redford et al, 2010). A 
further study used transgenic mice which over-produced IL-10 under the control of 
the IL-2 promoter, and found that this increased IL-10 production led to failure to 
control Mtb at later stages of infection (Turner et al, 2002).  
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These differences observed between these studies are likely to be due to 
variation in the strain of mouse used, strain of Mtb used and route of infection 
(Redford et al, 2011). In addition, the majority of these studies were carried out 
using C57Bl/6 and BALB/c mice, which are relatively resistant to Mtb infection, and 
may therefore not provide the best model for human TB (Redford et al, 2011). The 
CBA/J mouse is dramatically more susceptible to Mtb, and produce increased levels 
of IL-10 following infection (Turner et al, 2002). Importantly, Redford et al (2010) 
showed that blockade of IL-10 signalling during Mtb infection in CBA/J mice can 
reduce Mtb levels in the lungs, and enhance the Th1 response. IL-10 may therefore 
play an important role in more susceptible mouse models of Mtb.  
1.4.1.4.2. IL-10 in human TB 
Several studies have found that IL-10 mRNA and protein are detectable in 
the lungs of patients with active TB (Barnes et al, 1993; Bonecini-Almeida et al, 
2004; Almeida et al, 2009). In addition, neutralisation of IL-10 during stimulation of 
PBMCs from PPD
+
 positive donors led to enhanced T cell proliferation and IFNγ 
production, suggesting that IL-10 can suppress Mtb specific T cell responses during 
human TB (Gong et al, 1996; Rojas et al, 1999). However, although a large number 
of studies have been carried out addressing whether IL-10 polymorphisms are 
associated with reduced or increased protection against Mtb, results have generally 
been inconclusive (Redford et al, 2011).  
1.4.2. Suppression of the immune response to Mtb by Tregs 
Regulatory T cells (Tregs) are another important mechanism for the 
regulation of the immune response. These cells are important for the prevention of 
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autoimmunity, and can also regulate the immune response to infection, in order to 
prevent immunopathology (Fehervari and Sakaguchi, 2004; Belkaid and Tarbell, 
2009). Tregs are induced during the immune response to Mtb in both mice and 
humans, and can regulate the induction of the protective immune response (Urdahl et 
al, 2011). The transfer of Mtb-specific Tregs into Mtb infected mice at day 11 post-
infection resulted in increased bacterial growth at later timepoints, and delayed the 
expansion of effector T cells (Shafiani et al, 2010). In addition, co-transfer of Tregs 
with CD4
+
 T cells into RAG
-/-
 infected with Mtb blocked the protective effects of 
CD4
+
 T cells (Kursar et al, 2007). Furthermore, depletion of Tregs from mice 
infected with Mtb results in lower bacterial loads in the lung and spleen, and was 
accompanied by increased IFNγ production by CD4+ T cells (Scott-Browne et al, 
2007). Thus, Tregs appear to play an important regulatory role during Mtb infection 
by specifically targeting the T cell response (Urdahl et al, 2011).  
1.5. Tuberculosis and type I IFN 
1.5.1. Background 
There are three families of IFN, known as type I, II and III. IFNγ is the only 
member of the type II IFN family, and is known to be a crucial component in the 
immune response to Mtb due to its stimulatory effects on macrophages (Flynn and 
Chan, 2001a). The type I IFNs consist of more than 20 IFNα genes and a single 
IFNβ gene. There are several further subtypes of type I IFNs, such as IFNκ, IFNδ, 
IFNε and IFNτ, but these are only expressed in specific tissues and are not found in 
all species (Theofilopoulos et al, 2005). The more recently discovered type III IFNs, 
also known as IFNλ, consist of IFNλ1, IFNλ2 and IFNλ3 (also known as IL-29, IL-
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28A and IL-28B) in humans, and IFNλ2 and IFNλ3 in mice (Donnelly and Kotenko, 
2010). 
The type I IFNs were discovered in 1957 as soluble factors capable of 
inhibiting viral replication (Isaacs and Lindenmann, 1957). Almost all cells of the 
body are capable of producing and responding to type I IFN, although some, such as 
pDCs, are specialised to secrete large amounts (Asselin-Paturel et al, 2001; Colonna 
et al, 2004). Although long regarded as purely antiviral effectors, the type I IFN are 
now known to regulate a wide range of immune functions, and play a role in a 
number of bacterial infections, including Mtb (Trinchieri, 2010).  
1.5.2. The Regulation of type I IFN production 
The master regulators of type I IFN production are the transcription factors 
IRF3 and IRF7 (Decker et al, 2005). IRF3 is expressed constitutively, and serine 
phosphorylation of IRF3, either by TBK-1 or IKKε, causes it to dimerise and 
migrate to the nucleus where, along with other transcription factors, it activates 
transcription of the IFNβ gene (Decker et al, 2005). Signalling by low levels of IFNβ 
leads to activation of IRF7, which then stimulates the expression of IFNα and the 
further expression of IFNβ (Marie et al, 1998; Sato et al, 1998). 
Various bacterial and viral components trigger type I IFN production in 
immune cells. TLR3 and TLR4, in response to double-stranded viral RNA and 
bacterial LPS respectively, activate IRF3 via the TRIF dependent pathway (Kawai 
and Akira, 2010). Double-stranded viral RNA also activates the cytoplasmic 
receptors RIG-I and MDA-5, leading to IRF3 activation through MAVS and TBK1 
(Kawai and Akira, 2010). Finally the NLRs, NOD1 and NOD2, trigger type I IFN in 
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response to components of peptidoglycan (Trinchieri, 2010) and it is this NLR-
dependent pathway which is thought to mediate type I IFN induction in response to 
Mtb, through Rip2 and IRF5 (Pandey et al, 2009). 
However, type I IFN induction in pDCs appears independent of the 
amplification loop that operates in other cells. Instead, single-stranded RNA and 
CpG stimulate the rapid activation of IRF7 through TLR7 and TLR9, and induce 
high levels of IFNα and IFNβ through a MyD88-dependent pathway (Colonna et al, 
2004; Guiducci et al, 2006). This difference is due to the trafficking of CpG to 
different endosomes in pDCs compared to conventional DCs (Honda et al, 2005). 
However, the type of CpG used to stimulate pDCs affects whether high levels of 
IFNα are induced; CpG-A localises to early endosomes and induces high levels of 
IFNα, whereas CpG-B localises to late endosomes and does not induce IFNα 
(Guiducci et al, 2006). 
1.5.3. IFN signalling 
The three families of IFNs signal through distinct receptors, but share many 
downstream signalling molecules and induce overlapping gene expression (Der et al, 
1998; Stark et al, 1998; Donnelly and Kotenko, 2010). Signalling by the IFNs is 
summarised in Figure 1.5. All members of the type I IFN family signal through a 
common receptor, a heterodimeric molecule consisting of IFNAR1 and IFNAR2 
(known as the IFNαβR), and the downstream signalling from this receptor has been 
extensively characterised (Stark et al, 1998) (Figure 1.5). In response to binding, the 
two subunits of the IFNαβR change conformation and dimerise, resulting in the 
phosphorylation and activation of the receptor associated Janus family kinases Tyk2 
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and Jak1, and the phosphorylation of the intracellular domain of the IFNαβR (Stark 
et al, 1998; Decker et al, 2005). This creates a docking site for STAT1 and STAT2 
molecules, which are then phosphorylated by Jak1 and Tyk2, causing them to form 
STAT1:STAT2 heterodimers and migrate to the nucleus, where they associate with 
the transcription factor IRF9 to form the interferon-stimulated gene factor 3 (ISGF3) 
complex (Stark et al, 1998; Decker et al, 2005). The ISGF3 binds to a consensus 
sequence, the interferon stimulated response element (IRSE), in the promoters of 
interferon stimulated genes (ISGs) to activate their transcription (Stark et al, 1998; 
Decker et al, 2005).  
IFNγ signals through a receptor consisting of IFNGR1 and IFNGR1. Ligand 
binding results in activation of Jak1 and Jak2, and the predominant transcriptional 
complex activated by IFNγ are homodimers of STAT1. This complex migrates to the 
nucleus and activates the transcription of genes with an IFNγ-activated site (GAS) in 
their promoter (Stark et al, 1998). Type I IFN can also stimulate the formation of 
STAT1 homodimers, leading to overlap between IFNγ and type I IFN inducible 
genes (Platanias, 2005) (Figure 1.5).  
The three subtypes of IFNλ signal through a separate receptor to type I IFN, 
consisting of a unique IFNλ-R1 receptor subunit coupled to IL-10R2 (Donnelly and 
Kotenko, 2010). However, the IFNλ receptor, like the IFNαβR, is associated with 
Jak1 and Tyk2, and also activates the ISGF3 complex, inducing very similar gene 
expression to type I IFN, and similar antiviral activity (Donnelly and Kotenko, 
2010). 
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Figure 1.5. An overview of signalling pathways activated by IFNs. Adapted from 
Platanias et al, (2005) 
1.5.4. Type I IFN in protection against viral infection 
Type I IFNs were discovered, and named, on the basis of their ability to 
interfere with viral replication (Isaacs and Lindenmann, 1957) and mice deficient in 
type I IFN through the deletion of the IFNAR1 subunit of the IFNαβR (Ifnar1-/- 
mice) are highly susceptible to certain viral infections (van den Broek et al, 1995; 
Theofilopoulos et al, 2005). 
This activity is due to the potent antiviral genes induced by type I IFN. 
Prominent among these are protein kinase R (PKR), 2’5’oligoadenlyate synthetase 
(2’5’OAS), RNAse L and Mx proteins (Sadler and Williams, 2008). These proteins 
inhibit viral replication in a variety of ways, and mice deficient in these genes are 
susceptible to viral infection (Sadler and Williams, 2008). Protein kinase R is a 
serine threonine kinase that phosphorylates the translational initiation factor eiF2, 
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leading to inhibition of translation (Stark et al, 1998; Sadler and Williams, 2008). 
2’5’OAS enzymes produce short 2’5’oligoadenylate molecules which activates the 
RNAse L, which in turn destroys viral dsRNA. Type I IFNs also induce many 
members of the TRIM family of proteins (Rajsbaum et al, 2008), some of which 
have antiviral activity (McNab et al, 2010). However, the understanding of the anti-
viral effects of type I IFNs is still in its infancy, as the functions of the vast majority 
of type I IFN inducible genes are not known (Stetson and Medzhitov, 2006). 
1.5.5. Type I IFN in bacterial infection 
In recent years, the recognition that type I IFN can affect many immune 
processes besides mediating antiviral immunity has led to investigations into the role 
of type I IFN in bacterial infection (Trinchieri, 2010). Broader functions of type I 
IFNs include activating DCs in response to TLR ligands (Asselin-Paturel et al, 
2005), stimulating DCs to cross-present antigen to CD8
+
 T cells (Le Bon et al, 
2003), enhancing the survival of activated T cells (Marrack et al, 1999), inducing 
IFNγ in CD8+ T cells (Cousens et al, 1999) and NK cells (Hunter et al, 1997), and 
regulating the humoral immune response (Le Bon et al, 2001). 
Studies investigating the role of type I IFN in bacterial infection have made 
use of mice lacking the receptor for type I IFN (Ifnar1
-/-
 mice). These mice have 
been challenged with a variety of bacterial pathogens, and it has become clear that 
type I IFN can have both positive and negative effects for the host, depending on the 
infection (Bogdan et al, 2004; Decker et al, 2005; Trinchieri, 2010). Ifnar1
-/-
 mice 
challenged with group B streptococcus (GBS), Streptococcus pneumoniae and 
Escherichia coli all had increased mortality compared to wild-type controls, showing 
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an essential role for type I IFNs in response to these pathogens (Mancuso et al, 
2007). Type I IFN was also found to be essential for defence against Streptococcus 
pyogenes (Gratz et al, 2011).  
However, in some infections type I IFN can play a negative role in host 
resistance to infection. This first became apparent in the context of Listeria 
monocytogenes infection. Three papers published in 2004 showed that Ifnar1
-/-
 mice 
infected with Listeria had reduced bacterial burdens in the spleen and liver compared 
to wild-type mice, showing that in the absence of type I IFN, the immune response is 
more effective (Auerbuch et al, 2004; Carrero et al, 2004; O'Connell et al, 2004). 
The mechanism behind these negative effects of type I IFN is unclear. Two of these 
studies found that apoptosis of splenic lymphocytes was reduced in Ifnar1
-/-
 mice 
(Carrero et al, 2004; O'Connell et al, 2004). In addition, Auerbuch et al (2004) 
showed that the levels of IL-12p70 in the serum of Ifnar1
-/- 
mice are elevated 
compared to wild-type mice, suggesting that type I IFNs negatively regulate IL-12. 
More recently, Rayamajhi et al (2010) showed that type I IFN could downregulate 
the expression of the IFNγ receptor (specifically IFNGR1) on the surface of Listeria 
monocytogenes infected macrophages, leading to a reduced responsiveness to IFNγ 
in these cells.  
Similar results have recently been demonstrated in the context of Francisella 
tularensis infection, with Ifnar1
-/-
 mice showing enhanced bacterial clearance (Henry 
et al, 2010). In this study, type I IFN was suggested to suppress IL-17 production 
from γδ T cells (Henry et al, 2010). In general, type I IFN seems to play a protective 
role against extracellular bacteria, such as Streptococci, but a negative role against 
intracellular bacteria, such as Listeria monocytogenes and Francisella tularensis. 
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1.5.6. Type I IFN in Mtb infection 
The role of type I IFN in Mtb infection has been the subject of much 
investigation, mostly using mouse models of Mtb infection. However, contradictory 
results have been observed, with some studies reporting a beneficial role for type I 
IFN in the immune response, whilst others have found a detrimental role. The results 
of these studies are summarised in Table 1.1 at the end of this section. As shown in 
Table 1.1, the majority of studies suggest that type I IFN hinders the immune 
response to Mtb.  
A study by Manca et al (2001) compared infection of mice with HN878, a 
hypervirulent strain of Mtb, with other less virulent strains. They found that HN878 
induced higher levels of type I IFN from mouse lungs, but a less potent Th1 response 
(Manca et al, 2001). Treatment of mice with recombinant type I IFN led to reduced 
survival times following Mtb infection (Manca et al, 2001). The authors concluded 
that virulent strains of Mtb induce type I IFNs as a pathogenic mechanism, in order 
to blunt the crucial Th1 response (Manca et al, 2001). A further study by the same 
group showed that another hypervirulent strain, W4, also induced more type I IFN in 
the lungs of mice compared to non-hypervirulent strains (Manca et al, 2005). This 
study also found that Ifnar1
-/-
 mice survived longer than wild type mice following 
Mtb infection, showing that mice are better protected against Mtb in the absence of 
type I IFN signalling (Manca et al, 2005). Subsequently, Ordway et al (2007) found 
that Ifnar1
-/-
 mice infected with five different Mtb strains showed decreased bacterial 
counts in the lung at later time-points post-infection. However, there was no 
difference in the survival of these mice (Ordway et al, 2007). Stanley et al (2007) 
also compared resistance of wild-type and Ifnar1
-/-
 mice to Mtb infection and found 
Chapter 1: Introduction 
 
62 
 
that Ifnar1
-/-
 mice had reduced bacterial burdens in the spleen, but the lung was not 
affected. In general, all of these studies reported decreased bacterial burdens in the 
lungs or spleen of Ifnar1
-/- 
mice compared to wild-type, suggesting that type I IFN 
plays a negative role during Mtb infection. In support of this conclusion, mice 
deficient in a prominent ISG, protein kinase R (PKR), were also shown to have 
reduced burdens of Mtb following infection (Wu et al, 2012). PKR was shown to 
promote IL-10 production from macrophages infected with Mtb, and inhibit 
responsiveness to IFNγ (Wu et al, 2012). 
More recently, a novel strategy was used to study the effects of type I IFN in 
Mtb infection. Antonelli et al (2010) treated Mtb-infected mice intranasally with 
poly-IC, an analogue of dsRNA that can induce large amounts of type I IFN from 
immune cells through TLR3. They found that mice treated with Poly-IC had a 
dramatic increase in bacterial load in the lung, accompanied by increased lung 
pathology and decreased survival (Antonelli et al, 2010). Importantly, this effect was 
not seen in Ifnar1
-/-
 mice, demonstrating that the negative effects of Poly-IC were 
type I IFN dependent (Antonelli et al, 2010). Treatment of mice with Poly-IC was 
accompanied by the CCR2-dependent migration of a myeloid population to the lung, 
which seemed to be permissive for Mtb growth (Antonelli et al, 2010).  
Limited evidence correlates type I IFN with beneficial effects in Mtb 
infection (Table 1.1). Some studies with Ifnar1
-/-
 mice have shown reduced 
resistance to infection with mycobacteria, although they conflict with other studies 
described above. Kutchey et al (2006) showed that Ifnar1
-/-
 mice had increased 
growth of BCG early in infection and Cooper et al (2000) found similar results with 
Mtb Erdman, suggesting that type I IFN may be required for an optimum immune 
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response to Mtb. The differences between these and other studies may be a result of 
the use of differing strains of mice, strains of mycobacteria and routes of infection. 
More recently, Desvignes et al (2012) generated mice deficient in both type I IFN 
and IFNγ signalling, and found that these mice showed greater susceptibility to Mtb 
compared to IFNγ single knockout mice. The authors concluded that type I IFN can 
play a protective role in the absence of IFNγ signalling, possibly through partial 
compensation of IFNγ activities (Desvignes et al, 2012). 
Recently, the potential role of type I IFN in human disease was highlighted. 
Berry et al (2010) carried out whole-blood transcriptional profiling of patients with 
active and latent TB, as well as healthy controls, and found a 393 gene signature in 
the blood of active patients, which correlated with disease severity and was 
diminished upon antibiotic treatment. Modular and pathway analysis of this 
signature showed it to contain genes associated with both type I IFN and IFNγ 
signalling. By carrying out analysis of separated cells, this signature was found to be 
specific to neutrophils and macrophages (Berry et al, 2010). A subsequent 
independent study also found an upregulation of IFN inducible genes in the blood of 
active TB patients (Maertzdorf et al, 2011). However, the effects of type I IFN 
signalling in human TB patients are unclear. 
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Reference Experimental  
strategy 
Mouse 
Strain 
Route of Mtb 
infection 
Strain of 
Mtb 
Read-out Concluded role of type I IFN 
Cooper et al 
2000 
WT vs. Ifnar1
-/-
 mice B6/129 Aerosol Erdman Lung CFU Positive – early increase in Mtb 
levels in Ifnar1
-/-
 mice 
Manca et al 
2001 
Intranasal treatment 
with recombinant 
IFNαβ 
B6D2/F1 Aerosol HN878 and 
CDC1551 
Survival and lung 
CFU 
Negative – reduced survival time 
in IFNαβ treated mice, and 
increased lung CFU 
Manca et al 
2005 
WT vs. Ifnar1
-/-
 mice B6D2/F1 Aerosol HN878 Survival and 
Lung CFU 
Negative – longer survival in 
Ifnar1
-/-
 mice 
Kutchey et al 
2006 
WT vs. Ifnar1
-/-
 mice 129S6/SvEv Aerosol BCG Lung CFU Positive – early increase in BCG 
levels in Ifnar1
-/-
 mice 
Ordway et al 
2007 
WT vs. Ifnar1
-/-
 mice C57Bl/6 
controls, 
A129 
Ifnar1
-/- 
Aerosol H37Rv, 
HN878, 
CSU123. 
CSU93 
Erd KO1 
Survival and 
Lung CFU 
Negative – increased lung CFU 
in Ifnar1
-/-
 mice but no change in 
survival 
Stanley et al, 
2007 
WT vs. Ifnar1
-/-
 mice C57Bl/6 Intravenous Erdman Lung/Spleen 
CFU 
Negative – increased CFU in the 
spleen 
Antonelli et 
al, 2010 
Intranasal treatment 
with Poly-ICLC 
C57Bl/6 Aerosol H37Rv Survival and 
Lung CFU 
Negative – reduced survival time 
and increased Mtb in Poly-ICLC 
treated mice 
Desvignes et 
al, 2012 
IFNγR-/- vs. Ifnar1-/-
IFNγR-/- mice  
C57Bl/6 Aerosol H37Rv Survival and 
Lung CFU 
Positive – could play a protective 
role in the absence of IFNγ 
Table 1.1. Summary of previous literature investigating the role of type I IFN in Mtb infection 
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1.6. Microarray as a tool for studying host-pathogen 
interactions 
1.6.1. Background 
A common aim in biological research is to determine which genes change 
expression under different biological conditions. Well-studied examples include 
studying the responses of cells to a given stimulus over time or comparing healthy 
and diseased tissues. Knowledge of the genes that change under these differing 
conditions can give insights into the mechanisms behind these processes. For 
example, if a gene is upregulated in cancerous tissue compared to healthy tissue, this 
may indicate oncogenic properties of this gene. Techniques for studying gene 
expression involve detecting and quantifying the amounts of a given mRNA in a 
sample, using techniques such as PCR. However, these strategies, although 
powerful, are limited by the fact that the expression of only a small number of genes 
could be determined. Furthermore, this results in bias, where experimenters 
determine the expression of genes they already predict may be involved. The advent 
of DNA microarray technology in the mid-1990s revolutionised the study of gene 
expression, as it allowed the simultaneous and rapid quantification of thousands of 
mRNA species from a biological sample, and thus provided a global and unbiased 
picture of gene expression. Although the generation of such large amounts of data 
has its own problems and obstacles, particularly in regard to data analysis and 
statistical methods, the large number of published microarray studies revealing 
insights into various biological processes is testament to the power of this technique 
(Jenner and Young, 2005; Pascual et al, 2010).  
Chapter 1: Introduction 
 
66 
1.6.2. Analysis of gene expression by microarray 
A DNA microarray consists of a solid surface known as a chip, typically 
made of glass or plastic, onto which short single-stranded DNA sequences are added. 
These DNA sequences are known as probes, and each binds to a complementary 
mRNA sequence. Analysis of gene expression by microarray includes several stages. 
First, total mRNA must be extracted and purified from the biological samples in 
question. This mRNA is then amplified, to give a sufficient amount of material for 
analysis, and then labelled with a specific fluorescent marker to allow detection. The 
labelled mRNA is then hybridised with the microarray chip in order to allow binding 
of the DNA probes with complementary mRNA species. Thus, if the complementary 
mRNA of a given DNA probe is present in a sample, it will bind to the 
complementary probe, and binding can be detected by exciting the fluorescent tags 
on the mRNA molecules with light of the appropriate wavelength. The chip is then 
scanned to generate an image showing the points of fluorescence on the chip and the 
image is processed to numerically determine the relative intensity at each of the 
probes on the chip (Heller, 2002).  
There are a number of different microarray platforms available from different 
companies (Heller, 2002). The differences between the platforms involve how the 
DNA probes are attached to the microarray surface. This is achieved either through 
deposition, in which the DNA probes are synthesised separately and then deposited 
onto the surface, or in situ synthesis, where the probes are synthesised directly onto 
the chip surface (Heller, 2002). 
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1.6.3. Illumina BeadArray technology 
A recently developed and widely used technology for depositing DNA 
probes onto a microarray chip is BeadArray technology developed by Illumina 
(Illumina, 2005), unlike previous technologies such as Affymetrix technology, which 
attached the probes directly to the chip by in situ synthesis, BeadArray technology 
attaches multiple copies of each 50 base-pair oligonucleotide probe to silica beads of 
approximately 3μm in diameter (microbeads) (Illumina, 2005). These beads are then 
randomly self-assembled into microwells on the surface of the chip, in a defined grid 
pattern, with each bead located approximately 5.7μm from adjacent beads (Illumina, 
2005). Importantly, each probe contains both a region for mRNA binding and an 
“address” sequence. The address sequence allows the location of each bead, and 
therefore each probe, on the chip to be determined, a process known as decoding 
(Illumina, 2005). This information is then used to determine which probes have 
bound their complementary mRNA, following hybridisation of the chips with biotin-
labelled mRNA. Additionally, approximately 30 identical beads with the same probe 
are present on each chip, meaning that the abundance of each mRNA species is 
measured multiple times, increasing the accuracy of the measurement (Illumina, 
2005).  
1.6.4. The application of microarray in studying the immune 
response 
Since its development, DNA microarray technology has been used to study a 
wide range of diseases and conditions. Approaches have included the analysis of 
samples from patients with various conditions, as well as more specific interactions 
using in vitro assays. The power of microarray in these scenarios is the ability to 
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generate a global analysis of transcription, which can lead to the generation of new 
hypotheses and candidate genes or pathways that were previously unsuspected to be 
involved.  
The use of microarray in studying disease was first proposed in a study by 
Golub et al (1999), where investigators found gene signatures that could discriminate 
between patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. 
These techniques have subsequently been applied to a range of different cancers. For 
example, transcriptional profiling is now used to distinguish different classes of 
breast cancer, and to predict patient outcome and response to chemotherapy (Sotiriou 
and Pusztai, 2009). Microarray has also been applied to the study of autoimmune 
diseases, and has yielded new insights into the pathogenesis of previously poorly 
understood conditions (Pascual et al, 2010). Transcriptional profiling of peripheral 
blood mononuclear cells (PBMCs) from patients with the autoimmune condition 
systemic lupus erythematosus (SLE) revealed a signature associated with type I IFN 
signalling and neutrophils (Bennett et al, 2003). Type I IFN was subsequently shown 
to prime neutrophils to undergo netosis, resulting in the release of neutrophil 
extracellular traps (NETs), resulting in the generation of the auto-antibodies against 
nuclear antigens, which lead to SLE pathogenesis (Garcia-Romo et al, 2011). Similar 
approaches were applied to systemic onset juvenile idiopathic arthritis (SoJIA), an 
autoimmune condition affecting children and characterised by fever, rash and 
arthritis (Pascual et al, 2010). Transcriptional profiling of PBMCs from SoJIA 
patients revealed an upregulation of IL-1β production, and treatment of patients with 
anakinra, an IL-1 receptor antagonist, dramatically improves the symptoms of SoJIA 
patients (Pascual et al, 2005).  
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These techniques have also been applied to infectious diseases, leading to 
novel insights into disease pathogenesis. Blood signatures were shown to 
discriminate patients with influenza, E. coli and S. aureus infection, which may aid 
in the differential diagnosis of these conditions (Ramilo et al, 2007). As discussed 
above, profiling of the whole blood of patients with active and latent TB compared 
to healthy controls found an IFN signature specific to patients with active TB (Berry 
et al, 2010). This could potentially aid in the diagnosis of active TB, which is not 
straightforward (Barry et al, 2009), and also reveals a potential role for type I IFN in 
disease pathogenesis (Berry et al, 2010). These studies demonstrate that microarray 
can be effectively applied to generate new insights into disease pathogenesis, and to 
potentially diagnose disease and predict disease outcome.  
However, microarray has also been extensively used to study specific disease 
processes at the cellular level. This has been effective in answering more specific 
questions about the behaviour of certain cells and the functions of signalling 
pathways. Many studies have applied this approach to understand the interactions 
between immune cells and pathogens or pathogen-derived products, and this has 
shed light on how immune cells respond to pathogens, the signalling pathways 
involved in these responses, and how pathogens attempt to subvert these processes 
(Jenner and Young, 2005).  
Microarray was first used to study host-pathogen interactions by Zhu et al 
(1998), using human fibroblasts infected with human cytomegalovirus. Since then 
many studies have profiled the response of a diverse array of cell types to various 
pathogens, including viruses, bacteria, protozoa and fungi (Jenner and Young, 2005). 
A common theme to emerge from these studies is a large amount of overlap in the 
transcriptional response of immune cells to different pathogens (Jenner and Young, 
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2005). For example, Nau et al (2002) stimulated human macrophages with E.coli, S. 
typhi, S. typhimurium, S. aureus, L. monocytogenes, Mtb and BCG, and identified a 
common response including cytokines, chemokines, transcription factors and cell-
surface receptors. A similar “core response” was found by a large-scale meta-
analysis of published host-pathogen microarray studies (Jenner and Young, 2005). 
The reasons for this overlap reflects the fact that diverse pathogens can all activate 
TLR signalling pathways, which culminate in the activation of common transcription 
factors (Jenner and Young, 2005). This is reflected in the fact that purified TLR 
ligands such as LPS can recapitulate a large part of the macrophage activation 
programme (Nau et al, 2002). However, pathogen-specific responses have also been 
identified by microarray studies of infected immune cells. For example, Nau et al 
(2002) found that Mtb induced lower levels of mRNA for IL-12p40 and IL-15 
compared to other pathogens. In addition, Chaussabel et al (2003) found pathogen 
specific response to a variety of intracellular pathogens, including Mtb, in human 
macrophages and DCs.  
A further application of microarray is to study the role of specific molecules 
and signalling pathways by making use of mouse gene knockout technology (Jenner 
and Young, 2005). In these experiments, the response of immune cells from WT 
mice can be compared to cells from mice deficient in particular molecules, and thus 
the genes regulated by a particular molecule can be determined globally (Jenner and 
Young, 2005). For example, Gilchrist et al (2006) used microarray and other systems 
biology techniques to identify the transcription factors ATF3 as a negative regulator 
of the macrophage response to LPS. This was confirmed by stimulating Atf3
-/-
 
macrophages with LPS and analysing the transcriptional response by microarray, 
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which found that a number of pro-inflammatory mediators such as IL-12, TNF and 
iNOS were upregulated in Atf3
-/-
 macrophages (Gilchrist et al, 2006).  
A number of microarray studies have investigated the transcriptional 
response of innate immune cells to Mtb infection. A recent study found that type I 
IFN inducible genes were upregulated in human macrophages infected with Mtb 
(Wu et al, 2012), in keeping with the IFN signature observed in active TB patients 
(Berry et al, 2010). Microarray analysis of Mtb-infected murine macrophages found 
that genes involved in steroid biosynthesis were upregulated in response to the 
hypervirulent Mtb isolate HN878, possibly reflecting a virulence strategy employed 
by this strain (Koo et al, 2012). A study by Tailleux et al (2008) was the first to use 
microarray to determine the gene expression of both Mtb and the host cell (human 
macrophages and DCs) simultaneously. This study found cell-specific response to 
Mtb; for example macrophages but not DCs, upregulated genes encoding vesicular 
(v)-ATPase subunits (Tailleux et al, 2008). In addition, Mtb responded differently to 
macrophages and DCs; Mtb showed an increased stress response within DCs 
compared to macrophages, possibly reflecting the fact that DCs present a less 
permissive environment for Mtb growth compared to macrophages (Tailleux et al, 
2008). Microarray has also been used to study the role of particularly signalling 
molecules in the transcriptional response of innate cells to Mtb. Transcriptional 
profiling of Mtb-infected macrophages deficient in the enzymes iNOS (Ehrt et al, 
2001), the signalling molecule MyD88 (Shi et al, 2003) and the type I IFN receptor 
Ifnar1 (Shi et al, 2005) has revealed important roles for these molecules in 
transcriptional regulation in response to Mtb. Notably, induction of a number of 
important genes including iNOS and IP10 was found to be MyD88-independent, but 
dependent on the IFNαβR, thus revealing important regulatory mechanisms that 
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occur in response to Mtb infection (Shi et al, 2005). Thus, microarray is a powerful 
tool for generating new insights into the response of innate immune cells to Mtb, and 
the mechanisms employed by Mtb to subvert this response. These studies are 
discussed in more detail in Chapter 3. 
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2.1. Mice 
C57Bl/6 (B6), B6 Ifnar1
-/-
, B6 Il10
-/-
, B6 Tpl2
-/-
, B6 Tpl2
-/-
Ifnar1
-/-
 and B6 
Tpl2
-/-
Il10
-/-
 were bred and housed under specific pathogen free conditions at the 
MRC-NIMR under UK Home Office regulations. Female mice were used between 8-
20 weeks of age.  
2.2. Reagents 
2.2.1. Cell culture medium 
Cell culture medium used for all experiments was RPMI 1640 (Lonza) 
supplemented with 5% heat-inactivated fetal calf serum (FCS) (Biosera), 0.05mM 2-
mercaptoethanol (Sigma), 2mM L-glutamine (Lonza), 1mM sodium pyruvate 
(Lonza) and 10mM HEPES (Lonza). This is subsequently referred to as cRPMI. 
2.2.2.  Recombinant IFNs 
Recombinant IFNβ was purchased from PBL and recombinant IFNγ was 
purchased from R&D systems. IFNβ was used at 2ng/ml unless otherwise indicated 
and IFNγ was used at 5ng/ml.  
2.2.3. Inhibitors 
The MEK1/2 inhibitor PD0325901 was purchased from Philip Cohen 
(University of Dundee, Scotland, UK) and reconstituted in Dimethyl sulfoxide 
(DMSO; Sigma). PD0325901 was used at a concentration of 0.1μM. 
2.2.4. Mtb 
All experiments using Mtb were carried out under bio-safety containment 
level 3 conditions. Mtb H37Rv was originally from the London School of Hygiene 
and Tropical Medicine (LSHTM) and grown at the MRC-NIMR. Mtb H37Rv was 
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grown by seeding either 100µl of frozen stock, or picking colonies on 7H11 plates, 
into 10ml of liquid 7H9 culture broth (BD Difco) supplemented with 0.05% Tween-
80 (Sigma), 0.5% Glycerol (Sigma) and 10% oleic acid-albumin-dextrose catalase 
(OADC; BD Difco). 10ml cultures were placed in a rotor at 37ºC, rotating at 25rpm 
and growth was monitored by reading optical density at 600nm. When OD was 
approximately 1, 1ml of the rotating culture was added to 50ml 7H9 culture broth in 
a roller bottle, which was placed on a roller at 37ºC, at 2rpm. OD was monitored as 
above and when OD was approximately 1, Mtb was centrifuged for 20mins at 
3000rpm to pellet cells, and the pellet was washed twice in phosphate-buffered 
saline (PBS) to remove any remaining media, and then resuspended in PBS. A 
slower spin was then carried out (10mins at 800rpm) to remove Mtb clumps, and the 
supernatant was aliquotted into freezing vials, 1ml per vial, and stored at -80
º
C. To 
determine the number of viable colony forming units (CFUs) of Mtb per tube in the 
stock, vials were thawed and serially diluted onto 7H11 plates supplemented with 
OADC. For each new stock, selected vials were plated onto blood agar plates, to 
ensure no contamination with other microorganisms. These vials were then thawed 
and used to infect macrophages as described below. 
2.3. In vitro differentiation and infection of macrophages 
2.3.1. Generation of murine macrophages from the bone marrow 
To generate bone marrow-derived macrophages, bone marrow cells were 
flushed from the femurs and tibia of mice and seeded into bacterial plates (Sterilin) 
at 0.5x10
6
 cells/ml, in 8ml cRPMI containing 10% FCS and 20% L929 cell-
conditioned medium (LCCM) which contains macrophage colony-stimulating factor 
(M-CSF). At day 4, 10ml fresh cRPMI containing 10% FCS and 20% LCCM was 
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added. At day 6, non-adherent cells were discarded, 5ml ice-cold PBS was added and 
plates were incubated at 4ºC for 15mins. Macrophages were then removed from the 
plate, pelleted by centrifugation at 1200rpm for 7mins and resuspended in cRPMI 
(5% FCS). Macrophages were counted and seeded into 24-well flat-bottomed tissue 
culture plates (Corning) at 1x10
6
 cells/ml, in a final volume of 1ml. For the 
microarray experiment presented in Chapter 3, macrophages were seeded into 6-well 
flat-bottomed tissue culture plates (Corning) at 1x10
6
 cells/ml, in a final volume of 
3ml. Cells were rested overnight and on day 7 medium was removed, cells were 
washed once with PBS and infected as described below. Macrophage purity was 
found to be approximately 98% based on expression of CD11b and F4/80 by FACS 
analysis. 
2.3.2. Infection of macrophages with Mtb 
Macrophages were infected with Mtb at a multiplicity of infection (MOI) of 
2:1 (bacteria: cell). Mtb was left in the wells until the supernatant or cells were 
harvested. The number of bacteria in the inoculum was determined by serial 
dilutions on 7H11 plates supplemented with 10% OADC. 
2.3.3. Enumeration of intracellular Mtb in macrophages following 
infection 
To determine the number of intracellular Mtb CFUs present in macrophages 
following infection, supernatants were harvested, macrophages were washed once 
with PBS to remove extracellular bacteria and 1ml of 0.2% saponin (Sigma) was 
added for 1hr at 37 ºC to lyse the cells. This suspension was then serially diluted and 
plated onto 7H11 plates supplemented with OADC, and colonies were counted after 
14-16 days at 37ºC. 
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2.4. Cytokine quantification by ELISA 
For quantification of cytokine concentrations in cellular supernatants, cell-
free supernatants were harvested at the indicated time point post-infection and 
measured by enzyme-linked immune-adsorbent assay (ELISA). Commercially 
available kits were used for TNFα, IL-12p70 and IL-27 (eBioscience), IL-1β (R&D 
systems) and IFNβ (PBL), and were used according to the manufacturer’s 
instructions. Matched antibody pairs were used for IL-10 and IL-12p40. Details of 
ELISAs used are shown in Table 2.1.  
Cytokine Standard 
starting 
concentration 
Coating 
antibody 
Detection antibody Substrate Detection 
limit 
IL-10 10ng/ml JES-2A5, 
5µg/ml 
(DNAX) 
SXC-1, 0.25µg/ml 
(BD biosciences) 
TMB 40pg/ml 
IL-12p40 50ng/ml C15.6, 
5µg/ml  
(DNAX) 
C17.8, 0.5µg/ml  
(DNAX) 
ABTS 
 
50pg/ml 
TNFα 10ng/ml n/a n/a TMB 20pg/ml 
IL-12p70 10ng/ml n/a n/a TMB 20pg/ml 
IL-1β 10ng/ml n/a n/a TMB 20pg/ml 
IFNβ 1000pg/ml n/a n/a TMB 20pg/ml 
IL-27 10ng/ml n/a n/a TMB 20pg/ml 
Table 2.1. Details of ELISAs used for quantification of cytokines 
2.5. Protein analysis by Western blotting 
For Western blot analysis, macrophages were rested overnight in cRPMI 
containing 1% FCS, and then stimulated with IFNγ at 5ng/ml in cRPMI with 0% 
FCS. At the indicated times post-stimulation, cells were lysed in RIPA buffer (0.1% 
SDS, 1% NP-40, 50 mM NaCl, 0.5% deoxycholate acid, 50 mM, Tris HCl, pH 8.0, 2 
mM EDTA, 2 mM sodium-pyrophosphate, 50 mM sodium fluoride, 100 mM 
vanadate (all from Sigma-Aldrich), and complete EDTA-free protease inhibitor 
cocktail (Roche)). The concentration of protein in the lysates was determined by 
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BCA assay (ThermoScientific). Protein in the samples were then denatured by 
adding sodium dodecyl sulfate (SDS). 
20ug of protein was loaded onto a 12.5% poly-acrylamide gel, which was run 
at 45mA for approximately 4hr to separate the proteins according to size. The protein 
in the gel was then transferred onto a methanol-activated membrane (Millipore) 
overnight at 180mA. The membrane was then blocked for 1hr at room temperature in 
20ml PBS with 5% milk and 0.05% Tween-20 (Sigma). The membrane was then 
incubated with the primary antibody; total STAT1 (Cell Signalling; 1/1000 dilution 
overnight at 4ºC), Tyr701 phosphorylated STAT1 (Cell Signalling; 1/1000 dilution 
overnight at 4 ºC), or Actin as a loading control (Calbiochem; 1/5000 dilution for 2hr 
at room temperature), in 20ml PBS with 5% milk and 0.05% Tween-20. The 
secondary antibody (HRP-Conjugated Goat Anti-Rabbit IgG; Southern Biotech), at 
1/2000 dilution in 20ml PBS with 5% milk and 0.05% Tween-20, was then added for 
1hr at room temperature. The membrane was then developed using ECL (Millipore) 
and photographic paper.  
2.6. RNA extraction and purification 
2.6.1. Harvesting and purification of RNA 
At indicated time point post-infection, macrophage supernatants were 
harvested and cells were washed once with PBS. 350µl RLT buffer (Qiagen) with 
1% 2-mercaptoethanol was added to lyse cells. Lysates were stored at -80ºC until 
further processing. Lysates were homogenised using QIAshredder kits (Qiagen) and 
RNA was purified using RNeasy Mini Kits (Qiagen). An optional on-column DNA 
digestion step was performed using RNase-Free DNAse sets (Qiagen). All kits were 
used according to manufacturer’s instructions. The concentration of purified RNA 
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was determined using a NanoDrop 1000 spectrophotometer (NanoDrop Products, 
Thermo Scientific). For RNA to be used for microarray analysis, RNA quality was 
assessed using an Agilent 2100 Bioanalyser (Agilent technologies). All samples had 
an RNA integrity number (RIN) of >9.3, which indicated high quality. Purified RNA 
was stored at -80
º
C for further processing.  
2.6.2. Conversion of RNA to cDNA for qPCR analysis 
RNA was reverse transcribed to cDNA using High Capacity cDNA Reverse 
Transcription kits (Applied Biosystems) using the master mix shown in Table 2.2.  
Reagent Company Volume per reaction 
(final volume 20µl) 
Final 
Concentration 
RNA N/A 10µl N/A 
RT buffer Applied Biosystems 2µl N/A 
dNTPs Applied Biosystems 0.8µl 4mM 
Random Primers Applied Biosystems 2µl N/A 
MultiScribe Reverse 
transcriptase 
Applied Biosystems 1µl 2.5U/µl 
RNAsin Promega 0.5µl 1U/µl 
Nuclease-free H2O Promega 3.7µl N/A 
Table 2.2. Reagents used for reverse transcription master mix 
This mixture was incubated at 25ºC for 10mins, 37ºC for 2hrs then 85ºC for 
5mins. Following conversion to cDNA, remaining RNA was digested by using 
RNAse H (Invitrogen), at a final concentration of 0.03U/µl, for 30mins at 37ºC. 
cDNA was then diluted to a final concentration of 5µg/ml and used for qPCR 
analysis as detailed below.  
2.6.3. qPCR analysis 
The expression of target genes was determined by qPCR (7900HT; applied 
Biosystems). Samples were placed in a 96-well optical reaction plate (Applied 
Biosystems) with volumes of reagents as shown in Table 2.3. Each plate also 
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contained a no-template control with 4.5ul H20 replacing the cDNA, to control for 
contamination. The temperature and cycle number of the qPCR reactions is shown in 
Table 2.4. FAM-labelled Taqman primer probes were used to probe for specific 
genes. Following the reaction, the delta Ct (∆Ct) method was used to determine the 
expression value of the gene of interest (GOI) relative to a house-keeping gene, Hprt 
(hypoxanthine guanine phosphoribosyl transferase) using the following formula: 
∆Ct GOI = 1.8(CtHprt – CtGOI) x 100000 
 
Reagent Company Volume per reaction 
(final volume 10µl) 
Final 
concentrations 
cDNA n/a 4.5µl 11.25ng/µl 
Taqman universal 
PCR master mix 
Applied 
Biosystems 
5µl n/a 
Taqman primer 
probe 
Applied 
Biosystems 
0.5µl 900nM 
Table 2.3. Reagents used for qPCR analysis 
 
 
Temperature Time No. Cycles 
50ºC 2mins 1 
95ºC 10mins 1 
95ºC/60ºC 15s/1min 40 
Table 2.4. Temperatures and times used for qPCR reactions 
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Target Gene Applied Biosystems 
catalogue number 
Il10 Mm_00439616_m1 
Il12a Mm_00434165_m1 
Il12b Mm_00434174_m1 
Tnf Mm_00443258_m1 
Il1b Mm_00434228_m1 
Ifngr1 Mm_00599890_m1 
Ifna2 Mm_00833961_m1 
Ifna5 Mm_00833976_m1 
Ifna6 Mm_0170358_s1 
Ifnb1 Mm_00439552_s1 
Fos Mm_00487425_m1 
Egr1 Mm_00656724_m1 
Jmjd3 Mm_01332680_m1 
Ier3 Mm_00519290_g1 
Dusp1 Mm_00457274_g1 
Dusp5 Mm_01266106_m1 
Hprt Mm_00446968_m1 
Table 2.5 Taqman primer probes used for qPCR 
2.7. Microarray processing and data analysis 
2.7.1. Amplification 
For microarray analysis, 300ng of total RNA was reverse transcribed to 
cDNA, purified and used as a template for in vitro transcription to generate biotin 
labelled, antisense complementary RNA (cRNA) target molecules, using the 
Illumina TotalPrep-96 RNA Amplification Kit (Illumina) according to the 
manufacturer’s instructions. The concentration of purified cRNA was determined 
using a NanoDrop 1000 spectrophotometer (NanoDrop Products, Thermo 
Scientific).  
2.7.2. Hybridisation 
750ng of biotin-labelled cRNA was hybridized overnight to Illumina Mouse 
WG-6 V2.0 Beadchip arrays (Illumina). The arrays were then washed, blocked, 
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stained and scanned on an Illumina BeadStation 500 following the manufacturer’s 
protocols. Illumina BeadStudio software (Illumina) was used to generate signal 
intensity values from the scans. 
RNA amplification for the microarray data presented in Chapter 3 was 
performed by Dr Christine Graham of the Division of Immunoregulation, MRC 
National Institute for Medical Research, Mill Hill, London, UK. Hybridisation of 
cRNA to arrays, scanning and pre-processing for the microarray data presented in 
Chapter 3 was performed by Quynh-Anh Nguyen, Microarray Core Facility, Baylor 
Institute for Immunology Research, Dallas, Texas. RNA amplification and 
hybridisation for the microarray data presented in Chapters 4, 5 and 6 was carried 
out by Dr Harsha Jani of the Division of Systems Biology, MRC National Institute 
for Medical Research, Mill Hill, London, UK. 
2.7.3. Microarray data analysis 
2.7.3.1. Data pre-processing, normalisation and removal of undetectable 
transcripts 
Illumina BeadStudio software was used to subtract background from signal 
intensity values. GeneSpring GX version 11 (Agilent Technologies) was used to 
perform further normalisation and data analysis. The following pre-processing and 
normalisation steps were applied to all microarray data presented. A threshold signal 
value of 10 was set, and all signal intensity values less than 10 were set to equal 10, 
to remove noise due to low values. Signal values were then log-transformed to the 
base 2. Per-chip normalisation was applied using the 75
th
 percentile shift algorithm. 
This normalisation reduces differences in gene expression due to technical variations 
between different samples within a chip, and between chips, such as differences is 
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labelling or hybridisation (Quackenbush, 2002). Per-gene normalisation was then 
applied by dividing the signal value for each gene in each sample by the median of 
the signal value for that gene across all samples. Prior to further analysis, all 
transcripts were filtered to select transcripts that were significantly detectable from 
background: those called ‘present’ in 100% of any one group of replicates (p<0.01). 
2.7.3.2. Fold-change and statistical analysis 
Following the removal of undetectable transcripts, fold-change and statistical 
analyses were applied to generate lists of differentially expressed transcripts, using 
GeneSpring. The specifics of the analyses carried out to generate lists of 
differentially expressed transcripts are presented in the relevant results section and 
figure legend. Fold change filters retained transcripts with greater than 2-fold 
changes in expression between conditions. For statistical analyses, two-way 
ANOVA (p<0.05) with Benjamini Hochberg FDR multiple testing correction was 
used. 
2.7.3.3. Hierarchical and k-means clustering 
Lists of differentially expressed transcripts generated by fold-change and 
statistical analysis were subjected to hierarchical clustering. This technique 
constructs a vertical dendrogram where transcripts with similar expression profiles 
across the condition are grouped together, and is useful in identifying patterns within 
the gene expression dataset (Quackenbush, 2002). The dendrogram is then displayed 
with gene expression shown as a red-blue heat map, with red indicating upregulation, 
blue indicating downregulation and yellow no change. For all hierarchical clustering 
a Pearson centred distance metric was used, as this clusters transcripts based on the 
expression profile of transcripts over the different samples, rather than the magnitude 
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of gene expression which is used by Euclidian-based distance metric (Quackenbush, 
2002). This was because transcripts with similar expression patterns, e.g. transcripts 
with expression at a particular time point, are likely to be co-regulated regardless of 
if one transcript is induced to a higher magnitude. In most cases, Pearson centred 
clustering was combined with complete linkage rule, which tends to generate 
compact clusters of a similar size (Quackenbush, 2002).  
A second form of clustering, k-means clustering, was also applied to lists of 
differently expressed transcripts, again using a Pearson centred distance metric. This 
method separates the transcripts into a defined number of clusters (k) which can then 
be analysed in more detail (Quackenbush, 2002).  
2.7.3.4. Functional analysis using IPA and GO analysis 
Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, Inc., Redwood, CA, 
USA, www.ingenuity.com) was used to determine signalling pathways associated 
with clusters of differentially expressed transcripts. IPA is a database containing 
more than 9,800 human, 7,900 mouse and 5,000 rat genes, which is manually 
curated with gene associations generated from over 200,000 full text scientific 
articles (Calvano et al, 2005). Gene lists generated as described above were uploaded 
into IPA, and Fisher’s exact test, with Benjamini Hochberg FDR multiple testing 
correction was used to determine statistically significant overlap between gene lists 
and canonical IPA signalling pathways. In this study, an interactions was considered 
significant if p<0.01. IPA was also used to overlay gene expression data onto a 
canonical pathway, with common genes highlighted either in red, if over-represented 
in the dataset, or blue, if under-represented.  
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Further functional analysis was carried out using gene ontology (GO) 
analysis in GeneSpring. This analysis uses the GO database, where genes are 
assigned ontologies relating to their molecular functions, associated biological 
processes and cellular location (Harris et al, 2004). Lists of genes can then be 
analysed with regard to their associated GO ontologies, and significant associations 
with particular terms can be calculated. 
2.8. Statistical analysis 
Statistical analysis on experimental data was carried out using PRISM 
software. T-test, 1-way ANOVA and 2-way ANOVA were used as indicated in the 
figure legend, with a significant result taken with a p-value of less than 0.05.  
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3.1. Background 
Macrophages are the immune system’s first line of defence against 
pathogenic microorganisms, populating key sites of the body where interactions with 
the outside environment occur, and engulfing and destroying foreign material, 
including bacteria. Macrophages also produce cytokines and chemokines which 
attract and activate other immune cells (Medzhitov and Horng, 2009). Alveolar 
macrophages in the lung are the first cells to encounter Mtb following infection, but 
Mtb has evolved mechanisms to survive within macrophages, generating a niche in 
which to replicate (Pieters, 2008). Alveolar macrophages, and recruited 
macrophages, are therefore a major reservoir for Mtb throughout the course of 
infection (Wolf et al, 2007). The interactions between Mtb and macrophages are 
therefore critical in determining the outcome of infection. 
Macrophages recognise pathogens through pattern recognition receptors 
(PRRs), which detect conserved features unique to microorganisms. Mtb is 
recognised by macrophages through Toll-like receptors (TLRs), C-type lectins 
including dectin-1, DC-SIGN and the mannose receptor (MR), and the Nod-like 
receptor NOD2 (Kleinnijenhuis et al, 2011). Recognition of a pathogen by PRRs on 
macrophages triggers many signalling pathways, resulting in the activation of 
transcription factors such as NF-κB, and the induction and repression of hundreds of 
genes involved in the antimicrobial response (Jenner and Young, 2005; Medzhitov 
and Horng, 2009). A thorough understanding of how the macrophage response is 
regulated will lead to new insights into the factors required to protect against 
pathogens such as Mtb, and how these pathogens are able to subvert this response to 
favour their own growth.  
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Given the complexity of the macrophage response to pathogens or pathogen 
derived products, microarray is an ideal tool to study this process, as it allows the 
user to determine the expression of thousands of genes in an unbiased manner. A 
number of studies have used microarray to study the response of human (Nau et al, 
2002; Chaussabel et al, 2003; Wang et al, 2003; Tailleux et al, 2008) or mouse (Ehrt 
et al, 2001; Shi et al, 2003; Shi et al, 2005; Koo et al, 2012) macrophages to Mtb. 
The major findings from these studies, and the cell types, time points and stimuli 
used are shown in Table 3.1. 
As shown in Table 3.1, these studies have led to important insights into the 
host pathogen interactions that occur in Mtb-infected macrophages. For example, Shi 
et al (2005) found that a number of immunologically important genes were induced 
by Mtb via type I IFN and STAT1 signalling, independently of TLRs, at 4hr post-
infection. A more recent study by Tailleux et al (2008) analysed the response of 
human macrophages and DCs to Mtb, and additionally profiled Mtb gene expression 
within these two cell types. This revealed cell-specific responses to Mtb by 
macrophages and DCs, with macrophages upregulating genes involved with 
phagosome acidification and vesicle trafficking (Tailleux et al, 2008).  
However, previous microarray studies of Mtb-infected macrophages have 
tended to use a limited number of time points (Table 3.1), and so the dynamics of the 
macrophage response to infection was not assessed (Ehrt et al, 2001; Chaussabel et 
al, 2003; Shi et al, 2003; Wang et al, 2003; Shi et al, 2005; Tailleux et al, 2008; Koo 
et al, 2012). In addition, the majority of these studies did not analyse macrophage 
gene expression at time points earlier than 4hr post-infection (Ehrt et al, 2001; 
Chaussabel et al, 2003; Shi et al, 2003; Wang et al, 2003; Shi et al, 2005; Tailleux et 
al, 2008; Koo et al, 2012) (Table 3.1). Although Nau et al (2002) analysed the 
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response of human macrophages to Mtb at 1hr and 2hr post-infection, the primary 
aim of this study was to compare the common macrophage response to various 
bacterial pathogens, and the response to Mtb was not analysed in detail. Microarray 
studies of LPS stimulated macrophages have found that gene expression can change 
rapidly following treatment, with clusters of upregulated genes observed as early as 
1hr post-stimulation (Gilchrist et al, 2006; Ramsey et al, 2008). These genes are 
likely to regulate the macrophage response at later time points, and could play an 
important role in the immune response. 
Here we carried out a microarray analysis of Mtb-infected macrophages over 
an extended time course, including both early and late time points. We found the 
macrophage response to Mtb to be highly dynamic, with many clusters of genes 
induced or repressed at different time points. This included early clusters of genes, 
which were induced at 30mins to 1hr post-infection. Analysis of these clusters by 
ingenuity pathway analysis (IPA) and gene ontology (GO) identified clusters of 
genes involved with a wide range of functions, some of which would protect the host 
against Mtb infection, and others that could be a result of Mtb virulence strategies to 
subvert the protective immune response. This illustrates the complexity of Mtb-
macrophage interactions, and provides a framework for future analyses. 
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Reference Cell type Mtb strain Time points Primary Findings 
Ehrt et al, 2001 Murine 
macrophages 
Clinical isolate 
1254 
24hr  Synergy between Mtb and IFNγ in induction of inflammatory 
genes, including iNOS 
 iNOS and NADPH oxidase found to be important 
transcriptional regulators in response to Mtb 
Nau et al, 2002 Human 
macrophages 
Erdman 0, 1, 2, 6, 12, 24hr  Defined common macrophage activation program in response 
to Mtb and various bacteria, including cytokines, chemokines, 
receptors and transcription factors 
 Response to Mtb not analysed in detail 
Chaussabel et al, 
2003 
Human 
macrophages 
and DCs 
DNS 16hr  Compared macrophage and DC response to Mtb and other 
intracellular pathogens 
 Found common and pathogen-specific cluster of genes 
 Type I IFN inducible and MHC class I related genes induced 
by Mtb and Toxoplasma gondii in DCs and macrophages 
 Cytokines, chemokines and NF-κB related genes induced by 
Mtb in macrophages and DCs 
Shi et al, 2003 Murine 
macrophages 
Clinical isolate 
1254 
24hr  Mtb transcriptional response largely MyD88-independent 
 MyD88 required for macrophage activation in response to 
IFNγ 
Wang et al, 2003 Human 
macrophages 
Erdman 4, 12, 24, 48hr  Found upregulation of cytokines, chemokines, proteasome 
components and STAT1 
Shi et al, 2005 Murine 
macrophages 
Clinical isolate 
1254 
24hr  Induction of several immunologically important genes, 
including RANTES, IRG1, IP10 and iNOS independent of 
MyD88 but dependent on type I IFN and STAT1 
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Tailleux et al, 
2008 
Human 
macrophages 
and DCs 
H37Rv 4, 18, 48hr  Cell-specific responses to Mtb identified 
 NADPH oxidase, phagosome acidification and intracellular 
trafficking regulated genes more strongly induced in 
macrophages 
 Type I IFN and TLR related genes more strongly induced in 
DCs  
 Profiling of Mtb gene expression found cell-specific 
adaptations to macrophages and DCs, with replication related 
genes upregulated in macrophages, and stress response genes 
upregulated in DCs 
Wu et al, 2012 Human THP-1 
macrophage-like 
cell-line 
11 W-Beijing 
strains and 
H37Rv 
4, 18, 48hr  Similar response to W-Beijing strains compared to H37Rv 
 Core response included many cytokines, chemokines and 
receptors 
 Found induction of many IFN-inducible genes, which 
overlapped with IFN-signature identified by Berry et al (2010)  
Koo et al, 2012 Murine 
macrophages 
HN878 and 
CDC1551 
6 and 24hr  Immune response genes induced by CDC1551 but not HN878 
at 6hr post-infection 
 Genes involved in lipid metabolism upregulated in response to 
HN878 but not CDC1551 at 24hr post-infection 
Table 3.1. Summary of previous microarray studies of innate immune cells infected with Mtb 
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3.2. Results 
3.2.1. The macrophage response to Mtb is temporally regulated  
To gain a global understanding of the transcriptional response of 
macrophages to Mtb infection, we began by using transcriptional profiling to study 
the global macrophage response to Mtb over an extended time-course, including both 
early and late time points. Macrophages were derived from the bone marrow of wild-
type (WT) mice, and were infected with the H37Rv strain of Mtb (which is used 
throughout this study) at a multiplicity of infection (MOI) of 2:1. This MOI was 
chosen based on preliminary experiments showing that an MOI of 2:1 activated 
macrophages to produce cytokines, but without causing significant cell death, and is 
used throughout this study. RNA was harvested from infected and uninfected 
macrophages at 0hr, , 30mins, 1hr, 3hr, 6hr and 24hr post-infection. Purified total 
RNA was amplified, labelled and hybridised to Illumina Mouse WG-6 V2.0 
Beadchip arrays, as described in the Materials and Methods, with duplicate 
biological samples for each condition. In addition, selected samples were run 
independently for a second time, and similar results were observed (data not shown). 
Background subtraction was carried out using BeadStudio (Illumina), and further 
analysis was carried out using GeneSpring (Agilent Technologies). 
The 42581 analysed transcripts were filtered first to select transcripts that 
were significantly detectable from the background: those called ‘present’ in 100% of 
any 1 group of 2 triplicates. This left 15018 transcripts. To gain an overview of the 
dataset, the 26 samples were subjected to unsupervised clustering, using a Euclidian 
distance metric with complete linkage, based on the expression of the 15018 
detectable transcripts. This technique clusters samples based on how similar they are 
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to each other, and thus shows the overall trends within the dataset (Quackenbush, 
2002). 
Figure 3.1 shows that the 26 samples were separated into two groups by 
unsupervised clustering. One group contained Mtb-infected samples at 3hr, 6hr and 
24hr, while the second larger group contained all uninfected samples and Mtb-
infected samples at 15mins, 30mins and 1hr. This suggests that the major Mtb-
induced transcriptional changes occur at 3hr, 6hr and 24hr post-infection, as these 
samples cluster separately from the uninfected controls. The Mtb-infected samples at 
15mins and 30mins cluster together with the uninfected controls (Figure 3.1), 
suggesting minimal changes have occurred in response to Mtb at these early time 
points. However, although the 1hr Mtb-infected samples cluster in the same groups 
as the uninfected controls, they are on a separate branch, suggesting that some 
changes are occurring at this time point (Figure 3.1).  
To investigate further, two filters were applied to the 15018 detectable 
transcripts, designed to retain only transcripts that changed in response to Mtb 
infection over time. First, transcripts were retained if their expression changed by 
greater than 2-fold in response to Mtb at any time point, relative to the mean of the 
uninfected controls at that time point. Second, transcripts were retained if they were 
statistically different with regard to infection and time, as determined by two-way 
ANOVA (p<0.05) with Benjamini Hochberg FDR multiple testing correction. This 
left 6479 Mtb-regulated transcripts. To study the expression profile of these 
transcripts over time, they were clustered hierarchically using Pearson centred 
distance metric and complete linkage (Figure 3.2). Hierarchical clustering groups 
transcripts with similar expression profiles into clusters, generating a global 
overview of the gene expression in a dataset (Butte, 2002; Do and Choi, 2008). A 
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Pearson based distance metric was used as it clusters transcripts on the basis on the 
trend of their expression profile, rather than the magnitude of the change, which is 
informative as similar trends of expression can indicate common regulation and 
biological function (Do and Choi, 2008). 
As predicted by unsupervised clustering of the samples (Figure 3.1), the 
majority of transcriptional changes in response to Mtb occurred at 3hr, 6hr and 24hr 
post-infection (Figure 3.2). No transcriptional changes were visible at 15mins post-
infection (Figure 3.2). However, a small number of transcripts were upregulated at 
30mins, and this increased slightly at 1hr post-infection (Figure 3.2), showing that 
certain genes are induced rapidly in macrophages following Mtb infection. This early 
response is likely to be important in inducing and regulating the later response of 
macrophages to Mtb. It was striking that the transcripts showed considerable 
heterogeneity in their expression profiles (Figure 3.2). Some clusters of transcripts 
remained upregulated or downregulated over relatively long periods of time, e.g. 
between 3hr and 24hr, whereas others were regulated only at one time point (Figure 
3.2).  
Taken together, this analysis shows that the macrophage response to Mtb 
occurs predominantly between 3hr and 24hr post-infection, but with small numbers 
of transcripts induced early (30mins-1hr) following infection. In addition, this 
response was highly dynamic, with groups of transcripts changing expression with 
varying kinetics. This illustrates the importance of using multiple time points, 
including early time points, to study the temporal response of immune cells to 
infection, as important transcriptional changes may be missed if few time points are 
used.  
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3.2.2. k-means clustering separates the macrophage response to Mtb 
into 24 clusters, based on their expression profiles 
Figure 3.2 shows that Mtb-induced transcription is complex, with many 
discrete clusters being up- or downregulated with varying kinetics. Clusters of 
transcripts with similar profiles are likely to be involved in shared processes, and to 
be regulated by common pathways or transcription factors (Do and Choi, 2008). In 
order to further study the regulation and function of these clusters, it was necessary 
to separate them into lists of transcripts which could be analysed in more detail. To 
achieve this, we used GeneSpring to separate the 6479 transcripts into clusters using 
k-means clustering. k-means clustering separates transcripts into a pre-defined 
number of clusters based on their expression profile (Butte, 2002). We used k-means 
clustering to separate the 6479 Mtb-regulated transcripts in 24 clusters, again using a 
Pearson centred distance metric. The 24 clusters varied in size, with the smallest 
(cluster 15) containing 51 transcripts and the largest (cluster 7) containing 707 
transcripts. Complete lists of the transcripts are presented in section 3.5 at the end of 
this chapter.  
The expression profiles of the 24 clusters are shown in Figure 3.3. Of the 24, 
17 clusters contained transcripts that were upregulated in response to Mtb infection 
and seven were downregulated, reflecting the higher number of upregulated 
transcripts and the greater heterogeneity of their expression (Figure 3.3). As 
predicted from Figure 3.2, the clusters varied enormously in their kinetics of 
induction or repression over time. Of those upregulated in response to Mtb, two 
showed changes at 1hr post-infection; cluster 8, which remained upregulated 
throughout the course of infection, and cluster 15, which was induced only 
transiently and returned to baseline by 3hr post-infection (Figure 3.3). The 15 other 
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upregulated clusters also showed considerable variability in their expression. Cluster 
1 (3hr), cluster 9 (6hr) and clusters 14 and 24 (24hr) were only upregulated at one 
time point following Mtb infection (Figure 3.3). Others remained upregulated over 
two time points; clusters 0, 2 and 20 at 6hr-24hr post-infection and clusters 5 and 12 
at 3hr-6hr post-infection (Figure 3.3). Finally, clusters 4, 6, 11, 19, 22 and 23 were 
induced by Mtb and remained upregulated at 3hr, 6hr and 24hr post-infection, 
although the peak and magnitude of expression varied between these clusters (Figure 
3.3). The downregulated clusters showed similar heterogeneity, with cluster 3 
downregulated only at 24hr post-infection, cluster 10 at 6hr and 24hr post-infection, 
clusters 7 and 17 at 3hr and 6hr post-infection and clusters 16 and 18 at 3hr, 6hr and 
24hr (Figure 3.3). In summary, the 6479 genes making up the macrophage response 
to Mtb can be separated into 24 clusters of induced and repressed genes, with large 
dynamic and temporal variability in their expression profiles.  
3.2.3. Mtb-regulated gene clusters are associated with a variety of 
functions and signalling pathways  
Having separated the transcriptional response of macrophages to Mtb into 24 
clusters, we next investigated the functions of these clusters, and the signalling 
pathways that regulate their expression. Two approaches were used; gene ontology 
(GO) analysis (using GeneSpring), which gives broad information as to the potential 
functions of transcript lists, and ingenuity pathway analysis (IPA) which gives more 
specific information on the signalling pathways associated with transcript clusters. 
Each of the 24 clusters were analysed by GO analysis and IPA, with the top 5 
significant overlaps for each analysis shown (p<0.01) (Figure 3.4.1-3.4.4). Where 
significant associations were found, these were confirmed by literature searching of 
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the relevant transcripts, under the column “literature associations”. In addition, 
function or signalling associations not picked up by IPA or GO analysis, but 
suggested by published literature, are shown in this column. 
Of the 24 clusters, eight showed no significant overlap with either GO terms 
or IPA signalling pathways (clusters 0, 1, 3, 6, 14, 18, 20 and 21) (Figure 3.4.1-
3.4.4). The remaining 16 clusters showed overlap with a wide range of biological 
processes and signalling pathways (Figure 3.4.1-3.4.4). These are discussed below 
selected clusters hierarchically clustered and visualised with a heat map to show the 
gene expression in more detail, with the relevant genes in each cluster indicated 
(Figures 3.5-3.17). 
3.2.3.1. Early clusters are associated with NF-κB and ERK MAP kinase 
signalling 
A small number of transcripts were upregulated at 30mins to 1hr following 
Mtb infection (Figure 3.2). k-means clustering separated these transcripts into two 
clusters with differing expression profiles (Figure 3.3). Cluster 8 contained 
transcripts that were induced early and remained upregulated throughout the 
infection, whereas transcripts in cluster 15 were induced only transiently, and were 
rapidly downregulated after peaking at 1hr post-infection (Figure 3.3).  
GO analysis of cluster 8 showed a strong association with terms involved 
with cytokines and chemokines, such as “cytokine activity” and “chemokine 
activity” (Figure 3.4.2). This was due to the presence of the cytokines Il1b and Tnf 
and the chemokines Ccl2, Ccl3, Ccl4, Ccl7, Cxcl1 and Cxcl2 (Figure 3.5). These 
cytokines and chemokines function to mediate inflammation and stimulate the 
recruitment of further immune cells to the site of infection, and are essential for a 
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protective response to Mtb infection (Flynn et al, 1995; Peters et al, 2001; Mayer-
Barber et al, 2011). The rapid production of these cytokines and chemokines by Mtb-
infected macrophages is likely to lead to the influx of further immune cells into the 
lung, and lead to the formation of the granuloma. Cluster 8 also includes several 
transcription factors including Irf1, Tgif1, Maff, Atf3 and Junb, suggesting that this 
early response also leads to subsequent waves of transcription. Cluster 8 also 
contains the immunosuppressive cytokine Il10 (Figure 3.5). IL-10 can inhibit the 
production of IL-1β and TNFα from macrophages (Fiorentino et al, 1991a; 
Fiorentino et al, 1991b; Moore et al, 2001) suggesting that this early pro-
inflammatory macrophage response is regulated to prevent host damage. 
The IPA signalling pathways that were associated with cluster 8 included 
“IL-10 signalling” and “IL-17 signalling” (Figure 3.4.2). However, induction of 
these pathways would require autocrine signalling, and this is unlikely given the 
extremely rapid induction of the transcripts in cluster 8. We therefore investigated 
the regulation of these transcripts in more detail by using IPA to determine the 
transcriptional regulators associated with the transcripts in cluster 8. As shown in 
Table 3.1, the most significant transcription factors associated with this cluster were 
the NF-κB family of transcription factors, which are known to induce pro-
inflammatory genes downstream of a wide variety of signals including TLRs 
(Vallabhapurapu and Karin, 2009). Genes in cluster 8 linked to NF-κB family 
members included Il1b, Tnf, Ccl2, Ccl4, Ccl7 and Cxcl2 (Figure 3.5). These data 
therefore suggest that NF-κB is rapidly activated in Mtb-infected macrophages, and 
this stimulates the production of vital cytokines and chemokines.  
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Transcriptional 
Regulator 
P-value of 
overlap 
NF-κB (complex) 1.95x10-13 
STAT3 2.20x10
-11 
EGR1 3.66x10
-10 
NFKB1 3.66x10
-10 
GLI2 1.20x10
-8 
Table 3.2. Transcriptional regulators associated with cluster 8 by IPA analysis 
Cluster 15, which was induced rapidly but transiently in Mtb-infected 
macrophages (Figure 3.6A), was associated with GO terms involved with gene 
regulation, such as “Regulation of transcription from RNA polymerase II promoter” 
and “Regulation of gene expression” (Figure 3.4.3). This was due to the presence of 
the transcription factors Fos, Fosb, Fosl2, Myc, Jun and Egr1 (Figure 3.6B). Early 
induction of these transcription factors would be expected to regulate transcription at 
later time points; for example, c-Fos (encoded by Fos) is known to regulate the 
production of IL-10, IL-12 and IFNβ downstream of TLR signalling (Dillon et al, 
2004; Kaiser et al, 2009). In addition, cluster 15 included the histone H3K27 
demethylase Jmjd3 (Agger et al, 2007), suggesting that chromatin remodelling may 
occur in response to Mtb.  
We noticed that cluster 15 contained many genes that are known targets of 
the ERK MAP kinase signalling pathway. This included the transcription factors Fos 
(Gineitis and Treisman, 2001; Kaiser et al, 2009) and Egr1 (Gineitis and Treisman, 
2001; Harada et al, 2001), the phosphatases Dusp1 (Chen et al, 2002) and Dusp5 
(Kucharska et al, 2009), Ier3 (Garcia et al, 2002; Hamelin et al, 2006) and the 
histone H3K27 demethylase Jmjd3 (Lin et al, 2011b) (Figure 3.6B). To validate the 
early expression of these genes, and the microarray data as a whole, qPCR was 
carried out using the same RNA as was used for microarray analysis. Figure 3.6C 
Chapter 3: The macrophage transcriptional response to Mtb 
 
100 
shows that Fos, Egr1, Dusp1, Dusp5, Ier3 and Jmjd3 were induced rapidly in 
macrophages infected with Mtb, but rapidly returned to baseline, confirming the 
results observed using microarray analysis. 
These results suggest that the ERK MAP kinase pathway is rapidly activated 
in macrophages in response to Mtb infection, and that this pathway leads to the 
induction of a transient cluster of transcription factors and transcriptional regulators. 
The ERK MAP kinase pathway is therefore likely to have an important bearing on 
the subsequent macrophage response. This prompted us to further investigate the role 
of the ERK MAP kinase pathway in Mtb-infected macrophages, and the results are 
presented in Chapter 5.  
3.2.3.2. Further pro-inflammatory genes are contained in cluster 23 
Like cluster 8, GO analysis of cluster 23 also showed a significant 
association with pro-inflammatory functions, including “myeloid leukocyte 
activation” and “inflammatory response” (Figure 3.4.4). This cluster, however, was 
expressed later than cluster 8, with expression first induced at 3hr post-infection, 
compared to 30mins-1hr post-infection for cluster 8, showing that the inflammatory 
response occurs in waves (Figure 3.7). This may suggest that different pathways and 
transcription factors regulate these two clusters. Cluster 23 contained the cytokines 
Il6, Il15 and Il27, the intracellular receptor Nod2, the cell surface receptor Cd40, the 
acute phase protein Saa3 (serum amyloid A3) and the TLR adaptor molecules 
Myd88 and Ticam1 (TRIF) (Figure 3.7). This cluster would therefore lead to 
enhanced inflammation, but also lead to more specific responses such as the 
activation of NK cells (IL-15) and the mediation of T cell activation of macrophages 
(Cd40), and illustrates the diversity of functions carried out by macrophages. 
Chapter 3: The macrophage transcriptional response to Mtb 
 
101 
3.2.3.3. Clusters associated with iNOS induction 
An important part of the macrophage response to Mtb is the production of 
reactive nitrogen intermediates (RNIs) by the enzyme iNOS, encoded by Nos2 (Chan 
et al, 1992; Chan et al, 1995). Two clusters were associated with the induction of 
RNIs by IPA analysis; cluster 12 showed significant overlap with the IPA pathway 
“role of nitric oxide and reactive oxygen species in macrophages” (Figure 3.4.3). and 
cluster 23 showed overlap with “production of nitric oxide and reactive oxygen 
species in macrophage” (Figure 3.4.4). However, the transcripts found to be involved 
with RNI induction, Rap1a, Rhou, Rhog, Rap1b, Jak2 and Pik3r5, are involved in 
many different signalling pathways. For example, Rap1a, Rhou, Rhog and Rap1b are 
small GTPases known to regulate a large number of biological process including 
cytoskeleton remodelling and cell-proliferation (Kaibuchi et al, 1999). This 
illustrates a caveat in the use of gene-list interpretation software such as IPA, and 
shows that associations should be confirmed by literature searching. However, the 
enzyme Nos2 (iNOS) was strongly induced by Mtb at 3hr post-infection, forming 
part of cluster 4 (Figure 3.8), suggesting that macrophages do produce RNIs in 
response to Mtb. 
3.2.3.4. Genes in cluster 4 are associated with the MHC class I antigen 
processing pathway and ubiquitination 
Cluster 4 contains 372 transcripts which are upregulated at 3-6hr post-
infection and remain upregulated up to 24hr post-infection (Figure 3.4.1; Figure 3.8). 
GO analysis of the transcripts in cluster 4 found a strong association with the GO 
terms “cytosol”, “cytoplasm” and “cytoplasmic part”, suggesting involvement with 
cytoplasmic processes (Figure 3.4.1). In addition, GO analysis found an overlap with 
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the GO term “proteasome complex”. This was due to the presence of numerous 
genes encoding subunits of the proteasome, including Psma4, Psma7, Psmb2, 
Psmb3, Psmb5, Psmb7, Psmd1, Psmd14 and Psme1 (Figure 3.8). The proteasome is 
a large, multi-subunit protease complex found in the cytoplasm, and functions to 
degrade proteins into short peptides (Vyas et al, 2008). The peptides produced are 
loaded onto MHC class I molecules and presented on the cell surface, allowing 
recognition of antigens by CD8
+
 T cells, which can lead to killing of the infected cell 
through apoptosis (Banchereau and Steinman, 1998). Induction of the proteasome 
genes in Mtb-infected macrophages suggests that the MHC class I pathway may be 
activated in response to infection. In support of this, cluster 4 also contained the 
MHC class I molecules, H2-K1 and H2-M2; and Erap1, an aminopeptidase which 
further processes peptides in the endoplasmic reticulum (ER) prior to their loading 
onto MHC class I molecules (Figure 3.8) (Saric et al, 2002).  
Analysis of cluster 4 by IPA found a highly significant overlap with “protein 
ubiquitination pathway” (Figure 3.4.1). Ubiquitin is a small protein that is covalently 
attached to other proteins by ubiquitin ligases, a process which regulates numerous 
cellular processes . The association between cluster 4 and ubiquitination was in part 
due to the proteasome subunits discussed above, as ubiquitination targets proteins to 
the proteasome for degradation (Malynn and Ma, 2010). However, cluster 4 also 
contained several ubiquitin ligases, including Smurf1, Ube2m and Ube2k (Figure 
3.8). This suggests that in response to Mtb infection, ubiquitin ligases are activated 
and this leads to the degradation of proteins via the proteasome. This may play an 
important role in the macrophage response, as ubiquitination has been shown to 
regulate many innate immune processes and signalling pathways, such as NF-κB 
signalling (Malynn and Ma, 2010). 
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3.2.3.5. Cluster 19 is associated with apoptosis 
Cluster 19, consisting of 212 transcripts induced from 3hr post-infection by 
Mtb (Figure 3.9), was strongly associated with GO terms involving apoptosis and 
cell-death (Figure 3.4.4). These were “programmed cell death”, “apoptosis”, “cell 
death” and “death” (Figure 3.4.4). Genes associated with these terms were the Bcl-2 
family members Bcl2a1b, Bcl2a1c, Bcl2a1d and Bcl3; the caspase Casp4; the death 
receptor Fas, the NLR family member Nlrp3; and the signalling molecules Ripk2 
and Traf2 (Figure 3.9).  
However, cluster 19 included genes with both pro-apoptotic and anti-
apoptotic function. The pro-apoptotic genes included Fas, a “death-receptor” which 
upon binding of FasL initiates apoptosis via its cytoplasmic death domain, leading to 
the activation of caspase 8. Caspase 8 (encoded by Casp8) was also induced by Mtb, 
although it was found in cluster 2, as its expression was induced at 6hr and 24hr 
post-infection. Cluster 19 also included Bcl2l11, which encodes for the protein Bim, 
a Bcl2 family member involved in the initiation of apoptosis (Figure 3.9) (Borner, 
2003). Induction of these genes suggested that macrophages undergo apoptosis in 
response to Mtb infection, which has been shown to be an important process as 
apoptosis of macrophages reduces the spread of Mtb within the lungs, and leads to an 
enhanced T cell response via cross-priming of CD8
+
 T cells (Behar et al, 2011).  
Anti-apoptotic genes in cluster 19 included Birc2 and Birc3, members of the 
inhibitors of apoptosis (IAP) family of proteins (Figure 3.9). IAP proteins inhibit the 
activity of caspases, the enzymes responsible for mediating apoptosis (Siegel, 2006). 
Apoptosis has an important role in limiting the viability and spread of Mtb, and leads 
to cross-priming of the CD8
+
 T cell response (Behar et al, 2011). As a result, virulent 
Mtb strains, including H37Rv, are known to actively prevent apoptosis, leading 
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instead to necrosis which promotes dissemination of Mtb (Divangahi et al, 2010; 
Behar et al, 2011). Induction of anti-apoptotic genes such as Birc2 and Birc3 may 
therefore represent a virulence strategy employed by Mtb to prevent apoptosis. 
3.2.3.6. Association of cluster 9 with steroid biosynthesis 
Both GO analysis and IPA analysis strongly linked cluster 9 to the synthesis 
of steroids (Figure 3.4.2). Transcripts in cluster 9 were upregulated specifically at 
6hr following Mtb infection (Figure 3.10). GO terms significantly associated with 
cluster 9 included “steroid biosynthetic process”, “sterol biosynthetic process” and 
“cholesterol biosynthetic process”. Sterols are a subgroup of steroids, and cholesterol 
is a sterol, strongly suggesting that genes involved in steroid biosynthesis are 
upregulated in response to Mtb infection. In support of this, IPA showed a highly 
significant overlap between genes in cluster 9 and the pathway “biosynthesis of 
steroids” (Figure 3.4.2). Genes in cluster 9 linked to steroid biosynthesis included the 
enzymes Fdps (farnesyl disposphate synthase), Mvd (mevalonate decarboxylase), 
Pmvk (phosphomevalonate kinase), Nhdsl (pterol-4-alpha-carboxylate 3-
dehydrogenase), Stard (Star-related lipid transfer protein 5) and Lss (Lanosterol 
synthase) (Figure 3.10). Taken together, these results show that macrophages 
activate pathways involving the biosynthesis of steroids at around 6hr post-infection 
with Mtb. This is relevant, as several studies have shown that cholesterol is vital for 
the entry of Mtb into macrophages, and its persistence within macrophages in vivo 
during latent infection (Gatfield and Pieters, 2000; Van der Geize et al, 2007; 
Pandey and Sassetti, 2008). Thus, production of cholesterol and other steroids by 
macrophages may favour the intracellular survival of Mtb. 
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Cluster 9 also contained genes linked to the proteasome and proteasome 
ubiquitination pathways, similarly to genes in cluster 4. GO analysis showed 
significant overlap between cluster 9 and “proteasome complex”, and IPA analysis 
showed significant overlap with “protein ubiquitination pathway” (Figure 3.4.2). 
Similarly to cluster 4, cluster 9 included several genes encoding subunits of the 
proteasome; Psmb10, Psma5, Psme2, Psmd8 and Psmb6 (Figure 3.10). Genes of the 
proteasome are therefore induced with different kinetics in Mtb-infected 
macrophages, with those in cluster 4 induced from 3hr, 6hr and 24hr post-infection, 
whilst those in cluster 9 were only induced at 6hr post-infection. This may reflect 
differing functions of the various proteasome subunits.  
3.2.3.7. A type I IFN-inducible cluster of genes in Mtb-infected macrophages 
Strikingly, cluster 2 showed highly significant overlap with the canonical 
pathway “Interferon Signalling” following IPA analysis (Figure 3.4.1). This was of 
interest as type I IFN has been reported to play a negative role during Mtb infection 
(Manca et al, 2001; Manca et al, 2005; Ordway et al, 2007; Antonelli et al, 2010) 
and an interferon signature was recently reported in the blood of patients with active 
TB (Berry et al, 2010). Cluster 2 contained 257 transcripts, which were induced by 
Mtb at 6hr and 24hr post-infection (Figure 3.11). Genes in this cluster linked to 
interferon signalling by IPA included the transcription factors Stat1, Stat2 and Irf9, 
the antiviral molecules Mx1, Oas1a, Oas1g, Oas2 and Oas3 and the IFN-inducible 
protein Ifit3 (Figure 3.11). Several other known IFN-inducible genes were also 
present in cluster 2. These included the transcription factors Irf2 and Irf7 (Tamura et 
al, 2008); the IFN-inducible proteins Ifi44 and Ifit2; and the antiviral gene Isg20 
(Espert et al, 2003) (Figure 3.11). In addition, cluster 2 included two members of the 
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tri-partite motif (TRIM) family of proteins, Trim34 and Pml (TRIM19), which have 
recently been suggested to play an important role in regulating the innate immune 
response (McNab et al, 2010).  
The IPA “interferon signalling” canonical pathway includes both type I IFN 
and IFNγ signalling. To determine the relative contribution to these pathways, 
transcripts in cluster 2 were overlaid onto the IPA “interferon signalling” pathway, 
with genes present in cluster 2 highlighted in red (Figure 3.12A). Genes involved in 
both type I IFN and IFNγ signalling were present in cluster 2. However, of the four 
genes involved in IFNγ signalling, three (Stat1, Irf9 and Psmb8) were common to 
type I IFN signalling, explaining the induction of this pathway in the absence of 
IFNγ signalling, and illustrating the overlap between these two pathways (Figure 
3.12A). The presence of genes unique to type I IFN signalling, Stat2, Mx1, Oas and 
Ifit3 strongly suggested that type I IFN signalling was responsible for this cluster. In 
support of this, Ifnb1, the gene encoding IFNβ, was upregulated at 3hr post-infection 
(Figure 3.12B), in keeping with the appearance of type I IFN-inducible genes at 6hr 
post-infection (Figure 3.11). However, IFNβ protein was consistently undetectable 
from macrophages infected with Mtb by ELISA (data not shown), suggesting that 
low but biologically active concentrations of type I IFN are induced by Mtb. Taken 
together, these data strongly suggest that type I IFN is induced by macrophages, in 
response to Mtb, and that this feeds back to regulate gene expression. This is in 
agreement with previous studies reporting type I IFN induction in Mtb-infected 
macrophages (Stanley et al, 2007; Pandey et al, 2009).  
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3.2.3.8. Downregulated clusters are associated with DNA replication, 
metabolism and cell-division 
Of the clusters that were downregulated following Mtb infection, several 
showed significant overlap with GO terms related to metabolism and cell-division. 
This was particularly strong for cluster 7 (Figure 3.4.2) and clusters 13, 16 and 17 
(Figure 3.4.3), which were downregulated between 3hr and 24hr post-infection 
(Figure 3.13-3.16).  
Genes in clusters 7 and 17 were significantly associated with metabolic 
processes, with highly significant overlap with the GO terms “cellular 
macromolecule metabolic process” and “cellular metabolic process” for cluster 7 
(Figure 3.4.2), and “catalytic activity” and “metabolic process” for cluster 17 (Figure 
3.4.3). This included numerous enzymes involved in metabolism and catabolic 
processes. Cluster 7 contained B4galt1 (beta 1,4-galactosyl transferase), Cbr1 
(carbonyl reductase 1), Coasy (CoA synthase), Dhdh (dihydrodiol dehydrogenase), 
Gpt2 (glutamic pyruvate transaminase), Lcmt1 (leucine carboxyl methyltransferase) 
and Umps (urindine monophosphate synthetase) (Figure 3.13). Cluster 17 contained 
Acp6 (acid phosphatase 6), Galt (galatcose-1-phosphate urididyltransferase), Gnpda1 
(glucosamine-6-phosphate deaminase 1) and Plcb2 (phospholipase C, beta 2) (Figure 
3.14).  
Cluster 13, which was strongly downregulated at 3hr, 6hr and 24hr (Figure 
3.15), contained genes with a significant overlap with GO terms involving cell-
division, including “mitosis”, “nuclear division” and “M phase of mitotic cell cycle” 
(Figure 3.4.3). Genes in cluster 13 associated with these terms were members of the 
cyclin family of proteins, Cnnm2 and Cnnm3, which control cell division through 
activation of the cyclin dependent kinases; the centromere proteins Cenph, Cenpk, 
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Cenpm and Cenpp; and the kinesin family members Kif11, Kif13A, Kif15, Kif18A, 
Kif20b, Kif21b, Kif23, Kif2c and Kif3a (Figure 3.15), which control chromosome 
segregation during mitosis (Mandelkow and Mandelkow, 2002).  
In keeping with a downregulation of genes involved in cell-division, the 
genes in cluster 16 were strongly associated with DNA replication, a vital stage in 
the cell-cycle (Figure 3.4.3). Genes in cluster 16 were downregulated at 6hr and 24hr 
following Mtb infection, although the downregulation was relatively mild compared 
to clusters 7, 13 and 19 (Figure 3.16). These genes were upregulated in the 
uninfected controls at 24hr post-infection, suggesting that DNA replication may 
occur in uninfected macrophages (Figure 3.16). GO terms associated with cluster 16 
included “DNA metabolic process” and “DNA replication (Figure 3.4.3). IPA 
confirmed this association, as cluster 16 was significantly linked with the IPA 
pathways “cell cycle control of chromosomal replication” and “pyrimidine 
metabolism” (Figure 3.4.3). The genes in cluster 16 that linked to DNA replication 
pathways included several members of the minichromosome maintenance complex, 
Mcm3, Mcm5, Mcm6, Mcm7 and Mcm10, which is involved in the initiation and 
elongation stages of DNA replication (Figure 3.16). Also in cluster 16 are two 
subunits of the GINS complex, Gins1 and Gins2, which are also involved in DNA 
replication (De Falco et al, 2007), and a subunit of the DNA polymerase enzyme, 
Pole (Figure 3.16). 
In summary, analysis of clusters 7, 13, 16 and 17 strongly suggests that 
macrophages down regulate genes involved in metabolism, cell-division and DNA 
replication in response to Mtb infection. This may be to allow the macrophages to 
direct resources towards antimicrobial processes, such as the production of 
cytokines, chemokines and antimicrobial molecules. 
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3.2.3.9. The downregulated cluster 10 is associated with lysosome function 
Although the majority of downregulated clusters were associated with either 
metabolism or cell-division, genes in cluster 10 showed a significant association 
with GO terms relating to the lysosome, including “lytic vacuole”, “lysosome” and 
“vacuole” (Figure 3.4.2). This was intriguing as lysosomes and lysomomal enzymes 
are vital for protection against intracellular pathogens such as Mtb, as fusion of 
vacuoles containing Mtb with lysosomes leads to the destruction of the bacteria and 
the generation of peptides for antigen presentation (Pieters, 2008). The genes in 
cluster 10 associated with lysosomes were predominantly genes encoding lysosomal 
enzymes. This included peptidases such as the cathepsins, Ctsf and Ctsb; Galc 
(galactosylceramidase), Hexa (hexosaminidase) and Tpp1 (tripeptidyl peptidase 1). 
In addition, several enzymes involved in carbohydrate digestion were present in 
cluster 10, including Mann2b1 (mannosidase) and Gusb (glucoronidase B) (Figure 
3.17). Given the importance of the lysosome in mediating Mtb killing in 
macrophages, it is possible that this downregulation of lysosomal genes is a 
virulence strategy of Mtb, designed to avoid macrophage killing and enabling Mtb to 
persist within the cell. 
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3.3. Discussion 
The interactions between Mtb and macrophages are complex, with the 
macrophage attempting to eliminate the bacteria, and Mtb trying to subvert these 
processes (Pieters, 2008). The outcome of these interactions may be critical in 
determining the progression of the disease. Here we carried out transcriptional 
profiling of Mtb-infected macrophages over an extended time course. This revealed 
that the macrophage response to Mtb changes greatly over time, with genes induced 
and repressed with varying kinetics. We separated these genes into 24 clusters using 
k-means clustering, and analysis of these with IPA and GO analysis found 
associations with a wide range of important processes, including inflammation, 
antigen presentation, apoptosis, protein ubiquitination, sterol biosynthesis, cell-
division and metabolism. 
3.3.1. The early transcriptional response to Mtb infection  
Previous microarray studies of Mtb-infected macrophages did not address the 
response of macrophages to Mtb earlier than 4hr post-infection (Ehrt et al, 2001; 
Chaussabel et al, 2003; Shi et al, 2003; Wang et al, 2003; Shi et al, 2005; Tailleux et 
al, 2008; Koo et al, 2012) (Table 3.1). We show here that although the majority of 
macrophage transcriptional changes occur at 3hr post-infection and later, a small 
number of transcripts were upregulated at between 30mins and 1hr post-infection. k-
means clustering showed that these transcripts comprised two main clusters; one 
with sustained upregulation up to 24hr post-infection (cluster 8), associated with 
induction of cytokines, chemokines and NF-κB signalling, and a second with 
transient upregulation, containing transcripts which peaked at 1hr post-infection and 
returned to baseline by 3hr post-infection (cluster 15), associated with transcriptional 
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regulation and ERK MAP kinase signalling. This illustrates the importance of 
including early time points in this analysis, particularly with regard to the transcripts 
in cluster 15, which would not have been detected had the analysis started at 3hr 
post-infection.  
Many of the genes in cluster 8 were pro-inflammatory in nature, such as the 
cytokines Tnf and Il1b, and the chemokines Ccl2, Ccl3, Ccl4, Ccl7, Cxcl1 and Cxcl2. 
The production of chemokines in particular results in the influx of further immune 
cells into the site of infection, which is a vital process during Mtb infection as it 
culminates in the formation of the granuloma which sequesters Mtb within foci of 
immune cells (Flynn et al, 2011). For example, loss of Ccl2 and Ccl7 signalling in 
Ccr2
-/-
 mice infected with Mtb led to a complete loss of monocyte recruitment to the 
lung, and failure to control the infection (Peters et al, 2001). TNFα and IL-1β are 
also highly pro-inflammatory in nature, although their precise function in the 
immune response to Mtb is unclear (Cooper et al, 2011). However, loss of either of 
these cytokines renders mice highly susceptible to Mtb infection (Flynn et al, 1995; 
Mayer-Barber et al, 2011). Thus, this early production of cytokines and chemokines 
by Mtb-infected macrophages in the lung is likely to represent a vital first stage in 
mounting a protective immune response. 
The transiently induced genes in cluster 15 included many transcription 
factors and transcriptional regulators, such as Fos, Egr1, Jun, Myc and the histone 
H3K27 demethylase Jmjd3. These transcription factors are likely to induce the 
transcription of the genes upregulated at later time points, leading to the cascade of 
gene activation observed. Further work will be needed to address the precise 
function of these transcription factors in the immune response to Mtb, making use of 
either specific inhibitors or gene knockouts. In particular, the induction of the histone 
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demethylase Jmjd3 is notable, in the light of recent studies showing that bacteria can 
stimulate chromatin modifications in host cells as a virulence mechanism, to modify 
gene expression (Hamon and Cossart, 2008). For example, the Listeria 
monocytogenes virulence factor LntA was recently shown to target the chromatin 
repressor BAHD1, which resulted in increased expression of type III IFN (Lebreton 
et al, 2011). To date, Mtb virulence has not been linked to chromatin remodelling, 
but the early induction of a histone demethylase in macrophages suggests that this 
may occur, and warrants further investigation. 
3.3.2. A type I IFN signature in Mtb infected macrophages 
Using IPA analysis, we identified a cluster of genes strongly linked to IFN 
signalling. This cluster (cluster 2) was induced at 6hr and 24hr post-infection, and 
contained many well known IFN-inducible genes including the transcription factors 
Stat1, Stat2 and Irf9 and the antiviral genes Mx1, Oas1a, Oas1g, Oas2, Oas3 and 
Isg20 (Stark et al, 1998; Sadler and Williams, 2008). Induction of this cluster 
occurred subsequently to the expression of IFNβ mRNA at 3hr post-infection, 
strongly suggesting that type I IFN was responsible for the induction of this cluster. 
Although IFNβ was not detectable at the protein level by ELISA, type I IFNs are 
known to often be produced at low but biologically active levels (Gough et al, 2012).  
Several previous studies have reported induction of type I IFNs, particularly 
IFNβ, in macrophages infected with Mtb (Giacomini et al, 2001; Stanley et al, 2007; 
Leber et al, 2008; Pandey et al, 2009; Manzanillo et al, 2012). This was shown to 
depend on cytosolic recognition of Mtb or Mtb-components by either NOD2 (Leber 
et al, 2008; Pandey et al, 2009) or a cytosolic DNA sensor (Manzanillo et al, 2012). 
In addition, the upregulation of type I IFN inducible genes has been reported in 
Chapter 3: The macrophage transcriptional response to Mtb 
 
113 
human macrophages and DCs infected with Mtb (Chaussabel et al, 2003; Tailleux et 
al, 2008; Wu et al, 2012). IFN-inducible genes are also upregulated in the blood of 
patients with active TB, but not those with latent TB or healthy controls (Berry et al, 
2010). Induction of type I IFN and IFN-inducible genes seems to be common to both 
human and mouse cells infected with Mtb, and may play an important role during 
infection.  
Mouse models have shown that type I IFN plays a detrimental role in the 
immune response to Mtb, with mice deficient in type I IFN signalling having lower 
bacterial loads following infection (Manca et al, 2005; Ordway et al, 2007; Stanley 
et al, 2007). The induction of type I IFN may therefore be a virulence strategy of 
Mtb to subvert the macrophage response. This is supported by the fact that induction 
of type I IFN by Mtb, both in vitro and in vivo, depends on the ESX-1 secretion 
system (Stanley et al, 2007). This secretion system is crucial for Mtb virulence, and 
loss of the genes encoding it accounts for the attenuation of BCG (Pym et al, 2002).  
The observation of type I IFN-inducible genes in Mtb-infected macrophages 
prompted us to further investigate how type I IFN regulates the macrophage 
response, and the results are shown in Chapter 4.  
3.3.3. Mtb induction of genes involved in cholesterol biosynthesis 
We found that a number of genes involved in the biosynthesis of steroids, 
including cholesterol, were upregulated following Mtb infection (cluster 9; Figure 
3.4.2). This was confirmed by both GO and IPA analysis and included the enzymes 
phosphomevalonate kinase (Pmvk) and mevalonate decarboxylate (Mvd), which are 
involved in the mevalonate pathway, a biosynthetic pathway that produces the 
precursors for a wide range of steroids, including cholesterol (Goldstein and Brown, 
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1990). These results are in agreement with a recent study by Koo et al (2012), which 
described the induction of steroid biosynthesis genes, including Mvd, by the 
hypervirulent strain of Mtb HN878, but not by the less virulent strain CDC1551. We 
show here that H37Rv also induces genes involved in steroid biosynthesis. Induction 
of these genes by Mtb therefore appears to be strain specific, and induction of these 
genes to differing levels may in part explain differences in virulence observed 
between different strains of Mtb.  
The induction of steroid biosynthesis genes may represent a virulence 
strategy of Mtb. It was reported that Mtb is able to metabolise cholesterol, and this is 
dependent upon genes in the mce4 operon, which encodes for transporters that 
transport cholesterol across the bacterial cell wall (Pandey et al, 2009). The 
importance of this was shown by the fact that mutant Mtb deficient in mce4 were 
unable to survive in the lung during the chronic stages of infection in mice, showing 
that cholesterol metabolism is required for Mtb persistence in vivo (Pandey et al, 
2009). In human TB the production of lipids such as cholesterol leads to the 
appearance of “foamy” macrophages in the lung, characterised by intracellular lipid 
droplets (Russell et al, 2009). Electron microscopy has shown that Mtb is closely 
associated with these lipid droplets in the lungs of TB patients, and it has been 
hypothesised that this provides an energy source which enables Mtb to persist within 
the lungs during the latent stage of infection (Pieters, 2001; Russell et al, 2009). In 
addition, cholesterol is required for the entry of mycobacteria into macrophages, 
through a variety of receptors (Gatfield and Pieters, 2000; Peyron et al, 2008). Our 
results therefore suggest that Mtb generates the production of these steroids such as 
cholesterol by manipulating host metabolism, through inducing enzymes involved in 
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the generation of lipids, and that this may enable Mtb to enter macrophages, and 
persist within them.  
3.3.4. Induction of apoptosis related genes by Mtb 
A prominent cluster of genes upregulated at 3hr, 6hr and 24hr post-infection, 
cluster 19 (Figure 3.4.4), was strongly associated with GO terms relating to the death 
of cells, including “apoptosis” and “programmed cell-death”. This strongly 
suggested that macrophages were undergoing cell death in response to Mtb. There 
are two main mechanisms leading to cell death; apoptosis and necrosis (Behar et al, 
2011). Necrosis is characterised by the disruption of the plasma membrane, whereas 
during apoptosis the integrity of the plasma membrane is preserved, and the cell 
breaks up into many small vesicles (blebbing) (Behar et al, 2011). The death of 
macrophages by apoptosis is known to promote the host response to Mtb, first 
because it leads to reduced viability of Mtb (Oddo et al, 1998; Divangahi et al, 2009) 
and second because the apoptotic vesicles contain Mtb antigens, which are taken up 
by DCs and used to cross-prime CD8
+
 T cells, leading to an enhanced CD8
+
 T cell 
response (Schaible et al, 2003; Winau et al, 2006; Divangahi et al, 2009). The 
expression of pro-apoptotic genes, such as Fas and Bcl2l11, is therefore likely to be 
protective in the host response. In support of this, apoptosis mediated through the 
Fas receptor has been shown to reduce Mtb viability in human macrophages (Oddo 
et al, 1998). 
However, Mtb has also been shown to actively inhibit apoptosis in 
macrophages, leading instead to necrosis which promotes inflammation and bacterial 
dissemination (Behar et al, 2011). Evidence for this comes from studies showing that 
virulent strains of Mtb induce greater levels of necrosis compared to avirulent 
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strains, which are more prone to induce apoptosis (Chen et al, 2006; Gan et al, 2008; 
Divangahi et al, 2009). The virulent strain of Mtb, H37Rv, has consistently been 
shown to induce greater levels of necrosis in macrophages compared to the avirulent 
strain H37Ra, through increased disruption of the mitochondrial membrane (Chen et 
al, 2006) and manipulation of the synthesis of eicosanoids (Gan et al, 2008; 
Divangahi et al, 2009). We also observe the upregulation of anti-apoptotic genes in 
Mtb-infected macrophages, specifically two members of the inhibitor of apoptosis 
(IAP) family, Birc2 and Birc3, which prevent apoptosis by inhibiting the activity of 
caspases (Siegel, 2006). Mtb may induce expression of Birc2 and Birc3 as a 
virulence mechanism, in order to prevent apoptosis, resulting in macrophage death 
by necrosis and increased bacterial dissemination. 
3.3.5. Upregulation of MHC class I-related antigen processing genes 
in Mtb-infected macrophages 
Cluster 4 (Figure 3.4.1) contained many genes involved with processing of 
antigens for presentation on MHC class I molecules. Antigens presented on MHC 
are derived from the cytosol of cells, and typically derive from cytosolic pathogens 
such as viruses (Vyas et al, 2008). Peptide antigens presented on MHC class I 
molecules are then recognised by CD8
+
 T cells, and this leads to death of the 
infected cell (Vyas et al, 2008). The generation of these peptides occurs through the 
action of the proteasome, which degrades proteins into short peptides which are then 
transported into the ER by the TAP (transporter associated with antigen processing) 
transporter. In the ER, peptides are further processed by peptidases such as the ER 
aminopeptidase (encoded by Erap1), loaded onto MHC class I molecules and 
transported to the cell surface (Vyas et al, 2008). Cluster 4 contained a large number 
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genes encoding subunits of the proteasome, two MHC class I molecules, H2-K1 and 
H2-M2, and the aminopeptidase Erap1. This strongly suggested that the MHC class 
I antigen presentation pathway was activated in Mtb-infected macrophages. 
CD8
+
 T cells are known to recognise Mtb antigens during infection, and 
although not as important as CD4
+
 T cells, still play an important role in containing 
bacterial growth (North and Jung, 2004). However, given that Mtb resides in the 
phagosome, which is restricted to the MHC class II pathway, how Mtb antigens enter 
the MHC class I pathway and activate CD8
+
 T cells has been an area of much 
research. Two pathways have been proposed for the entry of exogenous antigens into 
the MHC class I pathway (a process known as cross-priming or cross-presentation) 
(Vyas et al, 2008). First, antigens may exit from the phagosome into the cytosol, be 
processed by the proteasome and enter the ER via the TAP transporter, as in classical 
MHC class I antigen processing (the cytosolic pathway) (Vyas et al, 2008). Second, 
antigens in the phagosome may traffic to a vesicle containing recycled MHC class I 
molecules, and thus bypass the proteasome and ER (the vesicular pathway) (Vyas et 
al, 2008). In the context of Mtb, several studies have shown that cross-presentation 
of a variety of Mtb antigens by human monocyte derived DCs requires the 
proteasome and the TAP transporter, suggesting that Mtb antigens enter the cytosol, 
although exactly how Mtb antigens exit from the phagosome remains unclear 
(Lewinsohn et al, 2006; Grotzke et al, 2009; Grotzke et al, 2010). However, in 
contrast to these studies, cross-presentation of the 19kDa antigen of Mtb was shown 
to be TAP-independent (Neyrolles et al, 2001) and cross-priming of apoptotic 
vesicles by bystander-DCs was also shown to be proteasome-independent (Schaible 
et al, 2003), supporting a role for the vesicular pathway. Our results support a role 
for the cytosolic pathway, as many genes involved in this pathway, particularly 
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proteasome subunits and the TAP transporter, were upregulated by macrophages in 
response to Mtb. However, this does not exclude a role for the vesicular pathway, 
and it may be that both pathways are important depending on the Mtb antigen. 
3.3.6. Macrophages downregulate many genes in response to Mtb 
infection 
It was notable that, despite infection with Mtb being regarded as an 
“activating” signal for macrophages, almost as many transcripts were downregulated 
in response to infection, as were upregulated. This effect has been consistently 
observed in microarray studies of innate immune cells treated with a wide variety of 
pathogens and pathogen derived products including Mtb (Nau et al, 2002; 
Chaussabel et al, 2003; Ramsey et al, 2008), but the function of these genes has not 
been investigated in detail. In our study, GO analysis of several clusters of 
downregulated transcripts found them to be significantly associated with 
metabolism, cell-division and DNA replication. It therefore seems likely that 
macrophages shut off these processes in order to direct resources towards the 
antimicrobial response, such as the production of cytokines, chemokines and 
antimicrobial molecules as shown above.  
However, one cluster of downregulated genes was associated with lysosome 
function. Lysosomes are intracellular vesicles of low pH which contain various 
hydrolytic enzymes capable of destroying phagocytosed material, and the 
downregulated genes in this cluster included several lysosomal enzymes such as 
Cathepsin F (Ctsf) and Cathepsin B (Cfsb) (Vergne et al, 2004). Normally, 
phagosomes containing bacteria fuse with lysosomes, leading to bacterial killing and 
the generation of antigens for presentation on MHC class II molecules (Vyas et al, 
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2008). However, Mtb has evolved to block the maturation of the phagosome and its 
subsequent fusion with lysosomes, creating a “mycobacterial phagosome” in which 
it can replicate (Vergne et al, 2004). Mtb achieves this by preventing the 
accumulation of phosphatidylinositol 3-phosphate (PI3P) on the phagosome surface, 
a process which is required for phagosome maturation (Pieters, 2008). It is tempting 
to speculate that the downregulation of lysosome associated genes may represent an 
additional mechanism by which Mtb blocks phagosome-lysosome fusion. However, 
these genes are downregulated only at 24hr post-infection, well after the first entry of 
Mtb into the macrophages, and thus may instead be a natural response of 
macrophages to the establishment of infection. Further research will be needed to 
determine whether this represents a true virulence strategy of Mtb.  
3.3.7. Use of IPA and GO analysis to investigate functions associated 
with differentially expressed genes 
We used two independent strategies to try and determine the functions of 
clusters of genes generated by k-means clustering using GeneSpring. The first was 
gene ontology (GO) analysis, which uses the GO database, a resource where genes 
are annotated with terms relating to their function, based on the published literature 
(Harris et al, 2004). An example would be the cytokine TNFα, which is associated 
with the GO terms “cytokine” and “cytokine signalling” among others. A second 
approach, Ingenuity Pathway Analysis (IPA) was also used. We used IPA analysis to 
determine significant associations with canonical signalling pathways in IPA, which 
are built based on interactions reported in the literature (Calvano et al, 2005). 
STAT1, for example, would be linked to the IFN signalling pathway.  
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Our results highlight the pros and cons of both approaches. In general, IPA 
generated more specific information about the potential functions of different 
clusters. For example, IPA linked cluster 2 with IFN signalling, due to the presence 
of Stat1, Stat2, Irf9 and Mx1. In contrast, GO analysis found associations with the 
“immune process” and “immune system process”, vague terms which provide little 
information on the signalling pathways regulating these genes. However, GO often 
gave useful biological information on clusters in which no significant IPA clusters 
were found. For example, the downregulated clusters of genes linked to cell-division 
and metabolism by GO analysis showed no association with IPA pathways. This 
may reflect the fact that analysis of signalling pathways by IPA cannot encompass 
broad cellular functions such as metabolism.  
In general, however, the results of both IPA and GO analysis should be 
treated with caution, as the information in these databases is generated from vast 
amounts of published literature, which may not always be scientifically validated. 
For example, an interaction or function of a gene reported in a cell-line may not 
reflect its true function in a primary cell or in vivo. Thus, it is important to validate 
suggested IPA and GO functions by manually searching the published literature to 
confirm these associations. 
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3.4. Figures 
 
Figure 3.1. Mtb-infected samples at 3hr, 6hr and 24hr post-infection cluster 
separately from uninfected controls. WT macrophages were infected with Mtb and 
at the indicated time points post-infection RNA was harvested and analysed by 
microarray. Data was normalised, and undetectable transcripts were removed, as 
described in the Materials and Methods. Unsupervised clustering was then applied to 
the samples, using a Euclidian distance metric.  
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Figure 3.2. Macrophages infected with Mtb undergo dramatic transcriptional 
changes. WT macrophages were infected with Mtb and at the indicated time points 
post-infection RNA was harvested and microarray analysis was carried out. Data was 
normalised and undetectable transcripts were removed as described in the Materials 
and Methods. Differentially regulated transcripts were obtained by taking those that 
were at least 2-fold up- or downregulated in infected samples vs. controls at any time 
point, and those that were significantly different by two-way ANOVA p<0.05 with 
Benjamini Hochberg FDR multiple testing correction. This left 6479 transcripts, 
which were subjected to hierarchical clustering using Pearson centred distance 
metric and complete linkage. Normalised expression was visualised using a heat 
map.
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Figure 3.3. Mtb induced transcriptional changes can be separated into distinct 
clusters. The 6479 differently expressed transcripts in Figure 3.2 were separated into 
24 clusters by k-means clustering, using a Pearson Centred distance metric. The 
normalised expression profile of the transcripts in each cluster is shown.  
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Figure 3.4.1. Mtb-induced transcriptional clusters are associated with a wide 
range of GO terms and IPA pathways. Each of the 24 k-means clusters described 
in Figure 3.3. were analysed by GO and IPA. GO terms and IPA pathways with 
significant overlap (p<0.01) are displayed next to expression profiles of the 
corresponding cluster. Associations of the clusters with functions and signalling 
pathways as determined by literature searching, and the genes associated, are also 
shown.  
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Figure 3.4.2. Mtb-induced transcriptional clusters are associated with a wide 
range of GO terms and IPA pathways. Each of the 24 k-means clusters described 
in Figure 3.3. were analysed by GO and IPA. GO terms and IPA pathways with 
significant overlap (p<0.01) are displayed next to expression profiles of the 
corresponding cluster. Associations of the clusters with functions and signalling 
pathways as determined by literature searching, and the genes associated, are also 
shown.  
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Figure 3.4.3. Mtb-induced transcriptional clusters are associated with a wide 
range of GO terms and IPA pathways. Each of the 24 k-means clusters described 
in Figure 3.3. were analysed by GO and IPA. GO terms and IPA pathways with 
significant overlap (p<0.01) are displayed next to expression profiles of the 
corresponding cluster. Associations of the clusters with functions and signalling 
pathways as determined by literature searching, and the genes associated, are also 
shown.  
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Figure 3.4.4. Mtb-induced transcriptional clusters are associated with a wide 
range of GO terms and IPA pathways. Each of the 24 k-means clusters described 
in Figure 3.3. were analysed by GO and IPA. GO terms and IPA pathways with 
significant overlap (p<0.01) are displayed next to expression profiles of the 
corresponding cluster. Associations of the clusters with functions and signalling 
pathways as determined by literature searching, and the genes associated, are also 
shown.  
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Figure 3.5. Cluster 8 is associated with pro-inflammatory functions. (A) 
Expression profile of transcripts cluster 8. (B) Transcripts in cluster 8 were clustered 
hierarchically using Pearson centred distance metric with complete linkage. 
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Figure 3.6. Cluster 15 is associated with ERK MAP kinase signalling. (A) 
Expression profile of cluster 15. (B) Genes in cluster 15 were clustered 
hierarchically using Pearson centred distance metric with complete linkage. (C) The 
same RNA was analysed by qPCR for expression of selected genes in cluster 15. 
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Figure 3.7. Cluster 23 is associated with pro-inflammatory functions. (A) 
Expression profile of cluster 23. (B) Transcripts in cluster 23 were clustered 
hierarchically using Pearson centred distance metric with complete linkage. 
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Figure 3.8. Cluster 4 is associated with the MHC class I antigen presentation 
pathway, and ubiquitination. (A) Expression profile of cluster 4. (B) Transcripts in 
cluster 4 were clustered hierarchically using Pearson centred distance metric with 
complete linkage. 
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Figure 3.9. Cluster 19 is associated with apoptosis and cell-death. (A) Expression 
profile of cluster 19. (B) Transcripts in cluster 19 were clustered hierarchically using 
Pearson centred distance metric with complete linkage. 
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Figure 3.10. Cluster 9 is associated with steroid biosynthesis. (A) Expression 
profile of cluster 9. (B) Transcripts in cluster 9 were clustered hierarchically using 
Pearson centred distance metric with complete linkage. 
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Figure 3.11. Cluster 2 is associated with IFN signalling. (A) Expression profile of 
cluster 2. (B) Transcripts in cluster 2 were clustered hierarchically using Pearson 
centred distance metric with complete linkage. 
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Figure 3.12. Type I IFN is strongly associated with genes in cluster 2. (A) 
Transcripts in cluster 22 were overlaid on the canonical pathway of IPA for 
Interferon Signalling. Genes over-represented in Cluster 2 are shaded in red. (B) 
Normalised Expression of Ifnb1 determined by microarray analysis following Mtb 
infection of macrophages.  
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Figure 3.13. Cluster 7 is associated with metabolism. (A) Expression profile of 
cluster 7. (B) Transcripts in cluster 7 were clustered hierarchically using Pearson 
centred distance metric with complete linkage. 
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Figure 3.14. Cluster 17 is associated with metabolism. (A) Expression profile of 
cluster 17. (B) Transcripts in cluster 17 were clustered hierarchically using Pearson 
centred distance metric with complete linkage. 
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Figure 3.15. Cluster 13 is associated with cell-division. (A) Expression profile of 
cluster 13. (B) Transcripts in cluster 13 were clustered hierarchically using Pearson 
centred distance metric with complete linkage. 
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Figure 3.16. Cluster 16 is associated with DNA replication. (A) Expression 
profile of cluster 16. (B) Transcripts in cluster 16 were clustered hierarchically using 
Pearson centred distance metric with complete linkage. 
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Figure 3.17. Cluster 10 is associated with lysosomes. (A) Expression profile of 
cluster 10. (B) Transcripts in cluster 10 were clustered hierarchically using Pearson 
centred distance metric with complete linkage. 
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3.5. Transcripts present in the 24 k-means clusters shown in 
Figure 3.3 
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Cluster 0 
0610037M15Rik Eno1 Ly78 Slfn10 
1700029F09Rik Eprs Ly9 Smox 
2010106G01Rik Faf1 M6pr Smox 
2500002E12Rik Fam116b Map3k7 Smox 
2810407C02Rik Fancl Mlx Snx2 
5730455P16Rik Flrt2 Mlx Snx2 
AA960436 G3bp2 Mmp9 Sphk2 
Abcc5 Gba Nol3 Stat1 
Acp2 Gde1 Nr1h3 Stat6 
Acp2 Gipc1 Nr1h3 Symbol 
Actb Glrx Ociad1 Taf12 
Acvrl1 Gm885 P4ha1 Tapbpl 
Adam8 Gnat3 Papd4 Tarbp2 
Adam8 Gpr35 Papd4 Tbc1d9 
Ahcyl1 Gsdmdc1 Parp3 Tcirg1 
Ahsa1 Gsta3 Pdcd6ip Tcirg1 
Akt3 Gstm2 Pilra Tor1a 
Alg12 H2-D4 Pilra Tor1aip1 
Asph H2-K1 Pilrb1 Tpx2 
Asph H2-Q6 Pira4 Trdmt1 
Atf2 H2-Q7 Pkm2 Trim21 
Atl3 H2-Q8 Pkm2 Tspan3 
B230311C12Rik H2-Q8 Pla2g7 Tspo 
B230312A22Rik H2-T10 Plod3 Tspo 
Baz2b Hcls1 Pmm2 Tyk2 
BC002236 Hmgn3 Por Ube2l6 
BC025458 Hmgn3 Pou3f1 Vrk2 
Bst1 Hsp105 Psmd2 Wars 
C1galt1 Hsp90ab1 Rbm10 Zdhhc24 
Calr Hspa9 Rims3 Zfp313 
Cd72 Idua Rin2 Zubr1 
Cdc27 Kif3b Rnf114  
Cep170 Lgals9 Rnf135  
Cnp Lin54 Rtn3  
Copg LOC100044756 Sco1  
Cul2 LOC100045963 Sept8  
Cyfip1 LOC100046056 Sgk3  
D330045A20Rik LOC209372 Sla  
D430044G20Rik LOC224487 Slc10a7  
Dedd LOC229810 Slc11a1  
Dnajc2 LOC230765 Slc11a1  
Dock4 LOC238943 Slc11a1  
Dync1i2 LOC241293 Slc13a3  
EG433633 LOC547150 Slc13a3  
EG630499 LOC624198 Slc28a2  
EG667977 LOC668631 Slc7a7  
Elac2 LOC674135 Slfn10  
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Cluster 1 
1110004P21Rik D8Ertd82e Rasgef1a  
1300014I06Rik D930042A21Rik Rbm12  
1700029G01Rik Ddx28 Rhof  
2600011E07Rik Elovl6 Rps6ka5  
4831426I19Rik Fam123a Selp  
4831426I19Rik Fancc Sh3gl1  
4930477M19 Fancc Shb  
4933428G20Rik Foxp1 Sipa1l2  
5033413D16Rik Gpr132 Slc35e4  
5730494J16Rik Hectd2 Socs2  
5830411I20 Hs3st3b1 Specc1  
5930403N24Rik Irgq Swap70  
6430527G18Rik Itpkc Swap70  
9130604K18Rik Klf5 Tal1  
Adrbk2 Lfng Tgfbr1  
Adss Llgl2 Tiam1  
Agfg2 Lmna Tjp2  
AI115600 Lmna Tjp2  
Ankrd28 LOC233400 Tle3  
Ankrd28 LOC380617 Tnfrsf12a  
Asxl1 LOC380992 Tnfsf14  
Atp13a3 LOC383067 Tnfsf14  
B130015M16Rik LOC384646 Tnfsf4  
B3gnt7 Lpl Ttl  
B430005K18Rik Map2k3 Unc119b  
Bahd1 Mapkapk3 Wdhd1  
BC022687 Mixl1 Whsc1  
BC026996 Mixl1 Zbtb32  
Bcl2l11 Mmp10   
Bcl2l11 Mpp5   
Bcl2l11 Mpp7   
Bcor Odc1   
Bcor Pdgfa   
Bzw2 Pdgfb   
Capn2 Pdgfb   
Capn2 Phldb1   
Capn2 Plat   
Catnb Plec1   
Cd70 Plekhf1   
Cd80 Plekhg2   
Cdc14a Plekhg2   
Cdca4 Pmp22   
Cdca4 Prickle3   
Cdk5r1 Pscd3   
Cdk6 Ptbp1   
D130063H01Rik Rab15   
D230048P18Rik Rab3il1   
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Cluster 2 
1110018G07Rik BC013712 Gpr141 LOC240921 
1600014C10Rik BC023892 Gpsm2 LOC380616 
1600014C10Rik BC023892 Gstt1 LOC380706 
1700034P14Rik BC050811 Gtpbp2 LOC383125 
1700041G16Rik BC094916 Gvin1 LOC435565 
1810035L17Rik Bcl9 Gys3 LOC547380 
2210009G21Rik Bxdc5 H2-M3 LOC623121 
2310010B21Rik C130020C07Rik H2-Q5 LOC623121 
2310033F14Rik C130026I21Rik H2-Q5 LOC625360 
2410025L10Rik C130026I21Rik H2-T10 LOC667370 
2810425O13Rik Cab39l H2-T10 LOC667776 
2810439F02Rik Casp8 H2-T23 LOC673556 
4921517J08Rik Casp8 H2-T24 Mad 
4930555L11Rik Ctsc Hdlbp Mid1 
4930599N23Rik Ctsc Homer1 Mlkl 
4932438A13Rik D11Lgp2e Hook2 Mlkl 
4932441K18Rik D14Ertd668e Hrh2 Morc3 
4933407C03Rik D14Ertd668e Ifi44 Mov10 
4933412E12Rik D17Wsu92e Ifit2 Ms4a6c 
5031414D18Rik Dbnl Ifit2 Ms4a6d 
5033414K04Rik Dck Ifit3 Ms4a6d 
5133401N09Rik Ddx58 Ifit3 Mx1 
5830484A20Rik Ddx60 Igsf9 Naip2 
6330578E17Rik Dennd1a Il18 Oas1b 
6430402L23Rik Dhx58 Il18 Oas1b 
6430573D20Rik Dhx58 Irf2 Oas1g 
A330042I21Rik Dpysl2 Irf7 Oas1g 
A530023O14Rik Dusp28 Irf9 Oas1g 
A530032D15Rik E230011J22Rik Isg20 Oas2 
A530083B17Rik EG240327 Keap1 Oas3 
Adap2 EG240327 Keap1 Oasl1 
Adar EG432555 Keap1 Oasl1 
Adar EG665378 Keap1 Oasl1 
Aftph Eng Lgals8 Oasl2 
AI451617 Enpp4 Lgals8 Oasl2 
Aldh1b1 Epsti1 Lgals9 OTTMUSG00000016644 
Ankle2 Epsti1 Lgals9 P2ry13 
Aoah Fam162a LOC100039742 Pgm2 
Apba3 Fbxw17 LOC100040462 Pgm2 
Arid4a Fcgr1 LOC100043347 Phc2 
Asb13 Fez2 LOC100044190 Phf11 
Ascc3 Frmd4a LOC100044190 Phf11 
Ass1 G3bp2 LOC100046469 Plekha4 
Atp7a Gbp10 LOC100046469 Plod3 
AU022870 Gm885 LOC100046469 Pml 
Azi2 Golga3 LOC100047052 Pml 
B430306N03Rik Golga3 LOC234360 Pml 
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Cluster 2 Continued 
Prpf4 Trafd1   
Psmb8 Trafd1   
Psmb8 Trafd1   
Psmb9 Trim34   
Pttg1 Trim34   
Pvrl2 Tyki   
Pvrl2 Ube1l   
Raf1 Usp18   
Rbl1 Vps11   
Rbm43 Vps37b   
Rilpl1 Vti1a   
Rnf213 Whsc1l1   
Rnf214 Whsc1l1   
Rnf34 Zbp1   
Rps4y2 Zbp1   
Samhd1 Zcchc2   
Samhd1 Zcchc6   
Scarf1 Zfp821   
Sf1 Zfp821   
Sfxn2 Znfx1   
Sgcb    
Slc25a12    
Slfn1    
Slfn9    
Smc5l1    
Smc5l1    
Smpdl3b    
Snd1    
Snx2    
Sp100    
Sp100    
Sp140    
Srgap2    
Stard3    
Stard3    
Stat1    
Stat2    
Stx16    
Tagap    
Tap1    
Tbc1d13    
Tdrd7    
Tlr3    
Tmem184b    
Tnfrsf14    
Tnfsf10    
Tpst1    
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Cluster 3 
1600021P15Rik Gm527 Rcsd1  
2410081M15Rik Gmds Rhbdf1  
2610204M08Rik Gpr137b Rin3  
2700060E02Rik Gpr176 Rnu65  
4632419I22Rik H2afz Rplp0  
4632427E13Rik H3f3b Rrad  
5430440L12Rik Herpud1 Rtn1  
5830411K21Rik Herpud1 Rtn1  
6720406L13Rik Hmgb2 Rtn1  
8030481K01Rik Hopx Scap  
A130062D16Rik Ifitm1 Slc39a10  
A130065C13Rik Ifitm1 Slc44a1  
Actl6a Ifitm1 Smyd2  
Adamtsl4 Igf2bp3 Snora65  
Adcy3 LOC242703 Snora70  
Apex1 LOC268569 Snx25  
Apoe LOC675899 Stbd1  
Atp13a3 Lpl Tardbp  
B3Gat3 Mad2l1 Tmem150  
B4galnt1 Mad2l1 Tmem176a  
Bex2 Man1a Tmem176b  
Bzw2 Map1lc3a Tmem55b  
C130078A06Rik Mapre2 Trim3  
Ccl6 Mapre2 Trps1  
Cd109 Mgea5 Tubb2b  
Cd9 Mki67 Ube2n  
Cfl1 Mt1 Uck2  
Chst7 Ncl Uck2  
Clec4b1 Nde1 Uck2  
Crebl2 Ndrg1 Zadh2  
D12Ertd647e Ndrl   
D12Ertd647e Nelf   
D330028D13Rik Nelf   
Dgka Nola3   
Dgka Olfm1   
Dhcr24 Olfm1   
Dhx9 Olfm1   
Dpep2 Pam   
Dpep2 Pif1   
E130012A19Rik Pkd2   
E430031D18Rik Pkmyt1   
Eef1d Ppic   
Emp2 Ppic   
Fin15 Ptpla   
Fkbp5 Purb   
Galnt10 Pusl1   
Gdpd1 Rbbp4   
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Cluster 4 
1100001G20Rik Atp6v0a2 Dnclc1 Hsp90aa1 
1110008F13Rik Azi2 Dock4 Hspa1a 
1110008F13Rik B130017M24Rik Dst Hspa1b 
1700095J19Rik B4galt7 Dtnb Hspd1 
1700112C13Rik Bak1 Dync1h1 Ifnb1 
1700112E06Rik BC021438 Dync1i2 Igfbp7 
1700123O20Rik BC067047 Dynll1 Il15ra 
1810055G02Rik Bfar Ece2 Il2rg 
2010209O12Rik Bfar Edg5 Il7 
2210009G21Rik Bxdc1 EG432448 Inhba 
2210019E14Rik C1galt1c1 EG433182 Irak3 
2400010D15Rik C3 EG622339 Irf5 
2810405F04Rik C330023M02Rik EG630499 Itgal 
2810439F02Rik Casp1 Egln3 Kif1b 
3110050N22Rik Cbwd1 ENSMUSG00000053338 Klc1 
4930518I15Rik Ccdc59 Erap1 Kpna6 
4930556B16Rik Ccng1 Esd Lamp2 
4933430I17Rik Cd180 Esd Lamp2 
5730596K20Rik Cd200 Esd Larp5 
9130005N14Rik Cd200 Esrra Layn 
9430043O10Rik Cd200 Evl Ldha 
9630025H16Rik Cenpj F630107D10Rik Lemd2 
9930022F21Rik Cept1 Fam164a Lnpep 
A630001G21Rik Cfb Fancl LOC100043796 
AA589481 Chordc1 Fpr1 LOC100044215 
Aars Clip2 Gbp2 LOC100044948 
Abcf2 Cndp2 Gca LOC100044968 
Abhd2 Cnih4 Gclm LOC100045967 
Abhd2 Cox17 Glipr2 LOC100046039 
Abhd2 Cox18 Glrx1 LOC100046163 
Abr Cox18 Gmppb LOC100046163 
Acot7 Creld2 Gng12 LOC100046469 
Acot7 Creld2 Gpr31c LOC100048554 
Acp2 Crem Gsdmdc1 LOC193533 
Adar Cst7 Gsdmdc1 LOC194744 
Afp Ctsz Gtf2a1 LOC219049 
Akt3 Ctsz Gtf2f1 LOC223653 
Aldoa Cugbp1 H2-K1 LOC224163 
Ankrd37 Cycs H2-M2 LOC234882 
Armc7 Cycs Hat1 LOC245892 
Arv1 Cycs Hax1 LOC381947 
Arv1 D0H8S2298E Hdc LOC384343 
Ascc2 D230004N01Rik Hk3 LOC385905 
Asns D4Ertd22e Hmox1 LOC386067 
Asns D630022O22Rik Hn1 LOC634015 
Asns Dnajb11 Hp LOC671434 
Atl3 Dncic2 Hsf2 LOC677317 
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Cluster 4 Continued 
Lrp11 Plekhf2 Psme4 Sra1 
Magohb Polb Ptges Srpr 
Marco Por Ptk2b St3gal5 
Mdh2 Por Ptpn6 Stau2 
Med7 Ppa1 Ptrh2 Stx3 
Mif Ppap2a Rab21 Tapbpl 
Mif Ppap2a Rassf1 Tarbp2 
Mir16 Ppap2a Rassf1 Tfg 
Mitd1 Ppm1h Rchy1 Tmbim4 
Mkks Ppp1r11 Rilpl1 Tmem120a 
Mmp25 Ppp1r11 Rin2 Tmem171 
Mod1 Prdx1 Rnf135 Tmem49 
Mrpl39 Prdx1 Rnf135 Tmem68 
Mrps10 Prdx5 Rnf31 Tmem77 
Mrs2 Prdx5 Rrbp1 Tpi1 
Mthfd2 Prkrip1 Rrbp1 Tpi1 
Nckap1 Prkrip1 Rtn2 Trem3 
Nln Procr Rtn3 Treml4 
Nlrc4 Prokr1 Saa1 Treml4 
Nmi Prpf38a Sco1 Tsg101 
Nmt1 Psma4 Scoc Tspan3 
Noc4l Psma7 Sdc1 Tspo 
Nos2 Psmb2 Sepw1 Tssc1 
Npc1 Psmb2 Serpinb2 Ttc1 
Npc2 Psmb3 Sh3bp2 Ttc9c 
Npy Psmb5 Siat9 Ttc9c 
Nqo1 Psmb7 Sipa1l1 Txn1 
Nus1 Psmb7 Skap2 Ubap1 
Osbpl3 Psmb7 Slc11a1 Ube2k 
Osbpl3 Psmc1 Slc12a3 Ube2m 
Otud3 Psmc2 Slc16a3 Uchl1 
P4ha1 Psmc2 Slc22a4 Upk3b 
P4ha2 Psmc4 Slc25a10 Upp1 
Pcsk7 Psmc4 Slc35b1 Upp1 
Pdia6 Psmc5 Slc39a7 Upp1 
Pdzd11 Psmd1 Slc3a2 Usp25 
Pdzd11 Psmd1 Slc7a2 Wdr68 
Pdzd11 Psmd1 Slc7a8 Xkr8 
Pex11a Psmd11 Slc7a8 Zfp710 
Pfkl Psmd11 Slco3a1 Zkscan6 
Pgam1 Psmd12 Smg7 Zmynd15 
Pgk1 Psmd12 Smurf1  
Phf20l1 Psmd14 Snx11  
Pik3cb Psmd14 Snx16  
Pkp4 Psmd7 Snx20  
Pkp4 Psme1 Soat2  
Plekha2 Psme1 Sra1  
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Cluster 5 
1500010G04Rik Capzb F2r LOC100040592 
2300006M17Rik Car2 F730011O15Rik LOC100044177 
2310007G05Rik Ccdc93 Fam13b LOC100045280 
2410015C20Rik Ccdc94 Far1 LOC100045280 
2610027C15Rik Ccl24 Fcgr2b LOC100045343 
2610103J23Rik Ccl9 Fchsd2 LOC100045439 
2610304I02Rik Ccnyl1 Fgr LOC100046025 
2900057D21Rik Ccrn4l Foxp4 LOC100047856 
2900073G15Rik Ccrn4l Furin LOC100048221 
3110003A17Rik Cd244 Furin LOC100048706 
3202002H23Rik Cd44 Fzd1 LOC100048721 
4832412D13Rik Cd44 Fzd5 LOC381066 
4932442L11Rik Cd44 G3bp1 LOC385032 
4933424B01Rik Cd74 Gda LOC677008 
4933432P15Rik Cd74 Gfi1 Map3k6 
8030402P03Rik Cd82 Gng4 Mapkapk2 
9130223C08Rik Cdc37 Gnl3 Mapkbp1 
9430008C03Rik Cdc42ep4 Grwd1 Mark2 
9430080K19Rik Cdkn2a Gtpbp4 Mat2a 
A430093F15Rik Cdv3 H2-Aa Mat2a 
A530026H04Rik Cdv3 H2-Eb1 Mcf2l 
Acat2 Chst11 Hivep3 Mesdc1 
Acot10 Ciita Hivep3 Mfsd7c 
Actn1 Cobll1 Hnrnph1 Mkl2 
Adam17 Cp Hnrpab Mkl2 
Adam17 Cstf2 Hnrpll Mobkl2c 
Adamts4 Cx3cl1 Hrb Mon1b 
Aebp2 Cyp51 Htra4 Mrgpra2 
Aebp2 D11Moh35 Icosl Mtmr14 
Alcam D130004H04Rik Idi1 Mtmr14 
Alkbh D230007L07Rik Igf2r Mtmr14 
Anxa1 D430020J02Rik Igsf6 Myadm 
Anxa3 Dcbld2 Il13ra1 Mycl1 
Anxa3 Dcun1d5 Il17rd Myo10 
Anxa5 Ddx21 Il4i1 Myo10 
Appl1 Dlg3 Ing5 Myo10 
Aqp9 Dmtf1 Insig1 Myo1g 
Arnt E130014J05Rik Ipo5 Narg1 
B230334I05Rik E430028B21Rik Itgb1 Ncoa5 
B630005N14Rik Ednrb Jdp2 Net1 
BC046404 Ednrb Jmjd2a Nfe2l2 
Brp17 Ednrb Jmjd2a Nfkb1 
C230043G09Rik Eid3 Kpna3 Nfkb1 
C330006P03Rik Eif1a Kremen Nola2 
Cacnb3 Eif2c3 Lad1 Notch1 
Calcrl Emp1 Lck Nupl1 
Camkk2 Erdr1 Ldlr Oplah 
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Cluster 5 Continued 
Optn Six1 Tsc22d1  
Optn Slc11a2 Tshz1  
Paf1 Slc11a2 Ubtd2  
Pcdh7 Slc12a4 Ubtd2  
Pcdh7 Slc2a6 Ubtd2  
Phldb1 Slc30a4 Vasn  
Plec1 Slc39a14 Wdr92  
Plekhg2 Slc39a14 Wsb2  
Plekho2 Slc41a2 Zbtb33  
Pogk Smcr8 Zdhhc21  
Ppp1r10 Snn Zfp263  
Ppp2cb Snn Zhx2  
Ppp4r1 Spag9 Zic4  
Prdm1 Spag9 Znrf1  
Prkcd Spata13 Zwint  
Ptbp1 Sphk1   
Ptbp1 Sqle   
Ptpn1 Sqle   
Ptrf Srebf2   
Rab6 Ssr3   
Rac3 St7   
Rai12 Stard7   
Rai12 Stard7   
Rai12 Stat5a   
Rassf4 Stat5a   
Rassf4 Stx6   
Rassf4 Syk   
Rbm12 Syncrip   
Rcl1 Tcfec   
Rela Tha1   
Reps1 Tirap   
Rffl Tmem120b   
Rffl Tmem176a   
Rnf145 Tmtc2   
Rnpc3 Tnfaip2   
Rras2 Tnfaip2   
Rrs1 Tnfrsf5   
Rufy3 Tnfrsf6   
Samsn1 Tnfrsf9   
Sbno2 Tnfrsf9   
Scamp1 Tnip1   
Schip1 Tpbg   
scl0001233.1_26 Traf3   
scl0002617.1_582 Trim36   
Sdad1 Trim36   
Sept11 Trim36   
Shisa3 Trip10   
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Cluster 6  
1300018I05Rik Cd274 Gbp3 LOC100047963 
1600029O10Rik Cd69 Gbp5 LOC100048105 
2010106G01Rik Cep350 Gbp6 LOC100048299 
2010106G01Rik Cep350 Gbp6 LOC100048346 
2310008I22Rik Chac1 Ggnbp2 LOC100048556 
2310044G17Rik Chmp4b Glipr2 LOC100048556 
2410013I23Rik Clec4a1 Glipr2 LOC100048583 
2610208M17Rik Cp Gng12 LOC271505 
2700055A20Rik Cp Gss LOC277707 
2700055A20Rik Crlf3 Gss LOC385639 
4933409L06Rik Csf3r Hdc LOC638301 
9030625A04Rik Csf3r Hk1 LOC667034 
9130230N09Rik Csf3r Hp LOC668492 
A030007L17Rik Ctsc Hp LOC674706 
A430084P05Rik Cxcl10 Ifi204 LOC675594 
A430084P05Rik Cxcl10 Ifi205 LOC676748 
A930026L03Rik Cxcl9 Ifi35 Lox 
AA467197 D17Wsu92e Ifi47 Lsm12 
AA960436 D17Wsu92e Ifih1 Lsm12 
Acsl1 D430007J11Rik Ifitm1 Ly9 
Adar D4Wsu132e Ifrg15 Lyrm1 
AI451557 Daxx Igtp Mad 
AI607873 Dcp2 Iigp2 March1 
Aim1 Ddx24 Il15ra Mfsd7 
Aim2 Ddx24 Il15ra Mfsd7a 
Anxa4 Dlm1-pending Il15ra Mizf 
Anxa6 Dtx3l Il20ra Mnda 
Arid5b E330016A19Rik Iqsec2 Mthfd2 
Arl4a Eif2ak2 Irgb10 Mvp 
Ascc3 Eif5 Irgm1 Mx2 
Atl3 Etnk1 Irgm1 Nab1 
Atp10a Etnk1 Irgm1 Nampt 
B230339H12Rik F7 Jak3 Nod1 
Bambi-ps1 F730045P10Rik Klhl5 Nr3c1 
Batf2 Fam20b Lamp2 Nrap 
C230055K21Rik Fcgr2b Lass6 Nt5c3 
C330023M02Rik Fcgr2b Lcn2 Oas1a 
C330023M02Rik Fcgr2b LOC100038830 Oas1g 
C330023M02Rik Fgl2 LOC100038882 Ogfr 
Caprin1 Fmo3 LOC100041137 Otud5 
Capza2 Fpr2 LOC100044430 Oxsr1 
Cbl Frag1 LOC100045567 Parp12 
Ccdc25 Frag1 LOC100045644 Parp14 
Ccdc50 Fyb LOC100046393 Parp14 
Ccdc59 Gbp2 LOC100047619 Parp8 
Ccdc86 Gbp2 LOC100047707 Pcgf5 
Ccl5 Gbp3 LOC100047963 Peli1 
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Cluster 6 Continued 
Peli1 Sp100   
Pex11a Stx4a   
Pik3ap1 Taar3   
Pilra Tap2   
Pira1 Tapbp   
Pira11 Tapbpl   
Plekhf2 Tcirg1   
Plekhm3 Tcof1   
Plekhm3 Tgfbi   
Pmm2 Tgfbi   
Pols Tgs1   
Ppp3cc Tgtp   
Prpf38a Tm9sf4   
Prpf38a Tm9sf4   
Prpf4 Tor1aip1   
Ptprc Tor1aip2   
Rab3d Tor3a   
Rab8a Trex1   
Rac2 Trex1   
Ralb Trim21   
Rap2c Trim26   
Rap2c Trim30   
Rapgef2 Ube2l6   
Rasa4 Ubg   
Rasa4 Usp18   
Rhbdd2 Wars   
Rin2 Wars   
Rp23-357i14.1 Wdfy1   
Rsad2 Zfp295   
Rtp4 Znfx1   
Samd8 Zubr1   
Samd9l Zwint   
Sav1    
Scl30a1    
Sclo30a1    
Sema4a    
Serpina3f    
Serpina3g    
Setdb2    
Setdb2    
Sh3bp5    
Slamf8    
Slc30a1    
Slco3a1    
Slco3a1    
Slfn5    
Smg7    
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Cluster 7 
0610009O20Rik 5530400K22Rik BC088983 Cyb561d1 
0610042C05Rik 5730409G15Rik Bcdin3d D15Wsu169e 
1110034A24Rik 5730478M09Rik Bola1 D430028G21Rik 
1110034A24Rik 5830482F20Rik C030002B11Rik Dgcr6 
1190007I07Rik 5930434B04Rik C030026E19Rik Dgkz 
1200013B08Rik 5930434B04Rik C130050O18Rik Dguok 
1300018I17Rik 6330503K22Rik C130065N10Rik Dhdh 
1500031H01Rik 8430432M10Rik C2cd2l Dhdh 
1500031L02Rik 9330129D05Rik C2cd3 Dhx34 
1500041N16Rik 9330134C04Rik C530028I08Rik Dhx57 
1700022C21Rik 9330175B01Rik C820007E08Rik Disp1 
1700023M03Rik 9330177P20Rik C87436 Dmwd 
1700030J22Rik 9630031D17Rik Casp9 Dmwd 
1700030K09Rik 9630058J23Rik Cbr1 Dnmbp 
1700065O13Rik A130010J15Rik Ccdc111 Dnmt1 
1810009O10Rik A330057G13Rik Ccdc111 Dok2 
1810015C11Rik A830007P12Rik Ccdc123 Dscr3 
1810043G02Rik AB112350 Ccdc123 Dscr3 
1810043G02Rik Abcd1 Ccdc28b Dusp19 
1810048J11Rik Abcd4 Ccdc28b Dusp6 
2010003O18Rik Acad8 Ccdc45 Dusp6 
2210011G09Rik Acad8 Ccdc77 E2f1 
2210012G02Rik Adck4 Ccdc97 EG240038 
2210018M11Rik AI256775 Ccnd1 EG433224 
2210021J22Rik AI467606 Ccnd1 Endogl1 
2210410D02Rik Alg2 Ccnd1 ENSMUSG00000054212 
2310001H12Rik Angptl6 Ccnd3 Epb4.1 
2310007F21Rik Apobec1 Ccrk Epb4.1l1 
2310007F21Rik Arhgap25 Ccrk Epb4.1l1 
2310007F21Rik Arhgap27 Cdc2l6 Etv1 
2310047B19Rik Arhgef18 Cecr5 Fam120b 
2310079N02Rik Arl16 Chchd5 Fblim1 
2400009B08Rik Arl6 Chchd8 Fbxl4 
2410004L22Rik Arrdc3 Chek2 Fbxo31 
2410017P07Rik Atf7ip Chek2 Fbxo9 
2410018C17Rik Atmin Chst12 Fgd4 
2410019G02Rik Atp5s Cisd1 Fgd4 
2410075B13Rik B230333C21Rik Cmas Fli1 
2610010A15Rik B3galnt1 Cml1 Gab3 
2610019A05Rik B4galt1 Coasy Gab3 
4732460K03Rik Bbs5 Cog7 Gapt 
4930430F08Rik BC016495 Coq10a Gatc 
4930455F23Rik BC021790 Coq4 Gdf9 
4930455F23Rik BC032203 Cpeb3 Gemin6 
4930455G09Rik BC044804 Creb3 Gm169 
4932415G12Rik BC049806 Creb3l3 Gorasp1 
4932415G12Rik BC066140 Csk Gpt2 
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Cluster 7 Continued 
Gsg2 Mettl8 Pdlim2 Setdb1 
Gtf3c1 Mfsd9 Per1 Sfi1 
Gtrgeo22 Mlh3 Per1 Sfrs17b 
H6pd Mmab Phf17 Sfxn4 
Hdac5 Mocos Phf20 Sip1 
Helb Mon1a Pik3r2 Sipa1 
Helb Mppe1 Pms2 Sirt4 
Hexdc Mpv17l Pnpla6 Skp2 
Hhex Mrpl2 Ppcs Slc12a9 
Hip1 Mrps35 Ppm2c Slc25a38 
Hmg20a Mtrf1 Ppp1r3b Slc25a45 
Htr2b Myo7a Prim2 Slc29a3 
Ift88 Narf Psg23 Slc35c2 
Inpp5d Nbr1 Ptger2 Slc38a9 
Irf2bp2 Ncrna00117 Ptpn7 Slc45a4 
Katnb1 Nek1 Pwwp2b Slc8a1 
Kbtbd7 Nfatc1 Rab11fip3 Smad3 
Kbtbd7 Nfatc1 Rab19 Smad3 
Kif13b Nfic Rab19 Smarcal1 
Kif5c Nfic Rab27a Smyd4 
Klhdc1 Nlrx1 Rab39 Snx30 
Klhl22 Nlrx1 Rab3a Spg20 
Lancl1 Nme7 Ralgps1 Spsb2 
Lbh Nme7 Rasl2-9 Stambpl1 
Lbh Nme7 Rassf2 Synj2 
Lcmt1 Nte Rbbp9 Taf5 
Lcmt1 Nudt1 Rbbp9 Taf6 
Limk2 Nudt22 Rfc1 Tcte3 
LOC100043555 Obfc2a Rftn2 Tdrd3 
LOC100044103 Ociad2 Rftn2 Tex2 
LOC100044298 Ociad2 Rhobtb2 Tex2 
LOC100044468 Orai3 Rmnd1 Tg737Rpw 
LOC100044636 Orc5l Rpap1 Thnsl1 
LOC100045981 Orc5l Rpap2 Tial1 
LOC226486 Osgepl1 Rpap3 Tmem129 
LOC676420 Oxr1 Rprd1a Tmem218 
Lrrc20 Paox Rps6ka1 Tmem218 
Lrrk1 Paox Rrm2b Tmem86a 
Lrrk1 Paox Rwdd2b Tnfaip8l2 
Map3k12 Pard6a Samd1 Tnfrsf13b 
Map3k7ip1 Pard6a Saps2 Tnrc6c 
Map3k7ip1 Pbx2 Sbk Trim45 
Mapk1ip1 Pcgf1 scl0001487.1_50 Tsc22d3 
Mcph1 Pddc1 scl0015365.1_6 Tsc22d3 
Mcph1 Pdlim2 Sec22c Tsen2 
Mertk Pdlim2 Senp7 Ttc5 
Mertk Pdlim2 Sesn2 Ttf2 
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Cluster 7 Continued 
Tusc4    
Txnip    
Tyw1    
Uaca    
Ubac1    
Ubfd1    
Uhrf1bp1    
Uhrf1bp1    
Umps    
Unc119    
Uvrag    
Vars2    
Vegfa    
Vps26b    
Vps33b    
Wdr60    
Wdr60    
Wdr76    
Wipf1    
Zbtb1    
Zbtb24    
Zc3h6    
Zc4h2    
Zfp386    
Zfp41    
Zfp41    
Zfp467    
Zfp512    
Zfp512    
Zfp688    
Zfp825    
Zfyve26    
Zranb3    
Zw10    
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Cluster 8 
1110031I01Rik Hist2h3c1 Tgif1  
2310016C08Rik Ibrdc3 Tgif1  
2310016C08Rik Id2 Tmem49  
4930431B09Rik Id2 Tmem49  
5430427O19Rik Ifrd1 Tmem49  
5830435K17Rik Il10 Tnf  
6030408C04Rik Il1b Tnf  
9130227N12Rik Il2rg Tnfaip3  
A530093H06Rik Ireb2 Tnfsf9  
Atf3 Irf1 Traf6  
Atl2 Irf1 Zfp36  
Atl2 Irf1 Zrsr2  
Axud1 Irf1   
B230120H23Rik Irf1   
BC031781 Jmjd3   
Ccdc21 Junb   
Ccl2 Kctd12   
Ccl3 Klf6   
Ccl4 Klf6   
Ccl4 LOC100046232   
Ccl7 LOC100046406   
Ccl7 Lrp12   
Ccnl1 Maff   
Ccrl2 Map3k8   
Cebpb Mib1   
Coq10b Myd116   
Coq10b Nfkbia   
Cxcl1 Nfkbia   
Cxcl2 Nfkbiz   
Cxcl2 Pde4a   
Cybb Phlda1   
Dicer1 Pim1   
Dusp2 Plk2   
Dusp2 Plk3   
Dusp4 Pvr   
Dyrk2 Rasgef1b   
EG622976 Rasgef1b   
Ets2 Rgs1   
Gadd45b Rgs1   
Gadd45b Rgs1   
Gdf15 Rusc2   
Gm129 Sgk1   
Gm129 Slc25a33   
Gp49a Socs3   
H3f3b Socs4   
Hist1h3h Tbc1d10a   
Hist2h3b Tgif1   
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Cluster 9 
0710001C05Rik Azi2 Hist2h2aa1 Mocs1 
1110038F14Rik B430201A12Rik Hist2h2aa2 Morf4l2 
1110038F14Rik B430201A12Rik Hist2h2ac Mscp 
1110059G02Rik Bat5 Hsd17b7 Mvd 
1700013A01Rik Cacybp Hspa5 Nampt 
1700085B03Rik Ccdc88b Hspa8 Ncf4 
1810009K13Rik Cct7 Htr4 Nkiras1 
1810035L17Rik Cd69 Hvcn1 Noc4l 
2210407N10Rik Clcn7 Hvcn1 Nox1 
2310061F22Rik Clec5a Ifitm3 Nsdhl 
2610002M06Rik Clec5a Ifna6 Nsdhl 
2610103J23Rik Clecsf5 Il15 Nt5dc3 
2810021O14Rik Copg Ints12 Nubp1 
2810430B18Rik Csda Kars Nubp1 
2900045G02Rik Dapk1 Lass6 OTTMUSG00000000971 
3830402I07Rik Dcbld2 Lass6 Panx1 
4631409F12Rik Dgat2 Lig3 Panx1 
4732458O05Rik Dld Lims1 Papss2 
4930453N24Rik Dnajb6 LOC100045999 Pcyt2 
4930599N23Rik Dusp11 LOC100047184 Pdia5 
5330426P16Rik E330016A19Rik LOC100048105 Pdss1 
5730508B09Rik Eapp LOC100048105 Pgam1 
5730589K01Rik Edf1 LOC100048803 Pgbpll 
6330416G13Rik Efhd2 LOC235997 Pgd 
9530018I07Rik EG632248 LOC236223 Phtf2 
A030007L17Rik Eif4g2 LOC380756 Pik3r6 
A530088I07Rik Ep400 LOC383293 Pik3r6 
AA691260 Esrra LOC384104 Plekhf2 
Aacs Exosc10 LOC385662 Pmvk 
Abca7 Expi LOC621823 Pno1 
Acot9 Fabp5 LOC624784 Pnp1 
Adamtsl5 Fbxo18 LOC637082 Pnpt1 
Adar Fcgr2b LOC638034 Pofut1 
Adhfe1 Fdps LOC665181 Ppm1k 
Adrbk1 Fmnl2 LOC666559 Ppm1k 
Agrn Gm941 LOC666652 Ppm1k 
Agtrap Gm960 Lsm12 Prpf38a 
Aig1 Gna15 Lss Psma5 
Aim2 Gphn Mafk Psmb10 
Alkbh5 Gphn Map2k1 Psmb10 
Amdhd1 Gphn March1 Psmb6 
Ankrd17 Gpr126 March10 Psmd6 
Anp32a Gss Mdfic Psmd8 
Anxa4 Gtpbp6 Mdk Psme2 
Atp6v1d Herc1 Mina Ptprc 
AW146242 Hisppd1 Minpp1 Rab1 
Axl Hist2h2aa1 Mmp2 Rab9 
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Cluster 9 Continued 
Ranbp2 Vps26   
Rbm19 Vps29   
Rfwd2 Vps54   
Rtn4r Wdr43   
Rwdd1 Whdc1   
Sap30 Wtap   
Sc4mol Xrn2   
Scfd1 Ythdf1   
Scrn1 Ywhaz   
Seh1l Zbtb5   
Sh3kbp1 Zdhhc5   
Sh3kbp1 Zfp213   
Siat7b Zfp319   
Slc23a2 Zfp622   
Slc25a37 Zfp710   
Slc25a44 Zyx   
Slc31a1    
Slc35f5    
Sltm    
St13    
St18    
St3gal3    
Stard5    
Stard5    
Stx4a    
Surf4    
Taf15    
Tbrg4    
Tcirg1    
Tcof1    
Timm17a    
Timm8a1    
Tmem128    
Tmem77    
Tmsb10    
Tnfsf15    
Tomm70a    
Tor1aip2    
Tpst2    
Traf5    
Txndc4    
Ube2e2    
Ubl4    
Ush2a    
Usp25    
Vcan    
Vcpip1    
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Cluster 10 
1110003F05Rik Ak3 Cdkl2 EG629383 
1190002F15Rik Aldh16a1 Cdkl2 EG633570 
1700052O22Rik Aldh2 Cdkn3 Eif4b 
1700054E11Rik Aldh5a1 Cenpa Emb 
2210008N01Rik Ang Centd3 Emr4 
2210013O21Rik Angptl2 Chi3l3 ENSMUSG00000043795 
2210039O17Rik Anln Cib2 Ephx1 
2210411K11Rik Anp32e Cib2 Epm2aip1 
2300002D11Rik Aof1 Ckap2l Epm2aip1 
2310003H01Rik Aph1b Clec4b1 F13a1 
2310004I03Rik Aplp2 Clec7a F630001K14Rik 
2310047M10Rik Apoa2 Clecsf12 Fah 
2310047M10Rik Apoc1 Copz2 Fam129a 
2610019E17Rik Apoc1 Copz2 Fam131a 
2810025M15Rik Arhgap6 Copz2 Fam132a 
2810417H13Rik Arhgap6 Copz2 Fam168b 
2900093K20Rik Arpp19 Cox7a2l Fbxw8 
3000003G13Rik Arsb Csad Fcgrt 
3110007F17Rik Atg16l2 Csf1r Fcgrt 
3110013H01Rik Atg9b Csf1r Fcna 
3300005D01Rik Atp2a3 Ctns Fcrls 
4933421H10Rik Atp2a3 Ctsb Fgf13 
5133400G04Rik Atp6v0a1 Ctsf Fh1 
5133400G04Rik Atpif1 Cyp27a1 Fhit 
5830434P21Rik Atxn3 Cyp27a1 Fin14 
5830454D03Rik Aurka Cyp27a1 Fkbp7 
6330509M05Rik Avpi1 Cyp4f18 Fkbp9 
6530406A20Rik Aytl2 Cyp4f18 Frmd6 
6720467C03Rik Bahcc1 D16Bwg1494e Fxyd2 
6720467C03Rik BC004728 D6Ertd365e Gadd45a 
7330410H16Rik BC004728 D830044I16Rik Gadd45a 
8430410A17Rik Bcas3 D9Ertd392e Galc 
9030418K01Rik Birc5 Dapk1 Galnt10 
9630007E23Rik Birc5 Dapk1 Gas6 
9830001H06Rik Birc5 Dcun1d4 Gcap27 
A130070G01Rik Blm Ddb2 Gcat 
A930005G04Rik C230096C10Rik Diap3 Glb1l 
A930024F17Rik C430049K18Rik Dicer1 Glg1 
Abcb1b C920004C08Rik Dnmt3b Gm1673 
Abcb4 Ccnb1 Dpep2 Gm1673 
Abi2 Ccnb1 Dtd1 Gng10 
Abi2 Cd300a Eef1b2 Gng10 
Aco1 Cdan1 Eef1b2 Gpx3 
Adck5 Cdc20 Efemp2 Gstk1 
Aff4 Cdc20 EG245190 Gstm5 
AI481316 Cdc20 EG245297 Gusb 
AI850995 Cdca3 EG382843 H2afx 
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Cluster 10 Continued 
H2-DMa LOC667005 Nup210 Rpl31 
H2-DMa Lsm6 Nusap1 Rpl4 
H2-Ke6 Lsm6 Oip5 Rpo2tc1 
Hadhb Ltbp3 Pabpc4 Rps15 
Hexa Ltc4s Pabpc4 S100a1 
Hist1h2ag Ltf Pccb S100a4 
Hist1h4k Lyzl4 Pccb S100a9 
Hist1h4m Lztr1 Pcp4l1 Sag 
Hsd17b4 Macrod1 Pcp4l1 Satb1 
Iap Maged1 Pdzk1ip1 Scrib 
Igf1r Maml2 Phpt1 Sdf4 
Igfbp4 Man2b1 Plk1 Sema6b 
Igfbp4 Man2b1 Pon2 Sepp1 
Igh-6 Matk Ppa2 Sepp1 
Igh-6 Matk Prc1 Serinc3 
Igsf4a Mboat1 Prkd3 Serpinb6a 
Il6st Mbtd1 Prkd3 Serpinf1 
Immp2l Mgl1 Prkg1 Sfrs5 
Khk Mgl2 Prodh Sft2d2 
Khk Mgl2 Pros1 Sidt2 
Kif22 Mgst3 Prps1 Sidt2 
Kif4 Mgst3 Ptpla Slc12a2 
Klk1b1 Mmd Ptprs Slc12a2 
Klk1b11 Mprip Ptprs Slc22a18 
Krr1 Mrc1 Rab34 Slc26a6 
Lass5 Msr2 Rab34 Slc29a1 
Lbr Msr2 Rab34 Slc9a9 
LOC100041932 mtDNA_ND2 Rab38 Smyd2 
LOC100042199 mtDNA_ND4L Rab5b Sord 
LOC100044439 mt-Nd4l Rabgap1l Sort1 
LOC100046770 Myo1c Ramp1 Sort1 
LOC100046853 Napsa Rapsn Spag5 
LOC100046891 Napsa Rapsn St3gal2 
LOC100047214 Napsa Rapsn St8sia4 
LOC100047214 Nav1 Rbbp4 St8sia4 
LOC100048123 Ncaph2 Retsat Stab1 
LOC100048461 Ncaph2 Retsat Stmn1 
LOC214403 Ncf2 Rora Sts 
LOC280487 Ncl Rpl10a Sulf2 
LOC380692 Ndufb11 Rpl18a Sult1a1 
LOC381114 Ngfrap1 Rpl21 Suv39h1 
LOC381578 Ngp Rpl21 Syce2 
LOC382707 Niban Rpl21 Tacc1 
LOC384710 Nlgn2 Rpl22 Taf9b 
LOC622655 Nme3 Rpl23 Tcea2 
LOC633945 Npepl1 Rpl27a Tgfbr1 
LOC640739 Nrcam Rpl31 Timp2 
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Cluster 10 Continued 
Tk1    
Tle1    
Tm4sf5    
Tm7sf4    
Tmem32    
Tnfsf12    
Tnfsf14    
Top2a    
Tpp1    
Trem2    
Trf    
Trip12    
Trmt1    
Usp28    
Usp7    
Vegfb    
Vkorc1    
Vkorc1    
Vkorc1    
Wdr77    
Wtip    
Zcchc14    
Zdhhc3    
Zdhhc8    
Zfp367    
Zfp496    
Zkscan17    
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Cluster 11 
1110059P08Rik BC030335 Eif4a1 Insig1 
1200002N14Rik BC039210 Eif4e Irak2 
1700047I17Rik1 Bcl6 Eif4g1 Itga5 
1700047I17Rik1 Bdh2 Eif4g1 Itgav 
1700108L22Rik Brd2 Eif4g2 Itgb4bp 
2210412D01Rik Btaf1 Eif6 Jag1 
2310047D13Rik Bzw1 Elavl1 Kcnn4 
2310061F22Rik C630022N07Rik Ell2 Kif1b 
2410042D21Rik Camk2d Elovl1 Kif1b 
2510009E07Rik Ccnc Emilin2 Kif1c 
2610028A01Rik Cct8 Emilin2 Kpna1 
2610103J23Rik Cenpt Eno2 Krit1 
4733401O04Rik Chic2 Ergic1 Larp-pending 
4921505C17Rik Chic2 Ext1 Lcp2 
4933424B01Rik Chst11 Fbs1 Ldlr 
4933428A15Rik Ciapin1 Flnb Leng1 
6330409N04Rik Clec2d Flnb LOC100046025 
6330409N04Rik Clec4d Fmnl2 LOC100046855 
6330548G22Rik Clec5a Fnbp1l LOC100047393 
6330569M22Rik Clic4 Fyb LOC100047934 
8030448M07Rik Clic4 Fzd7 LOC271490 
A530088I07Rik Col18a1 Galnt6 LOC433261 
A730020L20Rik Cpeb4 Ggta1 LOC670044 
A730042J05Rik Creb1 Gls Lrp8 
A730098D12Rik Csf2rb Gmeb2 Lrrc59 
A930029N17Rik Cts6 Gnb4 Lrrc59 
Abce1 Cul1 Gnl3 Lrrc59 
Abi1 Cxcl16 Gnptab Lrrfip2 
Abr Cxcl16 Gpr137b Lrrfip2 
Acbd3 Daam1 Gpr68 Ltv1 
Adarb1 Dcp1a Gpr84 Mafg 
Adora2b Dcun1d3 Gpr84 Mak16 
Afg3l2 Ddhd1 Gpr85 Map4k3 
Agpat4 Ddx21 Gpr85 Mapk11 
Akna Denr Gspt1 Mapre1 
Alg11 Denr Gtf2f2 Mark2 
Ampd3 Dhps Gtf3c4 Mast2 
Apol7c Dhx15 Hmgcr Mast2 
Appbp1 Dhx15 Hnrnpab Mdn1 
Arl8a Dock10 Hsd17b12 Memo1 
Atp6v1e1 Dot1l Hspbap1 Mon1b 
Atp6v1h Dtwd1 Htra1 Mrpl52 
Atpbd3 Dus2l Htra1 Mrps18b 
Baz1a E030040G24Rik Ifnar2 Mrps18b 
BC004044 Eea1 Igf2r Mtdh 
BC004044 Eef1e1 Ikzf1 Mtpn 
BC027231 EG627624 Inpp5b Nck1 
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Cluster 11 Continued 
Nfkb2 Samsn1 Ube2f  
Nfyb Sdc1 Ube2z  
Ninj1 Sec24b Uso1  
Nip7 Seh1l Usp14  
Nol10 Seh1l Usp16  
Nol5 Sertad1 Usp2  
Nrbf2 Sestd1 Utp11l  
Nup62 Sf1 Vasp  
Otud4 Sfrs2 Wbp4  
Pak4 Sfrs2 Wdr59  
Pdcd10 Sfrs3 Wdsof1  
Pdlim7 Sfrs3 Ywhae  
Peli3 Sh3bgrl Ywhag  
Pgls Sh3bgrl2 Zc3h7a  
Pgs1 Sh3bgrl2 Zc3h7a  
Plxna2 Slc30a6 Zfpn1a1  
Pou2f2 Slc30a7 Zxdc  
Ppfia1 Slc39a13   
Ppfia1 Slc39a13   
Ppfia1 Smad2   
Ppm1b Smc6   
Ppm1b Snap29   
Ppp2ca Spred1   
Ppp4r1 Srfbp1   
Ppp4r2 Srxn1   
Pprc1 St3gal1   
Psd4 St7   
Ptpn11 Syncrip   
Ptpn12 Tbrg4   
Ptpn2 Tcerg1   
Rab10 Tes   
Rab32 Tes   
Rabep1 Tgm2   
Rabep1 Timp1   
Rai12 Tmem168   
Rai14 Tmem38b   
Ranbp1 Tmem38b   
Rapgef1 Tnip2   
Rasa2 Tpm4   
Rasa2 Tra2a   
Rbpms Trappc10   
Rbpms Ttc19   
Rexo4 Txnrd1   
Rgs16 U2af2   
Rps6ka4 Uba5   
S100pbp Ube2d3   
Samd4b Ube2f   
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Cluster 12 
1200016E24Rik Dnaja2 Rnf220  
1520402A20Rik Dnaja2 Sertad2  
2010002N04Rik Dscr1 Sertad2  
2210037E17Rik Dusp16 Siah2  
2310024N18Rik Dusp16 Skil  
2610103N14Rik Dusp16 Slc20a1  
4732435K05Rik E130014J05Rik Spsb1  
4833438C02Rik E330037I15Rik Srebf2  
4933417E08Rik EG622976 St6galnac4  
5430414B19Rik Erdr1 St6galnac4  
5730552E08Rik Frap1 Syncrip  
8030462N17Rik Gna13 Tiparp  
9430049I24Rik Hnrnpd Tle3  
A630072M18Rik Hnrpll Tlr2  
A630097K09Rik Il17ra Tmem23  
AI504432 Il1r2 Tnfaip2  
Arap1 Il20rb Trps1  
Arap1 Itgp Ugcg  
Arg2 Jak1 Vti1a  
Arhgap26 LOC380629 Wsb1  
Arhgef3 LOC381140 Zfp382  
Auh LOC432554 Znrf1  
B230343A10Rik Lrp12   
B230378H13Rik Map3k6   
B830007D08Rik Map3k7ip2   
Bcl10 Map4k4   
Bhlhb2 Mapk6   
Btg1 Mapk6   
Btg1 Mobkl2b   
C330006D17Rik Mt2   
C330023M02Rik Mtf1   
C430002D13Rik Nfkbib   
C530027B15Rik Nsbp1   
Cd14 Nsun2   
Cd33 P2ry2   
Cd33 Pde4b   
Cd83 Phf19   
Chd7 Plaur   
Chic2 Plek   
Cias1 Ppp1r10   
Cish Prdm2   
Crk Prdm2   
Crk Rangap1   
Cul1 Rbpms   
D030041G07Rik Rffl   
D230037D09Rik Rffl   
D630023B12Rik Rnd3   
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Cluster 13 
0610007C21Rik 2410015N17Rik A430106D13Rik Arsg 
0610007C21Rik 2410018G20Rik A630097D09Rik Ascc1 
0610007C21Rik 2410018G20Rik A930005H10Rik Ascc1 
0610009L18Rik 2610014I16Rik A930010I20Rik Asph 
0610011F06Rik 2610024M03Rik Abca9 Asxl1 
0610037D15Rik 2610029K11Rik Abcb8 Atg2a 
0610040B10Rik 2610036L11Rik Abcg1 Atg2a 
0910001A06Rik 2610039C10Rik Abhd14b Atp6v1g2 
1110001A07Rik 2610307O08Rik Abtb1 Atxn1 
1110002B05Rik 2610510J17Rik Acaa2 Aurkb 
1110003E01Rik 2610528E23Rik Acaa2 AV249152 
1110012D08Rik 2700033B16Rik Acaa2 Avpi1 
1110013L07Rik 2700045P11Rik Acaa2 AW112037 
1110029I05Rik 2700094K13Rik Acadm AW212394 
1110032E23Rik 2700094K13Rik Acads B930037P14Rik 
1110046J11Rik 2810017I02Rik Acap3 B930041F14Rik 
1110062M06Rik 2810410A03Rik Acot1 Bbs2 
1190002A17Rik 2810422J05Rik Acox3 Bbs9 
1300010F03Rik 2900024C23Rik Acox3 BC018371 
1500041B16Rik 3000004C01Rik Acp2 BC021381 
1700023B02Rik 3110001A13Rik Acpl2 BC023744 
1700025G04Rik 3110001O07Rik Acvr2b BC024659 
1700025K23Rik 3110001P07Rik Adcy7 BC031353 
1700034H14Rik 3830612M24 Add3 BC038156 
1700054N08Rik 4632428N05Rik Add3 Bckdha 
1700081H05Rik 4833420G11Rik Agap1 Bhlhb9 
1700109H08Rik 4930402E16Rik Agxt2l2 Btbd11 
1810013B01Rik 4930481A15Rik AI480653 Btbd6 
1810015A11Rik 4930563B10Rik AI662250 Btbd6 
1810044D09Rik 4930577N17Rik Akr7a5 Bub1b 
2010005O13Rik 4933427G23Rik Aktip Bub1b 
2010011I20Rik 4933437K13Rik Ank C430004E15Rik 
2010107H07Rik 4933439C10Rik Antxr2 C730029F17Rik 
2210010L05Rik 5031439G07Rik Anxa9 C79407 
2210010N04Rik 5133400G04Rik Ap1g2 C920007D24Rik 
2310005P05Rik 5330438D12Rik Ap2a2 Calcoco1 
2310014D11Rik 5430406J06Rik Ard1 Camk2b 
2310014G06Rik 5730405I09Rik Ard1a Casp6 
2310040A07Rik 5730550L01Rik Arhgap15 Ccbl1 
2310047K21Rik 6330414G02Rik Arhgap15 Ccbl1 
2310051N18Rik 6430590I03Rik Arhgap18 Ccdc5 
2310061C15Rik 9030607L17Rik Arhgap6 Ccl27 
2310061J03Rik 9130019O22Rik Arhgef4 Cd163 
2410002F23Rik 9330186A19Rik Arhgef6 Cd209f 
2410002F23Rik 9530058B02Rik Arhgef6 Cd28 
2410006H16Rik 9530058B02Rik Arl4c Cd300a 
2410008K03Rik 9830001H06Rik Arl4c Cd3eap 
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Cluster 13 Continued 
Cd79b Ctnnd2 Entpd4 Gstz1 
Cd79b Ctps2 Eps8 Gtse1 
Cd8b Cxcr3 Espl1 Guk1 
Cd97 Cxcr4 F630025I20Rik Guk1 
Cd97 Cxx1a F730031O20Rik Gusb 
Cd97 Cxx1c Fads1 Gyg 
Cdc14b Cyhr1 Fahd2a Gzmd 
Cdc20 Cyhr1 Fam102a H13 
Cdc23 Cytip Fam134b H2afv 
Cdc2a D030029J20Rik Fancm H2afv 
Cdc42ep3 D14Ertd449e Fbxl10 Hddc2 
Cdca2 D17H6S56E-5 Fbxl10 Hddc2 
Cdca3 D230007K08Rik Fbxo44 Hectd3 
Cdca7 D2Ertd750e Fcrl1 Helz 
Cdca8 D4Wsu114e Fcrl1 Hfe 
Cdca8 D630004K10Rik Fgfr1op Hfe 
Cdkn2c D930015E06Rik Fh1 Hgf 
Cdkn2c D930028F11Rik Fmo5 Hint2 
Cenph Daglb Fnbp1 Hist1h1c 
Cenpk Dcun1d4 Foxm1 Hist1h1c 
Cenpm Ddah2 Foxo1 Hist1h2ad 
Cenpp Depdc6 Fvt1 Hist1h2ad 
Centd1 Dhrs3 Galnt12 Hist1h2af 
Cep55 Dhrs7 Gamt Hist1h2ah 
Cercam Dhrs7 Ganc Hist1h2ah 
Chn2 Dlgap5 Ganc Hist1h2ai 
Chst3 Dnajc12 Ganc Hist1h2ak 
Chst3 Dph3 Gcc2 Hist1h2an 
Cirbp Dtd1 Ggnbp1 Hist1h2ao 
Ckb Dusp22 Git2 Hist1h3e 
Cln6 Dync2li1 Glrx2 Hist1h3f 
Clspn E030020A01Rik Glt8d3 Hist2h2be 
Clspn E2f2 Glul Hpgd 
Cmtm8 E2f2 Gm114 Hrsp12 
Cnksr3 E2f2 Gmpr Hrsp12 
Cnnm2 E330036I19Rik Gnb5 Hs6st1 
Cnnm3 Ebi2 Gnb5 Hscb 
Cnrip1 Ebpl Gpld1 Hsd17b11 
Cry2 Ebpl Gpr155 Ica1 
Crygn Eef2k Gpr155 Icam2 
Cryl1 Efcab4a Gpr171 Idh2 
Cryz Efcab4a Gpr19 Ier5l 
Cryz EG328314 Gpr34 Ifngr1 
Csad EG433229 Gpr34 Ift140 
Csnk1g2 Eif4ebp2 Gpsm1 Ift140 
Ctdsp2 Enc1 Gspt2 Ihpk1 
Ctdspl Entpd1 Gstt3 Il6ra 
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Cluster 13 Continued 
Imp3 LOC100045877 Mras Pmf1 
Impa2 LOC100047226 Mrps31 Pmm1 
Iqgap3 LOC100047634 Mxd4 Pnpla7 
Itfg3 LOC100047670 Mxd4 Pnpo 
Itga6 LOC100047936 Mxi1 Pold4 
Itgb5 LOC100048434 Myo5a Porcn 
Ivd LOC100048845 Myom1 Ppa2 
Ivns1abp LOC100048845 Nacc2 Ppap2c 
Ivns1abp LOC226017 Naprt1 Ppm1d 
Ivns1abp LOC329416 Nav1 Ppp1r9a 
Kctd17 LOC333331 Nav1 Prcp 
Kif11 LOC380927 Ncapd2 Prep 
Kif13a LOC381629 Ndc80 Prkacb 
Kif15 LOC630146 Ndrg3 Prkrir 
Kif18a LOC634327 Ndst1 Prps2 
Kif20b LOC638935 Ndst1 Ptgs1 
Kif21b LOC674195 Ndst1 Ptgs1 
Kif23 Lonrf3 Neurl2 Ptgs1 
Kif23 Lpin1 Nipsnap1 Ptpn18 
Kif2c Lrrc40 Nostrin Pxmp4 
Kif3a Lrrc45 Noxo1 Rab6b 
Kif3a Lrrfip1 Nrm Rabl4 
Kifap3 Luc7l2 Nt5dc2 Rad51 
Kifap3 Lyplal1 Oxct1 Ranbp10 
Klf2 Man1c1 P2ry1 Rapgef6 
Klhl21 Man1c1 Pacs1 Rapgef6 
Klhl24 Mansc1 Padi2 Rarres2 
Klhl6 Map4k1 Paics Rasgrp3 
Klhl6 Map4k2 Paip2 Rbm38 
Kmo Marveld1 Paip2b Rbm38 
Lama3 Mbp Parp1 Rcbtb2 
Leprel2 Mbtps1 Pbk Rdm1 
Lgals4 Mcee Pcbp4 Rell1 
Lig1 Mcm4 Pdcd4 Retnlg 
Lig1 Mcm7 Pdcd4 Rgs10 
Lman2 Mctp1 Pdcd4 Rhbdd3 
Lmnb1 Mdh1 Pde1c Rhebl1 
LOC100039496 Metrn Pdgfc Rhoj 
LOC100040353 Mfng Peg13 Rmnd5b 
LOC100042970 Mfsd3 Peli2 Rnase4 
LOC100043308 Mical1 Pfas Rnase6 
LOC100043821 Mical1 Phactr2 Rnf167 
LOC100043821 Mical1 Phka2 Rogdi 
LOC100044204 Mkrn1 Pkib Rom1 
LOC100045005 Mospd1 Plscr4 rp9 
LOC100045457 Mospd3 Plxnc1 rp9 
LOC100045738 Mospd3 Plxnc1 Rrm1 
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Cluster 13 Continued 
Rsrc1 Tbc1d2 Trp53inp1  
Samd4 Tbc1d2 Tspan4  
Scarf2 Tbc1d5 Ttc3  
Scotin Tbc1d8 Ttc3  
Selenbp2 Tbl1xr1 Ttc3  
Sema6b Tbrg1 Ttc7  
Sept6 Tcea2 Txnrd2  
Sesn1 Tcea3 Ube2h  
Sesn1 Tceal1 Uhrf1  
Setd7 Tceal1 Ulk1  
Setx Tcf19 Ulk2  
Sft2d2 Tex261 Ulk2  
Sft2d3 Tfdp2 Unc119b  
Sgol2 Tgfbr2 Urod  
Sgpp1 Tgfbr2 Vapb  
Sidt2 Thbd Vps13b  
Ski Thtpa Vrk1  
Slc13a2 Tle1 Wbp5  
Slc15a2 Tlr5 Wbscr27  
Slc15a2 Tmc6 Wdr45  
Slc17a5 Tmc6 Wdr51b  
Slc19a1 Tmc6 Wdr51b  
Slc25a13 Tmem110 Wdr6  
Slc39a12 Tmem141 Wipi2  
Slc46a3 Tmem141 Wwp1  
Slc7a4 Tmem154 Wwp1  
Slco2b1 Tmem168 Wwp1  
Smad5 Tmem184c Xpr1  
Smap2 Tmem25 Xpr1  
Smc3 Tmem53 Ydjc  
Smc4 Tmem71 Ypel3  
Snhg10 Tmem82 Zdhhc3  
Sorl1 Tnfsf13b Zfhx3  
Spc25 Tnfsf13b Zfhx3  
Srgap3 Tnni2 Zfp219  
Srpk3 Tnrc6b Zfp219  
Ssbp3 Tns1 Zfp282  
St6gal1 Tpcn1 Zfp36l1  
Stab1 Tpcn1 Zfp524  
Stab2 Tpcn1 Zfp704  
Stxbp5 Tpk1 Zfp770  
Suclg2 Tpk1 Zfp99  
Suclg2 Treml1 Zmat3  
Sufu Trim47 Znf512b  
Syp Trim59 Zzz3  
Tardbp Trim59   
Tbc1d17 Troap   
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Cluster 14 
1500011B03Rik Cnp Oas1c Tnnc1 
1500019C06Rik Coq5 Oas1d Tubg1 
1700112E06Rik Cox6a2 Ocel1 Unc13d 
1700113I22Rik Creb3l1 Ociad2 Unc13d 
1700113I22Rik Cryba4 Ogfrl1 Usp45 
2210012G02Rik Cryzl1 P2ry14  
381484 Cutc P2ry14  
4930486L24Rik Cutc P2ry14  
4930539E08Rik D14Ertd231e Pcnp  
4933403G14Rik D330050I23Rik Pde7b  
4933425L03Rik Ddit3 Per2  
5330420J21Rik Ddit3 Pigl  
5330431N19Rik Fam100b Pla2g2e  
5730403B10Rik Fbxw7 Plekhm1  
6330442E10Rik Fgfbp3 Pnpla1  
6330442E10Rik Gm1276 Prei4  
6530401N04Rik Gng11 Prelid2  
9330175B10Rik Gpatch2 Ptcd2  
9530048O09Rik Gpkow Pten  
Acbd4 Gtf2h2 Ralgps2  
Acbd4 Gypc Rgs14  
Acpp Hap1 Rhbdd1  
Adck1 Hist3h2a Rhov  
Amigo3 Homer1 Rnf141  
Angpt2 Ints9 Rnf141  
Ankle2 Itgam Samhd1  
Ankle2 Itpr1 Sass6  
Arhgap4 Itprip Sfxn5  
Arid3b LOC100036521 Sh3bp1  
Bbs4 LOC100041137 Siglec1  
Bcdo2 LOC100045266 Sirpb1  
C330008K14Rik LOC100046843 Sirpb1  
C79267 LOC100047419 Slc12a9  
C79267 LOC381524 Slc16a6  
Capn10 LOC386288 Slc2a9  
Casp3 Lrrk2 Stoml1  
Ccdc125 Ltb4r1 Stoml1  
Ccdc134 Mag Stoml1  
Ccdc99 Ms4a6b Tbl2  
Ccl25 Msl3l2 Tbxas1  
Ccl25 Mtmr3 Thada  
Cd1d1 Nat6 Thbs1  
Cd22 Nisch Timeless  
Cd300lf Nsmaf Tlr13  
Cdk5rap2 Nsun4 Tmcc3  
Cep164 Nt5m Tmem126b  
Cln8 Nt5m Tnfrsf26  
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Cluster 15 
1500041J02Rik Spata3   
3010031K01Rik Vegfa   
5430434G16Rik Wdr62   
8030474H12Rik Zfp703   
8430403J19Rik    
A430073A17Rik    
Areg    
Chka    
Cited2    
Cited2    
Cited2    
Cpeb2    
Csf2    
Dpep3    
Dusp1    
Egr1    
Egr2    
Egr3    
Egr4    
Errfi1    
Fos    
Fosb    
Fosl2    
Gem    
Grasp    
Id3    
Idb2    
Ier2    
Ier3    
Irs2    
Jmjd3    
Jun    
Klf4    
Lcp2    
LOC100045678    
LOC240672    
Mapk6    
Myc    
Nfkbid    
Osm    
Pde4b    
Pim3    
Plau    
Pmaip1    
Pmaip1    
Sfrs5    
Smad5    
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Cluster 16 
1500001E21Rik Cd300lb Fhod1 Mras 
1700034H14Rik Cdc45l Fibp Mrps25 
1700034H14Rik Cebpa Fignl1 Mrps25 
1700123D08Rik Cenpi Fmnl1 Mthfd1 
2310022K01Rik Chd6 Fuca1 Mybl2 
2310038D14Rik Chtf18 Fvt1 Nanos1 
2610002D18Rik Ckap2 Galnt9 Nap1l1 
2610020C11Rik Cmbl Gart Nap1l1 
2610203C22Rik Col4a1 Gbl Ncf2 
2610302F08Rik Col4a5 Gbl Ncoa4 
2810405K07Rik Col4a5 Gbl Nrp 
2810408P10Rik Crem Gemin4 Nuak1 
3830430K15Rik Crem Gins1 Nup85 
4932441P04Rik Cspp1 Gins2 Olfml3 
5730407K14Rik Cx3cr1 Gmnn OTTMUSG00000000421 
5930418K15Rik Cxcl14 Hey1 Pcgf6 
6330403M23Rik Cxcl14 Hirip3 Phka2 
7530408C15Rik Cyp2s1 Hist1h3f Pla2g15 
9330147J08Rik D030063E12 Hprt1 Pole 
9530053J19Rik D230014K01Rik Idh1 Polr1b 
9630025I21Rik D630036H09Rik Idh3a Polrmt 
9830144J08Rik D6Wsu163e Il27ra Pparg 
Acot2 Dm15 Kntc1 Pparg 
Adal Dmkn Lbcl1 Ppm1l 
Adssl1 Dmkn Lbr Prmt7 
Adssl1 Dnajc28 Lmnb2 Psmc3ip 
Ahrr Dtymk LOC100041567 Psmf1 
Angptl4 Dtymk LOC100045677 Ptchd1 
Antxr2 E030038D23Rik LOC100047264 Ptger2 
Arhgef1 E130016E03Rik LOC100047273 Rad50 
Arrb1 E230029C05Rik LOC100048280 Rad51 
Arrb1 E230029F23Rik LOC237877 Rad51ap1 
Asf1b E330009F12Rik LOC382264 Rad51ap1 
Atad2 E430018J23Rik LOC384453 Rgs11 
AU020206 Ear2 LOC385659 Rnf167 
AV028368 Ear2 Lrrc39 Rnf167 
B230312I18Rik Ear3 Map2k6 Rnmt 
B930008G03Rik EG226654 Mcm10 Rnmt 
Blm Eif4a2 Mcm10 Rpa2 
Brip1 Ermp1 Mcm3 Rpa2 
Brp16 Esco2 Mcm5 Rrm2 
C85492 Exosc6 Mcm6 Serpinb6b 
Camk2n2 F630043A04Rik Mcm6 Serpine2 
Cand1 F730047E07Rik Mcm6 Sesn1 
Ccne2 Fancd2 Mcm7 Sgol1 
Cd151 Fanci Melk Shcbp1 
Cd207 Fen1 Mphosph9 Slc24a3 
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Cluster 16 Continued 
Slc27a3    
Slc37a1    
Slc37a2    
Sort1    
Sox4    
Spc25    
Tbx6    
Tdrd3    
Tfrc    
Tfrc    
Tgfb3    
Tk1    
Tmem48    
Tmem81    
Trub1    
Trub1    
Tspan33    
Ttbk2    
Tyms    
Tyms    
Tyms-ps    
Ube2t    
Ung    
Vamp5    
Wdr90    
Wrb    
Wwp1    
X99384    
Zfp101    
Zfp119    
Zfp60    
Zfp608    
Zfp760    
Zfp87    
Zfp87    
Zfp94    
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Cluster 17 
0610006I08Rik A530055J02Rik Brrn1 Decr1 
0610006I08Rik A630006E02Rik C030048B08Rik Dedd2 
0910001L09Rik A630091F01Rik C130022E19Rik Dfna5h 
1110018J18Rik Aaas C330006A16Rik Dhrs7 
1110018J18Rik Abcc3 C76746 Dnahc11 
1110049F12Rik Abhd11 C79407 Dnajc12 
1500010J02Rik Abhd12 Cacna1f Dppa3 
1500010J02Rik Abhd8 Camk1 Dscr1l2 
1500011H22Rik Accs Camk1 Dym 
1700008F19Rik Acp6 Camk1 Dyrk1b 
1700026L06Rik Acss1 Camk1d E230008N13Rik 
1700041B20Rik Actr8 Camk2g Ech1 
1810009O10Rik Adi1 Car9 Echs1 
1810020D17Rik Adipor1 Car9 EG546143 
1810030N24Rik Adssl1 Casp6 EG623230 
2210011C24Rik Akap8l Ccdc120 EG667410 
2210404O07Rik Akr7a5 Ccdc28a Ela1 
2210410E06Rik Akr7a5 Ccrk ENSMUSG00000053178 
2310005E10Rik Aldh4a1 Cdan1 Etaa1 
2310005L22Rik Aldh4a1 Cdc14b Ethe1 
2310007H09Rik Alg6 Cdk5rap3 Eya1 
2310007H09Rik Als2cr13 Ceacam2 Fahd1 
2310047A01Rik Als2cr13 Cenpq Fam108a 
2310047B19Rik Ankmy2 Chaf1a Fam110a 
2310067B10Rik Anks6 Chst14 Fam110a 
2410091C18Rik Ap1b1 Cln6 Fam122b 
2610003J06Rik Appl2 Cluap1 Fam168a 
2610044O15Rik Arhgap19 Cnot6l Fam168a 
2700084L06Rik Arhgap19 Comt Fbxl12 
4833420G17Rik Arhgap24 Comt Fbxl20 
4833427B12Rik Arhgap9 Ctla2b Fbxo21 
4930534B04Rik Armc3 Ctnnbip1 Fbxw4 
4930572J05Rik Armc3 Cugbp2 Fchsd1 
4931406C07Rik Arrdc2 Cugbp2 Fgd2 
4933427D14Rik Asnsd1 Cxx1b Fhod1 
5033430I15Rik Atp13a2 Cyb5r1 Gab3 
5430405C01Rik AW544981 D10627 Galt 
5730403M16Rik B130019G13Rik D10Ertd322e Galt 
5730455P16Rik B230342M21Rik D330008I21Rik Gats 
9030025P20Rik B3gnt1 D3Ertd300e Gats 
9030025P20Rik B3gnt8 D6Wsu176e Gcdh 
9030025P20Rik B3gnt8 D6Wsu176e Gcnt1 
9130211I03Rik Bag4 D930015E06Rik Gcnt1 
9130221H12Rik BB128963 D930049D19Rik Gdpd3 
9530064J02 BC038925 Dalrd3 Gdpd5 
A230057M07Rik BC039093 Dbndd2 Ggcx 
A530050E01Rik Bin1 Dbp Gigyf1 
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Cluster 17 Continued 
Gm114 Klc4 Naprt1 Pou6f1 
Gm166 Klhdc2 Nat15 Ppapdc2 
Gna12 Ldb1 Ncapd3 Ppp1r12c 
Gng2 Lincr Ncapg2 Prkcb 
Gnpda1 Lincr Ncapg2 Prkra 
Gnpda1 Lman2l Ncaph Prr12 
Gnpda1 Lnx2 Ndufb8 Prune 
Golm1 LOC100040799 Nfatc1 Prune 
Golm1 LOC100044159 Nfic Ptplad2 
Gpn3 LOC100044204 Nfic Ptpn22 
Gpr146 LOC100047028 Nhlrc1 Pus3 
Gpr146 LOC100047260 Nicn1 Pycrl 
Gpr162 LOC100047762 Nme4 Pygb 
Gpr162 LOC100047863 Nme4 Pygl 
Gpt1 LOC100048589 Nme7 Rab11fip5 
Gtf3a LOC269515 Nosip Rab11fip5 
Hagh LOC381691 Npal3 Rab3il1 
Haghl LOC382010 Nqo2 Rab4a 
Haghl LOC383077 Nr2f6 Rabl2a 
Havcr2 LOC628836 Nudt19 Rap1gap 
Havcr2 LOC668047 Nudt7 Rasgrp4 
Hdac10 LOC674427 Nudt7 Rassf2 
Hdac5 LOC676420 Ogfod2 Rassf3 
Hdac5 Lrmp Oit3 Rassf5 
Hebp1 Lrmp Ophn1 Rb1 
Hemk1 Lrrc27 Osbpl11 Rb1 
Hes6 Lrrc28 P2rx7 Rbak 
Hexdc Lyl1 P2rx7 Rcan3 
Hip1 Mad1l1 P2ry12 Rcbtb2 
Hisppd2a Manba Pacrg Rev3l 
Hist1h2bm Manba Pcnt Rfc4 
Hmg20a Map3k1 Pcyox1 Rfx1 
Hmgcl Map3k14 Phf3 Rfxap 
Hmgcl Mat2b Pias3 Rhobtb1 
Hs2st1 Mcm2 Pias3 Rhobtb1 
Hyi Mfsd7b Pigyl Rnf150 
Ift122 Mgst2 Pigz Rnf167 
Ift81 Mknk2 Pkib Rpa1 
Il6ra Mospd1 Pkib Rpa3 
Impa2 Mospd1 Pkig Rrm1 
Iqce Mpg Pkig Rrp1b 
Iqgap2 Mpst Plcb2 Rsdr1-pending 
Iqgap2 Msh6 Plekhg3 Sac3d1 
Irf2bp2 Msh6 Plxdc1 Sars 
Itgb3bp Mta3 Pmm1 Scamp5 
Jarid1b Mtr Poli Scp2 
Kdelc1 Myo18a Polk Sema4b 
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Cluster 17 Continued 
Sepn1 Tpmt   
Setd2 Tpra40   
Sgsh Trmt2b   
Sh3bp5l Trove2   
Sirt3 Tspan32   
Sirt5 Ttc39a   
Slc16a6 Ttc7   
Slc2a3 Uchl3   
Slc2a8 Uhrf1bp1l   
Slc35c2 Umps   
Slc41a3 Usp30   
Slc46a1 Vps33b   
Smarca2 Wbp1   
Smg6 Wbp1   
Smpd2 Wdr21   
Snta1 Wdr81   
Snx14 Wipi1   
Snx33 Wwp1   
Snx5 Xrcc1   
Snx5 Xrcc6   
Spint1 Xrcc6   
Spr Yipf2   
Ssbp3 Zc4h2   
Susd3 Zdhhc14   
Taf3 Zer1   
Tatdn3 Zfhx2   
Tbxas1 Zfp202   
Tbxas1 Zfp251   
Tctn3 Zfp280c   
Tctn3 Zfp36l1   
Tec Zfp36l1   
Terf2 Zfp414   
Them2 Zfp707   
Tipin    
Tk2    
Tle6    
Tm6sf1    
Tm7sf3    
Tmem107    
Tmem143    
Tmem65    
Tmem8    
Tmem8    
Tmem9    
Tnfrsf22    
Tob1    
Tpmt    
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Cluster 18 
0610009B22Rik 3010026O09Rik A530017D24Rik B930030B22Rik 
0710007G10Rik 3110078M01Rik A530082C11Rik Bace1 
1110001C23Rik 4632417N05Rik A630084D02Rik Bbc3 
1110003O08Rik 4732486I23Rik A730063M14Rik Bbc3 
1110008L16Rik 4733401I05Rik A730063M14Rik BC002230 
1110032A13Rik 4831403C07Rik A930008G19Rik BC003498 
1110032A13Rik 4832420L08Rik A930026I22Rik BC019806 
1110034G24Rik 4833442J19Rik AA415398 BC025076 
1110048D14Rik 4930429O20Rik Aasdh BC049806 
1110058L19Rik 4931426K16Rik Aatk BC053749 
1110068E08Rik 4932417I16Rik Abcb7 Bckdk 
1190002N15Rik 4933411K20Rik Abcc10 Bcl2l13 
1190028F09 4933439C20Rik Abcd2 Bcl7a 
1200011O22Rik 5330401P04Rik Abcd2 Bcl9l 
1300007F04Rik 5330401P04Rik Acn9 Bcs1l 
1500004F05Rik 5330414O08Rik Acn9 Best1 
1500012M23Rik 5630401D24Rik Acot1 Bmf 
1700012H17Rik 5630401D24Rik Acsf3 Brwd1 
1700021K19Rik 5730419I09Rik Acsl3 Btbd1 
1700023B02Rik 5730593F17Rik Adal C030006K11Rik 
1700023B02Rik 5730601F06Rik Adcy7 C030010B13Rik 
1700027M01Rik 5730601F06Rik Adcy9 C030014I23Rik 
1700027M01Rik 5830454E08Rik Adrb2 C030025P15Rik 
1700034H14Rik 6030413G23Rik AI595366 C530044N13Rik 
1700052N19Rik 6230416J20Rik AI847670 C730026J16 
1700065O13Rik 6230427J02Rik AI875142 C87436 
1810007P19Rik 6330403E01Rik Als2cr13 C920006O11Rik 
1810011H11Rik 6330419J24Rik Ankrd10 Cables1 
1810011H11Rik 6430511F03 Ankrd47 Casp2 
1810049H13Rik 6430540M20Rik Anks6 Cbr3 
1810063B05Rik 6430548M08Rik Ap4m1 Cbx6 
2010004M13Rik 6430548M08Rik Ap4m1 Cbx7 
2010312A17Rik 6530415H11Rik Ap4m1 Cbx8 
2010320M18Rik 6720456H20Rik Aph1c Ccdc85b 
2210408F11Rik 9130204C11Rik Aplf Cdc25b 
2210419D22Rik 9230112E08Rik Arl11 Cdc6 
2310035K24Rik 9330133O14Rik Arrb1 Cdk5rap1 
2310036D04Rik 9330175B01Rik Asb2 Cenpm 
2310036D22Rik 9430093I07Rik Atg2b Cenpn 
2310040G24Rik 9530055J05Rik Atmin Clspn 
2610035D17Rik 9630015D15Rik Atp10d Cmkbr2 
2700049A03Rik 9930012K11Rik Atp5sl Cnot10 
2810410C14Rik A130010J15Rik Azi1 Cnr2 
2810440J20Rik A130039H17Rik B3gnt9 Cnr2 
2900024O10Rik A130092J06Rik B3gnt9 Comt 
2900026A02Rik A230106J09Rik B430320J11Rik Coq9 
2900057K09Rik A430107D22Rik B4galt4 Cryz 
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Cluster 18 Continued 
D15Bwg0759e Fut10 Kifc1 Msrb2 
D630014A15Rik Fut10 Klhdc5 Mtus1 
D6Wsu163e Galnt10 Klhl17 Mtus1 
D830050J10Rik Gm561 Klhl24 Myst4 
D930048N14Rik Gm561 Klhl6 Nat8l 
Ddx26b Gne Krba1 Nckipsd 
Deb1 Gpr160 Ldoc1l Ndor1 
Def6 Gpr65 LOC100045780 Ndor1 
Dgkd Gpsm1 LOC100046254 Nedd9 
Dgkg Gstt2 LOC100046775 Nedd9 
Dhcr7 Gtf2i LOC100047480 Nek3 
Diras2 Gtf2ird2 LOC100047839 Neurl 
Diras2 Gtf2ird2 LOC225897 Nfam1 
Dnajc28 Gtf3a LOC270152 Nfatc1 
Dnase2a Gyg LOC384890 Nisch 
Dph3 H1f0 LOC386486 Nmnat3 
E030007N04Rik H2afj LOC670089 Notch4 
E130102H24Rik H2afj Lpin1 Nrp1 
E130302P19Rik Hes6 Lrig3 Nrp1 
E130306D19Rik Hes6 Lrrc27 Nthl1 
E330020G21Rik Hgf Lrsam1 Nuak1 
Efcab4a Hist1h3a Maf Nudt18 
Efnb1 Hist2h2be Maf Nudt6 
EG545216 Hmgcl Mafb Numa1 
Elac1 Hmha1 Map3k7ip1 Obfc1 
Elmo2 Hoxa7 Mapk14 Olfr802 
Elp3 Hoxb4 Mapk1ip1 Orc3l 
Eno3 Hscb Mapk1ip1 ORF19 
Epn2 Ick Marveld1 Otub2 
Ercc5 Ick Mast3 P2ry5 
Ercc5 Ift81 Mbd5 Pank1 
Erp29 Il16 Mbp Paqr7 
Etl4 Incenp Mef2c Parc 
F8a Ing3 Mef2c Parp2 
Fam110b Ing4 Mef2c Parp2 
Fam119a Ing4 Megf8 Patz1 
Fam160a2 Ing4 Meis1 Pbx2 
Fance Ino80b Mett11d1 Pcmtd2 
Fbxl6 Ints7 Mib2 Pcyox1l 
Fbxo10 Irak4 Mknk1 Pcyt1b 
Fbxo31 Irf2bp1 Mknk1 Pdcd4 
Fbxo32 Itfg2 Mks1 Pdik1l 
Fbxo32 Kank3 Mlycd Pdss2 
Fdxr Kctd12b Mns1 Pdxk 
Foxred2 Kctd12b Mpg Pex11c 
Frat2 Kctd12b Msh2 Pex6 
Fuk Kctd2 Msrb2 Pfkfb2 
  
Chapter 3: The macrophage transcriptional response to Mtb 
 
178 
 
Cluster 18 Continued 
Pfkfb4 Rmnd5b Tmem103 Zfp579 
Pfkm Rnf166 Tmem132a Zfp692 
Pgm2l1 Rnf167 Tmem143 Zfp810 
Phf14 Rnu6 Tmem144 Zfp90 
Phf7 Rragb Tmem19 Zfp97 
Phlda3 Rttn Tmem38a Zfyve27 
Phlda3 Rwdd2 Tmem41a Zkscan14 
Pick1 Rxrb Tmem51 Zkscan5 
Pik3c3 Samd10 Tnfaip8l2 Zmym3 
Pik3ip1 Sec14l1 Tnfrsf21  
Pik3r2 Sec14l1 Tns4  
Pik3r4 Sec14l1 Top3b  
Pla2g4b Sec15l1 Triap1  
Plekhg3 Sec22c Trim62  
Plxdc1 Serac1 Trmt2b  
Pold1 Sirt5 Trove2  
Polg2 Siva1 Trp53inp1  
Polg2 Skp2 Trrp2  
Poll Slc16a13 Tspan14  
Ppapdc2 Slc16a13 Tspan4  
Ppm1m Slc19a2 Ttc30b  
Ppp2r5e Slc25a16 Ttll4  
Prkag2 Slc35a5 Txnip  
Prkd2 Slc35a5 Ulk1  
Pscd1 Slc35c2 Use1  
Pter Slc37a4 Usp20  
Ptpdc1 Slc40a1 Vars  
Ptpn21 Slc5a6 Vgll4  
Ptpro Smpd3 Wdr18  
R3hcc1 Snrk Wdr18  
Rab3a Snx14 Wipi2  
Rab40c Snx21 Xpa  
Rad54l Socs6 Xpc  
Rage Sp3 Ypel3  
Rapgef6 Spata2L Zbtb45  
Rasa3 Spry3 Zbtb45  
Rasa3 Ssbp2 Zfhx2  
Rbak Stard8 Zfp12  
Rchy1 Stard8 Zfp148  
Recql5 Suv420h2 Zfp161  
Rgl2 Synpo Zfp251  
Rgl2 Taf6 Zfp277  
Rgs18 Tarsl2 Zfp277  
Rgs2 Tef Zfp383  
Rgs2 Tep1 Zfp39  
Rhod Thap11 Zfp472  
Ripk1 Tle1 Zfp472  
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Cluster 19 
1190002H23Rik Cul2 LOC100040573 Rab12 
1190008K20Rik Cybb LOC100044376 Rabgef1 
1200009I06Rik Cyld LOC100045737 Ralgds 
2310004N11Rik D630048P19Rik LOC100045950 Rcan1 
2600010E01Rik Dnajb6 LOC100048721 Rcl1 
2610030H06Rik Dock10 LOC100048858 Rcl1 
2810470D21Rik Dusp4 LOC666025 Rel 
3110043O21Rik Dusp4 LOC667337 Relb 
3830421F03Rik E2f5 LOC676704 Rffl 
4921514E18Rik Edn1 Lrch1 Rilpl2 
4930461P20Rik Ehd1 Ly9 Ripk2 
9030216K14Rik Eif2c2 Malt1 Rnf12 
9030611K07Rik Eif2c3 MALT-1 Rnf14 
9830169E20Rik Eif5 Manbal Rnf2 
A530045M11 Elavl4 Mapk1ip1l Rnf38 
Aff1 Etf1 Marcks Rod1 
Aff1 F630047D10Rik Marcksl1 Rps6ka3 
Ak2 Fas Marcksl1 Rusc2 
Ankrd50 Fas Marcksl1 Sbds 
Arl5c Fbxl5 Mdm2 Sdc4 
B3gnt5 Fgd6 Mdm2 Sestd1 
B4galt5 Flrt3 Mdm2 Sf1 
BC003324 Fmn Mlp Skil 
BC031781 Fndc7 Mmp13 Slc25a25 
Bcl2a1b Gas7 Mmp13 Slc4a7 
Bcl2a1c Gas7 Mtmr14 Slfn2 
Bcl2a1d Gas7 Ndel1 Sntb2 
Bcl2a1d Gdap10 Nfkbie Snx18 
Bcl2l11 Gja1 Nlrp3 Sox12 
Bcl3 Gna13 Nup98 Spn 
Birc2 Gnal1 Nup98 Sqstm1 
Birc3 Gpr109a Nupl1 Srfbp1 
C130032J12Rik Gramd1a Orc4 Srgn 
C230067O06Rik Gramd1b Patl1 Srgn 
Casp4 Hbegf Pcgf3 Ssfa2 
Ccdc82 Hipk2 Pi4k2b St6galnac4 
Cdc42ep2 Hnrpdl Pip5k1a Stk40 
Cdkn1a Hook3 Pip5k1a Stx11 
Cdkn1a Ibrdc3 Pkn2 Stx3 
Cdkn1a Icam1 Plagl2 Stx6 
Cdkn2b Il1a Plscr1 Tacc1 
Ch25h Il1a Plscr1 Tagap 
Clec4e Il4ra Ptgs2 Tagap 
Csf1 Klf7 Ptpn23 Tagap1 
Csnk1d Klf7 Pvr Taok1 
Csnk1d Klf7 Pvr Taok1 
Csnk1d Lmo4 Pxn Tcp1 
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Cluster 19 Continued 
Tdg    
Tlr6    
Tmem2    
Tmem2    
Tmem2    
Tmem39a    
Tnip1    
Tollip    
Traf1    
Traf2    
Traf3ip2    
Tsc22d2    
Tspyl3    
Tubb6    
Ube3a    
Ugcg    
Vps37c    
Ybx3    
Yrdc    
Zc3h12a    
Zc3h12a    
Zeb2    
Zfp131    
Zswim4    
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Cluster 20 
0610010F05Rik LOC380741   
4932409G17Rik LOC433943   
4933439M10Rik LOC624083   
5530401A10Rik Lrch3   
5830407P18Rik Mllt3   
9030612M13Rik Mllt3   
9030619K07Rik Morf4l1   
9930016I07Rik Msi2   
A130019H11Rik Mtssk   
A530020A01Rik Ncoa6ip   
A530089A20Rik Nfatc3   
Acap2 Peli1   
Acss2 Pira2   
Arhgap10 Pira3   
Arrdc4 Pira6   
B130008D24Rik Pira6   
B230342N21Rik Plac8   
B430305P08Rik Ppargc1b   
Bach1 Ppp2r3a   
BC003314 Slc23a1   
BC030336 Stk19   
C630011I23 Tbc1d20   
Cd164 Tbl1x   
Cep110 Vps13c   
Chd1 Wins2   
Chd1 Wwox   
Cnp1 Xrn2   
Creb5 Zfp26   
D130077B20Rik Zfp26   
D16Ertd472e Zfp91   
D430035B07Rik Zfp91-cntf   
Ddx24    
Dph5    
Gprc5b    
Hspa4l    
Ifi203    
Ifitm6    
Ift172    
Ift172    
Ilf3    
Kctd6    
Kif9    
LOC100038908    
LOC100040462    
LOC100043402    
LOC100046746    
LOC270589    
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Cluster 21 
1700007P14Rik Brcc3 Galns LOC385019 
1700020O03Rik Bst2 Gapdh LOC385780 
1810033B17Rik C1rl Gba LOC547343 
1810047K05Rik C1rl Gde1 LOC56628 
2010005H15Rik Cadps Gla LOC667597 
2010305C02Rik Capg Glipr2 Lrrc8 
2600001G24Rik Carhsp1 Gp6 Lst1 
2810035J02Rik Casz1 Gpr35 Ly6a 
2900090M10Rik Ccdc23 Grina Ly6c1 
4930578N16Rik Ccdc41 Gstm2 Ly6e 
4930583H14Rik Cd22 Gstm2 Ly6e 
5330431N19Rik Cd38 Gstt4 Mical2 
9030425E11Rik Cd52 Gtpbp8 Mill2 
9130230L23Rik Cdc37l1 Gtpbp8 Mocs2 
9130230L23Rik Cdkn1c Gys1 Mov10 
A530023O14Rik Cdkn2d H2-Q7 Mov10 
A530023O14Rik Cerkl H2-T22 Mrpl47 
A530064D06Rik Chchd10 H2-T23 Mxd1 
A530064D06Rik Chchd6 H2-T23 Ndufs4 
A630012P03Rik Clic5 Hmga1 Ndufs4 
A630082K20Rik Crcp Hspa1a Nes 
A630085K21 Csprs Hspa1b Nfxl1 
AA691260 Ctsk Hspa1l Odz4 
Abi3 Cyfip2 Hyal1 ORF9 
AI427809 Cyln2 I830077J02Rik Orm1 
Aif1 D11Lgp2e Ifi44 Orm2 
Aif1 D130040H23Rik Il12rb1 Osbp2 
Aifm2 D330045A20Rik Il21r OTTMUSG00000002038 
Akap12 D330045A20Rik Il21r Parp11 
Akr1a4 Dap3 Inpp4b Pdk3 
Aldh18a1 Dcakd Insl6 Phospho2 
Ankfy1 Dcn Itgb7 Pkp4 
Antxr1 Ddx19b Kcnab1 Plcl2 
Antxr1 Dera Kcnab1 Ppp2r5c 
Ap3m2 Dgkz Kctd1 Pqlc2 
Apol9b Dnajc2 Klra2 Prm1 
Arg1 E030034P13Rik Lgals3bp Prm1 
Arg1 Eed LOC100042427 Pstpip1 
Armcx6 EG277333 LOC100042427 Ptk2 
Ascc2 EG433016 LOC100042427 Pwwp2b 
Atf7ip EG545385 LOC100046746 Rabl5 
B130024L21Rik Elk3 LOC100047052 Rpe 
B930075F07 F8 LOC100047904 Scoc 
BC017643 F8 LOC223672 Scyb11 
BC094916 Fcgr4 LOC331595 Sell 
Bcap31 Gadd45g LOC381048 Serf1 
Brcc3 Gadd45g LOC381787 Siglece 
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Cluster 21 Continued 
Siglece    
Siglece    
Slamf9    
Slc24a6    
Slc36a1    
Slc39a3    
Slc6a12    
Slc6a19    
Slfn4    
Slpi    
Smcr7    
Smox    
Smox    
Snx7    
Spsb4    
Stat1    
Taf12    
Tbc1d9    
Tcf7l2    
Tlcd2    
Tlcd2    
Tmem33    
Tmprss4    
Tmsb10    
Tmsb10    
Tpst2    
Trib3    
Trib3    
Trim29    
Ufsp1    
Ugt1a6a    
Ugt1a6b    
Upk3b    
Vamp4    
Vegfc    
Wdr20b    
Wnk2    
Wnt6    
Wnt6    
Xylt2    
Yipf6    
Zdhhc24    
Zfp821    
Znhit1    
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Cluster 22 
0610037L13Rik BC003885 Eif5 Lrrc59 
1100001F19Rik Bcl2l1 Eif5a Lrrfip2 
1200015F23Rik Bcl2l1 Elovl1 Mgat4b 
1200015F23Rik Bfar Epb7.2 Mier3 
1700009P03Rik Birc2 Esd Mina 
1810013L24Rik Bnip2 Eya3 Minpp1 
2010311D03Rik C230091E03Rik Fam176b Mobk1b 
2310036I02Rik Caprin1 Fubp1 Mobkl1a 
2310047O13Rik Cav1 Fusip1 Mobkl2c 
2400003C14Rik Ccdc93 G3bp1 Mrpl3 
2410042D21Rik Ccnc Gabpb1 Msn 
2510010F15Rik Ccnc Gabpb1 Mtch2 
2810407C02Rik Ccnyl1 Gfm1 Mtmr14 
2810408M09Rik Cct3 Gnb1 Nab1 
2810408M09Rik Cct3 Golt1b Nab1 
2900097C17Rik Cct6a Gosr2 Naif1 
4833439L19Rik Cct6a Gosr2 Nfkbie 
4933401P20Rik Cd74 Gpc1 Nipsnap3a 
5730589K01Rik Cd86 H2-Ab1 Nol5a 
6430527G18Rik Cdc42se1 H2-Ab1 Nsfl1c 
9430065L19Rik Chuk Hip2 Nup54 
9930111J21Rik Clic4 Hn1l Pcdh7 
A830007F21Rik Col18a1 Hnrnph1 Pcmt1 
Abcf1 Col4a2 Hnrnph1 Pfkp 
Abi1 Crk Idh3a Phgdh 
Abpb Crkl Ikbkg Pi4k2b 
Acsl4 Crlf3 Ilf3 Pias4 
Acsl5 Crls1 Ilf3 Pik3ap1 
Acsl5 Csda Irak2 Pkn2 
Acvr1b Csf2rb Itpkb Plekha1 
Aebp2 Csf3r Khdrbs1 Pofut2 
Agfg1 Ctps Krit1 Pot1b 
Agpat1 Ctps Larp4 Ppfibp1 
AI848100 Cugbp1 Lcp1 Ppfibp2 
Ak2 Cul2 Lmnb1 Ppfibp2 
Alg8 Cux1 LOC100040505 Ppp2r2a 
Anp32a Cyp20a1 LOC100043675 Ppp3cc 
Ap2b1 D11Moh35 LOC100048726 Ppp4r1 
Ap2b1 D4Wsu132e LOC100048796 Psmd10 
Apob48r Dctn4 LOC224732 Psmd5 
App Dhrs9 LOC245350 Psmd7 
Arhgap10 Dnajb6 LOC384315 Pstpip2 
Arpc5 Dnm1l LOC432555 Ptafr 
Asb6 Dnm1l LOC432730 Ptbp1 
Atg4d Dnm1l LOC434200 Ptges3 
Atic Eif3b LOC629364 Ptk9 
BC003885 Eif4a1 LOC630729 Ptpn12 
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Cluster 22 Continued 
Ptpn12 Tagln2   
Ptpn12 Tcp1   
Ptpn12 Tes   
Ptprj Tlr1   
Pvrl2 Tlr6   
Rab18 Tnfrsf1a   
Rab7 Tnfrsf1a   
Rac3 Tnfrsf1a   
Rad9 Tnfrsf1b   
Raet1b Tnfrsf1b   
Ran Tomm40   
Rars Tpm3   
Raver1 Tpm4   
Rg9mtd2 Traf5   
Rgs3 Tssc1   
Rhoc Ttc39b   
Rhoc Ube2e1   
Rnf11 Ube2f   
Rnf111 Ubqln1   
Rnf14 Ubxd7   
Rnf41 Ubxn8   
Rwdd1 Usp12   
Sbno1 Usp6nl   
Sfrs10 Usp7   
Sfrs2 Vcam1   
Sgk3 Vdac3   
Sgk3 Vps26a   
Sgk3 Wapal   
Sgk3 Wdr1   
Sla Wdr37   
Sla Wdr37   
Slc16a10 Zdhhc6   
Slc44a1 Zdhhc6   
Slc7a7 Zfp207   
Slc7a7 Zfp238   
Slc9a8 Zfp238   
Spata5l1    
Spcs3    
Spic    
Spic    
Srm    
Srp54    
Srxn1    
Srxn1    
St3gal1    
Stip1    
Stx3    
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Cluster 23 
0610007L01Rik Atf4 Dgkh H2-Ab1 
1190003J15Rik Atf4 Dnmt3l H60a 
1200015F23Rik Atxn2 Dnmt3l Hck 
1200016B10Rik Batf Dst Heatr6 
1500034J01Rik BC004022 Dtx2 Hivep1 
2310047O13Rik BC006779 Dtx2 Hsp90aa1 
2400003C14Rik BC006779 Dtx2 Ifi205 
2400003C14Rik BC017647 Dync1li1 Ifi205 
2410131K14Rik Bid E2f3 Ifngr2 
2610029J22Rik Bmp1 E430021P16Rik Ifngr2 
2810408M09Rik Brd2 Eaf1 Igf2bp2 
2810423A18Rik Brd2 Ebi3 Ikbke 
2810474O19Rik C030046E11Rik Edg2 Il15 
2810474O19Rik C78339 Edg2 Il15 
4632411B12Rik Camk2d EG432649 Il15 
4930461P20Rik Camk2d EG665369 Il1rn 
4933426M11Rik Camk2d EG665685 Il1rn 
5730525O22Rik Car13 Etv6 Il1rn 
5730528L13Rik Casp4 F10 Il27 
6030448M23Rik Casp4 Fabp3 Il6 
6330548G22Rik Casp7 Fgd6 Irg1 
A030007L17Rik Ccdc50 Fip1l1 Irg1 
A030007L17Rik Ccdc93 Frag1 Itga5 
A130015P11Rik Ccnd2 Fscn1 Itpkb 
A630077B13Rik Ccnd2 Gabpa Jak2 
Acp5 Cd40 Gbe1 Jak2 
Acsl4 Cd40 Gbp5 Jmjd6 
Acsl4 Cd40 Gca Katna1 
Acsl5 Cd40 Gch1 Kctd9 
Adora3 Cldnd1 Gch1 Kif3b 
Adprhl1 Clecsf9 Gcnt2 Kif3c 
Adrm1 Cln5 Gnal1 Kif3c 
Aff1 Cnot4 Gna-rs1 Klc1 
Agfg1 Col4a3bp Gnb4 Larp1 
AI849286 Col4a3bp Golgb1 Larp-pending 
Ak2 Col4a3bp Gorasp2 Lcp2 
Ak3l1 Cpeb4 Gosr2 Leng9 
Akirin1 Cpeb4 Gp38 Lilrb4 
Alas1 Cpne2 Gp49a Lmo4 
Amz2 Csnk1g1 Gpatch3 LOC100044395 
Ap2b1 D12Ertd553e Gpd2 LOC100044475 
Apobec3 D3Ucla1 Gpd2 LOC100046483 
Appbp2 D7Bwg0611e Gpr18 LOC100046741 
Arfgef2 Daam1 Gpr85 LOC100046781 
Arih1 Daam1 Gsk3b LOC100046781 
Arnt Dcp1a Gtf2a1 LOC100046817 
Arnt Dcp1a Gyk LOC100047323 
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Cluster 23 Continued 
LOC100048583 Ppfia3 Sh2b2 Tnip1 
LOC100048726 Ppp1r12a Sh3glb1 Tnip1 
LOC236864 Ppp1r15b Slamf1 Traf1 
LOC237459 Ppp1r15b Slamf1 Trim56 
LOC381891 Ppp2r1b Slamf7 Triobp 
LOC382157 Prkx Slc11a2 Triobp 
LOC632684 Prkx Slc15a3 Trip12 
LOC635086 Psd4 Slc2a1 Trip12 
LOC641240 Psmd10 Slc30a7 Trip12 
Lrp10 Psmd10 Slc31a2 Upf1 
Lrrc25 Ptafr Slc4a11 Usp42 
Lrrc8c Ptges Slc6a6 Usp6nl 
Luzp1 Ptgir Slc7a11 Vapa 
Mapk1ip1l Pum2 Slc7a11 Vav1 
Mcoln2 Rab10 Slc7a11 Vim 
Med21 Rap1b Slc7a2 Wapal 
Mefv Rap2c Slco4a1 Wdr37 
Metap1 Rapgef5 Slmo2 Ywhaz 
Mettl6 Rapgef5 Smurf1 Zbtb7a 
Mfap3l Rapgef5 Snx10 Zeb1 
Mfhas1 Rars Socs1 Zfp238 
Mgat4a Rasgrp1 Sod2 Zfp281 
Micall2 Rassf4 Sp1 Zfp281 
Micall2 Rbms1 Src Zfp513 
Mitf Rbpj Stat3 Zfp654 
Mmp13 Rbpms Stat3 Zfp654 
Mmp14 Rgl1 Stat3 Zfp800 
Msn Rgl1 Stau2 Zfpn1a1 
Myd88 Rhbdf2 Stx11 Zmynd15 
Myd88 Rhog Stxbp1  
Nab1 Rhou Tank  
Napg Riok3 Tank  
Nat5 Riok3 Tank  
Nfe2l1 Riok3 Tapt1  
Nod2 Rlf Tax1bp1  
Nploc4 Rnf139 Tbc1d1  
Nrp2 Rnf14 Tbk1  
Nrp2 Rufy3 Thrap2  
Nupr1 Saa3 Ticam1  
Pafah1b1 Sbno2 Timp1  
Pik3r5 Sdccag3 Tlk2  
Pkn2 Senp5 Tlk2  
Plaa Setd8 Tmem132a  
Pofut1 Setd8 Tmem178  
Poldip3 Setd8 Tmem63b  
Ppap2b Sfmbt1 Tnfrsf11a  
Ppfia3 Sfpi1 Tnfrsf1b  
Table 3.3. Complete list of transcripts from the 24 clusters shown in Figure 3.3. 
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4.1. Background 
The type I IFNs, which include IFNβ and several subtypes of IFNα, are a 
family of cytokines that signal through a single shared receptor, the IFNαβR (Stark 
et al, 1998). A key property of type I IFN is its antiviral activity. This is due to the 
induction of several potent antiviral genes by type I IFN, including the GTPase Mx1 
(myxovirus resistance 1); members of the 2′,5′-oligoadenylate synthetase (OAS) 
family, Oas1, Oas2, Oas3 and Oasl; protein kinase R (encoded by Prkr) and the 
ubiquitin-like protein Isg15 (IFN-stimulated protein of 15kDa). As a result, mice 
unable to signal through type I IFN (Ifnar1
-/-
 mice) are profoundly susceptible to 
certain viral infections (Muller et al, 1994). 
More recently, a number of studies have shown that type I IFN plays a role in 
bacterial infection (Decker et al, 2005; Trinchieri, 2010). However, the role of type I 
IFN in bacterial infection is complex, and not always beneficial to the host. In vitro, 
type I IFN can limit the replication of certain bacteria, including Chlamydia psittaci 
and Chlamydophila pneumonia (Carlin et al, 1989; Buss et al, 2010) and Legionella 
pneumophila (Schiavoni et al, 2004). Type I IFN can also induce killing of the 
parasitic protozoan Leishmania major, both in macrophages and in vivo, through the 
induction of iNOS (Diefenbach et al, 1998; Mattner et al, 2000). In addition, Ifnar1
-/-
 
mice have been shown to be more susceptible to infection with group B streptococci, 
Escherichia. coli and Streptococcus pneumoniae, showing that type I IFN enhances 
the immune response to these bacterial pathogens (Mancuso et al, 2007).  
In other bacterial infections, however, type I IFN production leads to a 
reduction in host resistance (Decker et al, 2005; Trinchieri, 2010). This was first 
shown for Listeria monocytogenes infection, with Ifnar1
-/-
 mice having reduced 
bacterial burdens in the spleen and liver following infection, compared to WT 
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controls (Auerbuch et al, 2004; Carrero et al, 2004; O'Connell et al, 2004). Type I 
IFN in this context was reported to promote the apoptosis of lymphocytes in the 
spleen, which subsequently led to the induction of IL-10 and a suppression of the 
immune response to Listeria monocytogenes (Carrero et al, 2004; O'Connell et al, 
2004; Carrero et al, 2006). More recently, a novel mechanism was proposed 
whereby type I IFN inhibited the responsiveness of Listeria monocytogenes-infected 
macrophages to IFNγ (Rayamajhi et al, 2010).  
A number of studies have shown that type I IFN plays a negative role in Mtb 
infection. Ifnar1
-/-
 mice are better protected against Mtb infection, with reduced 
bacterial loads in the lung or spleen following infection (Manca et al, 2005; Ordway 
et al, 2007; Stanley et al, 2007). In addition, treatment of Mtb-infected mice with 
recombinant IFNαβ led to dramatically reduced survival (Manca et al, 2001). 
However, how type I IFN inhibits the immune response to Mtb is poorly understood. 
More recently, Antonelli et al (2010) used Poly-ICLC, a molecule that induces large 
amounts of type I IFN via TLR3, to study the role of type I IFN in Mtb. Treatment of 
Mtb-infected mice with Poly-ICLC led to increased bacterial loads in the lung, and 
reduced survival, in a type I IFN-dependent manner (Antonelli et al, 2010). This was 
associated with the CCR2-dependent influx of an Mtb-permissive population of 
myeloid cells into the lung (Antonelli et al, 2010). Type I IFN has also been reported 
to suppress the production of the vital pro-inflammatory cytokines IL-1α and IL-1β 
from macrophages and DCs in the lungs of Mtb-infected mice (Mayer-Barber et al, 
2011). This shows that type I IFN can affect the immune response to bacterial 
pathogens in a variety of ways.  
A recent study has suggested that type I IFN may play a role in human TB 
infection. Berry et al (2010) found that patients with active TB had a signature of 
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393 genes in the blood, which distinguished them from individuals with latent TB or 
healthy controls. This signature was significantly associated with both type I IFN 
and IFNγ signalling, and was found predominantly in neutrophils and monocytes in 
the blood (Berry et al, 2010). However, what effect type I IFN has on the outcome of 
TB in human patients is unclear.  
We were prompted to investigate how type I IFN affected the macrophage 
response to Mtb following the observation that many type I IFN inducible genes 
were upregulated in macrophages following infection (see previous chapter). We 
found that endogenous type I IFN regulated the production of many genes from Mtb-
infected macrophages, including Nos2, Ccl2 and Ccl7. Furthermore, addition of type 
I IFN was shown to regulate the production of cytokines from Mtb-infected 
macrophages, promoting the production of the suppressive cytokine IL-10, but 
inhibiting the production of the protective cytokines IL-1β, TNFα and IL-12p40. 
These effects may go some way to explain the detrimental role of type I IFN during 
Mtb infection. 
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4.2. Results 
4.2.1. Endogenous type I IFN promotes IL-10, IL-12p40 and TNFα 
from Mtb-infected macrophages, but inhibits IL-1β 
As results in the previous chapter, showing induction of IFNβ mRNA and 
type I IFN inducible genes, strongly suggested that type I IFN was produced by 
macrophages in response to Mtb, we began by investigating the effects of 
endogenous type I IFN on macrophage function by deriving macrophages from the 
bone marrow of Ifnar1
-/-
 mice, which are unable to respond to type I IFN. Type I 
IFN has been shown to affect the production of cytokines, including IL-10, IL-12 
and IL-1, from macrophages treated with TLR ligands (Gautier et al, 2005; Chang et 
al, 2007; Guarda et al, 2011). To determine if autocrine type I IFN also regulated 
macrophage cytokine production in response to Mtb, macrophages derived from WT 
and Ifnar1
-/-
 mice were infected with Mtb and cytokine production was determined 
by ELISA at 24hr post-infection.  
In response to Mtb infection, WT macrophages produced low levels of IL-
12p40, and significant levels IL-10, TNFα and IL-1β, as previously reported 
(Giacomini et al, 2001) but did not produce IL-12p70 (Figure 4.1). However, 
production of IL-12p40 from Mtb infected macrophages was significantly lower in 
Ifnar1
-/-
 macrophages, showing that endogenous type I IFN is required for the 
production of low levels of IL-12p40 (Figure 4.1). The same trend was observed for 
IL-10, which was around 4-fold lower in Ifnar1
-/-
 macrophages (Figure 4.1). In 
contrast, Mtb induced much higher levels of IL-1β in Ifnar1-/- macrophages, showing 
that endogenous type I IFN suppresses production of IL-1β (Figure 4.1), as 
previously reported (Novikov et al, 2010; Guarda et al, 2011; Mayer-Barber et al, 
2011). However, levels of the important pro-inflammatory cytokine TNFα were 
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around 3-fold lower in the absence of type I IFN signalling (Figure 4.1). This shows 
that endogenous type I IFN can regulate the production of both pro- and anti-
inflammatory cytokines from Mtb-infected macrophages.  
4.2.2. Endogenous type I IFN regulates transcription in Mtb infected 
macrophages 
Having shown that endogenous type I IFN could affect cytokine production 
from macrophages, we next investigated whether the global transcriptional response 
of macrophages to Mtb was affected by endogenous type I IFN, as type I IFN can 
regulate the transcription of many hundreds of genes (Der et al, 1998). To 
investigate this in an unbiased fashion, we used microarray analysis to compare the 
transcriptional response of WT and Ifnar1
-/-
 macrophages. WT and Ifnar1
-/-
 
macrophages were infected with Mtb and RNA was harvested at 0hr and 6hr post-
infection. The RNA was then purified, amplified and hybridised to Illumina Mouse 
WG-6 V2.0 Beadchip arrays, as described in the Materials and Methods, with 
triplicate biological samples for each condition. 6hr post-infection was chosen for 
this analysis, as this was the peak of transcription for most genes following Mtb-
infection, and also the time point when the majority of IFN-inducible genes were 
upregulated (see Chapter 3). Following background subtraction, GeneSpring was 
used to further analyse gene expression.  
After normalisation and the removal of undetectable transcripts, as described 
in the Materials and Methods, fold-change and statistical filters were used to 
generate differentially regulated transcripts. Transcripts were retained if i) they were 
induced by 2-fold by Mtb in either WT or Ifnar1
-/-
 macrophages, ii) they were 
significantly regulated between WT and Ifnar1
-/-
 macrophages as determined by two-
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way ANOVA (p<0.05) with Benjamini Hochberg FDR multiple testing correction 
and iii) they were at least 2-fold different between WT and Ifnar1
-/- 
macrophages 
infected with Mtb at 6hr post-infection. This left 844 transcripts, which were 
clustered hierarchically using Pearson centred distance metric. 
As shown in Figure 4.2, around half of the 844 transcripts were regulated 
positively by type I IFN in response to Mtb infection. The expression of these 
transcripts was greatly reduced in Ifnar1
-/-
 macrophages compared to WT controls 
(Figure 4.2). A proportion of these were also strongly regulated by type I IFN at 0hr, 
and in the medium controls at 6hr, suggesting that macrophages produce basal type I 
IFN to maintain constitutive gene expression (Figure 4.2). Figure 4.2 also shows that 
endogenous type I IFN can negatively regulate gene expression in response to Mtb, 
as a number of transcripts were upregulated to a greater extent in Ifnar1
-/-
 
macrophages compared to WT. In addition, two further clusters showed that type I 
IFN can affect the downregulation of genes. One cluster was downregulated only in 
WT macrophages, whereas another was downregulated only in Ifnar1
-/-
 macrophages 
(Figure 4.2). This shows that type I IFN can have both positive and negative effects 
on Mtb-induced transcription in macrophages.  
To analyse these different clusters in more detail, k-means clustering was 
used to separate the 844 transcripts into six clusters based on their expression profile, 
using Pearson centred distance metric. Six clusters were chosen based on the fact 
that six major groups of transcripts could be distinguished by the dendrogram in 
Figure 4.2. Heat-maps and expression plots of these six clusters are shown in Figure 
4.3, along with a selection of relevant genes from each cluster. Complete lists of the 
transcripts found in each cluster are presented in section 4.5 at the end of this 
Chapter.  
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Figure 4.3 shows that three of the six clusters consisted of transcripts that 
were positively regulated by type I IFN following Mtb infection (clusters 0-2). 
However, these clusters varied in their dependence upon type I IFN. Strikingly, 
transcripts in cluster 1 were strongly regulated by type I IFN at 0hr and in uninfected 
macrophages at 6hr, showing that expression of these transcripts is induced by low 
levels of type I IFN at baseline (Figure 4.3). Mtb infection led to a further 
upregulation of the transcripts in cluster 1 at 6hr post-infection, and this was 
dependent upon endogenous type I IFN (Figure 4.3). This shows that Mtb induces 
additional type I IFN production above that produced at baseline, and that this 
stimulates further gene induction. The genes in Cluster 1 included many antiviral 
genes, such as Mx1, Mx2, Oas1a, Oas1b, Oas1g, Prkr and Samhd1 (Sadler and 
Williams, 2005), suggesting that type I IFN may promote a constitutive antiviral 
state in macrophages. Cluster 1 also contained type I IFN-dependent members of the 
TRIM protein family, including Pml, Trim14, Trim21 and Trim30 (Rajsbaum et al, 
2008; McNab et al, 2010) (Figure 4.3). In addition, several components of the MHC 
class I antigen presentation pathway were found in cluster 1, suggesting that type I 
IFN may promote antigen presentation. This included Tap1, a component of the TAP 
transporter which transports cytosolic antigens into the ER, and two proteasome 
subunits Psmb7 and Psmb8. The transcription factors Stat1 and Stat2, and the 
antimicrobial effector Irgm1 (which encodes LRG-47) were also found in cluster 1 
(Figure 4.3).  
In contrast to cluster 1, transcripts in clusters 0 and 2 were relatively 
unaffected by basal type I IFN, showing similar expression in WT and Ifnar1
-/-
 
macrophages at 0hr (Figure 4.3). However, upregulation of these transcripts by Mtb 
at 6hr post-infection was abrogated in Ifnar1
-/-
 macrophages (Figure 4.3). Genes in 
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cluster 0 included Nos2 (encoding for the enzyme iNOS), the cytokine Il18 and the 
chemokines Cxcl9 and Cxcl10. Cluster 0 also contained the TRIM family member 
Trim26, showing that different members of this family can be differentially regulated 
by basal type I IFN. Genes in cluster 2 included the cytokine Il27 and the 
chemokines Ccl2, Ccl5 and Ccl7 (Figure 4.3). In addition, both cluster 0 and cluster 
2 contained genes related to apoptosis. These included Apaf1 (apoptotic peptidase 
activating factor 1) and Casp7 (caspase 7) (Figure 4.3). This may suggest that type I 
IFN regulates the induction of apoptosis, as previously reported in the context of 
Listeria monocytogenes infection (Carrero et al, 2004; Carrero et al, 2006). Taken 
together, these results show that endogenous type I IFN positively regulates a wide 
range of genes in Mtb-infected macrophages, and this includes genes involved in a 
number of biological processes including the antiviral response, antigen presentation 
and apoptosis. 
The remaining three clusters of transcripts (cluster 3-5) showed very different 
expression profiles to the genes in clusters 0-2. Transcripts in cluster 4 were 
upregulated to much higher levels in Ifnar1
-/-
 macrophages compared to WT, 
showing that type I IFN suppresses the upregulation of these transcripts (Figure 4.3). 
In contrast, transcripts in cluster 3 were downregulated to greater extent in Ifnar1
-/-
 
macrophages compared to WT. Type I IFN therefore acts to prevent the 
downregulation of these transcripts (Figure 4.3). Finally, transcripts in cluster 5 were 
downregulated in a type I IFN-dependent manner, as no downregulation was 
observed in Ifnar1
-/-
 macrophages (Figure 4.3). Several of the genes in these clusters 
have links to cell-division, including Ccng2 (Cyclin G2), which is part of cluster 3; 
Cdkn2b (cyclin-dependent kinase inhibitor 2B), part of cluster 4 and Skp2 (S-phase 
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kinase-associated protein 2), in cluster 5 (Figure 4.3). This may suggest that type I 
IFN regulates cell-division.  
To further investigate the functions of these six clusters, each was analysed 
by GO analysis and IPA (Figure 4.4). As expected, the genes in cluster 0-2 were 
associated with IFN signalling by IPA (Figure 4.4). Cluster 1 showed significant 
overlap with the IFN signalling canonical pathway, with cluster 0 also linked to 
“Role of Jak1, Jak2 and Tyk2 in interferon signalling” and “Jak/Stat signalling” 
(Figure 4.4). Cluster 0 was also linked to IL-15 signalling, reflecting the presence of 
Il15 and Il15ra in this cluster (Figure 4.4). However, no significant overlap with GO 
terms or IPA pathways was observed for the genes in clusters 3-5 (Figure 4.4). 
Further analysis will be required to determine the functions of these genes.  
4.2.3. Exogenous type I IFN promotes IL-10 production from Mtb-
infected macrophages, but inhibits IL-12p40, TNFα and IL-1β 
Results presented in Figure 4.1 showed that type I IFN produced by 
macrophages in response to Mtb infection could feed back and regulate the 
production of cytokines; positively regulating IL-10, IL-12p40 and TNFα but 
negatively regulating IL-1β. However, many cells types can produce type I IFN 
during infection, such as fibroblasts, myeloid DCs and pDCs (Theofilopoulos et al, 
2005). During Mtb infection in vivo, type I IFN produced by other cell types could 
therefore act on infected macrophages. We therefore investigated whether exogenous 
type I IFN could also regulate cytokine production from Mtb-infected macrophages, 
by infecting macrophages with Mtb in the presence or absence of increasing doses of 
recombinant murine IFNβ. The production of cytokines was determine by ELISA at 
24hr post-infection (Figure 4.5A). In addition, RNA was harvested from 
Chapter 4: Type I IFN regulates the macrophage response to Mtb 
 
198 
macrophages infected with Mtb with or without IFNβ and analysed by qPCR, to 
determine if IFNβ regulated cytokine production at the mRNA level (Figure 4.5B). 
Based on the results in Figure 4.5A, a dose of 2ng/ml of IFNβ was used for the 
qPCR experiments in Figure 4.5B.  
IL-12p40 protein production from Mtb-infected macrophages was 
significantly suppressed by addition of IFNβ (Figure 4.5A). This was despite the fact 
that endogenous type I IFN is required for maximum IL-12p40 production (Figure 
4.1) and demonstrates that endogenous and exogenous type I IFNs can have opposite 
effects. Addition of IFNβ did not suppress IL-12p40 at the mRNA level, suggesting 
that post-transcriptional regulation is likely to be involved (Figure 4.5B). IL-12p40 
plays an important role in vivo in the immune response to Mtb, stimulating DCs to 
migrate to the draining lymph nodes and activate the protective CD4
+
 T cell response 
(Khader et al, 2006). Suppression of IL-12p40 production by IFNβ may therefore 
delay the activation of this response.  
Although IL-12p70 production was below the limit of detection at the protein 
level, IFNβ suppressed Il12a mRNA (Figure 4.5B), which encodes the p35 subunit 
of IL-12p70. This suggests that IFNβ may be able to inhibit IL-12p70 production 
from cells that produce IL-12p70 in significant amounts, such as DCs, when 
appropriately stimulated. 
In keeping with the effects of endogenous type I IFN, addition of IFNβ 
enhanced IL-10 protein production from macrophages in a dose-dependent manner 
(Figure 4.5A). Although small effects were seen with the addition IFNβ at low doses 
(20pg and 200pg/ml) a significant effect was only observed with doses of 2ng/ml 
and higher (Figure 4.5A). Importantly, addition of IFNβ at 2ng/ml in the absence of 
Mtb did not induce IL-10 production, demonstrating that IFNβ enhances IL-10 
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production in concert with another stimulus, rather than inducing IL-10 itself (Figure 
4.5A). IFNβ also promoted IL-10 mRNA production (Figure 4.5B). In response to 
Mtb alone, Il10 mRNA was rapidly induced, peaking at 1hr post-infection, but then 
rapidly returned to baseline levels at 6hr post-infection (Figure 4.5B). Addition of 
IFNβ led to sustained IL-10 mRNA transcription, with significantly higher levels 
seen at 6hr post-infection compared to untreated controls (Figure 4.5B). This 
suggests that in the context of Mtb infection, type I IFN could promote IL-10 
production, which may lead to a suppression of the immune response.  
Also in agreement with the effect of endogenous type I IFN, IFNβ 
dramatically inhibited IL-1β protein production from Mtb infected macrophages 
(Figure 4.5A). This is in keeping with previous studies (Novikov et al, 2010; Guarda 
et al, 2011; Mayer-Barber et al, 2011). A significant reduction was seen with the 
lowest dose of 20pg/ml of IFNβ, and IL-1β protein production was dramatically 
suppressed with higher IFNβ doses (Figure 4.5A). IFNβ suppressed transcription of 
Il1b mRNA at 6hr and 24hr post-infection (Figure 4.5B), showing that type I IFN 
can inhibit the transcription of pro-IL-1β, as reported by Guarda et al (2011) in 
macrophages stimulated with various inflammasome activating stimuli such as LPS 
and alum. However, this study also showed that type I IFN could suppress the 
activation of the inflammasome in macrophages, suggesting that IFNβ may have 
multiple mechanisms to suppress IL-1β production (Guarda et al, 2011). 
IFNβ also inhibited TNFα production from infected macrophages, with a 
significant effect seen at doses of 2ng/ml and higher (Figure 4.5A). Suppression of 
TNFα and IL-1β by type I IFN may have negative consequences in vivo, as both are 
required for protection from Mtb (Flynn et al, 1995; Mayer-Barber et al, 2011). 
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However, addition of IFNβ did not affect the transcription of Tnf, suggesting that 
post-transcriptional mechanisms may be involved (Figure 4.5B).  
As a control, we next determined whether the effects of IFNβ on cytokine 
production were dependent on the IFNαβR. This would rule out the possibility that 
our IFNβ preparation was contaminated with PRR ligands, as such effects would 
occur independently of the IFNαβR. WT and Ifnar1-/- macrophages were infected 
with Mtb with or without IFNβ at 2ng/ml, and cytokine production determined at 
24hr post-infection. As shown in Figure 4.6, IFNβ promoted IL-10, but inhibited IL-
12p40, TNFα and IL-1β from Mtb-infected macrophages, in keeping with previous 
results. However, these effects were totally dependent on the IFNαβR, as no change 
in cytokine production in response to IFNβ was observed in Ifnar1-/- macrophages 
(Figure 4.6). This confirms that IFNβ regulates cytokine production through type I 
IFN receptor signalling, and rules out any possible effects of contamination.  
Taken together, these results show that exogenous IFNβ can affect the 
production of cytokines from Mtb-infected macrophages, and that this probably 
occurs via both transcriptional and post-transcriptional mechanisms. These results 
would be predicted to have a negative effect on Mtb infection in vivo, as IFNβ 
promoted the suppressive cytokine IL-10, whilst inhibiting the protective cytokines 
IL-12p40, TNFα and IL-1β. 
4.2.4. Effects of type I IFN on cytokine production are not due to 
regulation of Mtb survival  
One possible explanation for the effects of type I IFN on cytokine production 
could be that type I IFN affects Mtb survival within macrophages, thus changing the 
amount of PRR stimulation and the subsequent induction of cytokines. To address 
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this, the effect of both endogenous and exogenous type I IFN on Mtb survival in 
macrophages was determined by serial dilution and plating, as described in the 
Materials and Methods. 96hr post-infection was chosen for this time point, as this 
was when an effect of IFNγ on Mtb survival was observed.  
 As shown in Figure 4.7A, addition of IFNβ at 2ng/ml had no effect on the 
levels of Mtb within macrophages at 96hr post-infection. In addition, comparison of 
bacterial levels in WT compared to Ifnar1
-/- 
macrophages at 96hr showed that 
endogenous type I IFN did not affect Mtb survival (Figure 4.7B). This shows that 
type I IFN modulates cytokine production independently of effects on Mtb survival.  
4.2.5. IFNβ suppresses pro-inflammatory cytokine production in 
part via autocrine IL-10 
IL-10 is a potent anti-inflammatory cytokine (Moore et al, 2001) and has 
been shown to inhibit IL-12, IL-1β and TNFα production from APCs (Fiorentino et 
al, 1991a; Fiorentino et al, 1991b; D'Andrea et al, 1993). We found that addition of 
IFNβ potently enhanced IL-10 production from infected macrophages. It was 
therefore possible that IFNβ may suppress the production of IL-12, IL-1β and TNFα 
indirectly, through increasing the amount of IL-10 acting on the cells.   
The ability of IFNβ to affect IL-12, IL-1β and TNFα was therefore assessed 
in the absence of IL-10, using Il10
-/-
 macrophages. WT and Il10
-/- 
macrophages were 
infected with Mtb in the presence or absence of IFNβ. In WT macrophages, IFNβ 
again suppressed IL-12p40, IL-1β and TNFα, whilst enhancing IL-10 (Figure 4.8), 
as previously shown. As expected, in Il10
-/-
 macrophages levels of the pro-
inflammatory cytokines IL-12p40, TNFα and to a lesser extent IL-1β were increased, 
showing that endogenous IL-10 is capable of inhibiting production of these 
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cytokines (Figure 4.8). Importantly, the suppressive effect of exogenous IFNβ on IL-
12p40 production was diminished in Il10
-/-
 macrophages, showing that increased IL-
10 production is the major mechanism behind the suppression. However, a 
significant decrease in IL-12p40 production in response to IFNβ was still observed 
in Il10
-/-
 macrophages, suggesting additional IL-10-independent mechanisms (Figure 
4.8).  
In the case of TNFα however, the suppressive effect of IFNβ was completely 
lost in Il10
-/-
 macrophages (Figure 4.8). Whereas in WT macrophages IFNβ 
suppressed TNFα by around 2-fold, IFNβ had no effect in the absence of IL-10, 
showing that IFNβ suppresses TNFα entirely through enhancing IL-10 production 
(Figure 4.8).  
In contrast, IFNβ still effectively suppressed IL-1β production in Il10-/- 
macrophages, meaning that this effect is independent of IL-10 (Figure 4.8). In WT 
and Il10
-/-
 macrophages, IFNβ suppressed IL-1β by around 3-fold (Figure 4.8). This 
is in agreement with the fact that IL-1β seems generally less sensitive to the 
suppressive effects of autocrine IL-10, as there was a relatively small increase in IL-
1β levels between WT and Il10-/- macrophages infected with Mtb (Figure 4.8). This 
shows that IFNβ suppresses IL-12p40 and TNFα through increasing IL-10 
production, but that the effect of IFNβ on IL-1β is IL-10-independent. 
4.2.6. Type I IFN regulates IL-27 production 
The previous results show that the effects of IFNβ on IL-12p40 and TNFα 
occur indirectly, via increased IL-10 production. We therefore investigated further 
the mechanism by which IFNβ enhances IL-10 production from Mtb-infected 
macrophages. A previous study has shown that IFNβ can upregulate IL-27 
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production from LPS treated macrophages, and that IL-27 was responsible for 
increasing IL-10 (Iyer et al, 2010). As we had previously observed by microarray 
that Il27 mRNA was decreased in Ifnar1
-/-
 macrophages compared to WT, we 
investigated whether endogenous and exogenous type I IFN could promote IL-27 
production.  
WT and Ifnar1
-/-
 macrophages were infected with Mtb and production of IL-
27 was determined at 24hr post-infection. As shown in Figure 4.9A, IL-27 was 
induced by Mtb in WT macrophages. However, this was completely dependent on 
endogenous type I IFN, with no IL-27 detectable in Ifnar1
-/-
 macrophages (Figure 
4.9A). To determine if exogenous IFNβ could also promote IL-27 production, WT 
macrophages were infected with Mtb in the presence or absence of IFNβ. Figure 
4.9B shows that addition of IFNβ enhanced IL-27 production by around 2-fold from 
WT macrophages. These results demonstrate that both endogenous and exogenous 
type I IFN can promote IL-27 production from Mtb-infected macrophages. This 
presents a possible mechanism for the induction of IL-10 by type I IFN. However, 
further experiments using macrophages deficient for the IL-27 receptor will be 
required to confirm whether the enhancement of IL-27 accounts for the increases in 
IL-10 production stimulated by type I IFN.  
4.2.7. Pre-treatment of macrophages with IFNβ leads to an 
upregulation of IL-12p40 and IL-12p70 
Whereas endogenous type I IFN enhanced IL-12p40 production (Figure 4.1), 
exogenous IFNβ suppressed it (Figure 4.5A). One possible explanation was that the 
dose of type I IFN could have different effects; a low amount of endogenous type I 
IFN could promote IL-12p40, whereas the high exogenous dose of 2ng/ml could 
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suppress IL-12p40. However, Figure 4.5 shows that even much lower doses of 
exogenous IFNβ suppressed IL-12p40, suggesting that dose was not the reason. 
Another possibility was length of exposure to type I IFN. The results presented in 
Figure 4.2 strongly suggested that low levels of basal type I IFN are present at 
baseline. As macrophages are rested overnight prior to infection (see Materials and 
Methods) they would be exposed to this basal type I IFN for a significant length of 
time prior to infection. In contrast, exogenous IFNβ was always added at the same 
time as infection.  
To determine if length of exposure altered the effects of IFNβ on the 
production of IL-12p40 and other cytokines, macrophages were pre-treated with 
IFNβ for 12hr, 8hr, 4hr and 2hr prior to Mtb infection, with IFNβ added at 0hr as a 
control. Mtb only controls were included for each pre-incubation time to control for 
the effect of resting the macrophages for varying lengths of time prior to infection.   
As previously shown, IL-12p40 production was suppressed by addition of 
IFNβ at 0hr (Figure 4.10). This effect was also seen with addition of IFNβ at 2hr and 
4hr prior to infection (Figure 4.10). However, the effect was completely reversed by 
addition of IFNβ at 8hr and 12hr before infection, with IFNβ stimulating a dramatic 
increase of IL-12p40 (Figure 4.10). At 12hr this increase was greater than 10-fold 
compared to Mtb alone (Figure 4.10). Pre-treatment with IFNβ for 12hr also induced 
IL-12p70, although at barely detectable levels (Figure 4.10). Production of IL-12p70 
was notable, as it was not detectable from macrophages under other conditions. This 
shows that IFNβ can have opposite effects on IL-12 production from macrophages, 
depending on the time IFNβ is added relative to Mtb.  
In contrast to IL-12p40, IFNβ consistently upregulated IL-10 production, 
regardless of the time of addition, although this was most effective if IFNβ was 
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added at 0hr or 2hr (Figure 4.10). Of note, IFNβ upregulated IL-10 when added at 
8hr and 12hr, despite simultaneously promoting IL-12 production (Figure 4.10). This 
suggests that, when added at 8hr and 12hr prior to infection, IFNβ activates 
additional mechanisms to promote IL-12, and overcome the suppressive effects of 
IL-10. 
The effect of IFNβ on IL-1β was most effective when added at 0hr, and 
became steadily less effective at longer pre-treatment times (Figure 4.10). IFNβ had 
no significant effect if added at 12hr prior infection, and only a minimal effect if 
added 8hr prior to infection (Figure 4.10). This may suggest that the mechanisms for 
IFNβ suppression of IL-1β are activated transiently. TNFα was also suppressed more 
effectively by IFNβ if added closer to the time of infection (Figure 4.10). If added at 
2hr and 4hr prior to infection, IFNβ significantly suppressed TNFα. However, no 
significant effect was seen with IFNβ added at 8hr or 12hr prior to infection (Figure 
4.10). These results show that pre-treatment of macrophages with IFNβ can 
dramatically alter the effect on cytokine production in response to Mtb. 
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4.3. Discussion 
Type I IFN is known to play a detrimental role in the immune response to 
Mtb, as mice deficient in type I IFN have lower bacterial loads following infection 
(Manca et al, 2005; Ordway et al, 2007; Stanley et al, 2007). In addition, treatment 
of Mtb-infected mice with recombinant IFNαβ (Manca et al, 2001) or the type I IFN 
inducing molecule Poly-ICLC (Antonelli et al, 2010) led to reduced survival. Here 
we characterised the regulation of the macrophage response to Mtb by type I IFN. 
We found that both cytokine production and transcription were potently regulated by 
type I IFN. The effects of endogenous and exogenous type I IFN on cytokine 
production by Mtb-infected macrophage are summarised in Figures 4.11 and 4.12.  
4.3.1. The regulation of the macrophage response by endogenous 
type I IFN 
Following the observation of a type I IFN signature in Mtb-infected 
macrophages, it was important to confirm that these genes were type I IFN 
dependent, and also to determine the global effects of type I IFN on gene expression 
in response to Mtb. Using microarray analysis of WT vs. Ifnar1
-/-
 macrophages 
infected with Mtb, we found 844 transcripts that were regulated by endogenous type 
I IFN. These genes were regulated in a variety of ways. Some genes were dependent 
upon type I IFN for their expression, whilst other were induced to a greater extent in 
Ifnar1
-/-
 macrophages. This shows that type I IFN both induces and represses the 
transcription of genes. 
It was striking that the basal expression of many genes was lost in Ifnar1
-/-
 
macrophages, suggesting that low level constitutive type I IFN was produced by 
macrophages. The importance of constitutive type I IFN production has been 
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appreciated for many years (reviewed in Gough et al, 2012). However, our results 
show that different type I IFN inducible genes showed varying susceptibility to basal 
type I IFN, with many genes not affected by the loss of type I IFN at baseline. In 
general, antiviral genes such as Mx1, Oas and Prkr were strongly regulated by basal 
type I IFN, whereas more immune related genes such as Nos2, Cxcl10 and Ccl2 were 
not. This makes sense; whereas constitutive expression of antiviral genes may lead to 
a more rapid antiviral response, constitutive expression of pro-inflammatory genes 
such as Nos2, Cxcl10 and Ccl2 would be predicted to cause inappropriate 
inflammation. However, the mechanism behind this differing responsiveness is 
unclear. It may be that different genes respond to differing levels of type I IFN. 
Basally regulated genes may require relatively little type I IFN for their induction, 
whereas genes such as Nos2 require the increased levels generated following Mtb 
infection. Alternatively, induction of genes such as Nos2 may require addition 
transcriptional regulators besides those induced by type I IFN. For example, it was 
recently shown that both ISGF3 and NF-κB are required for Nos2 transcription in 
Listeria infected macrophages (Farlik et al, 2010). Thus type I IFN alone would be 
insufficient for Nos2 induction, with Nos2 only being expressed following the 
activation of NF-κB in response to Mtb infection.  
Many immunologically important genes were regulated by endogenous type I 
IFN in macrophages. These included Nos2, as discussed above, as well as Irgm1, 
which encodes for LRG-47 and the chemokines Ccl2, Ccl7 and Cxcl10 (IP-10). 
These genes are all important for protection against Mtb. Both iNOS and LRG-47 are 
crucial for the killing of Mtb in macrophages in response to IFNγ, and mice deficient 
in either gene cannot control Mtb infection (Chan et al, 1995; MacMicking et al, 
2003). Ccl2 and Ccl7 signal through the chemokine receptor CCR2 on monocytes, 
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and stimulate their migration from the bone marrow into the site of infection (Shi 
and Pamer, 2011). Ccr2 deficient mice do not recruit monocytes to the infected lung, 
and are unable to control Mtb infection (Peters et al, 2001). IP-10, in contrast, is 
required for T cell migration into the lung during infection (Khan et al, 2000). The 
promotion of these genes by type I IFN would therefore be predicted to have a 
beneficial effect on the host immune response in the context of Mtb infection. 
Indeed, induction of iNOS by type I IFN has been shown to be protective in the 
context of Leishmania major infection (Diefenbach et al, 1998; Mattner et al, 2000). 
However, type I IFN has consistently been shown to play a negative role during Mtb 
infection (Manca et al, 2005; Ordway et al, 2007; Stanley et al, 2007) as discussed 
above. It is possible that type I IFN has other functions that over-ride these 
potentially beneficial effects. However, the promotion of genes such as Ccl2 may not 
always be beneficial. Antonelli et al (2010) showed that induction of type I IFN by 
Poly-ICLC in Mtb-infected mice led to increased Ccl2 expression, in keeping with 
our results, but this led to the influx of a permissive myeloid population into the 
lung, leading to decreased survival. Thus, type I IFN may be a double-edged sword 
during Mtb infection. 
It should also be noted that, despite promoting the production of iNOS and 
LRG-47, type I IFN did not reduce the survival of Mtb within macrophages. This 
was the case both for endogenous and exogenous type I IFN. It is possible that type I 
IFN does not induce iNOS production to sufficient levels to mediate Mtb killing. A 
more potent activator of macrophages such as IFNγ, which activates additional 
killing mechanisms such as autophagy, may therefore be required to lead to 
macrophage killing of Mtb. However, we addressed the effect of IFNβ on Mtb 
survival only with adding IFNβ at the time of infection. As shown in Figure 4.10, 
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type I IFN can be a more potent stimulus when added prior to infection. Future 
experiments could therefore investigate whether pre-incubation of macrophages with 
IFNβ could mediate Mtb killing.  
4.3.2. The regulation of IL-10 by type I IFN 
We found that both endogenous and exogenous type I IFN could induce the 
production of IL-10 from macrophages. This is in keeping with several previous 
studies. Chang et al (2007) found that the induction of IL-10 by LPS in murine 
macrophages was dependent upon endogenous type I IFN. This study also showed 
that addition of IFNβ to macrophages could induce IL-10 (Chang et al, 2007). 
However, in this study, addition of IFNβ alone, without a secondary TLR stimulus, 
was sufficient to induce IL-10, whereas in our system a dose of 2ng/ml IFNβ alone 
did not induce IL-10; it only enhanced the production of IL-10 in response to Mtb. 
The reasons for this discrepancy are unclear, but may be due to differences in the 
protocols used to generate and stimulate macrophages. However, given that 
induction of IL-10 requires several different signalling pathways that are not known 
to be induced by type I IFN, such as NF-κB and ERK MAP kinase, it would seem 
likely that in the majority of cases, type I IFN would require a secondary TLR 
stimulation in order to affect the production of IL-10. 
Type I IFNs have also been shown to induce IL-10 in several other cell types. 
This includes cells of the innate immune system such as human monocytes (Aman et 
al, 1996) and human DCs (Wang et al, 2011). In addition, type I IFN has been 
shown to induce IL-10 from T cells. Levings et al (2001) showed that IFNα caused 
naive CD4
+
 T cells to differentiate into IL-10
+
 T-regulatory cells. More recently, 
Zhang et al (2011) showed that both IFNα and IFNβ could enhance IL-10 production 
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from Th17 cells, which was associated with a decrease in IL-17 production. The link 
between type I IFN and IL-10 therefore appears to occur in a number of different cell 
types, including both innate and adaptive cells, suggesting that this is an important 
regulatory mechanism.  
Various suggestions have been put forward as to the mechanism of IL-10 
induction by type I IFNs. Type I IFN induction of IRF1 and STAT3 has been 
reported to promote IL-10 from a human B-cell line (Ziegler-Heitbrock et al, 2003). 
In addition, type I IFN has been reported to induce IL-10 through glycogen synthase 
kinase 3 (GSK3) in human DCs. In mouse macrophages, type I IFN has been shown 
to induce IL-10 via autocrine induction of IL-27 (Iyer et al, 2010). We also found 
that both endogenous and exogenous type I IFN promoted IL-27 production from 
Mtb infected macrophages. Il27 was also found to be lower at the mRNA level in 
Ifnar1
-/-
 macrophages compared to WT, suggesting transcriptional regulation. We 
plan to further investigate whether IFNβ upregulates IL-10 production via IL-27 by 
adding Mtb and IFNβ to WT macrophages and macrophages from mice deficient in 
the receptor for IL-27 (WSX1
-/-
), and determining if IFNβ is still able to upregulate 
IL-10 production.  
More recently, a novel pathway has been implicated in IL-10 production, 
which may link to type I IFN. Protein kinase R (PKR), a strongly type I IFN 
inducible antiviral molecule, was shown to mediate IL-10 production in 
macrophages stimulated with LPS and dsRNA (Chakrabarti et al, 2008). 
Macrophages deficient in PKR were subsequently shown to produce lower levels of 
IL-10 in response to Mtb infection (Wu et al, 2012) although this study did not 
address the role of type I IFN in IL-10 production. In our microarray study, Prkr 
(encoding for protein kinase R) was dramatically lower in Ifnar1
-/-
 macrophages, 
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suggesting that PKR may play a role in IL-10 production. This could be further 
investigated by adding type I IFN to macrophages from mice deficient in PKR. 
IL-10 is known to play a negative role in the immune response to Mtb in 
vivo, resulting in a delayed and reduced Th1 response (Redford et al, 2010) and type 
I IFN has also been reported to inhibit the protective immune response during Mtb 
infection (Manca et al, 2005; Ordway et al, 2007; Antonelli et al, 2010). Our study 
suggests that a possible mechanism for the negative effects of type I IFN could be in 
part via induction of IL-10.  
4.3.3. Type I IFN regulation of IL-12 
IL-12 is an important cytokine in the immune response to Mtb, due to its 
ability to stimulate Th1 development and IFNγ production (Flynn and Chan, 2001a). 
In Mtb-infected macrophages, endogenous type I IFN was required for maximal IL-
12p40 production. However, this was in contrast to the fact that addition of 
exogenous IFNβ could potently suppress IL-12p40 production.  
A number of studies have shown that exogenous IFNα or IFNβ can inhibit 
the production of IL-12 from a variety of cell types, and in response to a variety of 
stimuli (Cousens et al, 1997; McRae et al, 1998; Byrnes et al, 2001; Dalod et al, 
2002; Heystek et al, 2003). In addition, Cousens et al (2007) showed that type I IFN 
also inhibited IL-12 in vivo during infection of mice with murine cytomegalovirus 
(MCMV), and that antibody blockade of IFNαβ in these mice enhanced early IFNγ 
production. Two of these studies showed that effects of type I IFN in suppressing IL-
12 were IL-10-independent (McRae et al, 1998; Byrnes et al, 2001) in contrast to our 
results showing a partial IL-10-dependence. However, these studies were carried out 
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in human monocytes and DCs, and used single TLR ligands, and it is possible that 
different mechanisms exist depending on the cell type and stimulus used.  
In contrast to the effects of exogenous type I IFN, Gautier et al (2005) 
showed that endogenous type I IFN was required for maximal IL-12p40 and IL-
12p70 production from murine DCs, in agreement with our results. DCs from mice 
lacking the IFNαβR produced markedly less IL-12p70 and IL-12p40 in response to a 
variety of single TLR ligands. The reason for the discrepancy between endogenous 
and exogenous type I IFN has not been explained. However, in our study the 
suppressive effects of IFNβ on IL-12 were reversed if macrophages were pre-treated 
for 8hr or 12hr with IFNβ. In this case, IFNβ could dramatically upregulate IL-12p40 
production. This result could explain the apparent contradictions between 
endogenous and exogenous type I IFN. It may also have implications for the role of 
type I IFN in vivo; the timing of type I IFN production in response to a pathogen 
may have opposite effects on IL-12 production, and thus skew the immune response 
in different directions.  
The mechanisms behind these opposing effects of type I IFN are at present 
unclear. However, IFNβ still increased IL-10 production from infected macrophages 
if added at 8hr or 12hr prior to infection, suggesting that pre-treatment activates 
additional, IL-12 stimulatory pathways that can overcome the suppressive effects of 
IL-10. A good candidate for this effect could be the transcription factor IRF1. IFNγ 
signals through IRF1 to induce IL-12 production (Liu et al, 2004) and type I IFN is 
also known to induce IRF1 activation (Tamura et al, 2008). Studies using IRF1 
deficient macrophages could address whether this transcription factor is required for 
the upregulation of IL-12 by macrophages pre-treated with IFNβ. 
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As macrophages produce only IL-12p40, and not IL-12p70, in response to 
Mtb, we were unable to assess the effects of IFNβ on IL-12p70 production. 
However, Il12a mRNA was suppressed by IFNβ, suggesting IFNβ could suppress 
IL-12p70. Future studies could address the effects of IFNβ on IL-12p70 in cells such 
as myeloid DCs, which are the major producers of IL-12p70 in vivo (Rothfuchs et al, 
2009). Suppression of IL-12p70 by IFNβ could have important consequences for 
Mtb infection, as IL-12p70 is absolutely required for protection, due to its effects in 
generating the Th1 response (Cooper et al, 2011).  
4.3.4. Type I IFN suppresses IL-1β production 
IL-1α and IL-1β are both critical in protecting the host from Mtb infection 
(Mayer-Barber et al, 2011). This requirement for IL-1 signalling explains why 
MyD88
 
deficient mice are highly susceptible to Mtb infection, as IL-1 signals 
through MyD88 (Cooper et al, 2011). We show that both endogenous and exogenous 
type I IFN could potently inhibit IL-1β production from Mtb infected macrophages. 
IL-1β was highly sensitive to IFNβ mediated suppression, with amounts as low as 
20pg/ml sufficient to inhibit IL-1β production. Suppression of IL-1β may represent a 
mechanism by which type I IFN increases the susceptibility of mice to Mtb infection. 
These results are in agreement with a recent study by Guarda et al (2011) 
which reported that both endogenous and exogenous type I IFN could inhibit IL-1β 
production from macrophages in response to several inflammasome activating 
stimuli such as LPS and alum. IFNβ suppressed production of pro-IL-1β at the 
mRNA level in response to LPS, in keeping with our results using Mtb (Guarda et al, 
2011). It was also shown that IFNβ could inhibit the activation of caspase-1 by the 
inflammasome, although this was specific to the NLRP3 and NLRP1b 
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inflammasomes, and not the AIM2 or IPAF inflammasomes (Guarda et al, 2011). As 
Mtb activates IL-1 production through the NLRP3 inflammasome (Cooper et al, 
2011) further work should address whether the assembly or activity of the NLRP3 
inflammasome is affected by type I IFN in Mtb-infected macrophages.  
A recent study has also shown that IFNβ inhibits both IL-1α and IL-1β 
production in vivo in mice infected with Mtb (Mayer-Barber et al, 2011). Type I IFN 
production suppressed IL-1α and IL-1β from both DCs and macrophages in the lung 
following Mtb infection, and this occurred through direct effects of type I IFN, as 
mixed bone-marrow chimeras showed that loss of Ifnar1 on the surface of myeloid 
cells resulted in increased IL-1 production from these cells (Mayer-Barber et al, 
2011). This study supports our findings that type I IFN suppresses IL-1β production, 
and shows that this may have important consequences in vivo. Furthermore, it has 
also been shown that type I IFN suppresses IL-1β production from human 
macrophages infected with Mtb (Novikov et al, 2010). Given that active TB patients 
have an IFN signature in the blood (Berry et al, 2010), it is possible that suppression 
of IL-1β by type I IFN may be occurring in humans with active TB. Further 
investigation is required to determine what effect this may have on the outcome of 
infection in TB patients.  
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4.4. Figures 
 
Figure 4.1. Endogenous type I IFN promotes IL-10, IL-12p40 and TNFα, but 
negatively regulates IL-1β, from Mtb-infected macrophages. WT and Ifnar1-/- 
macrophages were infected with Mtb. Cytokine levels in culture supernatant were 
determined at 24hr post-infection. Graphs show mean +/- standard error from the 
mean (SEM) (n=3). *, p<0.05, **, p<0.01, ***, p<0.001; unpaired t-test. Data is 
representative of at least three independent experiments. 
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Figure 4.2. Endogenous type I IFN regulates the macrophage transcriptional 
response to Mtb. WT and Ifnar1
-/-
 macrophages were infected with Mtb, RNA was 
harvested at 0hr and 6hr post-infection and microarray analysis was carried out. Data 
was normalised and undetectable transcripts were removed as described in the 
Materials and Methods. Differentially regulated transcripts were obtained by taking 
those that were at least 2-fold up- or downregulated in infected samples vs. controls 
in either strain at 6hr post-infection, and those that were significantly different 
between WT and Ifnar1
-/-
 by two-way ANOVA p<0.05 with Benjamini Hochberg 
FDR multiple testing correction. A further filter removed transcripts less than 2-fold 
different between WT and Ifnar1
-/-
 infected samples at 6hr post-infection. This left 
844 transcripts, which were subjected to hierarchical clustering with Pearson’s 
centred distance metric and average linkage, and visualised with a heat map. 
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Figure 4.3. Transcripts regulated by endogenous type I IFN in Mtb-infected 
macrophages can be separated into six clusters. The 844 differentially regulated 
transcripts shown in Figure 4.2 were separated into 6 clusters by k-means clustering, 
with Pearson centred distance metric. (A) Expression profiles and (B) heat maps of 
the 6 clusters. (C) Selected genes in the 6 clusters.  
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Figure 4.4. Overlap of the six clusters with IPA and GO terms. The transcripts in 
each of the 6 k-means clusters shown in Figure 4.3 were analysed by IPA and GO 
analysis. Overlap was considered significant if p<0.01.  
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Figure 4.5. Exogenous type I IFN enhances IL-10, and inhibits IL-12, IL-1β and 
TNFα, from Mtb infected macrophages. (A) WT macrophages were infected with 
Mtb in the presence or absence of IFNβ, added concomitantly at the indicated 
concentration. Cytokine levels in culture supernatant were determined at 24hr post-
infection. (B) WT macrophages were infected with Mtb in the presence or absence of 
IFNβ, added concomitantly at 2ng/ml. RNA was harvested at the indicated time 
points and qPCR analysis was carried out. Graphs show mean +/- SEM (n=3). *, 
p<0.05, **, p<0.01, ***, p<0.001; one-way ANOVA with Bonferroni post-test vs. 
Mtb only control (part A); two-way ANOVA with Bonferroni post-test (part B). Data 
is representative of two independent experiments. 
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Figure 4.6. IFNβ modulation of cytokine production requires the IFNαβR. WT 
and Ifnar1
-/-
 macrophages were infected with Mtb in the presence or absence of 
IFNβ, added concomitantly at 2ng/ml. Cytokine levels in culture supernatant were 
determined at 24hr post-infection. *, p<0.05, **, p<0.01, ***, p<0.001; N.S., not 
significant; unpaired t-test. Graphs show mean +/- SEM (n=3). Data is representative 
of three independent experiments. 
Chapter 4: Type I IFN regulates the macrophage response to Mtb 
 
221 
 
Figure 4.7. Endogenous or exogenous type I IFN does not regulate survival of 
Mtb within macrophages. (A) WT macrophages were infected with Mtb in the 
presence or absence of IFNβ, added concomitantly at 2ng/ml. At 96hr post-infection 
cell were lysed with 0.2% saponin and bacterial counts were determined by plating 
onto 7H11 plates supplemented with OADC. (B) WT and Ifnar1
-/-
 macrophages 
were infected with Mtb. At 96hr post-infection cell were lysed with 0.2% saponin 
and bacterial counts were determined by plating onto 7H11 plates supplemented with 
OADC. N.S.; not significant; unpaired t-test. Data is representative of two 
independent experiments. 
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Figure 4.8. IFNβ suppression of IL-12p40 and TNFα is partially dependent on 
IL-10. WT and Il10
-/-
 macrophages were infected with Mtb in the presence or 
absence of IFNβ, added concomitantly at 2ng/ml. Cytokine levels in culture 
supernatant were determined at 24hr post-infection. *, p<0.05, **, p<0.01, ***, 
p<0.001, N.S., not significant; unpaired t-test. Graphs show mean +/- SEM (n=3). 
Data is representative of three independent experiments. 
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Figure 4.9. Type I IFN promotes IL-27 production from Mtb-infected 
macrophages (A) WT and Ifnar1
-/-
 macrophages were infected with Mtb and levels 
of IL-27 in culture supernatant were determine by ELISA at 24hr post-infection. (B) 
WT macrophages were infected with Mtb in the presence or absence of 2ng/ml 
IFNβ, added at the time of infection. Levels of IL-27 in culture supernatant were 
determined by ELISA at 24hr post-infection. Graphs show mean +/- SEM (n=3). *, 
p<0.05, **, p<0.01, ***, p<0.001; unpaired t-test. Data is from one experiment. 
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Figure 4.10. IFNβ regulation of IL-12 depends on length of pre-treatment. WT 
macrophages were infected with Mtb in the presence or absence of IFNβ, added at 
the indicated time prior to infection at 2ng/ml. Cytokine levels in culture supernatant 
were determined at 24hr post-infection. *, p<0.05, **, p<0.01, ***, p<0.001; two-
way ANOVA with Bonferroni post-test. Graphs show mean +/- SEM (n=3). Data is 
from one experiment. 
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Figure 4.11. A summary of the effects of endogenous type I IFN on cytokine 
production from Mtb-infected macrophages.  
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Figure 4.12. The effects of exogenous type I IFN on cytokine production from 
Mtb-infected macrophages. 
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4.5. Transcripts present in six k-means clusters shown in 
Figure 4.3 
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Cluster 0 
0610009F02Rik A130072J07 Ccnd2 Hist2h3b 
1110008F13Rik A130072J07Rik Ccnd2 Hist2h3c1 
1110018G07Rik A430084P05Rik Cd69 Hmgn3 
1110018K11Rik A430108B07Rik Cept1 Hmgn3 
1110038F14Rik A530083B17Rik Ch25h I830077J02Rik 
1110038F14Rik A630001G21Rik Chdc1 Ifi205 
1110061O04Rik A630001G21Rik Cited2 Ifi205 
1110061O04Rik A630077B13Rik Cited2 IFNg 
1110061O04Rik A930026L03Rik Cited2 Ifrg15 
1200015F23Rik AA467197 Cox18 Il15 
1700001A24Rik AA589481 Creb5 Il15ra 
1700027J05Rik AA960436 Crkl Il15ra 
2010005J08Rik AA960436 Crlf3 Il15ra 
2010012F05Rik Adora3 Cspg2 Il15ra 
2010012F05Rik Aff1 Csrp1 Il18 
2210019E14Rik AI837181 Cxcl10 Il2rg 
2210019E14Rik Aim2 Cxcl9 Irf5 
2310008I22Rik Akt3 D11Lgp2e Katna1 
2310020F24Rik Akt3 D130064H19Rik Keap1 
2610202E01Rik Aldh1b1 D230004N01Rik Keap1 
2610208M17Rik Ankrd17 D5Ertd591e Keap1 
2610528H13Rik Apaf1 D630029K19Rik Klf4 
2700007B13Rik Apobec3 Dek LOC215088 
2700055A20Rik Arhgef3 Dll1 LOC223672 
2810012G03Rik Arid5b Dncic2 LOC227384 
2810407C02Rik Arl4 E330016A19Rik LOC241293 
2810407C02Rik Asah3 E430021P16Rik LOC381696 
2810474O19Rik Atp10a E430034L04Rik LOC382154 
2900002H16Rik Aytl1 EG240327 LOC383619 
4832412D13Rik Azi2 EG665378 LOC626578 
4921505C17Rik Bambi-ps1 F630035N16Rik Luzp1 
4930422J18Rik BC003885 Fem1c Mad 
4930453N24Rik BC016423 Flrt2 Mad 
4930555L11Rik BC038311 Gadd45g Mcm10 
4933412E12Rik BC049975 Gbp5 Mdk 
4933428L19Rik Bcl9 Gcnt2 Mmp2 
4933430F08Rik Bfar Gnb4 Mmp25 
5430427O19Rik Bfar Golga3 Myd88 
5730527J01Rik Bfar Golga3 Nab1 
5730537H01Rik Birc2 Gpsm2 Nos2 
5730589K01Rik Birc2 Gtpbp2 Ocil 
5730596K20Rik C130045I22Rik H2-Bf OTTMUSG00000005523 
6230400I06Rik C330023M02Rik H3f3b Parp8 
6430402L23Rik C330023M02Rik Hat1 Pcaf 
7420404O03Rik C630002C18Rik Hdc Pdk3 
9130230N09Rik Card4 Herc1 Peli1 
9830137M10Rik Ccl5 Hist1h3h Peli1 
  
Chapter 4: Type I IFN regulates the macrophage response to Mtb 
 
229 
Cluster 0 Continued 
Pfkp Tank   
Phc2 Tbc1d1   
Phca Tbc1d13   
Pi4k2a Tgtp   
Pik3cd Tlk2   
Plekha4 Tlk2   
Plekha4 Tlr3   
Plekhf2 Tmod3   
Plekhf2 Tmpo   
Pnp Tnfrsf1a   
Pols Tnfsf10   
Prpf38a Tnfsf15   
Prpf4 Trim21   
Prpf4 Trim26   
Pttg1 Trim56   
Rap2c Tyk2   
Rap2c Vrk2   
Rap2c Vrk2   
Rbl1 Wars   
Rfc3 Wars   
Rhoe Wars   
Rin2 Wdr20   
Rin2 Wdr37   
Rnf135 Whdc1   
Rnf135 Whsc1l1   
Rnf135 Ythdf1   
Rnf31 Zbtb5   
Sap30 Zcchc6   
Sav1 Zfpn1a1   
Scarf1 Zyx   
scl0001609.1_19    
scl0003154.1_1    
Setdb2    
Sgcb    
Sgk3    
Sgk3    
Slc25a28    
Slc28a2    
Smox    
Snn    
Socs1    
Stat3    
Stxbp3    
Tagap    
Tagap    
Tagap    
Tagap    
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Cluster 1 
0710001B24Rik C920008O22Rik Il15 Ogfrl1 
1500032H18Rik Ccr5 Il21r P2ry13 
1600014C10Rik Ccr5 Insl6 P2ry14 
1600014C10Rik Cnp1 Irgm Parp3 
1600029O10Rik Cnp1 Irgm Pcaf 
2310006J04Rik Cpeb3 Irgm Phf11 
2310016F22Rik Cutc Isg20 Pira5 
2310046K10Rik Cutc Itpr1 Pml 
2400003C14Rik D11Ertd759e Lgals9 Pml 
2410005K17Rik D11Lgp2e Lgals9 Pml 
2410025L10Rik D11Lgp2e LOC209387 Pou3f1 
2510004L01Rik D11Lgp2e LOC234360 Ppm1k 
2810453L12Rik D14Ertd668e LOC237751 Prkr 
4930566A11Rik D14Ertd668e LOC239122 Psmb8 
4930599N23Rik D430007J11Rik LOC240921 Psmb9 
4930599N23Rik D630022O22Rik LOC328833 Rab3d 
5031414D18Rik Daxx LOC380616 Rbm43 
5830484A20Rik Dbnl LOC380706 Rfc3 
6330442E10Rik Dck LOC380732 Samhd1 
6430573D20Rik Ddit4 LOC380741 Samhd1 
9830148G24Rik Ddx58 LOC381276 Samhd1 
9930016I07Rik Dlm1-pending LOC381287 scl000868.1_2 
9930111J21Rik Eng LOC382127 Scnm1 
A230050P20Rik Enpp4 LOC382177 Scotin 
A330042I21Rik Evi2b LOC384343 Sertad3 
A530023P05Rik F630107D10Rik LOC432555 Sirpb1 
A530060O05Rik Fbxo4 LOC434484 Slc28a2 
A630067N03Rik Fcgr1 LOC625360 Slfn1 
A630082K20Rik Frmd4a MGC6357 Slfn5 
A630085K21 G1p2 Mlkl Sn 
Adar Glipr2 Morc3 Snx2 
Aftph Glipr2 Mov10 Snx2 
AI451557 Gpr141 Mov10 Sp100 
AI481100 Gvin1 Ms4a6d Sp100 
Aim1 H2-T17 Ms4a6d St6galnac2 
Akap12 H2-T9 Mx1 Stat1 
Apaf1 Hars Mx2 Stat1 
Asah2 Hmox2 Nsmaf Stat1 
Asb13 Ifi205 Nsmaf Stat2 
Ass1 Ifi205 Nt5c3 Stat4 
AW538212 Ifi47 Oas1a Symbol 
B630009B09Rik Ifit2 Oas1b Tap1 
BC003314 Ifit2 Oas1b Tdrd7 
BC013712 Ifit3 Oas1g Timeless 
BC023892 Ift172 Oasl1 Tor3a 
BC051083 Igtp Oasl2 Tpst1 
BC094916 Il15 Ogfrl1 Trafd1 
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Cluster 1 Continued 
Trafd1    
Trex1    
Trex1    
Trim14    
Trim21    
Trim30    
Tspo    
Tspo    
Tspo    
Tyki    
Ube2l6    
Vrk1    
Zbp1    
Zc3hdc1    
Zcchc6    
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Cluster 2 
1110003E08Rik Ctsc LOC223594 Siat9 
1110061O04Rik Ctsc LOC230765 Siat9 
1110061O04Rik Ctsc Loh11cr2a Skil 
1200015F23Rik Cycs Lrp11 Slc25a25 
1600021P15Rik D630035N04Rik Mcoln2 Slc2a1 
1810009K13Rik Dncic2 Mid1 Slfn2 
1810038L18Rik Dusp1 Mlp Slpi 
2210009G21Rik Dusp2 Mlp Smg7 
2310016C08Rik Dusp4 Myadm Snn 
2310028H24Rik Edn1 Nab1 Snx10 
4631422O05Rik Etv3 Nat5 Socs3 
4930429A08Rik F10 Nck1 Spred1 
4930555L03Rik Fmnl2 Ncoa5 Sqstm1 
4931440N07Rik Gadd45b Nfkbie Stat3 
4933409L06Rik Gadd45g Nfkbie Stx11 
4933424M23Rik Gas7 Npy Stx11 
5730589K01Rik Gca Nupr1 Stxbp1 
5830457O10Rik Gca Pcdh7 Supt16h 
6030448M23Rik Gdf15 Pdcd1lg1 Surb7 
8030402P03Rik Glrx Pdzgef1 Tank 
9130202B12Rik Glrx1 Pkn2 Tbl1x 
9430023P16Rik Gna15 Plscr1 Tes 
9430065L19Rik Gnb1l Ppa1 Tlr2 
9530018I07Rik Gpr84 Ppp1r11 Tmem2 
A030007L17Rik Gpr84 Ppp2r5a Tmpo 
A630046C11Rik Hdac1 Psma4 Tnf 
Acate3 Hmgcr Psmb7 Tnf 
AI326906 Hmgcs1 Psmd10 Tra2a 
AI427138 Hn1 Ptges Upp1 
Armc8 Hn1l Rab32 Upp1 
AY078069 Hp Rab5a Upp1 
Aytl1 Hrb Ranbp1 Vcam1 
B230114J08Rik Hsd17b7 Rars Vdac3 
B430201A12Rik Ifnar2 Rars Wrd43 
B430201G11Rik Ikzf1 Rbms1 Zc3h7a 
BC004022 Il27 Rela Zfp281 
Brd2 Insig1 Rgl1 Zfp281 
Brd2 Irak2 Rgs1 Zfp36 
C130032J12Rik Irg1 Rgs1 Zfpn1a1 
Casp7 Irg1 Rgs1  
Ccl2 Jmjd2a Rps6ka3  
Ccl7 Khdrbs1 Sc4mol  
Ccl7 Kif3c Sema4a  
Ccrn4l Klf7 Sertad1  
Cd33 Lcn2 Sfrs10  
Chd1 Ldlr Sfrs3  
Cln5 LOC194744 Sgk3  
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Cluster 3 
1110025F24Rik C030026E19Rik L3mbtl3 Serpinb6b 
1200006F02Rik C1rl LOC270152 Slc12a9 
1500015G18Rik C230052I12Rik LOC383077 Slc8a1 
1700009P13Rik C920006O11Rik Loh12cr1 Slco2b1 
1700012H17Rik Casp2 Lpxn St8sia4 
1700012H17Rik Ccnd1 Luc7l2 Stard8 
1810020D17Rik Ccnd1 Maf Stard8 
2400003N08Rik Ccng2 Mbd5 Tal1 
2410015B03Rik Chd9 Mbnl1 Tcf4 
2410081M15Rik Cpeb3 Mcm10 Thbd 
2410193C02Rik Ctla2b Mcm6 Thbs1 
2610300B10Rik Cugbp2 Mcm6 Thsd1 
2700094F01Rik Cyp27a1 Mcm6 Tiam1 
2810413I22Rik Cyp27a1 Mcm7 Tlr8 
3010026O09Rik D030012E24Rik Mef2c Tm6sf1 
4930465J06Rik D5Ertd585e Mertk TNFαip8l2 
4930518I15Rik D5Ertd585e Mfsd9 TNFαip8l2 
4933427G17Rik Dclre1c Mier1 Tnfrsf22 
4933428I03Rik Dhrs8 Mppe1 Trim25 
5832424M12 Dusp6 Ms4a6b Txnip 
9630007E23Rik E130102H24Rik Msrb2 Txnip 
9830134K01Rik Ear10 Msrb2 Uaca 
9830139D05Rik Ehd4 Mtus1 Usf1 
A330080J22Rik Ehd4 Mtus1 Uvrag1 
A430105I05Rik F11r Ncoa1 Ypel3 
A830089I03Rik F730004D16Rik Nfatc2ip Zfp709 
Ap3m2 Fgd2 Nqo2 Zfyve26 
Apobec1 Fgd4 Nqo2 Zranb3 
Arhgap15 Fut10 Olfml2b  
Arhgap18 Gcnt1 Ophn1  
Arhgap25 Gcnt1 P2ry14  
Arl4 Gpr34 P2ry5  
Armc3 Gsg2 Paox  
Atm Gyg1 Paox  
Atm Gypc Plcl2  
AU020772 Hfe Prkdc  
B230342M21Rik Hfe Pscdbp  
Bach2 Hhex Rab39  
BC003236 Hook2 Rab7l1  
BC003236 Hpse Rasa3  
BC016201 Ier5l Rcbtb2  
BC023892 Ift172 Rhobtb1  
Bcl7a Ift172 Rnase4  
Birc1e Iqgap2 Rnase6  
Brip1 Kif5c Rps6ka5  
C030014I23Rik Klf4 Sca1  
C030025P15Rik Klra3 scl0015365.1_6  
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Cluster 4 
1300017K07Rik Chchd4 Mrps18b Srm 
1700012B18Rik Clecsf12 Mrps18b Tbrg4 
1700027M21Rik CRG-L1 Mybbp1a Tex292 
1700051E09Rik Csrp2 Nfkbil1 Uck2 
1810032O08Rik Cyb5 Nol1 Upf1 
2310061F22Rik D130063H01Rik Nol11 Zbtb17 
2310069P03Rik D19Bwg1357e Nol5 Zdhhc12 
2310073E15Rik D8Ertd457e Npn3 Zfp341 
2410131K14Rik Dnmt3l Nxn Srm 
2610318C08Rik Dnmt3l Panx1 Tbrg4 
2810012D02Rik Dph2 Panx1 Tex292 
2810430M08Rik Dusp3 Pdgfb Uck2 
4732435K05Rik E430031D18Rik Pdpk1 Upf1 
4930524J08Rik Ednrb Pdxp Zbtb17 
4930570C03Rik Ednrb Pelo Zdhhc12 
5031409G22Rik Ednrb Pim3 Zfp341 
5530400B01Rik F630001K14Rik Piwil2  
5730436H21Rik Fkbp11 Pknox1  
5730528L13Rik Fosl1 Polr3d  
6720458F09Rik Gfm Ppan  
8430421H08Rik Gm1960 Ppapdc1  
9430002A10Rik Gm22 Ppbp  
9430008C03Rik Gm237 Ppfibp2  
9930015A14Rik Gnl3 Ppp3cc  
9930022F21Rik Gpr68 Ptpre  
A130086G11Rik Grwd1 Ptrh1  
AA408556 Gss Rad23b  
AA691260 Heatr3 Rapgef1  
Acat2 Herpud1 Rassf4  
AF322649 Herpud1 Rassf4  
Afg3l2 Hmox1 Rgs3  
AI427809 Hvcn1 Rhob  
Akr1b8 Jmjd3 Rhof  
Alas1 Jund1 Rnu65  
Amotl1 Lad1 Rnu70  
Ampd3 Limd1 Ruvbl2  
Armc7 LOC245350 scl000209.1_5  
AW046014 LOC380625 scl0002445.1_75  
AW046014 LOC381330 Sdccag33  
BC022593 LOC384319 Setd8  
Bhlhb2 Maff Sf1  
Bmp1 Mdm2 Sla  
C77032 Mettl1 Slc7a11  
C77032 Mftc Slc7a11  
Cacnb3 Mki67 Slco4a1  
Ccl24 Mki67ip Srm  
Cdkn2b Mrps18b Srm  
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Cluster 5 
1110001E17Rik 5730403M16Rik C730026E21Rik Hyal1 
1110032E23Rik 5730547N13Rik C77080 Inpp5e 
1110059F07Rik 6330439P19Rik C86302 Irs2 
1190009E12Rik 6330505F04Rik C87436 Isca1 
1500031N24Rik 6430548M08Rik Ccnd1 LOC228790 
1500041O16Rik 6430548M08Rik Cd8b LOC241944 
1700027M01Rik 6430567E01Rik Cdc14b LOC381297 
1700041B20Rik 9130211I03Rik Centb5 LOC384281 
1700052N19Rik 9230102G06Rik Cerk Mad2l1bp 
1700054N08Rik 9330133O14Rik Chaf1a Map3k14 
1810010N17Rik 9830001H06Rik Chchd8 Map3k7ip1 
1810011H11Rik 9930031P18Rik Clspn Map3k7ip1 
1810013C15Rik A130092J06Rik Csnk2a1 Mapk1ip1 
1810015M01Rik A230106J09Rik D330014H01Rik Mast3 
1810045K06Rik A330103N21Rik D430036N24Rik Mbp 
1810049H13Rik A530065E19Rik D4st1 MGC32441 
2010015P12Rik AA407930 D930048N14Rik Mlh3 
2310003H01Rik AA408296 Deb1 Ncdn 
2310005P05Rik Aatk Dedd2 Ncf2 
2310036D04Rik Acot11 Def6 Ndst1 
2310042L06Rik Adcy9 Dnase2a Ndst1 
2310046O06Rik Adrb2 Dolpp1 Ndst1 
2410075B13Rik AI481316 Dusp7 Nisch 
2600005C20Rik AI842788 E030007N04Rik Nte 
2600005N12Rik Akt1s1 E430018J23Rik Nudt6 
2610002D18Rik Ankrd47 Ell Numa1 
2610009I02Rik Arl4c Ets1 Nup43 
2610029D06Rik Arrb1 Fahd1 Orc5l 
2610206C24Rik Ase1 Fance Ormdl3 
2610319K07Rik B230312I18Rik Fbxl10 P2ry6 
2810017I02Rik B230333C21Rik Fbxo31 Per1 
2810026P18Rik B3galt4 Fhod1 Per1 
3000003F02Rik B3gnt8 Fignl1 Pex11c 
3000003G13Rik B430214A04Rik Fpgs Pgpep1 
3110001A13Rik B430214A04Rik Fv1 Phf17 
3632413B07Rik BC006705 Galgt1 Pkd1 
3632413B07Rik BC016495 Gemin4 Pla2g4b 
3632413B07Rik BC025546 Gfer Plekhg3 
4430402O11Rik BC044804 Gig1 Ppgb 
4732471D19Rik BC049806 Gnb5 Ptpn21 
4733401I05Rik BC056929 Gpr146 Rab11fip5 
4833408A19Rik BC060631 Gpr146 Rab3il1 
4833425P12Rik BC061259 Grcc9 Rab40c 
4930438D12Rik Brd3 H13 Rbm38 
4930504E06Rik Brp16 Hpgd Rbm38 
4933402L21Rik C430004E15Rik Hps4 Repin1 
5630401D24Rik C530015C18 Hs1bp3 Rgs11 
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Cluster 5 Continued 
Rora    
Rpp14    
scl0002449.1_77    
Sec14l1    
Sema4b    
Sesn1    
Sesn1    
Ski    
Skp2    
Sla    
Slc16a6    
Slc16a6    
Slc19a2    
Slc25a38    
Slc40a1    
Slc5a6    
Snapc4    
Snx25    
Solh    
Sox4    
Spg20    
Strn    
Sufu    
Surf2    
Synj2    
Tbc1d10a    
Thap11    
Tmem143    
Tmem20    
Tmem24    
Tob1    
Tprkb    
Trim41    
Ttll4    
Uhrf1    
Ung    
Wdr22    
Wdr77    
Zfp251    
Zfp27    
Zfp422-rs1    
Zfp472    
Zfp50    
Zfp715    
Table 4.1.Complete list of genes in the 6 clusters shown in Figure 4.3. 
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Chapter 5. The TPL2-ERK pathway regulates the 
macrophage response to Mtb, through the 
suppression of type I IFN 
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5.1. Background 
In response to the recognition of pathogens and pathogen derived products, 
macrophages initiate an anti-microbial response, and generate inflammation. This 
occurs through PRRs, which recognise conserved molecular structures of pathogens, 
and activate signalling pathways leading to transcription (Smale, 2010). The most 
well characterised PRRs are the TLR family, which activate the Myd88 or TRIF 
dependent pathways, leading to the activation of NF-κB, MAP kinases and IRFs 
(Kawai and Akira, 2010). Mtb signals through TLRs, predominantly TLR2 and 
TLR9, but also activates non-TLR pathways including dectin-1 and NOD2 
(Kleinnijenhuis et al, 2011).  
MAP kinase signalling is made up of a three component protein kinase 
cascade; a MAP 3-kinase, which phosphorylates and activates a MAP 2-kinase, 
which in turn phosphorylates a MAP kinase (Symons et al, 2006). MAP kinases then 
phosphorylate a wide range of target proteins, including transcription factors. There 
are three families of MAP kinase; the extracellular signal-regulated kinases (ERK1 
and ERK2; referred to subsequently as ERK), the p38 MAP kinases and the c-Jun 
amino-terminal kinases (JNK1, JNK2 and JNK3) (Symons et al, 2006). The first 
MAP kinase pathway to be discovered, and the most well studied, is the ERK MAP 
kinase pathway (Gantke et al, 2012).  
Two MAP 3-kinases are known to lead to ERK activation; members of the 
Raf family, and TPL2 (Gantke et al, 2012). Both kinases phosphorylate and activate 
the MAP 2-kinases MEK1 and MEK2, which in turn phosphorylate ERK (Gantke et 
al, 2012). TPL2 is required for the activation of MEK1/2 and ERK downstream of 
TLR signalling, as shown by the fact that macrophages from mice deficient in Tpl2 
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are unable to activate ERK downstream of TLR2, TLR4 and TLR9 ligands (Dumitru 
et al, 2000; Kaiser et al, 2009). 
The ERK MAP kinase pathway (subsequently referred to as the TPL2-ERK 
pathway) has been shown to regulate the production of cytokines from TLR 
stimulated macrophages (Symons et al, 2006). Macrophages from mice deficient in 
Tpl2 were shown to have impaired production of TNFα in response to LPS (Dumitru 
et al, 2000; Rousseau et al, 2008). The effect of the TPL2-ERK pathway on TNFα is 
thought to be post-transcriptional, as levels of Tnf mRNA were the same in WT and 
Tpl2 deficient macrophages (Rousseau et al, 2008). The TPL2-ERK pathway is also 
required for optimal production of IL-10 (Agrawal et al, 2003; Dillon et al, 2004; 
Kaiser et al, 2009) and IL-1β (Mielke et al, 2009) in response to various TLR 
ligands. In contrast, the TPL2-ERK pathway is a negative regulator of IL-12 and 
IFNβ in macrophages stimulated with LPS and CpG (Kaiser et al, 2009; Yang et al, 
2011). The regulation of IL-10, IL-12 and IFNβ by TPL2-ERK has been shown to 
depend on the transcription factor c-Fos (Dillon et al, 2004; Kaiser et al, 2009). 
However, the mechanism by which TPL2-ERK signalling regulates IL-1β 
production is unclear.  
The cytokines regulated by TPL2-ERK signalling play important roles in the 
immune response to various pathogens. In general, however, Tpl2 deficient mice 
have been shown to be more susceptible to both Listeria monocytogenes and 
Toxoplasma gondii (Watford et al, 2008; Mielke et al, 2009). In the case of Listeria 
monocytogenes infection, this was linked to reduced IL-1β production, whereas 
increased susceptibility to Toxoplasma gondii was suggested to be due to loss of IL-
12 and IL-18 induced IFNγ production from CD4+ T cells, showing that TPL2-ERK 
signalling regulates cytokines from both innate and adaptive immune cells (Watford 
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et al, 2008; Mielke et al, 2009). However, the role of TPL-ERK signalling in Mtb 
infection has not been addressed. Given that TPL2-ERK regulates IL-12, TNFα and 
IL-1β, all of which are required for protection against Mtb (Flynn et al, 1995; 
Cooper et al, 1997; Mayer-Barber et al, 2011) and IL-10 and type I IFN, which play 
a detrimental role in the immune response to Mtb (Antonelli et al, 2010; Redford et 
al, 2010), this pathway would be predicted to play an important role in regulating the 
immune response to Mtb.  
As shown in Chapter 3, we identified a cluster of TPL2-ERK inducible genes 
expressed early in macrophages following Mtb infection. This prompted us to 
investigate the role of the TPL2-ERK pathway in regulating both cytokine 
production and transcription from macrophages in response to Mtb. We found that 
the TPL2-ERK pathway positively regulated IL-10, IL-1β and TNFα, whilst 
negatively regulating IL-12 and IFNβ, as has been reported in response to single 
TLR ligands. The TPL2-ERK pathway also regulated many genes at the 
transcriptional level. Importantly, several of the changes in cytokine production and 
transcription in Tpl2
-/-
 macrophages were as a result of increased type I IFN 
signalling. 
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5.2. Results 
5.2.1. The TPL2-ERK pathway regulates induction of early genes in 
response to Mtb infection 
Results from microarray analysis presented in Chapter 3 strongly suggested 
that the TPL2-ERK pathway was rapidly activated in response to Mtb. To determine 
the effect this pathway has on early gene regulation, we compared the response of 
WT macrophages to Tpl2
-/-
 macrophages, which are unable to activate ERK 
downstream of TLRs (Dumitru et al, 2000; Kaiser et al, 2009). WT and Tpl2
-/-
 
macrophages were infected with Mtb and at 1hr post-infection RNA was harvested 
and analysed by microarray. 
The microarray data was normalised and undetectable transcripts were 
removed as described in the Materials and Methods. Transcripts were then retained if 
they were induced >2-fold in response to Mtb in either strain, and if they were 
significantly differently expressed between WT and Tpl2
-/-
 macrophages by two-way 
ANOVA (p<0.05) with Benjamini Hochberg FDR multiple testing correction. This 
left 422 transcripts which were clustered hierarchically (Figure 5.1A). 
The majority of the 422 transcripts were regulated in the uninfected controls 
at 1hr post-infection (Figure 5.1A), possibly reflecting a role for Tpl2 in the 
macrophage response to growth factors present in the culture medium. However, a 
small cluster of 24 Tpl2-dependent Mtb-regulated transcripts was identified (Figure 
5.1B). This cluster included several genes present in cluster 15 of the microarray 
time-course, including Fos, Egr1, Dusp1 and Dusp5 (Figure 5.1B). In addition, a 
number of other genes were found to be regulated by the TPL2-ERK pathway. These 
included the chemokines Ccl2, Ccl4 and Ccl7, immunoresponsive gene 1 (Irg1) and 
the actin related gene Arc, which has previously been linked to ERK signalling 
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(Huang et al, 2007) (Figure 5.1B). The reduced expression of Fos and Egr1 in Tpl2
-/-
 
macrophages at 1hr post-infection was confirmed by qPCR analysis (Figure 5.1C). 
The TPL2-ERK pathway is therefore an important regulator of early transcription in 
Mtb-infected macrophages.  
5.2.2. The TPL2-ERK pathway negatively regulates IL-12 and IFNβ, 
but positively regulates IL-10, IL-1β and TNFα from Mtb infected 
macrophages 
The TPL2-ERK pathway has previously been shown to be a key regulator of 
cytokine production in innate immune cells, in response to a variety of TLR ligands, 
including LPS, CpG and Pam3CSK4 (Dumitru et al, 2000; Dillon et al, 2004; Kaiser 
et al, 2009; Mielke et al, 2009). This included several cytokines that have important 
effects in the immune response to Mtb including TNFα, IL-1β and IL-12, IL-10 and 
IFNβ. The regulation of cytokine production by TPL2-ERK signalling has been 
reported to be due to the activation of the transcription factor c-Fos (Dillon et al, 
2004; Kaiser et al, 2009), which we found was dependent on TPL2-ERK for its 
induction in response to Mtb (Figure 5.1). We therefore determined if the TPL2-ERK 
pathway also regulated cytokine production in macrophages in response to Mtb, 
which signals through both TLR and non-TLR receptors (Kleinnijenhuis et al, 2011). 
WT and Tpl2
-/-
 macrophages were infected with Mtb and cytokine production 
determined at 24hr by ELISA. In comparison to WT macrophages, Tpl2
-/-
 
macrophages produced markedly increased levels of both IL-12p40 and IL-12p70 in 
response to Mtb (Figure 5.2A). In addition, levels of IFNβ were also higher in Tpl2-/- 
macrophages (Figure 5.2A). The TPL2-ERK pathway therefore negatively regulates 
IL-12 and IFNβ production from Mtb infected macrophages. In contrast, levels of 
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IL-10, IL-1β and TNFα were reduced in Tpl2-/- macrophages, showing a positive 
effect of the TPL2-ERK pathway on the production of these cytokines (Figure 5.2A).  
To confirm these findings, a second independent approach was used to 
disrupt the TPL2-ERK pathway. This was important for two reasons; first that TPL2 
may have other phosphorylation targets besides MEK1/2 (although this has not yet 
been proven) (Gantke et al, 2011) and second because TPL2 is associated with the 
IKK family member p105 in steady state, and thus loss of Tpl2 may have effects on 
NF-κB signalling (Gantke et al, 2012). To address this, we inhibited TPL2-ERK 
signalling downstream of TPL2, using PD0325901, a highly specific inhibitor of 
MEK1/2 kinase activity. PD0325901, or DMSO as a vehicle control, was added to 
WT macrophages 30mins prior to Mtb infection, and cytokine production was 
determined at 24hr post-infection (Figure 5.2B). Results using the MEK1/2 inhibitor 
closely resembled the phenotype of Tpl2
-/-
 macrophages, with increased levels of IL-
12p40, IL-12p70 and IFNβ, but decreased levels of IL-10, IL-1β and TNFα, 
compared to macrophages treated with DMSO vehicle control (Figure 5.2B). This 
was also confirmed in primary Mtb infected monocytes from WT and Tpl2
-/-
 mice 
(McNab, O’Garra; data not shown). These results are in keeping with previous 
studies using single TLR ligands (Dumitru et al, 2000; Dillon et al, 2004; Kaiser et 
al, 2009; Mielke et al, 2009) and confirm that the TPL2-ERK pathway is an 
important regulator of cytokine production from Mtb infected macrophages. 
5.2.3. TPL2 negatively regulates IL-12 production independently of 
IL-10 
Interruption of the TPL2-ERK pathway leads to reduced IL-10 but increased 
IL-12 production (Figure 5.2). It was possible that the increased production of IL-12 
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observed was a result of lower IL-10 levels, as IL-10 is a potent inhibitor of IL-12 
from APCs (D'Andrea et al, 1993; Moore et al, 2001). To address this, Tpl2
-/-
 mice 
were crossed with Il10
-/-
 mice to produce Tpl2
-/-
Il10
-/-
 mice. Macrophages from Tpl2
-
/-
Il10
-/- 
mice, and WT, Il10
-/- 
and Tpl2
-/-
 macrophages, were infected with Mtb and the 
production of IL-12p40 and IL-12p70 was determined at 24hr post-infection. The 
crucial comparison in this experiment is between Il10
-/-
 macrophages and Tpl2
-/-
Il10
-
/- 
macrophages, as this shows the effect of removing TPL2-ERK signalling in the 
absence of endogenous IL-10. As shown in Figure 5.3, a significant increase in both 
IL-12p40 and IL-12p70 production was observed in Tpl2
-/-
Il10
-/-
 macrophages 
compared to Il10
-/-
 macrophages. This increase was to a similar level than the 
increase observed between WT and Tpl2
-/-
 macrophages (Figure 5.3). This shows 
that TPL2-ERK signalling regulates the production of IL-12 independently of IL-10.  
5.2.4. The TPL2-ERK pathway is an important regulator of 
transcription in Mtb infected macrophages 
Previous results demonstrate that the TPL2-ERK pathway regulates both the 
early macrophage response to Mtb and the production of cytokines. As a number of 
transcription factors were part of the early TPL2-ERK dependent response, we next 
assessed what impact this may have on subsequent gene expression at a later time 
point. In addition, this would reveal whether the regulation of cytokines by TPL2-
ERK signalling is transcriptional or post-transcriptional. To address this we carried 
out microarray analysis of WT and Tpl2
-/-
 macrophages infected with Mtb at 6hr 
post-infection, the peak of the transcriptional response to Mtb (see Chapter 3). The 
data were normalised and undetectable transcripts were removed, as described in the 
Materials and Methods. Differentially regulated transcripts were generated by 
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retaining those that were >2-fold upregulated by Mtb in either WT or Tpl2
-/-
 
macrophages, those that were significantly different between WT and Tpl2
-/-
 by two-
way ANOVA with Benjamini Hochberg FDR multiple testing correction, and those 
that were greater than 2-fold different between WT and Tpl2
-/-
 macrophages infected 
with Mtb at 6hr post-infection. With this analysis strategy, 104 Mtb-inducible 
transcripts were found to be differentially regulated between WT and Tpl2
-/-
 
macrophages at 6hr post-infection (Figure 5.4A).  
A prominent cluster was increased to a much greater extent in Tpl2
-/-
 
macrophages (Figure 5.4A). This included Il12a, which encodes for the p35 subunit 
of IL-12, in keeping with the fact that IL-12p70 is upregulated in Tpl2
-/-
 
macrophages at the protein level (Figure 5.2A). In addition, several subtypes of IFNα 
were in this cluster, including Ifna2, Ifna5 and Ifna6, showing that TPL2-ERK can 
regulate several members of the type I IFN family. The increased expression of 
Il12a, Ifna2, Ifna5 and Ifna6 in Tpl2
-/- 
macrophages was validated by qPCR (Figure 
5.4B). This cluster also included C2ta, which codes for the Class II transactivator, a 
master regulator of components of the MHC class II pathway (Boehm et al, 1997). 
This shows that a number of immunologically important genes are negatively 
regulated by TPL2-ERK signalling. In addition, several genes with more diverse 
functions were increased in Tpl2
-/- 
macrophages. This included two genes encoding 
calcium ion channels; Clic5 (chloride intracellular ion channel 5) and Cacnb3 
(calcium channel, voltage-dependent, beta 3 subunit). In addition, two genes 
involved in chromatin remodelling were upregulated in Tpl2
-/- 
macrophages; Hmgn3, 
involved in histone acetylation (Barkess et al, 2012), and Jmjd2a (KDM4A), a 
histone demethylase (Couture et al, 2007). This suggests that TPL2-ERK may 
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regulate histone modifications, which may have an important effect on gene 
regulation. 
A second prominent cluster of transcripts was downregulated in response to 
Mtb, but which were downregulated to a greater extent in Tpl2
-/-
 macrophages 
(Figure 5.4A). TPL2-ERK signalling therefore regulates both the induction and 
suppression of transcription in Mtb-infected macrophages. Genes in this cluster 
included a subunit of the IFNγ receptor (Ifngr1) and the enzyme arginase (Arg1) 
(Figure 5.4A). Reduced expression of Ifngr1 in Tpl2
-/-
 macrophages was confirmed 
by qPCR (Figure 5.4B). The stimulation of macrophages by IFNγ is vital for 
controlling Mtb infection, as this leads to the killing of intracellular Mtb. The 
downregulation of the Ifngr1 in the absence of TPL2-ERK signalling may therefore 
impair the host immune response to Mtb.  
The 104 differentially regulated transcripts did not contain IFNβ, IL-1β, 
TNFα or IL-10, despite differences in these cytokines being observed at the protein 
level in Tpl2
-/-
 macrophages compared to WT (Figure 5.2A). To determine if these 
genes were differentially regulated at the transcriptional level, qPCR analysis was 
carried out. In keeping with the protein data, levels of Il10 and Il1b were 
significantly lower in Tpl2
-/-
 macrophages, compared to WT, and IFNβ was 
significantly upregulated (Figure 5.4B). However, no difference was observed for 
Tnf, suggesting that TNFα is entirely regulated at the post-transcriptional level by the 
TPL2-ERK pathway, as previously reported (Dumitru et al, 2000; Rousseau et al, 
2008). 
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5.2.5. The TPL2-ERK pathway positively regulates IL-1β, and 
negatively regulates IL-12p70, through the suppression of type I 
IFN 
Following microarray analysis, it was clear that a prominent function of the 
TPL2-ERK signalling pathway is to negatively regulate type I IFN production, as in 
the absence of this pathway several members of the type I IFN family are increased, 
including IFNβ and three subtypes of IFNα (Figure 5.2; Figure 5.4). The results from 
Chapter 3 showed that endogenous type I IFN was an important regulator of both 
cytokine production and transcription in Mtb infected macrophages. It was therefore 
possible that some of the effects observed in the absence of TPL2-ERK signalling 
could be a result of increased type I IFN.  
In order to investigate the contribution of type I IFN to the phenotype of 
Tpl2
-/-
 macrophages, Tpl2
-/-
 mice were crossed with Ifnar1
-/-
 mice to produce Tpl2
-/-
 
Ifnar1
-/- 
mice. Thus, comparison of Tpl2
-/-
Ifnar1
-/-
 mice to Ifnar1
-/-
 mice would show 
the effect of blocking TPL2-ERK in the absence of type I IFN signalling. 
Macrophages from these mice and respective controls were then infected with Mtb 
and cytokine production was determined at 24hr post-infection. 
As shown previously, Tpl2
-/-
 macrophages produced increased amounts of 
IL-12p40 compared to WT, whereas Ifnar1
-/-
 macrophages produced less (Figure 
5.5). However, Tpl2
-/-
Ifnar1
-/-
 macrophages produced higher levels than Ifnar1
-/- 
macrophages (Figure 5.5). In both cases the increase was approximately 10-fold, 
showing that the increase in IL-12p40 production in the absence of TPL2 is 
independent of type I IFN, despite overall IL-12p40 being dependent upon type I 
IFN. However, although levels of IL-12p70 increased in Tpl2
-/-
 macrophages, the 
same increase was not seen in Tpl2
-/-
Ifnar1
-/- 
macrophages (Figure 5.5) showing that 
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the increased type I IFN observed in Tpl2
-/-
 macrophages drives increased IL-12p70 
production. 
Both TPL2 and type I IFN signalling are positive regulators of IL-10, and so 
IL-10 levels were lower in both Tpl2
-/-
 and Ifnar1
-/-
 macrophages, and lower again in 
Tpl2
-/-
Ifnar1
-/-
 (Figure 5.5). TPL2-ERK and type I IFN therefore regulate IL-10 
independently. A similar pattern was seen for TNFα production, as both TPL2 and 
type I IFN signalling are required for maximal production of TNFα (Figure 5.5). 
However, the decrease in IL-1β production seen in Tpl2-/- macrophages was 
not observed in the absence of type I IFN signalling; Tpl2
-/-
Ifnar1
-/-
 macrophages had 
comparable levels of IL-1β to Ifnar1-/- macrophages (Figure 5.5). The TPL2-ERK 
pathway therefore positively regulates IL-1β indirectly, through the suppression of 
type I IFN production. The increase in IFNβ production in Tpl2-/- macrophages is 
relatively small (Figure 5.2). However, previous results have shown that very low 
levels of exogenous IFNβ (20pg/ml) could inhibit IL-1β (see Chapter 4) showing 
that IL-1β is highly sensitive to suppression by type I IFN.  
5.2.6. The TPL2-ERK pathway regulates transcription by 
suppressing type I IFN production 
As TPL2-ERK regulates IL-1β and IL-12p70 production indirectly through 
type I IFN, it was also possible that increased type I IFN production was responsible 
for the broader transcriptional changes observed in Tpl2
-/-
 macrophages. To 
investigate this, microarray analysis was carried out using WT, Tpl2
-/-
, Ifnar1
-/-
 and 
Tpl2
-/-
Ifnar1
-/-
 mice infected for 6hr with Mtb. Following normalisation, the 
expression of the 104 Tpl2-regulated transcripts shown in Figure 5.5 was 
determined. 
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Many of the genes up or downregulated in Tpl2
-/-
 macrophages are regulated 
in a type I IFN dependent manner. A prominent cluster of genes, including Ifna2, 
Ifna5, Ifna6 and Il12a were not upregulated in Tpl2
-/-
Ifnar1
-/-
 macrophages relative to 
Ifnar1
-/-
 , despite being upregulated in Tpl2
-/-
 versus WT macrophages (Figure 5.6A). 
This data with Il12a is in keeping with the type I IFN dependent increase in IL-
12p70 at the protein level (Figure 5.5). The expression of Ifna2, Ifna5, Ifna6 and 
Il12a was validated by qPCR (Figure 5.6B). Other genes regulated in a type I IFN 
dependent manner included the TAP-related gene Tapbpl (TAP binding protein-
like), the chloride ion channel Clic5 and the GTP-activating Rgs3 (Figure 5.6A). 
This shows that many of the effects of TPL2-ERK on transcriptional regulation 
occur indirectly, through autocrine type I IFN.  
In addition, a further cluster was downregulated in Tpl2
-/-
 macrophages in a 
type I IFN dependent manner (Figure 5.6A). This included a subunit of the receptor 
for IFNγ, Ifngr1, expression of which was validated by qPCR (Figure 5.6B). 
Expression of the IFNγ receptor in macrophages is crucial during Mtb infection, as 
IFNγ stimulates macrophages to kill Mtb. Other genes in this cluster included the 
enzyme Arg1 (encoding for arginase) and Dusp6 (Figure 5.6A).  
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5.3. Discussion 
The response of macrophages to pathogens and pathogen-derived 
components is critical in protecting the host from infection. The signalling pathways 
that regulate this response downstream of PRRs are therefore of great interest. We 
show here that the TPL2-ERK MAP kinase signalling pathway is an important 
regulator of the macrophage response to Mtb. TPL2-ERK signalling regulated both 
early and late transcription in Mtb-infected macrophages. In addition, TPL2-ERK 
regulated the production of cytokines vital for protection against Mtb; TNFα, IL-1β 
and IL-12 (Cooper et al, 1995; Flynn et al, 1995; Mayer-Barber et al, 2011) and 
cytokines known to reduce resistance to Mtb; IL-10 and IFNβ (Antonelli et al, 2010; 
Redford et al, 2010). 
5.3.1. The regulation of cytokine production by the TPL2-ERK 
pathway 
We found that the TPL2-ERK pathway regulated a number of important 
cytokines in response to Mtb. TPL2-ERK positively regulated IL-10, IL-1β and 
TNFα in response to Mtb, but negatively regulated IL-12p40, IL-12p70 and IFNβ. A 
summary of the effects of TPL2-ERK signalling on macrophage cytokine production 
in response to Mtb is shown in Figure 5.7. 
These results are largely in agreement with previous studies with 
macrophages treated with single TLR ligands such as LPS, CpG and Pam3CKS4 
(Dumitru et al, 2000; Agrawal et al, 2003; Dillon et al, 2004; Rousseau et al, 2008; 
Kaiser et al, 2009; Mielke et al, 2009; Yang et al, 2011). One study has reported 
conflicting results; Xiao et al (2009) found that a mutation in Tpl2 resulted in 
impaired type I IFN production from peritoneal macrophages stimulated with TLR7 
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and TLR9 agonists. However, this study used mice in which Tpl2 was mutated using 
N-ethyl-N-nitrosourea (Xiao et al, 2009), a process which can result in only partial 
loss of function, as opposed to the complete loss of function in Tpl2
-/-
 mice.  
The transcription factor c-Fos, which is part of the early cluster induced by 
Mtb in a TPL2-ERK dependent manner, has previously been shown to promote IL-
10 production, and inhibit IL-12 and IFNβ, downstream of TPL2-ERK signalling 
(Dillon et al, 2004; Kaiser et al, 2009). Dillon et al (2004) showed that CD11c
+
 DCs 
from c-Fos deficient mice had reduced IL-10 production in response to LPS and 
Pam3CSK4. Subsequently, it was shown that retroviral expression of c-Fos in Tpl2
-/-
 
DCs was sufficient to inhibit IL-12p40, IL-12p70 and IFNβ production in response 
to CpG (Kaiser et al, 2009). We also observed that induction of Fos at the mRNA 
level was impaired in Tpl2
-/-
 macrophages, suggesting that the effects seen in Tpl2
-/-
 
macrophages may be due to a loss of c-Fos activity. Further experiments using mice 
deficient in Fos could address this.  
We show here that the important pro-inflammatory cytokine IL-1β is 
dependent upon TPL2-ERK signalling for its expression in macrophages infected 
with Mtb. This is in agreement with a previous study using TLR ligands such as LPS 
and Poly-ICLC (Mielke et al, 2009). In agreement with our study, Mielke et al 
(2009) showed that mRNA levels of pro-IL-1β were lower in Tpl2-/- macrophages, 
suggesting regulation at the transcriptional level. However, this study did not address 
the mechanism behind the regulation of IL-1 by TPL2-ERK signalling. Our study 
found that TPL2-ERK signalling positively regulates IL-1β production indirectly, via 
the negative regulation of type I IFN. Type I IFN is a potent suppressor of IL-1β 
production, and so if the TPL2-ERK pathway is blocked, levels of type I IFN 
increase and feed back to inhibit IL-1β. This was demonstrated by the fact that no 
Chapter 5: The TPL2-ERK pathway regulates the macrophage response to Mtb 
 
252 
loss of IL-1β was observed in Tpl2-/- macrophages if type I IFN signalling was also 
removed; Tpl2
-/-
Ifnar1
-/-
 macrophages had comparable levels to Ifnar1
-/-
 controls.  
The results presented here are limited to the study of bone marrow derived 
macrophages. Although macrophages are an important part of the innate immune 
response to Mtb, many other innate immune cells are infected, and produce 
cytokines, during infection (Wolf et al, 2007). Importantly, others in our laboratory 
have shown that monocytes taken directly ex vivo from the blood of WT and Tpl2
-/-
 
mice showed similar effects of TPL2-ERK signalling, with reduced IL-10, IL-1β and 
TNFα, and enhanced IL-12 and IFNβ, in Tpl2-/- monocytes (McNab, Ewbank, 
Stavropoulos, O’Garra; Manuscript submitted). This shows that TPL2-ERK 
signalling is likely to play an important role in vivo. Further work could address this 
effect in additional cell types. For example, myeloid DCs are reported to be the 
major producers of IL-12p70 in vivo during Mtb infection (Rothfuchs et al, 2009) 
and so the role of TPL2-ERK signalling in these cells could be of interest. In 
addition, it would be important to address the role of TPL2-ERK signalling in 
alveolar macrophages, as these are thought to be the first cells to encounter Mtb in 
vivo (Cooper, 2009).  
5.3.2. Wider transcriptional regulation by TPL2-ERK signalling 
The TPL2-ERK pathway is clearly an important regulator of cytokine 
production in response to Mtb infection in macrophages. However, microarray 
analysis in this study shows that TPL2-ERK signalling regulates many genes at the 
transcriptional level. This included both genes induced early following Mtb infection 
(at 1hr post-infection) and those induced later (6hr post-infection). Regulation of 
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these genes by TPL2-ERK may have important consequences in the macrophage 
response to Mtb.  
A number of early genes were regulated by TPL2-ERK signalling. This 
included the transcription factor c-Fos, which is likely to be involved in regulating 
cytokine production, as discussed above. The zinc-finger transcription factor Egr1 
was also found to be dependent upon TPL2-ERK for its expression downstream of 
Mtb. Egr1 is induced in response to many stimuli, and has been linked with a 
number of functions including growth control and apoptosis (Thiel and Cibelli, 
2002). Previous studies have shown that both enteropathogenic E.coli and 
Chlamydia pneumoniae induce Egr1 expression in HELA cells and RAW 
macrophages respectively (de Grado et al, 2001; Bea et al, 2003). In agreement with 
our results, the induction of Egr1 was in both cases found to depend on ERK 
signalling, as inhibition of MEK1/2 activity prevented Egr1 induction (de Grado et 
al, 2001; Bea et al, 2003). That Egr1 is induced during a number of different 
infections suggests it may be playing an important role in the immune response.  
Loss of TPL2-ERK signalling also regulated many genes at 6hr post-
infection. However, whereas TPL2-ERK was mainly a positive regulator of 
transcription at 1hr, it appeared to be mainly a negative regulator at 6hr post-
infection, with the majority of genes showing increased expression in Tpl2
-/-
 
macrophages. A number of these changes were due to increased levels of type I IFN 
signalling, as increases were not seen in Tpl2
-/-
Ifnar1
-/-
 macrophages relative to 
Ifnar1
-/-
 controls. This included several subsets of IFNα; Ifna2, Ifna5 and Ifna6. This 
is in keeping with the fact that expression of IFNα genes is known to depend on 
autocrine signalling through IFNβ, in a positive feedback loop involving IRF-7 
(Marie et al, 1998; Sato et al, 1998). Increased levels of IFNβ in Tpl2-/- 
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macrophages, which are observed at the protein level, therefore feed back to drive 
increased amounts of IFNα. 
5.3.3. The role of TPL2-ERK signalling in the in vivo response to 
Mtb 
Our results show that TPL2-ERK signalling regulates a number of cytokines 
known to have important effects in the immune response to Mtb. However, whether 
loss of TPL2-ERK signalling would have a beneficial or detrimental effect on the 
host response to Mtb is unclear. The positive regulation of TNFα and IL-1β by 
TPL2-ERK signalling would be expected to protect the host from Mtb, as both these 
cytokines are known to be required for protection (Flynn and Chan, 2001a; Mayer-
Barber et al, 2011). In addition, as type I IFN is thought to play a negative role in 
infection, the suppression of type I IFN by TPL2-ERK would also be predicted to 
benefit the host. In contrast, TPL2-ERK signalling positively regulates IL-10, known 
to suppress the immune response to Mtb (Redford et al, 2010) and negatively 
regulates IL-12, which is required for the protective Th1 response (Cooper, 2009). 
TPL2-ERK could therefore have both positive and negative effects on the response 
to Mtb. 
However, in vivo studies from our laboratory (carried out by F.McNab and 
E.Stavropoulos) have shown that Tpl2
-/-
 mice are more susceptible to Mtb infection 
than WT controls (McNab, Ewbank, Stavropoulos, O’Garra; manuscript submitted). 
Tpl2
-/-
 mice had around a 1-log increase in bacterial burden in the lungs and spleen 
following infection. Further investigation showed that the key reason for this 
increased susceptibility was increased type I IFN production, as the effect could be 
prevented by blocking type I IFN signalling; Tpl2
-/-
Ifnar1
-/-
 mice were no more 
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susceptible than Ifnar1
-/-
 controls (McNab, Ewbank, Stavropoulos O’Garra; 
manuscript submitted). This is in agreement with the in vitro results presented in this 
chapter, as many of the effects of blocking TPL2-ERK signalling, including the loss 
of IL-1β and changes in transcription, were due to an increase in type I IFN 
signalling.  
Tpl2
-/-
 mice were also more susceptible to infection with Listeria 
monocytogenes, with Tpl2
-/-
 mice showing increased bacterial burdens in the spleen. 
Again, this effect was dependent upon type I IFN (McNab, Ewbank, Stavropoulos 
O’Garra; manuscript submitted). TPL2-ERK signalling therefore protects the host 
from infection with both Mtb and Listeria through the suppression of type I IFN. 
Further investigation into the mechanism behind this effect found that increased type 
I IFN production suppressed the Th1 response in Tpl2
-/-
 mice. In contrast to results in 
vitro, Tpl2
-/-
 mice showed no increase in IL-12 production in the serum following 
infection with Listeria monocytogenes (McNab, Ewbank, Stavropoulos, O’Garra, 
manuscript submitted). This could be reversed, however, by removing type I IFN 
signalling, as Tpl2
-/-
Ifnar1
-/-
 mice showed dramatically increased IL-12p70 in the 
serum, and an increase in the Th1 cytokine IFNγ. This is in keeping with our in vitro 
results showing addition of exogenous IFNβ can suppress IL-12 production, and 
suggests that in vivo, high levels of type I IFN can suppress the Th1 response.  
Due to its role in the induction of TNFα, there is considerable interest in 
developing drugs that target TPL2, as a way to reduce TNFα levels in 
autoinflammatory diseases such as Crohn’s disease and rheumatoid arthritis (Gantke 
et al, 2012). TNFα neutralisation is already used as a treatment for these conditions. 
Our results illustrate, however, that inhibition of TPL2 does not only lead to reduced 
TNFα production; levels of other cytokines such as IL-12 and IFNβ may be 
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increased in the absence of TPL2. Inhibition of TPL2 may therefore have harmful 
side-effects; increased IL-12 may lead to the development of a Th1 response and 
host damage through the secretion of IFNγ by T cells (although this could be 
beneficial in the context of bacterial infection). However, increased type I IFN could 
result in susceptibility to bacterial infections such as Listeria monocytogenes and 
Mtb. Treatments that target TPL2 should therefore be used with caution. 
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5.4. Figures 
 
Figure 5.1. The TPL2-ERK pathway regulates early transcription in Mtb-
infected macrophages. (A) WT and Tpl2
-/-
 macrophages were infected with Mtb 
and at 1hr post-infection RNA was harvested and microarray analysis was carried 
out. Data was normalised as described in the Materials and Methods. Differentially 
regulated transcripts were obtained by taking those that were at least 2-fold up- or 
downregulated in infected samples vs. controls in either strain, and those that were 
significantly different by two-way ANOVA p<0.05 with Benjamini Hochberg FDR 
multi-test correction. This left 422 genes which were subjected to hierarchical 
clustering using Pearson centred distance metric and complete linkage (B) A cluster 
of 24 transcripts was found to be lower in Tpl2
-/-
 macrophages relative to WT 
control. (C) The same RNA was reverse transcribed to cDNA and expression of 
Egr1 and Fos was determined by qPCR. *, p<0.05; **, p<0.01; ***, p<0.001; 
unpaired t-test. 
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Figure 5.2. The TPL2-ERK pathway negatively regulates IL-12 and IFNβ, but 
positively regulates IL-10, IL-1β and TNFα, in Mtb infected macrophages. (A) 
WT and Tpl2-/- macrophages were infected with Mtb and cytokine levels in culture 
supernatant were determined at 24hr post-infection. (B) WT macrophages were pre-
treated for 30mins with either the MEK1/2 inhibitor PD0325901 or DMSO vehicle 
control, and infected with Mtb. Cytokine levels in culture supernatant were 
determined at 24hr post-infection. Graphs show mean +/- SEM (n=3). *, p<0.05, **, 
p<0.01, ***, p<0.001; unpaired t-test. Data is representative of at least two 
independent experiments. 
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Figure 5.3. The TPL2-ERK pathway regulates IL-12 independently of IL-10. 
WT, Tpl2-/-, Il10-/- and Tpl2-/-Il10-/- macrophages were infected with Mtb. 
Cytokine levels in culture supernatant were determined at 24hr post-infection. 
Graphs show mean +/- SEM (n=3). *, p<0.05, **, p<0.01, ***, p<0.001; one-way 
ANOVA with Bonferroni post-test. Data is representative of two independent 
experiments. 
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Figure 5.4. The TPL2-ERK pathway dramatically regulates transcription in 
Mtb infected macrophages. (A) WT and Tpl2
-/-
 macrophages were infected with 
Mtb and at 0hr and 6hr post-infection RNA was harvested and microarray analysis 
was carried out. Data was normalised as described in the Materials and Methods and 
undetectable transcripts were removed. Differentially regulated transcripts were 
obtained by taking those that were at least 2-fold up- or downregulated in infected 
samples vs. controls at any time-point, and those that were significantly different by 
two-way ANOVA p<0.05 with Benjamini Hochberg FDR multiple testing 
correction. A further 2-fold filter between WT and Tpl2
-/-
 infected samples at 6hr 
was also applied. This left 104 transcripts, which were subjected to hierarchical 
clustering using Pearson centred distance metric and complete linkage. Normalised 
expression was visualised using a heat map. (B) The same RNA was also reverse 
transcribed to cDNA and expression of indicated transcripts was analysed by qPCR. 
Graphs show mean +/- SEM (n=3). *, p<0.05; **, p<0.01, ***; p<0.001; N.S. not 
significant; unpaired t-test.  
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Figure 5.5. The TPL2-ERK and type I IFN pathways jointly regulate cytokine 
production from Mtb infected macrophages. WT, Tpl2-/-, Ifnar1-/- and Tpl2-/-
Ifnar1-/- macrophages were infected with Mtb. Cytokine levels in culture 
supernatant were determined at 24hr post-infection. Graphs show mean +/- SEM 
(n=3). Data is representative of three independent experiments. 
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Figure 5.6. Transcriptional changes in Tpl2-/- macrophages are partially 
dependent upon type I IFN signalling. (A) WT, Tpl2-/-, Ifnar1-/- and Tpl2-/-
Ifnar1-/- macrophages were infected with Mtb and at 0hr and 6hr post-infection 
RNA was harvested and microarray analysis was carried out. Data was normalised as 
described in the Materials and Methods and expression of the 104 transcripts in 
Figure 5.4 was determined. This list was subjected to hierarchical clustering using 
Pearson centred distance metric and average linkage. Normalised expression was 
visualised using a heat map. (B) The same RNA was reverse transcribed to cDNA 
and analysis of gene expression was carried out by qPCR. Graphs show mean +/- 
SEM (n=3) 
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Figure 5.7. A summary of the effects of TPL2-ERK signalling on cytokine 
production by Mtb-infected macrophages 
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6.1. Background 
Type I IFN and IFNγ have distinct activities and affect the immune response 
to Mtb in very different ways. IFNγ is critical in protecting the host (Flynn and Chan, 
2001) and mice deficient in IFNγ are unable to control infection with Mtb and die 
rapidly (Flynn et al, 1995; Cooper et al, 1995). In addition, humans with mutations 
in the IFNγ receptor are unable to mount a sufficient immune response to normally 
harmless mycobacteria, a syndrome known as Mendelian susceptibility to 
mycobacterial disease (MSMD) (Casanova et al, 2012). In contrast, type I IFN 
reduces host resistance to Mtb. Several studies found that mice deficient in the type I 
IFN receptor were better able to control Mtb infection, with reduced bacterial loads 
in the lung and spleen (Manca et al, 2005; Ordway et al, 2007; Stanley et al, 2007). 
In addition, increased levels of type I IFN either in response to a hypervirulent 
isolate of Mtb (Manca et al, 2001) or Poly-ICLC (Antonelli et al, 2009) leads to 
increased susceptibility to Mtb infection in mice.  
Type I IFN and IFNγ signal through separate receptors, but induce 
overlapping signalling pathways and overlapping sets of genes (Stark et al, 1998; 
Der et al, 1998). IFNγ signals through a receptor consisting of IFNGR1 and 
IFNGR2, whereas all type I IFNs signal through a single receptor made up of 
IFNAR1 and IFNAR2 (Platanias, 2005). Following binding, downstream signalling 
occurs through the Jak/STAT pathway (Stark et al, 1998). Both the type I IFN and 
IFNγ receptors are constitutively associated with Jak kinases; Tyk2 and Jak1 with 
the type I IFN receptor, and Jak1 and Jak2 with the IFNγ receptor (Stark et al, 1998). 
Binding of IFNs to their receptors causes the Jak kinases to tyrosine phosphorylate 
the receptors, creating docking sites for STAT proteins. Docking of STAT1 or 
STAT2 at the receptors results in their phosphorylation and activation, and the STAT 
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proteins then dimerise and translocate to the nucleus where they bind to regulatory 
sequences in the promoters of genes to activate transcription (Stark et al, 1998).  
Type I IFN signalling results in both STAT1 and STAT2 phosphorylation, 
and these proteins form heterodimers and associate with IRF9 to form the ISGF3 
complex (Platanias et al, 2005). ISGF3 binds to interferon stimulated response 
elements (ISREs) in the promoters of type I IFN inducible genes, and activates their 
transcription (Platanias et al, 2005). In contrast, IFNγ signalling only activates and 
phosphorylates STAT1, which forms homodimers and binds to IFNγ-activated sites 
(GAS) in gene promoters (Platanias et al, 2005). STAT1 is therefore required for the 
response to both type I IFN and IFNγ. 
Importantly, type I IFN and IFNγ signalling can cross-regulate each other. In 
particular, it has been shown that low levels of constitutive type I IFN are required 
for an optimal response to IFNγ (Takaoka et al, 2000; Gough et al, 2011). In these 
studies, murine endothelial fibroblasts (MEFs) from Ifnar1
-/-
 mice had a diminished 
antiviral response following addition of IFNγ (Takaoka et al, 2000; Gough et al, 
2010). Takaoka et al (2000) suggested that this was due to an association between 
IFNAR1 and IFNGR2, leading to a docking site for the recruitment and activation of 
STAT1. This priming effect was lost in Ifnar1
-/-
 MEFs (Takaoka et al, 2000). More 
recently, Gough et al (2011) suggested a mechanism whereby low constitutive type I 
IFN production is responsible for maintaining basal levels of STAT1, thus 
maintaining a pool of STAT1 which could be activated by IFNγ.  
However, type I IFN was also recently shown to inhibit the response of 
macrophages to IFNγ. Rayamajhi et al (2010) found that macrophages infected with 
Listeria monocytogenes lost their responsiveness to IFNγ, with reduced STAT1 
phosphorylation and reduced upregulation of MHC class II molecules on the cell 
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surface. This loss of responsiveness was shown to be due to type I IFN production 
by infected macrophages, which downregulated the IFNγ receptor subunit IFNGR1 
(Rayamajhi et al 2010). Type I IFN has therefore been shown to both promote and 
inhibit IFNγ signalling.  
IFNγ signalling on macrophages plays a vital role during Mtb infection, 
activating macrophages to kill intracellular Mtb through the induction of 
antimicrobial effectors such as iNOS and LRG-47 (Pieters, 2008). Type I IFN-
mediated loss of macrophage responsiveness to IFNγ could therefore prevent Mtb 
killing in vivo. This may explain in part the increased resistance observed in Ifnar1
-/-
 
mice (Manca et al, 2005; Ordway et al, 2007; Stanley et al, 2007). In addition, type I 
IFN may impact IFNγ signalling during human TB, as Berry et al (2010) showed 
that genes involved in both pathways are upregulated in neutrophils and monocytes 
in active TB patients. We therefore set out to determine how type I IFN may affect 
macrophage responsiveness to IFNγ in Mtb-infected macrophages.  
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6.2. Results 
6.2.1. Endogenous type I IFN inhibits the induction of IL-12 by IFNγ 
An important function of IFNγ is to regulate the production of cytokines in 
innate immune cells. IFNγ stimulates increased production of IL-12 (Ma et al, 2005) 
and TNFα from macrophages and DCs, but inhibits production of the 
immunosuppressive cytokine IL-10 (Hu et al, 2006). To determine if endogenous 
type I IFN could interfere with these properties of IFNγ in the context of Mtb 
infection, WT and Ifnar1
-/-
 macrophages were infected with Mtb in the presence or 
absence of IFNγ and the production of cytokines at 24hr post-infection was 
determined by ELISA.  
 Addition of IFNγ potently enhanced the production of IL-12p40 from Mtb-
infected WT macrophages (Figure 6.1). However, this induction of IL-12p40 by 
IFNγ was significantly enhanced in the absence of endogenous type I IFN, with 
around 3-fold more IL-12p40 produced in Ifnar1
-/-
 macrophages treated with IFNγ 
compared to WT (Figure 6.1). In addition, whereas no IL-12p70 was induced in Mtb-
infected WT macrophages treated with IFNγ, IL-12p70 was detectable in Ifnar1-/- 
macrophages (Figure 6.1). This demonstrates that endogenous type I IFN can inhibit 
the ability of IFNγ to stimulate the production of both IL-12p40 and IL-12p70 from 
Mtb-infected macrophages. 
IFNγ also stimulated enhanced TNFα production from Mtb-infected 
macrophages (Figure 6.1). However, this was unaffected by the presence of type I 
IFN, as a similar 3-fold increased in TNFα was observed in both WT and Ifnar1-/- 
macrophages (Figure 6.1). IFNγ in the absence of Mtb infection did not induce 
detectable levels of IL-12p40 or IL-12p70, but did induce a small upregulation of 
TNFα (data not shown).  
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In contrast to IL-12 and TNFα, IFNγ addition to Mtb-infected macrophages 
inhibited IL-10 production (Figure 6.1) as previously reported (Hu et al, 2006). 
Unexpectedly, given its generally pro-inflammatory properties, IFNγ also potently 
downregulated IL-1β production from Mtb-infected macrophages (Figure 6.1). 
However, the ability of IFNγ to suppress IL-10 and IL-1β was unaffected by 
endogenous type I IFN, with similar suppression observed in WT and Ifnar1
-/-
 
macrophages (Figure 6.1). Taken together, this shows that endogenous type I IFN 
specifically inhibits the induction of IL-12p40 and IL-12p70 by IFNγ in Mtb-
infected macrophages. As IL-12 is crucial in protecting the host against Mtb 
infection due to its ability to stimulate the Th1 response (Cooper et al, 1997), this 
may have detrimental consequences for the immune response to Mtb. 
6.2.2. Exogenous type I IFN blocks the regulation of IL-12p40 and 
IL-10 by IFNγ 
In vivo, type I IFN can be made by many cell types and may act upon 
infected macrophages in a paracrine manner (Theofilopoulos et al, 2005). Having 
previously shown that endogenous type I IFN could interfere with the ability of IFNγ 
to stimulate IL-12 production, we next investigated whether addition of exogenous 
IFNβ had similar effects. Mtb-infected macrophages were treated with IFNβ alone, 
IFNγ alone and a combination of IFNβ and IFNγ, with IFNs added at the time of 
infection. 
As shown in Figure 6.2, IFNγ enhanced IL-12p40 production, whereas IFNβ 
inhibited it, as previously shown. However, if IFNβ and IFNγ were added together, 
there was minimal upregulation of IL-12p40 (Figure 6.2). Exogenous IFNβ can 
therefore block the ability of IFNγ to induce IL-12p40 production, similar to the 
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activities of endogenous type I IFN. In the absence of IFNβ, IFNγ suppressed IL-10 
production by around 2-fold and addition of IFNβ enhanced IL-10 production 
(Figure 6.2). In contrast, addition of IFNβ to Mtb-infected macrophages increased 
IL-10 production (Figure 6.2) IFNβ also blocked the downregulation of IL-10 by 
IFNγ; addition of IFNγ in combination with IFNβ had no effect on IL-10 production 
relative to IFNβ alone (Figure 6.2). 
In contrast, the ability of IFNγ to suppress IL-1β production was not affected 
by IFNβ. Both IFNβ and IFNγ suppressed IL-1β production, with IFNγ having the 
more potent effect (Figure 6.2). However, addition of both IFNs together caused an 
additive decrease in IL-1β production (Figure 6.2) showing that the ability of IFNγ 
to suppress IL-1β is not blocked by IFNβ. In addition, the ability of IFNγ to 
upregulate TNFα production from Mtb-infected macrophages was unaffected by 
IFNβ (Figure 6.2). Addition of IFNγ led to a moderate increase of TNFα compared 
to Mtb alone, and a similar increase was observed if IFNβ was added concomitantly 
(Figure 6.2). Together, these results show that exogenous IFNβ specifically 
interferes with the ability of IFNγ to enhance IL-12 and inhibit IL-10 from Mtb-
infected macrophages.  
6.2.3. Endogenous type I IFN can inhibit IFNγ-induced killing of 
Mtb 
The key function of IFNγ in the context of Mtb infection is to activate 
macrophages to kill intracellular bacteria (Flynn and Chan, 2001). Given that 
endogenous or exogenous type I IFN could inhibit the ability of IFNγ to modulate 
cytokine production from macrophages, it was of interest to determine if it could also 
block IFNγ-mediated bacterial killing. To address this, WT and Ifnar1-/- 
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macrophages were infected with Mtb in the presence or absence of IFNγ and 
intracellular bacterial levels were assessed at 96hr post-infection. 
Addition of IFNγ led to a significant 2-fold reduction in Mtb at 96hr in WT 
macrophages (Figure 6.3). However, in Ifnar1
-/-
 macrophages this effect was more 
profound, with around a 4-fold reduction in Mtb levels (Figure 6.3). This was 
significantly lower than Mtb levels in WT macrophages stimulated with IFNγ 
(Figure 6.3). Endogenous type I IFN can therefore inhibit killing of Mtb by IFNγ. 
6.2.4. Type I IFN regulates IFNγ-induced transcription in Mtb-
infected macrophages 
IFNγ induces the transcription of numerous genes in order to mediate its 
effects (Der et al, 1998). Having shown above that endogenous type I IFN can 
inhibit the upregulation of IL-12 by IFNγ, and IFNγ-mediated killing, we next 
investigated the global effects of endogenous type I IFN on IFNγ-induced gene 
expression. This could give insights into additional functions of IFNγ that may be 
regulated by type I IFN, and may also suggest mechanisms for the effects observed 
previously. For this experiment we chose to treat WT and Ifnar1
-/-
 macrophages with 
IFNγ in the absence of Mtb, in order to specifically address the role of basal type I 
IFN on IFNγ-induced gene expression, as basal type I IFN has been reported to be a 
major regulator of IFNγ signalling (Takaoka et al, 2000; Gough et al, 2010).  
WT and Ifnar1
-/-
 macrophages were treated with IFNγ at 5ng/ml and RNA 
was harvested at baseline and at 6hr post-treatment. The RNA was then purified, 
amplified and hybridised to Illumina Mouse WG-6 V2.0 Beadchip arrays, as 
described in the Materials and Methods, with triplicate biological samples for each 
condition. Following normalisation and removal of undetectable transcripts as 
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described in the Materials and Methods. Further analysis was then used to identify 
IFNγ-inducible transcripts that were regulated by endogenous type I IFN. First, 
transcripts were retained if they were up- or downregulated by IFNγ at 6hr in either 
WT or Ifnar1
-/-
 macrophages, relative to untreated controls at 6hr. Second, 
transcripts were retained if they were statistically different between WT and Ifnar1
-/-
 
macrophages by two-way ANOVA with Benjamini Hochberg FDR multiple testing 
correction. This identified 396 transcripts that were differentially regulated between 
WT and Ifnar1
-/-
 macrophages. These 396 genes were clustered hierarchically using 
Pearson centred distance metric and complete linkage (Figure 6.4).  
As shown in Figure 6.4, type I IFN has diverse effects on IFNγ-induced 
transcription. A prominent cluster of transcripts was induced to higher levels by 
IFNγ in Ifnar1-/- macrophages compared to WT macrophages, in keeping with an 
inhibition of IFNγ function describe previously (Figure 6.4). However, IFNγ 
induction of other transcripts was dependent upon type I IFN, with reduced induction 
observed in Ifnar1
-/-
 macrophages (Figure 6.4). In addition, a number of IFNγ 
inducible transcripts were regulated by basal type I IFN (Figure 6.4).  
To separate these clusters for further analysis, k-means clustering was applied 
to separate the 396 transcripts into six clusters. Expression profiles and heat maps of 
these six clusters are shown in Figure 6.5, with relevant genes shown from each 
cluster. Complete lists of the transcripts found in each cluster are presented in section 
6.5 at the end of this Chapter.  
The transcripts in cluster 0 and cluster 1 were upregulated by IFNγ in WT 
macrophages, but this was dependent upon endogenous type I IFN, as reduced 
upregulation was seen in Ifnar1
-/-
 macrophages (Figure 6.5). Transcripts in cluster 1 
were completely dependent upon type I IFN for their expression, whereas transcripts 
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in cluster 0 showed partial dependence (Figure 6.5). Cluster 0 included the apoptosis 
related genes Fas and Casp8 (Caspase 8), suggesting that IFNγ may induce 
apoptosis in macrophages, in a type I IFN dependent manner. This may be a 
mechanism to reduce the viability of Mtb and increase cross-presentation (Behar et 
al, 2011). Cluster 0 also included the IL-1 receptor antagonist Il1rn. Both type I IFN 
and IFNγ suppress IL-1β production (Figure 6.1 and Chapter 4) but this data 
suggests that IFNs may also neutralise IL-1 through Il1rn production. Cluster 1, a 
small cluster of 24 transcripts, included the antiviral gene Isg20, in line with reported 
type I IFN-dependent antiviral activity of IFNγ (Takaoka et al, 2000; Gough et al, 
2010b).  
Transcripts in cluster 4 and cluster 5 were distinguished by being heavily 
dependent on type I IFN for expression at baseline, with dramatically lower 
expression in Ifnar1
-/-
 medium controls at 0hr and 6hr compared to WT (Figure 6.5). 
However, these transcripts were strongly induced by IFNγ in WT macrophages at 
6hr post-treatment. This shows that transcripts induced by type I IFN and IFNγ 
overlap, as previously reported (Der et al, 1998). Cluster 4 includes transcripts 
which, although being dramatically lower at baseline, are strongly induced in Ifnar1
-
/-
 macrophages by IFNγ, to levels comparable to the expression observed in WT 
macrophages treated with IFNγ, showing that IFNγ can effectively compensate for 
the lack of endogenous type I IFN for these genes. Genes in this cluster include the 
GTPases Gbp2, Gbp4, Gbp5, Gbp6, the transcription factor Stat1, the components of 
the TAP transporter Tap1 and Tap2, the chemokine Cxcl10 and Irgm1 (LRG-47). It 
is notable that genes which are considered to be primarily IFNγ-inducible, such as 
the Gbps (MacMicking, 2004), are strongly regulated by endogenous type I IFN.  
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Cluster 5 contains transcripts which are also heavily regulated at baseline by 
type I IFN, but in contrast to genes in Cluster 2, addition of IFNγ only partially 
restores transcription, and levels remain much lower than those seen in WT 
macrophages (Figure 6.5). Genes in this cluster included Oas1g, Oas2, Oas2l, Prkr; 
genes with prominent antiviral functions (Sadler and Williams, 2008). The fact that 
IFNγ cannot fully induce these antiviral genes in Ifnar1-/- macrophages may result in 
a loss of IFNγ-mediated antiviral activity, as previously reported (Takaoka et al, 
2000; Gough et al, 2010b). Cluster 5 also contained the transcription factors Stat2 
and Irf7.  
Transcripts in cluster 3 were induced to higher levels by IFNγ in Ifnar1-/- 
macrophages compared to WT, showing endogenous type I IFN can inhibit 
responsiveness to IFNγ, but only in the case of specific genes (Figure 6.5) in keeping 
with previous findings for cytokine regulation by IFNγ (Figure 6.1). Genes in this 
cluster include many MHC class II molecules such as H2-Aa, H2-Ab1, H2-DMa, 
H2-DMb1, H2-DMb2 and H2-Eb1. Cluster 4 also contains li (CD74) the invariant 
chain of MHC class II complex (Vyas et al, 2008). This suggests that type I IFN may 
be able to suppress the induction of antigen presentation by IFNγ via the MHC class 
II pathway. This could be important, as antigen presentation via MHC class II is vital 
for the induction of the protective CD4
+
 T cell response (Cooper, 2009). 
Finally, Cluster 2 contains genes that are downregulated to a greater extent in 
Ifnar1
-/-
 macrophages compared to WT (Figure 6.5). This cluster includes Cd28, 
Tlr7, Tlr8, Dusp1, Dusp4 and Dusp6.  
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6.2.5. Reduced STAT1 phosphorylation by IFNγ in the absence of 
endogenous type I IFN 
The predominant transcription factor activated in response to IFNγ signalling 
is STAT1, which forms homodimers and travels to the nucleus where it mediates the 
induction of IFNγ-inducible genes (Stark et al, 1998). Given that endogenous type I 
IFN dramatically regulates IFNγ induced transcription, and that type I IFN also 
signals through STAT1, the effect of type I IFN on this key signalling pathway was 
investigated by Western blotting. WT and Ifnar1
-/-
 macrophages were stimulated 
with IFNγ and lysates were collected at 0hr, 7.5mins, 15mins, 30mins and 1hr post-
stimulation. These were probed with antibodies against total STAT1, STAT1 
phosphorylated on tyrosine residue 701, the major phosphorylation site for STAT1 
activation (Platanias, 2005), or actin as a loading control.  
Levels of total STAT1 were dramatically reduced in Ifnar1
-/-
 macrophages 
(Figure 6.6), which is in keeping with the fact that STAT1 mRNA levels are also 
much lower in Ifnar1
-/-
 macrophages, as measured by microarray (Figure 6.5). This 
is in keeping with a previous report by Gough et al (2010), showing loss of basal 
STAT1 in Ifnar1
-/-
 macrophages MEFs. As expected, addition of IFNγ to WT 
macrophages led to rapid phosphorylation of STAT1 in WT macrophages (Figure 
6.6). However, IFNγ induced STAT1 phosphorylation in Ifnar1-/- macrophages was 
greatly reduced, possibly reflecting the lower levels of total STAT1 in Ifnar1
-/-
 
macrophages (Figure 6.6). This may explain why certain genes are induced at lower 
levels by IFNγ in Ifnar1-/- macrophages. 
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6.2.6. Type I IFN can regulate mRNA levels of the IFNγ receptor 
It has been previously reported that in macrophages infected with Listeria 
monocytogenes, type I IFN could inhibit the expression of the IFNGR1 subunit of 
the IFNγ receptor (Rayamajhi et al, 2010). This may explain the increased induction 
of some IFNγ inducible genes in Ifnar1-/- macrophages, as levels of the IFNγ 
receptor, and therefore IFNγ signalling, would be increased. To determine if type I 
IFN was capable of downregulating Ifngr1 in our system, exogenous IFNβ was 
added to WT macrophages, RNA was harvested and levels of Ifngr1 were measured 
by qPCR. As shown in figure 6.7A, addition of IFNβ led to a reduction in Ifngr1 
mRNA levels after 6hr of stimulation. This may partially explain how IFNβ is able 
to block the effects of IFNγ on cytokine regulation (Figure 6.2).  
We next determined whether Mtb infection of macrophages led to a 
downregulation of Ifngr1 mRNA, and whether this was dependent upon endogenous 
type I IFN, as was reported for Listeria monocytogenes infection of macrophages 
(Rayamajhi et al, 2010). WT and Ifnar1
-/-
 macrophages were infected with Mtb and 
mRNA levels of Ifngr1 were measured by qPCR. As shown in Figure 6.7B, Mtb 
infection resulted in a downregulation of Ifngr1 in WT macrophages at 6hr post-
infection. This was independent of type I IFN, as a similar effect was seen in Ifnar1
-/-
 
macrophages. This may represent an important virulence strategy by Mtb to subvert 
IFNγ mediated killing in macrophages. However, unlike for Listeria monocytogenes 
infection, this was independent of type I IFN. 
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6.3. Discussion 
Both type I IFN and IFNγ are produced during Mtb infection, but these two 
cytokines have opposite effects on host resistance to Mtb. Whereas IFNγ is critical 
for controlling Mtb infection (Flynn et al, 1995; Cooper et al, 1995), type I IFN 
reduces host resistance (Manca et al, 2005; Ordway et al, 2007; Stanley et al, 2007). 
Previous reports have shown that type I IFN and IFNγ can cross-regulate each other, 
with both positive and negative effects of type I IFN on IFNγ signalling reported 
(Takaoka et al, 2000; Rayamajhi et al 2010; Gough et al, 2010b). Here we show that 
type I IFN could inhibit IFNγ-mediated cytokine regulation, and IFNγ-mediated Mtb 
killing, in macrophages. However, transcriptional analysis revealed additional 
complexity, with type I IFN both positively and negatively regulating IFNγ-induced 
gene expression. Given the vital role of IFNγ in protecting against Mtb, this may 
have important consequences for the in vivo immune response to Mtb.  
6.3.1. Type I IFN inhibits key functions of IFNγ 
Rayamajhi et al (2010) reported that type I IFN inhibited macrophage 
responsiveness to IFNγ in the context of Listeria monocytogenes infection. This 
study found that the ability of IFNγ to stimulate MHC class II presentation on the 
macrophage surface was enhanced in the absence of type I IFN (Rayamajhi et al 
2010). This is in keeping with the results of our microarray analysis, showing that a 
number of MHC class II molecules, and the invariant chain li (CD74), were induced 
to a greater extent by IFNγ in Ifnar1-/- macrophages at the mRNA level. However, 
we also found that two further key functions of IFNγ were inhibited by type I IFN. 
First, type I IFN inhibited the ability of IFNγ to upregulate IL-12, and downregulate 
IL-10 from Mtb-infected macrophages. Second, type I IFN inhibited the ability of 
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IFNγ to stimulate Mtb-killing in macrophages. The inhibition of these activities of 
IFNγ in vivo by type I IFN may have profound effects on host resistance, and may go 
some way to explaining why mice deficient in type I IFN signalling mount a more 
effective immune response to Mtb (Manca et al, 2005; Ordway et al, 2007; Stanley 
et al, 2007). 
IFNγ is a potent activator of macrophages, and induces several pathways that 
result in the killing of Mtb, including induction of the enzyme iNOS, which 
generates antimicrobial free radicals such as NO2, the stimulation of autophagy, 
which leads to the destruction of Mtb in the phagosome, and the induction of several 
members of the GTPase family. T cell derived IFNγ is therefore thought to be the 
main mechanism by which Mtb is eliminated from the body (Flynn and Chan, 2001). 
However, Mtb is capable of surviving in the face of this robust Th1 mediated 
response, establishing a latent infection that can reactivate many years later. Mtb is 
therefore likely to have evolved a number of strategies to avoid and subvert this 
IFNγ-mediated Th1 response, in order to persist. Our results suggest that the 
induction of type I IFN in macrophages may be one such virulence strategy to blunt 
IFNγ killing.   
As discussed above, IFNγ activates several different killing mechanisms in 
Mtb-infected macrophages. Microarray analysis of WT and Ifnar1
-/-
 macrophages 
found a number of IFNγ-inducible genes to be more strongly induced in Ifnar1-/- 
macrophages. However, this did not include Nos2 (iNOS), Irgm1 (LRG-47) or 
members of the GTPase family. This does not rule out an inhibition of these factors 
by type I IFN; the microarray was only carried out at one time point (6hr) and thus 
the kinetics of the induction of these genes by IFNγ may have been altered by type I 
IFN. For example, these genes may have been induced more rapidly by IFNγ in the 
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absence of type I IFN. Alternatively, their induction may have been maintained over 
a longer period. Future analyses could repeat these experiments over several time 
points to address this.  
A further important function of IFNγ during the immune response is to 
stimulate cells such as macrophages and DCs to present antigens to naive T cells. 
IFNγ stimulated both MHC class I and class II antigen presentation. Induction of 
MHC class II genes occurs via the induction of the class II transactivator, a master 
regulator of class II gene expression (Boehm et al, 1997). In keeping with this, C2ta, 
encoding the class II transactivator, and many MHC class II molecules were strongly 
induced by IFNγ in macrophages. Strikingly, several MHC class II molecules were 
more strongly upregulated in Ifnar1
-/-
 macrophages, suggesting that endogenous type 
I IFN may block the ability of IFNγ to induce antigen presentation. Presentation of 
Mtb antigens on MHC class II molecules by APCs is a key stage in Mtb infection, as 
it leads to the activation of the protective CD4
+
 T cell response (Cooper, 2009). 
Further work should confirm whether type I IFN can block antigen presentation, in 
particular focussing on DCs, as these are known to activate CD4
+
 T cells in the 
lymph nodes during Mtb infection (Wolf et al, 2007; Reiley et al, 2008). For 
example, the ability of IFNγ-stimulated WT and Ifnar1-/- DCs to induce T cell 
proliferation or IFNγ production in vitro could be assessed.  
These results are reminiscent of several previous studies showing that Mtb 
could inhibit the macrophage response to IFNγ (Ting et al, 1999; Kincaid and Ernst, 
2003; Nagabhushanam et al, 2003; Fortune et al, 2004). These studies found that 
Mtb-infected macrophages showed reduced ability to upregulate MHC class II 
expression following IFNγ treatment, and this was found to be partially dependent 
upon IL-6 production from Mtb-infected macrophages (Nagabhushanam et al, 2003) 
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but seemed to be independent of effects on JAK-STAT signalling (Ting et al, 1999; 
Kincaid and Ernst, 2003). In addition, the suppression of IFNγ responsiveness by 
Mtb was shown to be both MyD88-dependent and -independent (Fortune et al, 
2004). Our results suggest that induction of type I IFN by Mtb-infected macrophages 
may represent an additional mechanism for inhibiting IFNγ responsiveness, and this 
may account for the observed MyD88-independent effects (Fortune et al, 2004), as 
type I IFN production in response to Mtb is MyD88-independent (Stanley et al, 
2007; Pandey et al, 2009).  
6.3.2. Mechanisms behind type I IFN and IFNγ cross-talk 
An important question following the observation that type I IFN could block 
the activities of IFNγ was how this occurs. One possible explanation, put forward by 
Rayamajhi et al (2010), was that type I IFN downregulates expression of the IFNγ 
receptor, specifically the Ifngr1 subunit. In keeping with these observations, we 
found that addition of IFNβ to macrophages led to a downregulation of Ifngr1 at the 
mRNA level. However, IFNβ downregulation of Ifngr1 only occurred after 6hr of 
treatment. This suggests that pre-treatment of macrophages with IFNβ would be 
required to inhibit responsiveness to IFNγ. However, we found that addition of IFNβ 
at the same time as IFNγ was able to block the regulation of cytokines by IFNγ. It 
therefore seems likely that other mechanisms may be involved.  
A second likely point of cross-regulation between type I IFN and IFNγ 
signalling is at the level of STAT1 activation, as both type I IFN and IFNγ signal 
through STAT1 (Platanias, 2005). We found that endogenous type I IFN was 
required for maximal STAT1 activation by IFNγ. This is in keeping with a study by 
Gough et al (2010) which found that in MEFs, endogenous type I IFN was required 
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was optimal STAT1 phosphorylation in response to IFNγ, and also for IFNγ-induced 
antiviral activity. Indeed, we found that the induction of many antiviral genes by 
IFNγ, including Mx1, Oas family members and Prkr was found to be dependent 
upon endogenous type I IFN, which may explain the loss of antiviral activity by 
Gough et al (2010).  
An important finding of this study is that endogenous type I IFN can regulate 
IFNγ-induced gene expression in a variety of ways in macrophages. Previous studies 
have shown both a positive (Gough et al, 2010) and negative (Rayamajhi et al, 2010) 
effect of type I IFN on IFNγ activities. Our microarray analysis found that both 
positive and negative effects can occur simultaneously, in a gene specific manner. 
IFNγ induced clusters of genes were identified that were induced to both higher 
levels, showing negative regulation, and lower levels, showing positive regulation, in 
Ifnar1
-/-
 macrophages. This illustrates the complexity of type I IFN and IFNγ cross-
talk, and suggests that several mechanisms of regulation may occur simultaneously. 
Regulation of both Ifngr1 and STAT1 phosphorylation may play a part in this. In 
addition, this may have important consequences for the host response to Mtb 
infection in vivo.  
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6.4. Figures 
 
Figure 6.1. Type I IFN signalling inhibits the ability of IFNγ to upregulate IL-12 
production from Mtb-infected macrophages. WT and Ifnar1
-/-
 macrophages were 
infected with Mtb in the presence or absence of IFNγ, added concomitantly at 
5ng/ml. Cytokine levels in culture supernatant were determined at 24hr post-
infection. *, p<0.05, **, p<0.01, ***, p<0.001; unpaired t-test. Graphs show mean 
+/- SEM (n=3). Data is representative of at least three independent experiments. 
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Figure 6.2. Exogenous IFNβ blocks the ability of macrophages to induce IL-12, 
and suppress IL-10, from Mtb-infected macrophages. WT macrophages were 
infected with Mtb in the presence or absence of IFNβ (2ng/ml), IFNγ (5ng/ml) or 
both together. Cytokine levels in culture supernatant were determined at 24hr post-
infection. *, p<0.05, **, p<0.01, ***, p<0.001, N.S. not significant; unpaired 
student’s t-test. Graphs show mean +/- SEM (n=3). Data is representative of three 
independent experiments. 
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Figure 6.3. Endogenous type I IFN inhibits IFNγ-induced killing of Mtb in 
macrophages. WT and Ifnar1
-/-
macrophages were infected with Mtb in the presence 
or absence of IFNγ, added concomitantly at 5ng/ml. At 96hr post-infection cell were 
lysed with 0.2% saponin and bacterial counts were determined by plating onto 7H11 
plates supplemented with OADC. **, p<0.01; unpaired t-test. Data is representative 
of two independent experiments. 
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Figure 6.4. Endogenous type I IFN dramatically regulates the macrophage 
transcriptional response to IFNγ. (A) WT and Ifnar1-/- macrophages were 
stimulated with IFNγ at 5ng/ml and at 0hr and 6hr post-infection RNA was harvested 
and microarray analysis was carried out. Data was normalised as described in the 
Materials and Methods and undetectable genes were removed. Differentially 
regulated transcripts were obtained by taking those that were at least 2-fold up- or 
downregulated in infected samples vs. controls at any time-point, and those that were 
significantly different by two-way ANOVA p<0.05 with Benjamini Hochberg multi-
test correction. This left 396 transcripts, which were subjected to hierarchical 
clustering using Pearson centred distance metric and complete linkage. Normalised 
expression was visualised using a heat map. 
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Figure 6.5. Clusters of genes are differentially regulated by type I IFN following 
IFNγ stimulation of macrophages. The 396 differentially regulated transcripts 
shown in Figure 6.4 were subjected to k-means clustering using Pearson centred 
distance metric, to generate 6 clusters. (A) Expression profiles of the six clusters. (B) 
The genes in each cluster were clustered hierarchically and visualised as a heat map. 
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Figure 6.6. STAT1 phosphorylation by IFNγ is impaired in the absence of 
endogenous type I IFN. WT and Ifnar1
-/-
 macrophages were stimulated with 5ng/ml 
IFNγ and whole cell extracts were prepared at the indicated time post-stimulation. 
Extracts were analysed by immuno-blotting using the antibodies shown. Data is from 
one experiment.  
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Figure 6.7. Type I IFN can regulate expression of the IFNγ receptor. (A) WT 
macrophages were treated with IFNβ at 2ng/ml, RNA was harvested at 0hr, 1hr and 
6hr, converted to cDNA and Ifngr1 mRNA levels determined by qPCR. (B) WT and 
Ifnar1
-/-
 macrophages were infected with Mtb. RNA was harvested at 0hr, 1hr and 
6hr, converted to cDNA and Ifngr1 mRNA levels determined by qPCR. Graphs 
show mean +/- SEM (n=3) *, p<0.05; **, p<0.01; ***, p<0.001; two-way ANOVA 
with Bonferroni post-test. Data is from one experiment. 
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6.5. Transcripts present in six k-means clusters described in 
Figure 6.5 
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Cluster 0 
1110059G02Rik Zranb3   
4930422J18Rik    
Adora2b    
Armcx6    
AY078069    
BC057079    
Brdt    
Bzw2    
Casp8    
Casp8    
Ccnd1    
Ccnd1    
Ccnd1    
Ccrn4l    
Csrp1    
Cxcl11    
Cxcl2    
Dmwd    
Elmo1    
Fas    
Furin    
Gadd45g    
Gadd45g    
Hmgn3    
Hmgn3    
Hspa2    
Hspa2    
Il18rap    
Il1rn    
Itpkb    
Klrk1    
Laptm4b    
LOC224532    
LOC240672    
LOC278097    
Mgl2    
Nup93    
Palm    
Ppa1    
Psip1    
Rhoj    
Slc24a3    
Ssbp2    
Timp1    
Tmpo    
Tnfrsf12a    
Vwf    
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Cluster 1 
1700027J05Rik    
2310016C08Rik    
Akap12    
Ccl3    
D030012E24Rik    
D030012E24Rik    
D630022O22Rik    
Dgat2    
I830077J02Rik    
Isg20    
LOC223672    
LOC270152    
Mmp13    
Mmp13    
Ogfrl1    
Paox    
Paox    
Pdk3    
Pou3f1    
Rin2    
Rin2    
Siat10    
Socs2    
Uaca    
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Cluster 2 
1110025F24Rik Fvt1 St6gal1  
1110032E23Rik Garnl3 Stk17b  
1300010M03Rik Gdf15 Thbs1  
1500010J02Rik Gtf2ird2 Tlr13  
1700023M03Rik Hdac5 Tlr7  
1810027I20Rik Hlx1 Tlr8  
2810408E11Rik Hvcn1 Tnfrsf22  
2810416G20Rik Ihpk1 Trim25  
3830612M24 Kif23 Uhrf1  
4933411B03Rik LOC329357 Ung  
6330406L22Rik LOC381484 Yaf2  
6430511F03 LOC383435 Zdhhc14  
6720463M24Rik Lpxn   
A930001D11Rik Lyl1   
AA408296 Mbd5   
Adam8 Mcm6   
Ahnak Mcm6   
Ankrd47 Mgst2   
Apobec1 Mospd1   
Arhgap18 Mospd1   
B930045J24Rik Mospd1   
Bach2 Msrb2   
BC006933 Msrb2   
Bcl2l11 Mtus1   
Birc1e Necap1   
Cbr3 Necap1   
Cd28 Necap1   
Cd28 Numa1   
Cd28 Olfml2b   
Cerk P2ry5   
Chaf1b Pank1   
Clec4a3 Pde2a   
Clspn Pparg   
Coq7 Ppp2r5d   
Cxcr4 Pscdbp   
Ddef1 Ptpn8   
Dgkz Rasa3   
Dleu2 Rassf2   
Dscr1 Rbm38   
Dusp1 Rcbtb2   
Dusp4 Ris2   
Dusp6 Selenbp1   
Ebi2 Setmar   
Ehd4 Sgol1   
Epb4.1l1 Slc9a3r1   
Epb4.1l1 Sox4   
Eya1 Srpk2   
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Cluster 3 
1300017K07Rik Pvrl2   
1810008K03Rik Pvrl2   
2210421G13Rik Rarres1   
5730528L13Rik Rasgef1b   
9130211I03Rik Sdccag33   
Acsl1 Synpo   
Asns Tbc1d2   
C230021P08Rik Tgfb1i4   
Card4 Tnfrsf5   
Ccl24 Vdr   
Cd40 Vdr   
Clec4n Ybx3   
Clec5a Zhx2   
Clec5a    
Clec9a    
Clecsf12    
Clecsf12    
Crsp2    
Ednrb    
F2rl1    
Fscn1    
Gbp2    
Gca    
Gja4    
H2-Aa    
H2-Ab1    
H2-Ab1    
H2-Ab1    
H2-Ab1    
H2-DMa    
H2-DMa    
H2-DMb1    
H2-DMb2    
H2-Eb1    
H2-M2    
Hivep3    
Igf2bp3    
Ii    
Ikzf1    
Kit    
Klf7    
Klhl6    
Klhl6    
Lass6    
LOC193676    
Pdlim1    
Prdx5    
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Cluster 4 
2010106G01Rik Gbp6 Stat1  
2600010E01Rik Glipr2 Stat1  
4933430F08Rik Glipr2 Tap1  
5133400O11Rik Gsdmdc1 Tap2  
5830484A20Rik Gvin1 Tapbpl  
9930111J21Rik H2-Q5 Trafd1  
A130015P11Rik H2-Q7 Trafd1  
A330042I21Rik H2-T23 Whdc1  
A530060O05Rik Ifi204   
A630077B13Rik Ifi205   
A630085K21 Ifi205   
AA467197 Ifi205   
AI451557 Ifi205   
AI481100 Ifi47   
Aif1 Igtp   
BC006779 Ii   
BC006779 Ii   
BC013712 Irg1   
BC023741 Irg1   
BC049975 Irgm   
C3 Irgm   
Casp4 LOC215405   
Ccl12 LOC240327   
Ccl12 LOC435565   
Ccl5 LOC620078   
Ccl7 Mlkl   
Ccl8 Nupr1   
Cd69 Parp14   
Cdkn1a Pdcd1lg1   
Clcn7 Psmb10   
Cp Psmb8   
Cxcl10 Psmb8   
Cxcl10 Psmb9   
D12Ertd647e Psme1   
D12Ertd647e Ptafr   
Dlm1-pending Rasgrp1   
F730045P10Rik Rhoe   
F830008K13Rik Rnase6   
Fcrl3 Samhd1   
Fpr-rs2 Samhd1   
Gadd45b Samhd1   
Gbp2 scl000868.1_2   
Gbp2 scl000868.1_2   
Gbp4 Serpina3g   
Gbp4 Slamf7   
Gbp5 Slco3a1   
Gbp6 Spn   
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Cluster 5 
2510004L01Rik Sp100   
Ass1 Stat2   
D11Ertd759e Tor3a   
D11Lgp2e Trex1   
D11Lgp2e Trex1   
D11Lgp2e Tyki   
D14Ertd668e Ube2l6   
D14Ertd668e Ube2l6   
Ddit3 Usp18   
Fcgr1 Usp18   
G1p2 Usp18   
H2-Q5    
H2-Q8    
H2-T23    
H2-T23    
H2-T9    
Ifi35    
Ifit2    
Ifit2    
Ifit3    
Ifitm1    
Ifitm3    
Irf7    
Isgf3g    
Isgf3g    
Lgals3bp    
Lgals9    
LOC380706    
LOC381276    
Luzp1    
Ly6a    
Ly6e    
Ly6e    
Oas1g    
Oas1g    
Oas2    
Oasl2    
Oasl2    
Olfr538    
Phf11    
Phf11    
Prkr    
Rnf34    
Sp100    
Sp100    
Table 6.1. Complete list of genes in six k-means clusters shown in Figure 6.5 
Chapter 7: Summary and future perspectives 
 
296 
Chapter 7. Summary and future perspectives 
  
Chapter 7: Summary and future perspectives 
 
297 
7.1. Summary 
In this study I have carried out a comprehensive analysis of the 
transcriptional response of macrophages to Mtb infection over time. The results have 
illustrated the complexity of Mtb-macrophage interactions, with clusters of genes 
induced with different kinetics after infection. Two clusters were upregulated rapidly 
in Mtb-infected macrophages (30mins-1hr post-infection); one containing many 
cytokines and chemokines, and a second containing several genes regulated by the 
TPL2-ERK pathway. Clusters upregulated at later timepoints contained genes 
involved in MHC class I antigen presentation, steroid biosynthesis, apoptosis and 
type I IFN signalling. Many of these processes are likely to be important in resisting 
Mtb infection, and activating the adaptive immune response. However, the induction 
of genes involved in steroid biosynthesis may represent a virulence strategy of Mtb, 
allowing it to survive and replicate within macrophages.  
The results of this initial microarray study prompted us to further investigate 
the role of two signalling pathways in the macrophage response; type I IFN and 
TPL2-ERK. Both pathways were found to regulate the production of important 
cytokines in response to Mtb infection. The TPL2-ERK pathway negative regulated 
the production of type I IFN, which indirectly enhanced the production of IL-1β, 
illustrating that early activation of the TPL2-ERK pathway can regulate the later 
macrophage response. The TPL2-ERK pathway also promoted the production of 
TNFα from Mtb infected macrophages, but inhibited the production of IL-12p40 and 
IL-12p70. Exogenous type I IFN enhanced the production of the immunosuppressive 
cytokine IL-10, which led to a suppression of IL-12p40 and TNFα, and also 
suppressed IL-1β independently of IL-10. In addition, microarray analysis of Mtb-
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infected macrophages deficient in Tpl2 or Ifnar1 showed that both type I IFN and 
TPL2-ERK signalling were important regulators of transcription in response to Mtb.  
Finally, we found that type I IFN could dramatically affect the macrophage 
response to IFNγ, both transcriptionally and functionally. Most importantly, type I 
IFN inhibited IFNγ-mediated upregulation of IL-12 production, and killing of Mtb, 
in macrophages, processes which are crucial to the protective immune response. 
Type I IFN can therefore regulate the immune response to Mtb at a number of stages, 
which is likely to explain the observation that mice deficient in type I IFN signalling 
mount a more effective immune response to Mtb.  
7.2. Future perspectives 
7.2.1. Transcriptional analysis of macrophages infected with diverse 
strains of Mtb 
Our study was carried out using a single strain of Mtb, H37Rv. Globally, Mtb 
strains show a large amount of genetic diversity, with several distinct lineages 
associated with particular geographic areas (Gagneux and Small, 2007). A number of 
studies have reported that Mtb strains differ dramatically in their virulence, a good 
example being the hypervirulent W-Beijing lineage (Nicol and Wilkinson, 2008). 
Results have also suggested that interactions with the innate immune system may 
explain the hypervirulence of strains such as W-Beijing family members; for 
example Reed et al (2004) showed that presence of a lipid unique to W-Beijing 
family members, phenolic glycolipid (PGL), could actively downregulate the 
production of pro-inflammatory cytokines from macrophages.  
A future direction would be to repeat the transcriptional analyses described in 
Chapter 3 with Mtb strains from several different lineages, including highly virulent 
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isolates such as members of the W-Beijing family. This is likely to reveal additional 
strain-specific virulence mechanisms possessed by highly virulent strains, and could 
lead to a better understanding of host-pathogen interactions. 
7.2.2. Mechanistic studies into the regulation of cytokines by type I 
IFN 
We found that both endogenous and exogenous type I IFN could regulate 
cytokine production from Mtb-infected macrophages. In some cases, we uncovered 
the mechanism behind these effects; for example, the suppression of IL-12p40 and 
TNFα by exogenous IFNβ was shown to be largely indirect, through the 
enhancement of IL-10 production. However, further research is required to 
understand the mechanisms behind other effects of type I IFN which were IL-10 
independent.  
Given that IL-10 underscores a number of effects of type I IFN, how type I 
IFN regulates IL-10 is of particular interest. A number of mechanisms have been put 
forward by other studies, for example IL-27 was suggested as an indirect mechanism 
for the enhancement of IL-10 by type I IFN (Iyer et al, 2010). This will be 
investigated in our system by using mice deficient in the IL-27 receptor component 
WSX-1. The effect of type I IFN on IL-10 appears to be transcriptional, as IFNβ led 
to a prolonged upregulation of IL-10 mRNA production in Mtb-infected 
macrophages. Thus, a potential avenue of enquiry would be to determine 
transcription factor binding at the IL-10 promoter; in particular the binding of type I 
IFN inducible transcription factors such as STAT1. The IL-10 promoter has been 
reported to contain STAT1 binding sites (Saraiva and O’Garra, 2010), suggesting 
this may present a potential mechanism. A further possibility is regulation of IL-10 
Chapter 7: Summary and future perspectives 
 
300 
mRNA stability by type I IFN. This is suggested by our findings showing that 
addition of IFNβ leads to sustained IL-10 mRNA levels, which could reflect 
increased stability as opposed to an enhanced transcription. IL-10 mRNA is known 
to be regulated at the level of stability by factors such as tristetraprolin (TTP) 
(Stoecklin et al, 2008) and type I IFN could be involved in regulating this process. 
We found that addition of IFNβ led to suppression of IL-1β at the 
transcriptional level. However, Guarda et al (2011) have shown that IFNβ could also 
regulate inflammasome activation in response to stimulation with LPS and alum, 
representing a further mechanism by which type I IFN could inhibit IL-1β. Future 
work could therefore determine if inflammasome activation by Mtb is inhibited by 
type I IFN.  
7.2.3. Regulation of immune processes by type I IFN in additional 
cell types, and in vivo, in response to Mtb infection 
In this study we investigated the response to Mtb in bone-marrow derived 
macrophages, as macrophages are a major host-cell for Mtb in vivo (Wolf et al, 
2007) and are thought to mediate the majority of Mtb killing (Flynn and Chan, 
2001). However, a number of other innate immune cells can become infected during 
infection, such as DCs and neutrophils (Wolf et al, 2007; Eum et al, 2009) and these 
cells can also produce cytokines in response to triggering of PRRs by Mtb. Future 
work could therefore address whether the pathways we describe here also regulate 
cytokine production in additional cell types.  
The major producers of IL-12 during in vivo Mtb infection are thought to be 
myeloid DCs (Rothfuchs et al, 2009). It would therefore be of interest to determine if 
IFNβ also suppresses production from myeloid DCs infected with Mtb. The role of 
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the TPL2-ERK pathway in suppressing IL-12 production could also be investigated 
in this cell type. This could be addressed using bone-marrow derived dendritic cells 
as a model. Findings in bone marrow derived dendritic cells could then be validated 
by analysing DC expression of IL-12 in vivo during Mtb infection.  
IL-10 can be made by many cell types besides macrophages, including innate 
cells such as DCs and neutrophils, and adaptive immune cells such as T cells and B 
cells (Saraiva and O’Garra, 2010). Thus, whether type I IFN promotes IL-10 
production in a wide range of immune cells, or specifically in macrophages, would 
be of interest. To address this, others in our laboratory are making use of 10BiT 
mice, IL-10 reporter mice in which cells expressing IL-10 upregulate Thy1.1 on the 
cell surface, which can be detected by flow cytometry (Maynard et al, 2007). We 
have crossed these mice with Ifnar1
-/-
 mice, and can thus address the role of type I 
IFN in promoting IL-10 production in vivo during Mtb infection, by comparing 
Thy1.1 expression in 10BiT WT mice with 10BiT Ifnar1
-/-
 mice. This strategy can 
thus be used to determine IL-10 production in a variety of immune cells during Mtb 
infection.  
Of particular interest is IL-10 production by neutrophils, as a recent study 
reported that neutrophils produced high levels of IL-10 in vitro in response to BCG 
and Mtb (Zhang et al, 2009) and IL-10 producing neutrophils have been isolated 
from patients with melanoma (De Santo et al, 2011). Given that the IFN signature 
described by Berry et al (2010) is largely found within neutrophils in the blood, type 
I IFN could potentially be driving IL-10 production from neutrophils.  
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7.2.4. Confirmation of microarray results by functional analyses 
Although microarray is a powerful tool for assessing the response of cells to 
stimulation or infection, a drawback of this technique is that it operates purely at the 
level of transcription. This is a caveat because gene expression is extensively 
regulated post-transcriptionally, through mechanisms such as mRNA stability, and 
covalent modifications such as phosphorylation and ubiquitination. Thus, a change 
in gene expression at the mRNA level may not correspond to increased protein 
production. We found that type I IFN could affect the expression of genes involved 
in a wide range of processes, besides cytokine production. For example, a number of 
apoptosis related genes were regulated by type I IFN and IFNγ. In addition, the 
induction of genes involved in the MHC class II antigen presentation pathway, such 
as MHC class II molecules and the invariant chain Ii, by IFNγ was inhibited by type 
I IFN. It is important therefore that these effects are confirmed at the protein level 
and by functional analyses. For example, apoptosis could be assessed by a number of 
different assays, such as TUNNEL staining, and antigen presentation could be 
assayed by incubating peptide-pulsed WT or Ifnar1
-/-
 DCs with TCR-transgenic 
naive T cells as a pool, and determining subsequent T cell proliferation or cytokine 
production.  
In addition to apoptosis and antigen-presentation associated genes, 
microarray analysis also revealed that type I IFN regulated production of iNOS, 
which is critical for killing of Mtb in macrophages (Chan et al, 1992), and the 
production of several chemokines such as Ccl2 and Ccl7, which are required for 
migration of monocytes to the Mtb infected lung (Peters et al, 2000). Regulation of 
iNOS could be confirmed by using Greiss’s reagent to determine the amount of nitric 
oxide in macrophages by spectrophotometry, as used by Ehrt et al (2001). The 
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regulation of chemokines by type I IFN could be determined either by ELISA, or by 
a more global multiplex analysis. This approach has the advantage of revealing 
potential post-transcriptional regulation of cytokines and chemokines by type I IFN.  
7.3. Conclusion 
This study reveals important signalling events that occur at different times 
following Mtb infection of macrophages, which are likely to have an impact on the 
outcome of Mtb infection in vivo. 
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